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Abstract 
Despite its great success, antiretroviral therapy (ART) fails to improve HIV-1-specific T-cell 
responses in treated individuals, although it does restore CMV-specific immunity. Furthermore, co-
infection with CMV has been associated with increased risk of non-AIDS-related morbidities. This 
thesis comprehensively characterises HIV-1- and CMV-specific T-cell responses in HIV-1-infected 
subjects, in the context of both ART and different progression rates. Proliferative responses to 
CMV and HIV-1 were evaluated in HIV-1-infected and uninfected healthy controls (HC). ART led to 
a discordant increase in CMV-specific proliferation relative to that observed for HIV-1. High 
proliferative responses to both viruses in elite controllers contrasted the low CMV-specific 
proliferation in HC. Strong induction of the suppressive cytokine IL-10 was observed in response to 
CMV and HIV-1 Nef, but not to Gag, and this was higher in ART-naïve individuals compared to 
treated patients. Still, HC exhibited the highest levels of CMV-specific IL-10, pointing to a 
regulatory role for IL-10 in these responses, possibly explaining the low proliferative responses in 
HC. Analysis of T-cell activation, differentiation and exhaustion revealed similar frequencies of HIV-
1-specific CD8 effector memory (TEM) cells between ART-naïve and treated individuals, but CMV-
specific CD8 TEM cells were higher in treated individuals correlating with the increased anti-CMV T-
cell function observed. Higher CD8 TEM and lower naïve CD8 T-cell frequencies were significantly 
associated with disease progression, whilst long-term non-progressors exhibited higher levels of 
CD8 terminally differentiated (TEMRA) cells. Moreover, CD8 T cells with an HLA-DR+CD38
- 
phenotype were elevated in treated individuals compared to both HC and ART-naϊve patients, and 
linked with cytotoxic activity in a non-progressor. Detection of replication-competent virus from HIV-
1 controllers at different outgrowth rates suggests reduced replicative fitness. Overall, these results 
detail the complex interplay between CMV and HIV-1 co-infection, the difference between ART-
mediated and spontaneous immune control and point to potential targets for immunotherapeutic 
interventions. 
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Chapter 1 Introduction 
1.1 Human Immunodeficiency Virus Infection and Acquired 
Immunodeficiency Syndrome 
The human immunodeficiency virus (HIV), despite its relatively short history as a human infection, 
represents one of the greatest challenges facing global health today. Although great advances 
have been made in understanding how the immune system responds but ultimately fails to protect 
against this virus, identifying vaccine targets has proven to be particularly difficult due to the 
enormous genetic diversity that it generates. A fundamental event in the pathogenesis of HIV 
infection lies in its preferential targeting of CD4 T lymphocytes (Douek et al., 2002), which results 
in a weakened immune system. Despite an initial strong immune response during the acute phase 
of infection (Streeck et al., 2009), several immune evasion strategies employed by HIV including 
the establishment of latency and generation of escape mutations, renders the host unable to clear 
infection (Deng et al., 2015). This is followed by a predominantly asymptomatic chronic infection, 
which if left untreated, ultimately progresses to acquired immunodeficiency syndrome (AIDS) 
(Goulder and Watkins, 2004; McMichael et al., 2010).  
 
The development of suppressive antiretroviral therapy (ART) has led to a great reduction in HIV-
related deaths and in many cases, HIV infection can now be considered as a life-long chronic 
illness manageable by ART (Deeks et al., 2013). However, although treatment coverage has 
increased, it remains unevenly distributed globally (UNAIDS, 2014), requires a rigorous adherence 
to avoid drug resistance and the long-term toxicities are still unknown. Effective ART does not 
eradicate the virus nor restore immune function, leading to increased incidence of several non-
AIDS-associated morbidities including cardiovascular disease, kidney disease, neurocognitive 
disorders and cancer (Deeks et al., 2013). It is thus becoming increasingly important to understand 
the process by which ART fails to restore HIV-specific immune responses even when initiated 
during early stages of infection. This will aid the development of immunotherapeutic interventions 
that can boost the immune system parallel to ART-mediated control of virus replication and 
disease progression (Barouch and Deeks, 2014). The case of the “Berlin patient”, who was 
functionally cured from HIV after undergoing stem-cell transplantation using donor cells 
homozygous for chemokine receptor 5 (CCR5) delta32 (Hutter et al., 2009), has reinvigorated the 
field because it provides a proof-of-principle that eradication of HIV is possible (Allers et al., 2011). 
1.1.1 Epidemiology and transmission modes of HIV infection 
Two years after the first AIDS-related cases in 1981, two independent teams led by Dr Robert 
Gallo and Dr Luc Montagnier, were the first to isolate and identify HIV as the etiologic agent of 
AIDS (Barre-Sinoussi et al., 1983; Gallo et al., 1983). More than three decades on it is now 
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estimated that over 35 million people are currently living with HIV, out of which approximately 19 
million are unaware of their HIV-positive status (UNAIDS, 2014). The majority of infections (24.7 
million) are in Sub-Saharan Africa, the region hardest hit by the epidemic and which accounts for 
over 74% of all AIDS-related deaths. Increased awareness and a substantial global effort have led 
to increased access to ART and a fall in new infections each year down to 2.1 million in 2013. 
However, the percentage of people not receiving ART is still 63% (UNAIDS, 2014), indicating that 
although great progress has been made, there is still much to be done.  
 
Molecular epidemiologic studies have traced the origin of the current HIV pandemic to the 1920s in 
the city of Kinshasa, located in what is now the Democratic Republic of Congo (Faria et al., 2014). 
It is thought that HIV was introduced to humans via multiple cross-species transmissions, probably 
via exposure to non-human primate blood, from the simian immunodeficiency virus (SIV). This is a 
closely related virus to HIV and occurs naturally in many species of nonhuman primates and 
monkeys (Heeney et al., 2006). Two distinct but closely related types of HIV have been identified. 
HIV-1 is the cause of the current pandemic and originates from SIVcpz in the Pan troglodytes 
troglodytes subspecies of chimpanzee (Gao et al., 1999). It is subdivided based on degree of 
sequence divergence into four different strains, which reflect the different cross-species 
transmissions believed to have occurred: the “major” group (M) which accounts for over 90% of 
cases; group O (outlier) endemic in Western Central Africa; group N (non-M and non-O); and a 
newly discovered strain designated P (putative) which probably originates from the gorilla simian 
immunodeficiency virus (SIVgor) (Plantier et al., 2009). Group M is further divided into 10 distinct 
clades (subtypes), of which Clade C is the predominant clade worldwide (prevalent in sub-Saharan 
Africa and India) and clade B is the most studied (prevalent in North America and Europe).  
 
The less virulent HIV-2, which is predominantly restricted to West Africa, is believed to have 
derived from the SIV variant in sooty mangabeys (Clavel et al., 1986; Hirsch et al., 1989; Sharp et 
al., 2001). Despite the similarities to HIV-1, individuals infected with HIV-2 rarely progress to AIDS 
(Poulsen et al., 1997), probably because of its SIV origin. SIV in sooty mangabeys can cause high-
level viraemia, infect and deplete CD4 T cells, yet not cause AIDS (Silvestri et al., 2003). The most 
common route of HIV-1 transmission follows exposure to infectious virus in the semen or mucosal 
surfaces. The inoculum includes a large number of different quasi species, however, due to the 
epithelial barrier in mucosal surfaces, it has been estimated that approximately 76% of infections 
arise from a single “founder” virus (Keele et al., 2008a), predominantly in a cell-associated manner 
(Kolodkin-Gal et al., 2013). Less frequent routes include vertical transmission (pregnancy, breast 
milk) and via injection drug use.  
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1.1.2 Structural biology and replication cycle of HIV-1  
HIV-1 belongs to the lentivirus genus, a subfamily of the Retroviriade family known as retroviruses. 
The RNA genome contains nine open reading frames of which three encode for the three 
polyproteins Gag, Pol and Env (Figure 1.1). These are major functional components that will make 
up the mature virion (Frankel and Young, 1998) (Figure 1.2). Proteolysis of these polyproteins 
gives rise to four Gag proteins; matrix (MA), capsid (CA), nucleocapsid (NC) and p6, and two Env 
proteins gp120 (SU) and gp41 (TM), all of which form the virion and outer envelope of HIV-1 
(Frankel and Young, 1998). The three Pol proteins: protease (PR), reverse transcriptase (RT) and 
integrase (IN), are three enzymes essential for viral replication and are also found within the 
particle together with three accessory proteins (Vif, Vpr and Nef), but not Tat, Rev (gene regulatory 
proteins) or Vpu (which facilitates virion assembly). 
 
 
Figure 1.1 HIV-1 genome structure.  
HIV-1 contains nine open reading frames (Gag, Env, Pol, Tat, Rev, Vpu, Vif, Vpr and Nef). These give rise to 
3 polyproteins of which Gag gives rise to structural proteins; Pol gives rise to enzymes involved in HIV-1 
replication; and Env gives rise to coating proteins. Adapted from (Lengauer and Sing, 2006). 
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Figure 1.2 HIV-1 virion structure.  
Adapted from (Robinson, 2002).  
 
The life cycle of HIV-1 begins when either a cell-free or cell-associated virion binds to the cell-
surface molecule CD4 via its envelope protein gp120 (Figure 1.3). This induces a conformational 
change to its structure, which in turn exposes binding sites to either the chemokine receptor type 5 
(CCR5) or chemokine receptor type 4 (CXCR4) (Eckert and Kim, 2001). The binding of either 
receptor determines the cell tropism of a particular viral isolate to be designated either R5 or X4 
tropic. R5 viruses are prevalent during the early stages of HIV-1 infection and are responsible for 
person-to-person transmissions whilst X4 viruses emerge more during late stages of infection and 
this is often associated with a sharp decline in CD4 T-cell counts and onset of AIDS (Gorry and 
Ancuta, 2011). The binding of gp120 to either CCR5 or CXCR4 results in further conformational 
changes that expose the subunit gp41, leading to a stable structure that allows fusion of HIV-1 with 
host cell membranes. This delivers the viral core into the cytoplasm where the genomic RNA is 
uncoated and converted into double stranded DNA (dsDNA) by the reverse transcriptase enzyme. 
The newly synthesized viral dsDNA is then translocated across the nuclear pore as part of the pre-
integration complex (Whittaker et al., 2000).  
 
In the nucleus, the enzyme integrase catalyzes the integration of viral DNA into the host 
chromosomal DNA. The target site of integration is not a random event, but preferentially occurs in 
active genes to promote viral replication (Schroder et al., 2002; Maldarelli et al., 2014; Wagner et 
al., 2014). This key event in the life cycle of HIV-1 facilitates the establishment of a viral reservoir, 
which ultimately prevents clearance of the virus (Chun et al., 1997b; Siliciano et al., 2003). 
Expression of viral transcripts from the integrated viral genome occur via the promoter located in 
the 5’ long terminal repeat (LTR) and is greatly enhanced by the regulatory protein Tat. The viral 
transcripts are then transported to the cytoplasm where the majority are translated and assembled, 
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a process regulated by the Rev protein (Pollard and Malim, 1998). The envelope proteins are not 
included in the assembly but are instead transported to the cell surface for incorporation into the 
outer membrane of the viral particle. As the viral particle buds and is released from the cell surface, 
it takes a fragment of the cell membrane with the envelope proteins (Morita and Sundquist, 2004), 
and undergoes a morphological change known as maturation (Frankel and Young, 1998). 
 
Figure 1.3 HIV-1 replication cycle.  
Adapted from (Barre-Sinoussi et al., 2013). 
 
1.1.3 Natural history of HIV-1 infection 
Following transmission, target cells of HIV-1 include CD4 T cells, macrophages and dendritic cells 
(DCs), all of which express the cell surface receptor CD4 and either of the co-receptors CCR5 or 
CXCR4 on their cell surfaces (Bleul et al., 1997; Douek et al., 2002; Verani et al., 2005; Piguet and 
Steinman, 2007). However, HIV-1 preferentially infects activated CD4 T cells and upon successful 
infection, the virus rapidly replicates and infects other mucosal CD4 T cells in the vicinity and virus-
infected cells travel to the draining lymph nodes, particularly gut-associated lymphoid tissue 
(GALT), where the presence of high numbers of activated CD4+CCR5+ memory T cells serve as 
sources for viral amplification and dissemination throughout the body (Douek et al., 2002; 
Brenchley et al., 2004). This sequence of events marks the onset of the acute phase of infection 
and is characterised by high levels of viraemia and depletion of memory CD4 T cells (McMichael et 
al., 2010).  
 
The viral reservoir is established early on, preferentially in activated memory CD4 T cells becoming 
infected as they are returning to a resting state. This leads to a stably integrated viral genome in a 
long-lived cell capable of sustaining continuous viral replication even amidst effective ART (Finzi et 
al., 1997; Siliciano et al., 2003). Macrophages and DCs may also serve as reservoirs, although the 
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extent to which they contribute to persistence is under current investigation (Keele et al., 2008b; Le 
Douce et al., 2010). The loss of CD4 T cells is characteristic throughout natural HIV-1 infection but 
is particularly devastating very early on after infection in mucosal tissues as shown by studies on 
the SIV model (Veazey et al., 1998; Mattapallil et al., 2005). Specifically, during the initial acute 
phase of infection 60-80% of memory CD4 T cells in the GALT may succumb to apoptosis either 
as a consequence of viral-induced cytophatic events or by CD8-mediated killing (Mattapallil et al., 
2005). This leads to breakdown of the mucosal barrier and increased permeability of the gut as a 
consequence of enterocyte apoptosis (the predominant cells in the small intestinal mucosa). 
Increased gut permeability allows translocation of microbial products such as lipopolysaccharides 
(LPS) into the systemic circulation, causing systemic immune activation (Brenchley et al., 2006).  
 
The induction and expansion of HIV-1-specific CD8 T-cell responses soon emerges and results in 
a sharp decline in the plasma HIV-1 RNA load and partial restoration of the CD4 T-cell counts 
(Borrow et al., 1994) (Figure 1.4). Levels of plasma HIV-1 RNA eventually fall to a relatively stable 
level termed “set point”, which varies between individuals and may have a prognostic value for 
rates of disease progression (Lavreys et al., 2006). The drop in plasma HIV-1 RNA levels to a viral 
set point marks the end of the acute phase and the onset of the chronic, often asymptomatic phase 
of infection. This lasts for an average of 10 years and is characterized by sustained immune 
activation, slowly declining CD4 T-cell counts and constant viral challenge (Pantaleo and Fauci, 
1996). High levels of activation on both CD4 and CD8 T cells are particularly characteristic of this 
stage and often a more accurate predictor of disease progression compared to plasma HIV-1 RNA 
levels alone (Giorgi et al., 1999; Hazenberg et al., 2003). Ultimately, the strong selection pressure 
of HIV-1-specific CD8 T cells coupled with rapid turnover (109 copies/day) (Ho et al., 1995; 
Perelson et al., 1996) and the high mutation rate of HIV-1, leads to outgrowth of viral variants 
containing escape mutations (Borrow et al., 1997). This results in immune escape from HIV-1-
specific CD8 T cells followed by progressive CD4 T-cell decline.  
 
A drop of CD4 T-cell count to below 200 cells/µl blood coincides with the breakdown of the immune 
system that results in the emergence of opportunistic infections in the advanced phase of infection, 
ultimately leading to the onset of AIDS (Pantaleo and Fauci, 1996). The most common AIDS-
associated infections include fungal infections (Candidiasis and Pneumocystis pneumonia), 
bacterial infections (Mycobacterium avium complex; MAC) and viral infections (Cytomegalovirus; 
CMV, and Kaposi’s sarcoma-associated herpesvirus; KSHV) (Lewin-Smith et al., 1998; Mesri et 
al., 2010).  
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Figure 1.4 The disease phases of HIV-1 
The relationship between plasma HIV-1 RNA load (red line), CD4 T-cell count (blue line) and CD8 T-cell 
count (green line) during the different stages of HIV-1 infection. Adapted from (Goulder and Watkins, 2004).  
 
1.1.4 Interaction between HIV-1 and the host immune response 
Cytokine responses 
The innate immune system has evolved to non-specifically recognise a wide variety of different 
antigen structures (including proteins, lipid structures or carbohydrates) through receptors called 
pattern-recognition receptors (PRRs) expressed on DCs and macrophages (Kumar et al., 2009). 
Studies have found that single stranded RNA viruses such as HIV-1 mainly trigger Toll-like 
receptor (TLR) 7 and TLR8, a subset of PRRs that recognise viral RNA (Lund et al., 2004; 
Gringhuis et al., 2010). Other TLRs such as TLR2, TLR4 and TLR9 may however also be involved 
(Martinelli et al., 2007; Thibault et al., 2009).  
 
Engagement of different TLR receptors by viral antigen activates various signalling pathways, 
resulting in the induction of distinct inflammatory cues aimed at blocking viral growth and recruiting 
other immune cells to the site (Stacey et al., 2009). Specifically, release of several cytokines in 
what may be referred to as a “cytokine storm” includes high levels of Type 1 Interferons (IFNs), IL-
15 and CXC-chemokine ligand 10 (CXCL10; also known as IP-10), which are transiently 
upregulated early on in HIV-1 infection. This is followed by release of IL-18, tumour necrosis factor 
α (TNF-α), IFN-γ and IL-22; some of which are involved in shutting down viral replication in infected 
cells while also promoting the activation of the immune response (Heil et al., 2004; Beignon et al., 
2005; Stacey et al., 2009; McMichael et al., 2010). The pro-inflammatory response storm induces a 
delayed increase in immunoregulatory cytokines such as IL-10, which function to limit inflammatory 
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responses (Stacey et al., 2009). The cytokine cascade observed during acute HIV-1 infection is 
more pronounced compared to those observed following hepatitis B and C infections, suggesting 
that the magnitude of this cascade may contribute to HIV-1 immunopathology during early infection 
(Stacey et al., 2009).  
 
Dendritic cells 
DCs are one of the major producers of the intense cytokine response observed in acute HIV-1 
infection. Often called sentinel cells, they are abundant in peripheral tissues and are crucial for 
initiating the adaptive immune response (Guermonprez et al., 2002). DCs are one of the first cell 
populations that encounter HIV-1 due to their localization in mucosal epithelia and in the T-cell 
areas of the lymphoid organs (Manches et al., 2014). As specialised antigen presenting cells 
(APCs), DCs capture antigen through their receptors (such as TLRs and DC-SIGN), process and 
present these on their cell surface for recognition by the T-cell receptors of CD4 and CD8 T cells 
(Guermonprez et al., 2002). During this process, DCs also provide the necessary co-stimulatory 
activation signals (cell-based and soluble factors) that instruct virus-specific T cells to proliferate, 
differentiate and acquire multiple antiviral and immunostimulatory effector functions. DCs 
themselves require activation signals (including exposure to certain inflammatory cytokines and 
engagement of co-stimulatory receptors; CD40) in order to undergo full maturation and upregulate 
different co-stimulatory molecules (CD80/CD86) that are needed to activate T cells.  
 
The response to HIV-1-engagement by its receptors depends on the type of receptor that is 
engaged, the DC subtype, its state of maturation and its interaction with other cells (Miller and 
Bhardwaj, 2013). Thus DCs, through their important modulation of adaptive responses, may drive 
aberrant T-cell responses during HIV-1 infection. For example, encounter with HIV-1 through TLR9 
but not TLR7, was shown to induce production of persistent levels of the pro-inflammatory cytokine 
IFN-α in plasmacytoid DCs (pDCs) (Martinelli et al., 2007), which may drive persistent immune 
activation (Benlahrech and Patterson, 2011; O'Brien et al., 2011). In addition, TLR9-mediated 
responses result in only a partial maturation of pDCs, restricting their ability to efficiently activate T 
cells and leading to low proliferative CD4 and CD8 T-cell responses when compared with other 
stimuli (O'Brien et al., 2011).  
 
Circulating levels of DCs decline during HIV-1 infection (Donaghy et al., 2001; Pacanowski et al., 
2001), probably as an indirect consequence of pro-inflammatory responses and mobilization into 
lymphoid tissues (Manches et al., 2014). Although HIV-1 infection of DCs is rare, they do express 
high levels of CCR5, CXCR4 and low levels of CD4 and may therefore function as cellular 
reservoirs for HIV-1 (Wu and KewalRamani, 2006). In addition, because of their early encounter 
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with HIV-1 it is thought that direct uptake of virions by DCs may promote HIV-1 dissemination by 
enhancing virion transfer to uninfected CD4 T cells (Piguet and Steinman, 2007).  
 
Natural killer cells 
Natural killer (NK) cells are large granular effector lymphocytes of the innate immune system, 
capable of directly destroying virus-infected cells or releasing cytokines to further modulate 
adaptive immune responses (Cooper et al., 2009). A key feature of NK cells is their “detection 
system” which involves a variety of inhibitory and activating cell surface receptors that are able to 
sense changes in their natural ligands. Many of these receptors are paired and consist of both 
activating and negative counterparts and the dynamic equilibrium of how these are engaged 
dictates whether or not NK cells are activated to kill target cells (Vivier et al., 2004). Among the 
inhibitory receptors are a highly polymorphic group called killer-cell immunoglobulin-like receptors 
(KIRs). These bind several major histocompatibility complex (MHC) class I molecules, a type of 
glycoproteins that are expressed on the cell surface of almost all nucleated cells and are involved 
in antigen-recognition by T cells (described below).  
 
NK cells survey the body for MHC class I expression with the purpose to detect downmodulation of 
this molecule (Parham, 2005), a mechanism used by several viruses including HIV-1 to evade 
recognition from cytotoxic CD8 T cells. As a cell is surveyed, failure to engage the inhibitory KIRs 
with an MHC molecule results in killing of the infected cell. If MHC molecules are present then the 
engagement provides a signal to the NK cell and suppresses its function. A number of studies 
have highlighted the impact that the interactions between KIRs and MHC molecules may have on 
HIV-1 disease progression (Carrington and Alter, 2012). Expression of KIR3DS1 and KIR3DL1 has 
been associated with delayed disease progression (Martin et al., 2002; Qi et al., 2006; Martin et al., 
2007). There is also evidence that NK cells exert pressure on HIV-1 as escape mutations to 
KIR2DL2+ NK cells have been observed in HIV-1 infection (Alter et al., 2011). Although NK cells 
lack any somatic diversification mechanisms like T and B cells, recent reports from both mouse 
models and human studies suggest that some NK populations develop and retain specific memory 
to a variety of viral antigens such as HIV-1, Influenza (Flu) A, vesicular stomatitis virus (VSV), and 
Cytomegalovirus (CMV) (Paust et al., 2010; Beziat et al., 2013). 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION 
28 
Humoral responses 
Approximately 13 weeks after HIV-1 transmission, high titres of antibodies that neutralise 
autologous virus can be detected, although virus variants that are resistant to neutralisation soon 
emerge (Wei et al., 2003). Broadly neutralizing antibodies (BNAbs), the gold standard for most 
successful vaccines, are rare in HIV-1-infected individuals and may only arise after several years 
of infection when the viral reservoir is already established (Wu et al., 2010; Zhou et al., 2010; 
Walker et al., 2011). Studies looking at how BNAbs develop will be important in guiding future 
development of antibody-based HIV-1 vaccines (Liao et al., 2013).  
 
The results of the HIV-1 vaccine phase III trial, RV144, involving more than 16,000 participants 
from Thailand, demonstrated that a prime-boost regimen of two genetically engineered vaccine 
candidates decreased the rate of HIV-1 infection by almost 31% but waned over time (Rerks-
Ngarm et al., 2009; Rerks-Ngarm et al., 2013). The transient protection was attributed to induction 
of weakly neutralizing antibodies to the V1/V2 region of the HIV-1 envelope (Env) protein involved 
in attachment and cell entry (Haynes et al., 2012; Zolla-Pazner et al., 2013). A recent study has 
also reported an exciting new approach; building an artificial protein called eCD4-Ig, which binds to 
two conserved sites of Env on the surface of HIV-1 and neutralizes it (Gardner et al., 2015). Four 
rhesus macaques inoculated with an adeno-associated virus (AAV) vector expressing eCD4-Ig 
were protected from infectious challenge. These results represent an important step towards 
developing a prophylactic vaccine with high efficacy. However, as HIV-1-specific CD8 T cells have 
been shown to be important for control of HIV-1 replication, development of a vaccine that induces 
efficient T-cell responses is also the focus of current research (McMichael and Koff, 2014). 
1.1.5 T-cell responses 
T cells are important mediators of the adaptive immune response. After a stringent process of 
selection in the thymus they emerge as mature T cells able to migrate through secondary lymphoid 
tissues and recognise foreign antigen whilst being tolerogenic towards self-peptides (Starr et al., 
2003; Fink, 2013). Each T-cell has one specificity and recognition of an antigen is mediated via 
their T-cell receptor (TCR), a cell surface heterodimer consisting of either disulphide-linked α- and 
β- or γ- and δ-chains (Rudolph et al., 2006). The majority of circulating T cells consist of αβ T cells 
and consequently more is known about these, however the understanding of γδ T cells in immune 
responses is increasing (Chien et al., 2014). TCRs with αβ chains recognise processed antigen 
(called peptides) that is presented in complex with MHC class I and class II molecules. A diverse 
repertoire of TCRs is generated during development in the thymus by random V(D)J recombination 
of non-contiguous gene segments, addition of non-germ line nucleotides by DNA-repair machinery 
and by pairing of different TCR-α and β chains (Nikolich-Zugich et al., 2004). On the other hand, 
MHC class I and II molecules are able to present a wide range of peptides because of the highly 
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polymorphic nature of the genes that encode them; the human leukocyte antigen (HLA) genes 
(Dean et al., 2002). MHC molecules are heterodimers consisting of a β-sheet straddled by two α-
helices (which make up the peptide-binding domain), and two Ig-like domains (Rudolph et al., 
2006). Polymorphisms are concentrated within regions of the peptide-binding site and this provides 
the variation in shape and chemical properties between different MHC class I molecules, resulting 
in different peptide-binding motifs (Falk et al., 1991).  
 
Two different pathways are involved in processing antigen into small peptides long enough to bind 
the two major classes of MHC molecules (York and Rock, 1996; Rudolph et al., 2006). In the 
endogenous pathway, peptides 8-10 amino acids (aa) in length, derived from intracellular 
degradation of proteins in the cytosol, are loaded onto MHC class I molecules to form tertiary 
structure complexes. These are displayed on the cell surface of all nucleated cells for recognition 
by the TCR of CD8 T cells but also NK cells. Infection by intracellular pathogens results in the 
display of foreign peptides on the cell surface, which are recognised by CD8 T cells primed to kill 
the infected cell. Class II MHCs present longer peptide fragments (>11 amino acids) that originate 
from proteolysis of extracellular antigens in endosomal-type compartments, and these are 
recognised by the TCR of CD4 T cells (Sebzda et al., 1999; Rudolph et al., 2006).  
 
In contrast to the constitutive expression of MHC class I molecules, MHC class II is upregulated 
mainly on professional APCs (macrophages, B lymphocytes and DCs) following activation of these 
cells. Engagement of the TCR by the peptide-MHC complex triggers the formation of the 
immunological synapse, a tightly regulated contact site between the T-cell and APC, formed by 
polarization of the actin skeleton, the microtubule network and intracellular vesicle traffic (Bromley 
et al., 2001). This facilitates the clustering of TCRs and several TCR-associated molecules 
including co-receptors (CD3 and CD4 or CD8) and co-stimulatory/adhesion molecules (including 
CD28, LFA-1 and CD2). Formation of the immunological synapse following antigen presentation by 
the APC to the T-cell is thought to be important for receptor signal transduction and full T-cell 
activation (Sprent and Surh, 2002).  
 
T cells that have not encountered antigen are defined as being naïve and these are metabolically 
quiescent, long-lived cells that re-circulate continuously at a low precursor rate between the blood 
and lymphoid tissues via the expression of adhesion molecules such as CD62L (L-selectin) and 
the lymph node homing receptor CCR7 (Sprent and Surh, 2002). In the presence of an invading 
pathogen, priming by mature APCs provides the secondary signals (CD80/CD86 engagement to 
CD28) that are needed for efficient activation. APCs also release different patterns of cytokines 
including IFN-γ and IL-4, which instructs different developmental pathways of T cells. Priming 
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initiates the downstream signalling events that cause T cells to proliferate and synthesize 
cytokines, including IL-2 which helps drive proliferation (Kaech et al., 2002; Williams and Bevan, 
2007; Harty and Badovinac, 2008). An expansion phase follows where the naïve T-cell 
differentiates into clonally expanded antigen-specific effector cells; CD8 cytotoxic T cells and CD4 
T-helper cells. Effector cells have diminished capacity to recirculate between the blood and 
peripheral lymph nodes as a result of downregulation of CD62L and CCR7, however they are 
capable of migrating to non-lymphoid tissues and sites of inflammation where they destroy infected 
cells (Lefrancois, 2006; Mueller et al., 2013).  
 
Following clearance of infection, the majority of antigen-specific effector T cells undergo a 
contraction and die from apoptosis leaving behind a small heterogeneous pool of memory T cells 
capable of rapidly responding to future infections with the same pathogen (Tanchot et al., 1997; 
Williams and Bevan, 2007; Cui and Kaech, 2010). Upon re-encountering antigen, antigen-specific 
memory T cells are able to more efficiently respond by replicating and differentiating into 
secondary effector cells without the need for co-stimulatory signals (Croft et al., 1994).  
 
In a seminal study, Sallusto and colleagues first described the presence of two distinct memory T 
cells that make up the circulating memory T-cell pool and could be classified based on CCR7 
expression (Sallusto et al., 1999). Effector function, proliferative capacity and migration potential 
differentiate the two T-cell populations (Sallusto et al., 1999; Jameson and Masopust, 2009). 
Central memory T cells (TCM) are defined by re-expression of CD62L and CCR7, which enables 
them to home to T-cell areas of secondary lymphoid organs where they predominantly reside 
(Lefrancois, 2006). TCM produce IL-2 but have little effector function, and readily proliferate and 
differentiate to effector and memory cells in response to antigenic stimulation (Sallusto et al., 1999; 
Sallusto et al., 2004).  
 
Effector memory T cells (TEM) have lost CCR7 expression, have low proliferative ability (Sallusto et 
al., 2004), but are able to migrate to inflamed peripheral tissues and display immediate effector 
function by producing IFN-γ and in the case of CD8 T cells; cytotoxic activity (Sallusto et al., 1999; 
Mueller et al., 2013). In recent years, studies have described populations of memory T cells that 
can permanently reside in peripheral tissues (including gut, skin and brain tissue) after an infection 
is cleared (Farber et al., 2014). These have been designated tissue-resident memory T cells (TRM) 
and may play an important role in controlling infection in mucosal tissues due to their high effector 
function (Mueller et al., 2013; Farber et al., 2014). CD62L+ T memory stem cells (TSCM) have also 
been described with a less differentiated phenotype compared to TCM (Gattinoni et al., 2011; Lugli 
et al., 2013) and their role as viral reservoirs in HIV-1 infection is the focus of current studies 
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(Buzon et al., 2014a). Once formed, T-cell memory is sustained via homeostatic signals including 
the cytokines IL-7 and IL-15 (Surh and Sprent, 2008).  
 
The process by which memory T cells are generated has been the focus of many studies due to its 
importance in guiding future immunotherapeutic and vaccination developments. Several different 
models of memory T-cell generation have been proposed (Moulton et al., 2006), however, a widely 
accepted view is that T-cell development follows a sequential differentiation towards a more 
differentiated phenotype of naïve to effector to memory T cells (Opferman et al., 1999). For 
example, stimulated naïve T cells can give rise to both TCM and TEM cells and TCM cells can give 
rise to TEM cells but not vice versa (Sallusto et al., 1999). There is however also evidence of 
asymmetric lineage differentiation. Two studies by Chang and colleagues have shown that 
asymmetric partitioning of the transcription factor T-box expressed in T cells (T-bet) between the 
daughter cells makes it possible for a single naïve T-cell to give rise to both effector and memory T 
cells in a mouse model (Chang et al., 2007; Chang et al., 2011) (Figure 1.5 A). T-bet together with 
another transcription factor called Eomesodermin (Eomes) have an essential role in regulating 
effector and memory T-cell differentiation (Intlekofer et al., 2005; Kaech and Cui, 2012).  
 
Although T-bet was first described as a regulator of CD4 lineage commitment (Szabo et al., 2000; 
Szabo et al., 2002), more is known about its function in CD8 T cells. In activated naïve CD8 T cells 
high levels of T-bet promotes differentiation toward effector and effector memory fates and induces 
upregulation of perforin and granzyme B in antigen-specific cells (Intlekofer et al., 2007; 
Hersperger et al., 2011; McLane et al., 2013). In contrast, Eomes expression increases as cells 
become more memory-like and is linked to long-lived TCM subset generation (Banerjee et al., 
2010). Moreover, knockout of the Eomes gene results in deficient generation of long-term memory 
T cells and homeostatic renewal (Banerjee et al., 2010). Inflammatory signals that are present 
during CD8 T-cell priming induce a gradient of T-bet expression (Joshi et al., 2007). This supports 
the concept that incoming signals from the environment imprint T cells with a transcriptional 
programme and the strength of these signals directs different developmental fates (Chang et al., 
2011; Opata and Stephens, 2013). This is relevant in the context of different persistent infections 
such as HIV-1, where increased inflammatory responses may polarize T-cell differentiation. For 
example, T cells primed under inflammatory conditions exhibit low proliferative potential and fail to 
differentiate into a memory phenotype, resulting in sustained effector cell numbers (Pham et al., 
2009). Based on these and other studies, it is becoming clear that although memory T-cell 
generation follows a linear pathway overall (Figure 1.5 B), naïve T cells can directly give rise to all 
subsets in the pathway. This will be determined by both internal and external cues including 
strength and duration of the antigenic stimulation and co-stimulatory signals received during 
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priming (Hamilton and Jameson, 2012). Specifically, differences in T-cell affinity (King et al., 2012), 
cytokine secretion (Joshi et al., 2007) and the history of previous antigen encounters may all 
contribute (Masopust et al., 2006).  
 
Two recent studies using different cell fate mapping techniques showed that one naïve T-cell 
bearing identical T-cell receptors could give rise to a phenotypically and functionally 
heterogeneous population of effector and memory T cells (Buchholz et al., 2013; Gerlach et al., 
2013), supporting the concept that each naïve T-cell, regardless of specificity, is influenced by 
variations in the microenvironment (Opata and Stephens, 2013). In addition, they showed that the 
secondary response could be predicted based on the outcome of the primary response profile. Low 
expansion coupled with differentiation into central memory T-cell phenotype resulted in a more 
robust secondary response (Buchholz et al., 2013; Gerlach et al., 2013). The presence of several 
different memory T-cell populations has led to the question of whether some populations are better 
than others for protective immunity against a given pathogen (Hamilton and Jameson, 2012). The 
long-lived TCM subset, due to its proliferative capacity, has been associated with control of various 
infectious diseases including HIV-1 (Wherry et al., 2003; Potter et al., 2007; Ndhlovu et al., 2012). 
However, cells with a TEM phenotype have also been implicated in control of certain systemic 
infections (Huster et al., 2006). The presence of TRM cells with effector functions similar to TEM cells 
in tissues, may play an important role in providing site-specific protection against invading 
pathogens including HIV-1 and is an area under current investigation (Gebhardt and Mackay, 
2012; Hamilton and Jameson, 2012).  
 
The markers used to identify T-cell differentiation subsets vary between studies. CCR7 together 
with the tyrosine phosphatase protein CD45 (isoform RA: CD45RA) identifies four different T-cell 
populations (Sallusto et al., 1999). This includes the previously mentioned naïve 
(CD45RA+CCR7+), TCM (CD45RA
-CCR7+) and TEM (CD45RA
-
CCR7
-
) subsets but also identifies 
cells with a terminally differentiated phenotype (TEMRA; CD45RA+CCR7
-). TEMRA cells exhibit high 
cytotoxic activity (including release of perforin) and low proliferative capacity (Sallusto et al., 1999). 
The co-stimulatory receptors CD28 and CD27 have also been associated with different stages of 
T-cell differentiation including early (CD28+CD27+), intermediate (CD28-CD27+) and late (CD28-
CD27-) phenotypes (Appay et al., 2002). Recently, Lee and colleagues incorporated all four 
differentiation markers to identify five different populations: naïve (CD28+CD27+CCR7+CD45RA+) 
and TCM (CD28
+CD27+CCR7+CD45RA-), both of which express CD28, and three populations that 
are CD28-: transitional (TTR) (CD28
-CD27+CCR7-CD45RA-), TEM (CD28
-CD27-CCR7-CD45RA-), 
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and TEMRA (CD28
-CD27-CCR7-CD45RA+) (Lee et al., 2014) (Figure 1.5 B). Other models include 
the use of CD45RO (expressed by memory T cells) and CD27 (Riou et al., 2012). Although 
considerable overlap occurs, other receptors and functions may differ between the subsets 
including migration patterns and different localisation sites (Thome et al., 2014), which need to be 
taken into consideration when comparing between studies. 
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Figure 1.5 Model of T-cell memory generation.  
Following an encounter with antigen, naïve T cells may give rise to both effector and memory T cells (A). On 
the whole however, differentiation follows a linear developmental pathway where less differentiated cells give 
rise to more differentiated effector and memory cells and the ability to secrete IFN-γ, TNF-α, IL-2 and perforin 
changes with increased differentiation (B). The cell surface markers commonly used to identify the different 
T-cell memory populations are listed, where (+) stands for expression and (-) denotes that expression is low 
or absent. TSCM – stem cell memory, TCM – central memory, TTM – transitional memory, TEM – effector 
memory, TEMRA – terminally differentiated effector memory. Adapted from (Gray, 2002; Mahnke et al., 2013; 
Opata and Stephens, 2013; Restifo, 2014). 
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CD4 T cells 
The role of the microenvironment is particularly important for instructing CD4 T-cell differentiation 
into distinct functional T helper (Th) subsets, all of which are defined by different functionalities, 
which enables them to provide help to diverse immune cell populations (Zhu and Paul, 2008; 
Swain et al., 2012). The most abundant of all CD4 T-cell subsets in the blood are Th1 cells and to 
a lesser extent Th2 cells. These two lineages promote different immune response pathways 
depending on the nature of the infection and the induction of one pathway antagonizes the other. 
Intracellular pathogens encountered by DCs will induce IL-12 production, which drives 
differentiation into CD4 Th1 cells and high levels of IFN-γ production. This promotes a cell-
mediated immune response, which involves increased phagocytosis by macrophages as well as 
NK and CD8 T cell-mediated cytotoxicity to destroy infected cells. Expression of the transcription 
factor T-bet appears to play an important role in promoting the Th1 cell fate while repressing the 
development of the Th2 and Th17 lineages in CD4 T cells (Hwang et al., 2005; Lazarevic et al., 
2011). DCs that encounter parasites and extracellular pathogens will instead produce IL-4, which 
promotes Th2 differentiation whilst suppressing Th1 and Th17 cells. Immune responses that are 
Th2-mediated stimulate a humoral response by promoting antibody class switching in B cells to 
IgE, which is important for antiparasitic responses (Zhu and Paul, 2008). However, another CD4 T-
cell subset called T follicular helper cell (TFH) is the predominant helper cell for B cells via 
production of IL-21 (King et al., 2008). 
 
Th1 cells are particularly important for the development of long-lived memory CD8 T cells 
(Shedlock and Shen, 2003; Williams and Bevan, 2007). CD8 T cells activated under inflammatory 
conditions without the help from CD4 T cells differentiate into memory CD8 T cells with poor 
secondary responses (Janssen et al., 2003; Williams and Bevan, 2007). In the context of HIV-1 
infection, maintenance of a balanced Th1 response has been reported to be beneficial and the 
depletion of CD4 T cells is often associated with CD8 T-cell dysfunction (Imami et al., 2002; 
Vingert et al., 2012). 
 
Th17 cells represent another type of CD4 T cells, and are important for maintenance of the 
mucosal barrier by controlling microbial infections at mucosal sites. Upon activation they release 
pro-inflammatory cytokines such as IL-17 and IL-22, which stimulates production of anti-microbial 
proteins on epithelial cells (Bettelli et al., 2007; Weaver et al., 2007). They are one of the first 
targets of HIV-1 due to their localization in mucosal tissues and levels of this subset are lost early 
in HIV-1 and SIV infection, thereby contributing to the de-stabilization of the mucosal barrier and 
systemic immune activation (Brenchley et al., 2008; Favre et al., 2009). The inflammatory 
response ensued by Th17 cells stimulates the expansion of another CD4 T-cell subset; regulatory 
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T cells (Treg). Tregs regulate immune responses by suppressing activation and proliferation of 
effector T cells in a cell-to-cell contact manner, via modulation of APC function or via the 
production of immunosuppressive cytokines such as IL-10 and transforming growth factor β (TGF-
β) (Vignali et al., 2008). Their immunosuppressive function acts as a counterbalance to Th17 pro-
inflammatory function. In HIV-1 infection, loss of Th17 cells has been associated with increased 
levels of Tregs and the resulting imbalance of Th17/Treg ratio has been linked to disease progression 
(Favre et al., 2010; Li et al., 2011a). The role that Tregs play in HIV-1 immunopathogenesis is 
somewhat controversial because Tregs are required to limit excessive immune activation but may 
also be detrimental by suppressing HIV-1-specific responses (Kinter et al., 2007; Chevalier and 
Weiss, 2013). A recent study reported that CD25+ Tregs indirectly inhibit HIV-1-specific CD4 T-cell 
responses by upregulating IL-10 production from monocytes (Kwon et al., 2012), suggesting that 
high levels are unfavorable. Low levels of Tregs have also been linked to control of HIV-1 infection 
(Hunt et al., 2011a), although the balance between Th17 and Tregs may be more relevant to 
assess, particularly for the resulting T-cell functionality (Favre et al., 2010; Brandt et al., 2011).  
 
The changes in CD4 T-cell subset dynamics during HIV-1 infection contribute to the overall 
depletion of CD4 T cells, which is particularly noticeable during acute infection. Loss of memory 
CD4 T cells during acute HIV-1 infection has been attributed to both direct infection (Cheynier et 
al., 1994), as well as killing by HIV-1-specific CD8 T cells and NK cells (Cheynier et al., 1994; 
Vieillard et al., 2005). However, it is not likely that these contribute to the progressive loss during 
chronic infection as relatively few CD4 T cells are actually infected in vivo (Chun et al., 1997a). 
Instead, bystander activation of uninfected CD4 T cells, as a consequence of persistent immune 
activation, is thought to play a major role (Sodora and Silvestri, 2008). This is supported by studies 
on SIV-infected sooty mangabeys, which exhibit low levels of immune activation despite having 
high levels of virus and experiencing CD4 T-cell depletion in the GALT (Silvestri et al., 2003). A 
recent study proposed that induction of the pyroptotic form of cell death in non-productively 
infected CD4 T cells might be fuelling HIV-1-associated inflammation and CD4 T-cell death (Doitsh 
et al., 2014).  
 
Regeneration and homeostatic proliferation is initially able to compensate for the depletion in CD4 
T cells, however progressive HIV-1 infection soon leads to defects in naïve CD4 T-cell generation 
as a consequence of diminished thymic function (Haynes et al., 2000; Douek et al., 2001). 
Homeostatic and antigen-specific proliferation of memory CD4 T cells becomes severely impaired 
during HIV-1 infection as a consequence of continuous viral replication, chronic immune activation 
and an imbalance of regulatory mechanisms (Okoye and Picker, 2013). In particular, continuous 
re-generation of the shorter-lived TEM compartment from CD4 TCM precursors is progressively 
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dysregulated in extra-lymphoid effector sites of SIV-infected rhesus macaques and ultimately 
results in a contracted TCM pool (Okoye et al., 2007; Okoye and Picker, 2013). Overall this severely 
impacts on CD4 T-cell function. Chronic antigen exposure has been shown to directly impair virus-
specific CD4 T-cell proliferation, co-stimulatory molecule expression and IL-2 production (McNeil et 
al., 2001; Iyasere et al., 2003; Harari et al., 2004). This may be rescued in vitro by exogenous IL-2 
(Iyasere et al., 2003; Younes et al., 2003), leading to several clinical studies investigating the 
administration of recombinant IL-2 (rIL-2) as a therapeutic agent in HIV-1 infection. However, 
although induction of IL-2-induced anti-HIV-1 responses have been reported (Sullivan et al., 2003), 
as well as significantly higher CD4 T-cell counts in the rIL-2 arms (Abrams et al., 2009) no overall 
clinical benefit was observed (Abrams et al., 2009). 
 
CD8 T cells 
Virus-specific CD8 T cells utilize multiple mechanisms to lyse virally infected cells both directly 
through cell-to-cell killing and indirectly through the secretion of cytokines, including IFN-γ and 
TNF-α (Williams and Bevan, 2007). Direct contact-dependent killing of infected cells proceeds 
through two pathways; the first involves lytic proteins that are released into the immunological 
synapse between the effector T-cell and its target (Cullen and Martin, 2008). Exocytosis of perforin 
facilitates the entry of serine proteases called granzymes, of which granzyme B is one of the most 
abundant (Cullen and Martin, 2008). These enter the target cell and induce apoptosis by cleaving 
and activating caspases (Chowdhury and Lieberman, 2008). The second pathway encompasses 
crosslinking of “death receptors” such as Fas on the target cell, which induce signalling pathways 
that lead to apoptosis (Ashkenazi and Salvesen, 2014).  
 
CD8 T cells play a pivotal role in controlling HIV-1. In the early stages of HIV-1 infection, the rapid 
expansion of CD8 T cells coincides with declining plasma HIV-1 RNA load (Borrow et al., 1994; 
Koup et al., 1994; Streeck et al., 2009). Moreover, an early study demonstrated that the 
experimental depletion of CD8 T cells in the rhesus macaque SIV model resulted in a rapid 
increase in plasma viraemia and a more rapid disease progression (Jin et al., 1999). CD8 T cells 
that emerge early on will target distinct parts (known as epitopes) of HIV-1 depending on the HLA-
specificity that they are restricted for. This results in an immunodominance hierarchy where certain 
HIV-1 epitopes are targeted more frequently. However, strong CD8 T-cell pressure coupled with 
the high mutation rate of HIV-1 leads to frequent selection of viral variants bearing escape 
mutations, resulting in a shift in the immunodominant pattern (Price et al., 1997). In this context, 
viral escape provides continuous stimulation that eventually leads to the expansion of HIV-1-
specific CD8 T cells and an inversion of the normal ratio between CD4 and CD8 T cells, which in 
HIV-1-uninfected people is generally over 1. The expanded CD8 T cells are persistently activated 
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(defined by CD38 and HLA-DR expression) and exhibit compromised functional responses. In 
particular, HIV-1-specific release of IFN-γ is often observed (Betts et al., 2001), whilst loss of IL-2, 
perforin and granzyme B production is coupled with diminished proliferative ability and cytotoxic 
activity in these cells (Imami et al., 2002; Migueles et al., 2002; Migueles et al., 2009). These are 
all characteristic of an exhaustive phenotype which accumulates in chronic progressors as 
discussed below. Chronic HIV-1 infection has also been associated with a skewed CD8 T-cell 
differentiation profile often described as an abnormal maturation block from TEM to TEMRA (Sallusto 
et al., 1999; Champagne et al., 2001). The block is in contrast to the terminally differentiated 
phenotype of CD8 T cells specific for the herpesvirus Cytomegalovirus (CMV) which induces 
protective immune responses (Appay et al., 2002; Lee et al., 2014). Inability to mature into fully 
differentiated effector cells could result in dysfunctional effector functions and affect the capacity of 
HIV-1-specific CD8 T cells to control viraemia (Champagne et al., 2001). However, studies also 
describe an accumulation of terminally differentiated HIV-1-specific T cells with reduced 
polyfunctionality (Riou et al., 2012), indicating that further understanding of the T-cell differentiation 
subsets and their phenotype is needed. 
1.1.6 Immune exhaustion 
T cells with an exhaustive phenotype are often described as being in a state of functional 
unresponsiveness, replicative senescence and increased sensitivity to apoptosis (Kuchroo et al., 
2014). The development of this phenotype coincides with the upregulation of inhibitory receptors 
such as programmed death-1 (PD-1) (Day et al., 2006). PD-1 belongs to the same family as the 
CD28 co-stimulatory receptor, however it has a co-inhibitory rather than co-stimulatory effect on 
activated T cells. Acting close to the TCR signalling complex, binding of PD-1 to either of its two 
ligands PD-L1 or PD-L2 results in suppression of proliferation and release of IFN-γ, TNF-α and IL-2 
(Keir et al., 2008). The level of inhibition depends on the strength of the TCR signal and the level of 
PD-1 expression. A recent study using an in vitro model reported that the recruitment of PD-1 to 
the immunological synapse greatly reduces T-cell antigen sensitivity by increasing the number of 
peptide/MHC/TCR interactions required for efficient Ca2+ fluxing (Wei et al., 2013). Low levels of 
PD-1 expression were enough to inhibit proliferative responses whereas higher levels were needed 
to suppress cytotoxicity activity (Wei et al., 2013).  
 
PD-1 inhibition may be overrun by a strong co-stimulatory signal from the APC in the form of CD28 
ligation. Thus, CD28 and PD-1 have opposite functions to ensure that activation of T cells occurs in 
the context of antigen presentation whilst limiting immune-mediated tissue damage during 
autoimmune responses (Keir et al., 2008). However, in the presence of persistent antigen, 
upregulation of PD-1 on exhausted T cells results in reduced T-cell antigen sensitivity and a 
progressive loss of effector functions, which attenuates host immune responses (Barber et al., 
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2006). In vitro blockade of the PD-1/PD-L1 pathway improves HIV-1-specifc CD8 T-cell 
proliferation and cytokine production (Day et al., 2006; Petrovas et al., 2006; Trautmann et al., 
2006), and has also been shown to be beneficial in other persistent infections such as hepatitis C 
virus (HCV) (Urbani et al., 2006), hepatitis B virus (HBV) (Boni et al., 2007) and lymphocytic 
choriomeningitis virus (LCMV) (Barber et al., 2006). Other inhibitory markers include, CTLA-4 
(predominantly found on CD4 T cells), T-cell immunoglobulin and mucin 3 (TIM-3) and CD160, all 
of which may on their own or together contribute to T-cell exhaustion in different conditions 
(Kaufmann et al., 2007; Sakhdari et al., 2012; Vigano et al., 2014).  
1.1.7 Chronic immune activation 
Persistent immune activation is a striking feature of HIV-1 infection and observed across several 
facets of the immune system as reviewed in (Appay and Sauce, 2008; Deeks, 2011; Douek, 2013; 
Rajasuriar et al., 2013). Multiple related events probably contribute to the increase, including 
translocation of pro-inflammatory microbial products across the epithelial lining of the 
gastrointestinal tract (Brenchley et al., 2006), ongoing HIV-1 replication (Ostrowski et al., 2008; 
Mavigner et al., 2009) and co-infections with other persistent viruses such as CMV (Hunt et al., 
2011b) and Hepatitis C (Kovacs et al., 2008). Collectively these result in increased inflammation as 
defined by elevated levels of pro-inflammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α), proteins 
involved in the coagulation cascade (D-dimers) and acute phase protein markers (serum amyloid 
A, C-reactive protein) (Appay and Sauce, 2008; Douek, 2013).  
 
Persistent activation of innate cells including monocytes, macrophages and DCs are important 
sources of pro-inflammatory cytokines, which drive both direct, and indirect activation of other 
immune cells (Anzinger et al., 2014). In particular this drives a polyclonal activation and 
proliferation of CD4 and CD8 T cells, and markers of T cell activation (CD38, and HLA-DR 
expression) correlate better with disease progression than viraemia (Giorgi et al., 1999; Hazenberg 
et al., 2003; Deeks et al., 2004). Naturally SIV-infected sooty mangabeys, which rarely exhibit 
AIDS-defining symptoms, have low activation levels. This is despite high levels of virus replication 
and acute CD4 T-cell depletion in the GALT, segmenting a role for immune activation in AIDS 
development (Silvestri et al., 2003).  
 
1.1.8 Treatment of HIV-1 
The introduction of effective ART in 1996 dramatically changed the morbidity and mortality of HIV-
1-infected individuals. In both high- and low-income countries, the life expectancy of patients living 
with HIV-1 and who have access to ART is approaching that of uninfected populations (Deeks et 
al., 2013; Johnson et al., 2013; Nakagawa et al., 2013). Effective ART generally consists of three 
different drugs aimed at blocking the different stages of the HIV-1 life cycle (Volberding and Deeks, 
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2010). These include nucleoside/nucleotide and non-nucleoside reverse transcriptase inhibitors, 
protease inhibitors, integrase inhibitors as well as fusion and entry inhibitors (Figure 1.6).  
 
Figure 1.6 Antiretroviral therapies target different stages of the HIV-1 life cycle. 
Adapted from Volberding and Deeks 2010 and Barre-Sinoussi et al., 2013. 
 
Comparative clinical studies have led to established first-line and second-line regimens that are 
considered the best combinations of currently available drugs to increase tolerability and avoid 
drug resistance. Initiation of ART results, in most cases, in a potent arrest of viral replication to 
below the limit of detection in standard assays (Perelson et al., 1997). This occurs within the first 
couple of weeks and is followed by a partial reduction in inflammatory markers and activation 
levels on various cell types including T cells (Hunt et al., 2003b; Kuller et al., 2008). A slow and 
biphasic increase of CD4 T-cell count ensues, with a rapid increase during the first months, 
followed by a more gradual rise over several years (Autran et al., 1997; Hunt et al., 2003a). The 
increase replenishes the CD4 T-cell pool and restores antigen-specific responses to opportunistic 
infections such as CMV and MAC, resulting in a better clinical outcome and reduced AIDS-related 
deaths (Li et al., 1998; Burton et al., 2006).  
 
Although ART improves immunity to opportunistic infections, one of the key challenges of ART is 
the inadequate improvement of the patient’s immune responses to HIV-1, as shown by the rapid 
increase in viraemia during treatment interruption (Burton et al., 2005; El-Sadr et al., 2006). This is 
due to the early establishment of a viral reservoir in memory CD4 T cells including TCM, transitional 
memory (TTM) and TSCM (Chun et al., 1997a; Finzi et al., 1997; Chomont et al., 2009; Buzon et al., 
2014a). Thus, although ART prevents de novo infection of target cells, integrated virus persists in a 
small fraction (approximately 1 in a million) of latently infected CD4 T cells that have a very long 
half-life (Finzi et al., 1999; Jaafoura et al., 2014). Upon reactivation these cells are capable of 
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seeding replication-competent virus (Siliciano et al., 2003). ART has little effect in reducing the size 
of this reservoir, thereby preventing clearance of HIV-1 and necessitating life-long ART (Siliciano et 
al., 2003; Jaafoura et al., 2014). Studies have investigated the effect of adding an entry or 
integrase inhibitor to the standard regimens (described as treatment intensification) but these have 
yielded variable results (Buzon et al., 2010; Hatano et al., 2011; Schulze zur Wiesch and van 
Lunzen, 2011).  
 
Targeting the pathways that maintain HIV-1 latency is an intense area of research and current 
strategies have employed various pharmacological compounds such as histone deacetylase 
(HDAC) inhibitors to induce expression of integrated provirus and reactivate latently infected 
memory CD4 T cells so that these cells may be eliminated by HIV-1-specific CD8 T cells (Margolis, 
2011; Archin and Margolis, 2014). However, despite the success in inducing expression of HIV-1 in 
vitro (Archin et al., 2012), clinical studies have not been able to translate this into a consistent 
decrease in the latent reservoir (Siliciano et al., 2007; Sagot-Lerolle et al., 2008). A recent study by 
Shan and colleagues reported that stimulation of CD8 T cells with HIV-1 peptide pools and IL-2 
prior to treatment with the HDAC inhibitor SAHA, increased the clearance of latently infected 
autologous CD4 T cells (Shan et al., 2012). Boosting the appropriate HIV-1-specific CD8 T-cell 
responses in patients on long-term ART might therefore be important for clearance of the latent 
reservoir (Shan et al., 2012). The need to do this reflects the inability of ART to improve certain 
aspects of HIV-1-specific responses. Treated patients continue to have reduced levels of naïve 
CD4 and CD8 T cells (Emu et al., 2014) and CD8 T cells have low proliferate capacity and 
diminished release of IL-2 and granzymes in response to HIV-1 antigen pools (Migueles et al., 
2009). Even after years of ART, patients may continue to exhibit low CD4/CD8 ratios (Emu et al., 
2014; Serrano-Villar et al., 2014), limited increases in naïve CD8 T-cell numbers and a continued 
shift in the differentiation status of CD8 T cells (Emu et al., 2014). 
 
The incomplete improvement of HIV-1-specific immune responses during effective ART may be 
explained by several factors, including ongoing low-level viral replication in tissues (Zhang et al., 
1999) and irreversible tissue dysfunction in the thymus, lymphoid organs and mucosal surfaces 
(Douek et al., 2001; Brenchley et al., 2006). These may contribute to the ongoing immune 
activation and inflammation observed in patients despite ART (Hunt et al., 2003b). Treated patients 
continue to have elevated levels of inflammatory markers including IL-6 and D-dimer (Kuller et al., 
2008; Funderburg et al., 2013), which have been linked to both AIDS and non-AIDS-associated 
morbidities (Kuller et al., 2008; Deeks, 2011). Furthermore, activation levels on CD4 and CD8 T 
cells remain elevated and may predict the level of immune reconstitution (Hunt et al., 2003b; 
Funderburg et al., 2013). Immune activation has emerged as a major challenge of the modern 
CHAPTER 1 
INTRODUCTION 
42 
antiretroviral era and is often described as an underlying contributor to HIV-1 immunopathogenesis 
both in untreated and treated individuals.  
 
The persistent immune dysfunction in treated patients has focused the attention on investigating 
when the right timing is to initiate ART. In the absence of AIDS-defining symptoms, the level of 
CD4 T-cell count is the primary factor used in deciding this, and several key studies have shown 
that initiating ART when CD4 T-cell counts are >350 cells/µl blood leads to better clinical outcomes 
with reduced incidence of AIDS and serious non-AIDS conditions (Emery et al., 2008; Kitahata et 
al., 2009; Sterne et al., 2009). These studies have led to recent changes in the guidelines of ART 
initiation and in the UK, treatment is currently advocated when CD4 T-cell counts are <350 cells/µl 
blood or sooner at patients request (Williams et al., 2014). The WHO has gone further, 
recommending treatment to patients with CD4 T-cell counts <500 cells/µl blood (WHO, 2013; 
Anglemyer et al., 2014). The benefits of starting ART even earlier (>500 cells/µl blood) have not 
been fully evaluated but current trials are underway (Babiker et al., 2013).  
 
The clinical benefits of early initiation of ART are likely due to a prevention of the irreversible 
damage that occurs during untreated HIV-1 infection. This is particularly demonstrated by studies 
on acute infection. Individuals treated within the first 4 to 6 months of infection exhibit higher 
restoration of CD4 T-cell counts (Le et al., 2013), lower levels of CD4 and CD8 T-cell activation 
and a significantly reduced HIV-1 reservoir, compared to subjects who delay ART (Pires et al., 
2004; Ananworanich et al., 2012; Jain et al., 2013). An early study also reported preserved Gag-
specific proliferative responses to HIV-1 (Rosenberg et al., 2000). Early initiation may even lead to 
durable control of viral replication as reported for 14 patients (termed post-treatment controllers) 
who initiated ART within ten weeks of infection and subsequently controlled viraemia for a median 
of 7.5 years after discontinuation (Saez-Cirion et al., 2013). Recently, a case study emerged about 
an HIV-1+ infant (referred to as the Mississippi baby) who was put on treatment within 30 hours of 
being born for approximately 18 months before ART was discontinued. Despite extensive testing 
researchers were unable to find traces of HIV-1 for up to two years, however detectable virus has 
now been reported and the child is back on treatment (Persaud et al., 2013; Ananworanich and 
Robb, 2014). Although HIV-1 control was only transient in this baby, it nonetheless provides a 
proof of principle that a functional cure may be achieved.  
 
Studies are also exploring the use of ART as prevention following a large international cohort study 
in serodiscordant couples, which reported that early initiation of ART in the infected partner 
reduced transmission to the uninfected partner by 96% (Cohen et al., 2011). The large reduction in 
transmission rates is probably due to reduced shedding of HIV-1 in genital secretions (Vernazza et 
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al., 2000; Graham et al., 2007). Furthermore, taking ART as pre-exposure prophylaxis (PreP) 
results in nearly 44% reduction in HIV-1 risk compared to placebo among men who have sex with 
men (MSM) (Grant et al., 2010).  
 
1.1.9 Spontaneous control of HIV-1 
As the HIV-1 epidemic was unfolding, reports emerged early on describing individuals who did not 
experience any decline in their CD4 T-cell counts and remained asymptomatic for several years 
without the need for treatment. Termed long-term non-progressors (LTNP), this rare group of 
individuals constitute approximately 5% of all chronically HIV-1-infected individuals and are 
typically defined as maintaining stable CD4 T-cell counts >450 cells/µl blood for a longer period of 
time (>7 years) (Grabar et al., 2009; Westrop et al., 2009; Mandalia et al., 2012). There are some 
reports describing LTNP with over 25 years of HIV-1 infection although it is becoming clear that 
some patients do eventually progress (Rodes et al., 2004; Westrop et al., 2009). An even smaller 
subset of individuals can be identified based on the level of HIV-1 RNA load in their plasma (Deeks 
and Walker, 2007). These patients are often defined as HIV controllers (HIC) or elite controllers 
(EC) depending on whether partial or total control of HIV-1 viraemia is observed (Migueles and 
Connors, 2010; Okulicz and Lambotte, 2011). The prevalence of these individuals in the HIV-1-
infected population varies between studies but is typically below 1% for EC (Okulicz and Lambotte, 
2011), and slightly higher for LTNP and HIV controllers (Grabar et al., 2009; Okulicz et al., 2009). 
 
There is a large variability in the definitions and criteria used to identify LTNP, HIC and EC, 
primarily because they appear to be a very heterogeneous group (Grabar et al., 2009; Theze et al., 
2011), with different factors probably accounting for spontaneous control in each individual. 
Indeed, studies have shown that certain characteristics are different between LTNP, HIC, and EC 
(Gaardbo et al., 2013). Nevertheless, considerable research has been focused on deriving the 
correlates of HIV-1 control from these individuals to guide future vaccine and immunotherapeutic 
developments (Cao et al., 1995; Pantaleo et al., 1995; Deeks and Walker, 2007; Walker and Yu, 
2013).  
 
There is evidence to suggest that the innate system plays an important role in the control of HIV-1 
infection. Macrophages from elite controllers have reduced susceptibility to HIV-1 infection (Saez-
Cirion et al., 2011) and pDCs exhibit improved function compared to chronic progressors (Barblu et 
al., 2012). Myeloid DCs isolated from elite controllers have increased antigen-presenting properties 
and diminished ability to secrete pro-inflammatory cytokines following TLR engagement, compared 
to both progressors and uninfected individuals (Huang et al., 2010). These studies demonstrate 
that the role of the innate immune system, although less significant compared to the adaptive 
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immune response, may contribute to the early events of HIV-1 control. One of the strongest factors 
associated with immune control has been derived from genome wide association studies (GWAS) 
on large cohorts of LTNP and EC. These have consistently demonstrated that single-nucleotide 
polymorphisms (SNPs) on the HLA genes encoding for MHC class I molecules (which govern 
antigen-specificity), have a strong influence on both viral control and delayed disease progression 
of HIV-1 (Fellay et al., 2007; McMichael and Jones, 2010; Pereyra et al., 2010). Allelic variations of 
HLA-B in particular, are over-represented in controllers (Pereyra et al., 2008; Goulder and Walker, 
2012). The best described protective alleles are B*57:01 and B*27:05 (Kaslow et al., 1996; 
Migueles et al., 2000; Salgado et al., 2011), but studies also suggest a beneficial impact of other 
alleles including B*14/Cw*08:02, B*52 and A*25 (Pereyra et al., 2010), and for African ethnicities 
B*57:03, B*58:01 and B*81:01 (Kiepiela et al., 2004; McLaren et al., 2012).  
 
The predominance of HLA-B alleles in controllers is not fully understood but does underscore the 
important role that cytotoxic CD8 T cells have in the spontaneous control of HIV-1 infection as 
discussed below. HLA-B alleles may be more resistant to HIV-1 Nef-mediated downmodulation 
compared to HLA-A alleles (Rajapaksa et al., 2012). Differences in folding patterns of HLA-B-
restricted MHC molecules might also play a role (Rizvi et al., 2014). GWAS have also linked 
genetic variants of HLA-C to control of plasma HIV-1 RNA load and disease progression, primarily 
thought to be mediated via modulation of CD8 T-cell and NK responses (Fellay et al., 2007; 
Thomas et al., 2009; Kulkarni et al., 2013). However, the majority of HIV-1-infected individuals 
expressing protective alleles will develop progressive disease and HIV-1 immune control is 
possible in the absence of protective alleles, indicating that these are neither necessary nor 
sufficient to control HIV-1 infection (Kiepiela et al., 2007; Pereyra et al., 2008). 
 
CD8 T cells and HIV-1 control 
Multiple studies have shown that HIV-1-specific CD8 T cells from controllers are qualitatively 
superior compared to those observed in chronic progressors. In particular, they retain several 
functions that are typically lost in chronically infected individuals such as proliferative capacity and 
cytotoxic activity (Migueles and Connors, 2002; Betts et al., Saez-Cirion et al., 2007; Imami et al., 
2013). This maintenance of high functionality is referred to as maintaining a polyfunctional 
response and is characterised by efficient process of de-granulation and release of perforin and 
granzyme B as well as release of cytokines IFN-γ, TNF-α, IL-2, and MIP-1β (Imami et al., 2002; 
Migueles et al., 2002; Betts et al., 2006; Migueles et al., 2008). Furthermore, the ability to respond 
to minimal amounts of antigen (referred to as high avidity) has been associated with efficient CD8 
T-cell responses (Almeida et al., 2007; Almeida et al., 2009). Several of these functions are 
associated with the protective alleles B*57:01 and B*27:05, and frequently target conserved 
CHAPTER 1 
INTRODUCTION 
45 
regions of the p24 capsid protein of HIV-1 Gag (Migueles et al., 2000; Borghans et al., 2007; 
Berger et al., 2011). Responses to Gag appear to be particularly important and are strongly 
associated with control of HIV-1 viraemia and a delayed disease progression (Kiepiela et al., 2007; 
Saez-Cirion et al., 2009), probably because escape mutations in Gag often result in reduced viral 
replication fitness (Goulder and Watkins 2004).  
 
A distinguishing feature of HIV-1-specific CD8 T cells from some but not all EC, is their ability to kill 
autologous CD4 T cells and this is primarily mediated via B*57-restricted responses to Gag (Saez-
Cirion et al., 2007; Saez-Cirion et al., 2009; Buckheit et al., 2013; Buzon et al., 2014b). HLA-B*57- 
and B*27-restricted CD8 T cells are also able to suppress replication of viruses harbouring escape 
mutations in Gag epitopes either via de novo CD8 T-cell responses (O’Connell et al., 2011a; 
Pohlmeyer et al., 2013), or by increased cross-reactivity of clonotypes (Chen et al., 2012). Cross-
reactive Gag-specific CD8 T cells have also been detected in HLA-B*27+ LTNP and were shown to 
persist for years compared to CD8 T cells restricted for HLA-A*02:01 (van Bockel et al., 2011). 
Increased survival was also demonstrated in another study where HIV-1-specific CD8 T cells 
restricted by HLA-B*57 and HLA-B*27 successfully evaded suppression by Tregs whereas, within 
the same individual, T cells restricted by other alleles did not  (Elahi et al., 2011). These cells were 
shown to directly kill Tregs in a granzyme B-dependent manner (Elahi et al., 2011). Studies such as 
these demonstrate the role of protective alleles in modulating HIV-1-specific CD8 T cells to HIV-1 
Gag by enhanced cross-rectivity and survival.  
 
Despite the strong role of protective alleles, not all controllers express protective alleles and some 
studies indicate that high functionality may be a general feature of HIV-1-specific CD8 T cells from 
controllers regardless of HLA-restriction (Betts et al., 2006). The ability to rapidly expand following 
HIV-1-specific stimulation and increased survival has been detected in CD8 T cells from EC even 
in the absence of protective HLA alleles (Lopez et al., 2011; Ndhlovu et al., 2012; Yan et al., 2013). 
Comparative studies where HLA-specificity is controlled for may yield important insights into why 
chronic progressors with protective alleles fail to control HIV-1. For example, poor HIV-1 control in 
HLA-B*57+/B*27+ chronic progressors has been associated with diminished proliferative potential 
compared to B*57+ LTNP (Migueles et al., 2002), and the absence of polyfunctional cytokine 
responses compared to B*27+ and B*57+ HIC (Techakriengkrai et al., 2013). Chronic progressors 
also exhibit reduced ability to suppress viral variants compared to EC harbouring the same 
protective alleles (Chen et al., 2012). Thus although protective alleles are important modulators of 
HIV-1-specific CD8 T-cell responses, the complex interplay between virus and CD8 T-cell 
specificity may results in different outcomes of disease progression. 
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A recent study reported that mutations in epitopes that are important for protein stability were 
linked to HIV-1 control and that this was not necessarily associated with protective HLA alleles 
(Pereyra et al., 2014). Moreover, a broader HIV-1-specific CD8 T-cell response during primary 
infection may contribure to slower disease progression rather than the presence of protective HLA 
alleles per se (Streeck et al., 2014). Eliciting broad CD8 T-cell responses is a central goal for both 
prophylactic and therapeutic T-cell based vaccines. However, a major barrier for therapeutic 
vaccine efficacy and HIV-1 cure is the predominance of latent virus in resting CD4 T cells that carry 
escape mutation and are therefore resistant to CD8 T-cell-specific killing. Recently, it was 
demonstrated that chronically infected patients do retain broad HIV-1-specific CD8 T-cell 
responses to integrated latent virus, however these require therapeutic boosting for efficient 
cytotoxic activity (Deng et al., 2015). The abilty of controllers to maintain broad CD8 T-cell 
responses in the absence of circulating HIV-1 antigen may therefore substantially contribute to 
HIV-1 immune control.  
 
Hihgly functional CD8 T cells in controllers likely reflects the low immune activation often observed 
in controllers, irrespective of HLA genotype. Without an inflammatory environment, HIV-1-specific 
CD8 T cells do not experience polyclonal activation and an exhausted programme that is ususally 
observed during untreated chronic infection. Negative regulators such as PD-1 are lower in LTNP 
(Zhang et al., 2007), resulting in higher levels of CD8 T cells with proliferative and cytolitic activity. 
Thus, understanding the phenotype will give important clues to the differences in functional 
responses and studies and studies aiming to delineate the characteristics of CD8 T cells will 
provide insight into the underlying mechanisms behind their dysfunction, which in the future may 
lead to identifying the correlates of protection such as those found in controllers.  
 
CD4 T cells and HIV-1 control 
Similar to CD8 T cells, the ability to retain polyfunctional responses is also imperative for CD4 T 
cells and HIV-1 immune control appears to depend on a robust Th1 response that is able to 
provide efficient help to CD8 T cells by expressing multiple cytokines including IFN-γ and IL-2 
(Potter et al., 2007). This is often associated with a central memory phenotype, high proliferative 
capacity (Potter et al., 2007) and Gag-specific responses (Ranasinghe et al., 2012). Higher 
functionality may be due to lower levels of inhibitory markers (CTLA-4) (Kaufmann et al., 2007) and 
an ability to respond to minimal amounts of HIV-1 antigen (Vingert et al., 2010). In contrast to CD8 
T cells, HIV-1-specific CD4 T cells are direct targets of HIV-1 (Douek et al., 2002) and therefore 
maintenance of stable CD4 T-cell count plays an important role in the control of HIV-1 (Okulicz et 
al., 2009).  
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Preservation of thymic function (defined by elevated levels of TCR excision circles; TRECs) has 
been linked to conserved CD4 T-cell counts in EC and LTNP (Westrop et al., 2009; Yang et al., 
2012). CD4 T cells in these patients may also be less susceptible to HIV-1 infection (Chen et al., 
2011; Saez-Cirion et al., 2011), although some studies have found that they are equally or more 
susceptible (Julg et al., 2010; O'Connell et al., 2011b) but that once infected produce fewer virions 
(O'Connell et al., 2011b). This is indicative of an enhanced ability to restrict HIV-1 replication. 
Indeed, enhanced gene expression of the restriction factor schlafen 11, an inhibitor of HIV-1 
protein synthesis, has been detected in EC (Abdel-Mohsen et al., 2013). There is also evidence 
that the gene expression profiles of CD4 T cells from a subset of ECs may resemble those of 
uninfected individuals (Vigneault et al., 2011). CD4 T cells are important regulators of the adaptive 
immune system and it might be that their early expansion provides the necessary help to other 
compartments and a better outcome overall. The presence of HIV-1-specific CD4 T cells with 
cytolytic activity may also be important. Longitudinal analysis of CD4 and CD8 T-cell responses in 
subjects with acute HIV-1 infection has shown that early expansion of CD4 but not CD8 T cells 
correlated better with HIV-1 control (Soghoian et al., 2012). The expanded cells exhibited 
enhanced cytolytic activity (perforin and granzymes).  
 
Viral factors and favourable disease outcome 
It is clear that the adaptive immune system plays an important role in spontaneous HIV-1 control, 
however the presence of HIV-1-specific CD8 T cells alone does not always explain this rare status. 
Multiple factors both from the host and the virus may instead contribute to the favourable outcome 
of these rare individuals (Gaardbo et al., 2012). The contribution of replicative fitness to HIV-1 
control is somewhat controversial. Early studies on LTNP identified a group of individuals that had 
been infected via blood transfusions from a single donor, who was an LTNP himself (Deacon et al., 
1995). Sequencing of the transmitted viral strain revealed a common deletion in the HIV-1 Nef 
protein and the U3 LTR that was present in all individuals (Deacon et al., 1995). The role of Nef 
has since been studied extensively as a cause of reduced viral fitness in delayed disease 
progression, because of its suppressive function and importance in enhancing virion infectivity 
(Landi et al., 2011). Nef stimulates viral replication and mediates downregulation of the MHC class 
I and II molecules as well as the CD4 co-receptor (Stumptner-Cuvelette et al., 2001; Landi et al., 
2011; Wang, 2013). Several more studies identified LTNP subjects that harboured HIV-1 strains 
with Nef-related sequence variations (Kirchhoff et al., 1995; Blaak et al., 1998; Kirchhoff et al., 
1999), however strains with large deletions of Nef appear to be rare in other cohorts (Miura et al., 
2008; Pushker et al., 2010).  
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One of the disadvantages of sequencing strategies as a method for examining reduced viral fitness 
is the inability to distinguish between replication-competent and defective forms of the viral 
genome, making it difficult to exclude integrated proviruses that are defective. Another strategy is 
to use viral outgrowth assays to induce HIV-1 replication from the plasma or viral reservoir (Chun 
et al., 1997a; Finzi et al., 1997). Different variations of this assay have facilitated the isolation of 
replication-competent virus from different cohorts of controllers with varying efficacy. Recently, this 
was carried out on five out of eleven HLA-B*57+ EC (Salgado et al., 2014) and replication-
competent virus had previously been detected in four out of ten EC by the same group (Blankson 
et al., 2007). It was not clear why it was not possible to isolate replication-competent virus in the 
other 12 individuals, warranting further studies. Individual protein function has also been 
investigated using chimeric viruses, revealing a lower replication capacity in the acute/early stages 
of HIV-1 infection of individuals who later went on to become HIV controllers (Miura et al., 2010).  
 
Subtle decreases in protein function may also contribute to HIV-1 immune control in some 
individuals. A recent study found that Nef clones from HLA-B*57+ EC exhibited poorer 
downregulation of MHC class I and II as well as CD4 compared to clones from B*57- EC 
(Mwimanzi et al., 2013). Env genes from EC subjects also appear to be subtly different to chronic 
progressors by encoding Env proteins that exhibit decreased entry efficiency (Lassen et al., 2009). 
Taken together, these data suggest that reduced replicative capacity and/or HIV-1 protein function 
may contribute to viral suppression in a fraction of HIV controllers and understanding this 
contribution to the controller profile will reduce heterogeneity and better define host- and viral 
specific responses that can be targeted. However the role of the host immune response will be 
equally important. Of the six LTNP originally identified by Deacon and colleagues, three individuals 
exhibited low (<2500 copies/ml) plasma HIV-1 RNA load and stable CD4 T-cell counts for over 10 
years (defined as slow progressors), after which two died and one eventually progressed 
(Zaunders et al., 2011). The other three had undetectable plasma viraemia (which would define 
them as EC) for over 26 years without signs of progression. Potent proliferative responses to HIV-1 
Gag p24 distinguished EC from the slow progressors. These studies indicate that both viral and 
host factors play a role in the outcome of disease progression (Zaunders et al., 2011), and 
therefore both need to be examined for a better understanding of a non-progressing status in 
controllers. 
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1.2 Human Cytomegalovirus (CMV) 
The progressive weakening of the immune system during untreated HIV-1 infection increases the 
risk of opportunistic infections, which although not normally pathogenic, nonetheless become 
detrimental to an immunocompromised host. Approximately 90-95% of HIV-1-infected individuals 
are co-infected with CMV, a β-herpes virus also known as human herpesvirus 5 (HHV5) (Kim et al., 
2006). Prior to the widespread use of effective antiretroviral combinations, CMV was one of the 
most common opportunistic infections in HIV-1-infected individuals, with up to 40% of individuals 
with advanced HIV-1 disease developing CMV-associated symptoms, resulting in significant 
morbidity and mortality (Palella et al., 1998; Steininger et al., 2006). In particular, HIV-1-infected 
patients with very low CD4 T-cell count (typically below 50 cells/µl blood) were at very high risk of 
developing CMV-associated end-organ disease (EOD) which includes retinitis, colitis and 
pneumonitis (Drew, 1992). With the introduction of suppressive ART, the incidence of CMV EOD 
has decreased markedly (Palella et al., 1998; Wohl et al., 2009), yet still occurs in a proportion of 
cases where drug resistance, adherence problems and patients presenting late with low CD4 T-cell 
counts are the most common cases (Steininger et al., 2006). In addition, cases may occur even in 
patients who respond to ART (French et al., 2000) and there is increasing evidence that CMV 
contributes to non-AIDS associated morbidity and mortality in ART-treated patients (Lichtner et al., 
2015), illustrating the important role of CMV as a co-pathogen in HIV-1 infection.  
 
1.2.1 Epidemiology of CMV  
Cytomegaloviruses have been identified in a wide range of animals including mice and rhesus 
macaques (Reddehase et al., 2002; Powers and Fruh, 2008). They are believed to have co-
evolved with their hosts and are thus well adapted to host immune responses making them highly 
species-specific. Human CMV is widely distributed in the world with a majority (50-90%) of the 
world’s population infected by early adulthood (Staras et al., 2006; Cannon et al., 2010). 
Transmission modes are similar to HIV-1, via mother-to-child, blood transfusions or sexually (Ho, 
2008). Following primary infection, the host is unable to clear CMV, but viral replication is usually 
suppressed by immune surveillance mediated by both the humoral and cellular immune systems 
(Hanley and Bollard, 2014). This allows the establishment of a predominantly symptomless, latent 
and life-long infection with rare episodes of clinical reactivation. However, in individuals with 
immature, compromised or suppressed immune function such as organ transplant, HIV-1-infected 
patients and neonates, the balance between viral maintenance and immune control is disturbed, 
leading to reactivation of virus and a wide spectrum of disease symptoms (Ho, 2008). It mainly 
manifests as CMV retinitis (an intraocular infection presenting with granular-appearing white dots in 
the eye), however up to 15% of presented cases are gastrointestinal related (Steininger et al., 
2006).  
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1.2.2 CMV structure and life cycle 
CMV belongs to the Herpesviridae family and its genome is one of the largest and most complex of 
the known herpesviruses (Ho, 2008). Virions consist of a 235kb long dsDNA core in an icosahedral 
nucleocapsid, which in turn is protected by a lipid bilayer envelope that contains a number of viral 
glycoproteins (Crough and Khanna, 2009). Found between the capsid and envelope is a 
proteinaceous layer, known as the tegument, which is a defining structural feature of herpesviruses 
and contains the majority of virion proteins including the lower matrix phosphoprotein 65 (pp65). 
Virions gain entry into a cell via binding of glycoproteins gB and gH to cellular receptors, which 
activate cellular transcription factors such as NF-κB and Sp1 (Figure 1.7).  
 
Upon entry, the viral capsid is transported to the nucleus, where the viral DNA is released and 
transcribed by the host cell machinery. Gene expression follows a regulated cascade, which 
initially involves the immediate-early (IE) genes (Tomtishen, 2012). These encode proteins that 
stimulate the expression of early and late genes that are required for DNA replication and viral 
packaging of the structural components that make up the virion during lytic infection. Expression of 
the late genes initiates capsid assembly in the nucleus whereby the dsDNA is encapsulated and 
the structure is transported to the cytoplasm where a second envelopment occurs (Johnson and 
Baines, 2011). This involves interaction with the viral assembly complex where the capsid acquires 
a tegument layer and viral envelope (Alwine, 2012). Enveloped virions are thereafter secreted to 
the cell surface in cytoplasmic vesicles where fusion with the plasma membrane leads to release of 
the virions (Johnson and Baines, 2011).  
 
Failure to express IE genes results in silencing of the lytic transcriptional programme and 
establishment of latent infection. This results in a lack of production of infectious virions and viral 
gene expression is restricted to a substantially reduced number of latency-associated transcripts 
(Goodrum et al., 2007; Poole et al., 2014). CMV infects a high variety of cell types including 
endothelial cells, epithelial cells, fibroblasts and smooth muscle cells and may disseminate into 
multiple organs (Bissinger et al., 2002; Goodrum et al., 2002). However, cells of the myeloid 
lineage, including CD34+ haematopoietic progenitor cells, are the primary targets in which CMV 
establishes latent infection (Mendelson et al., 1996; Goodrum et al., 2002). These precursor cells 
can then differentiate into a number of immune cell types including, monocytes, macrophages and 
DCs. The differentiation process and other environmental cues, results in periodic reactivation to a 
lytic infection leading to the production and spread of infectious virions (Soderberg-Naucler et al., 
1997). During chronic infection, low-level virus shedding occurs over extended periods of time and 
often in the absence of symptoms (McSharry et al., 2012). 
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Figure 1.7 CMV structure and life cycle.  
Adapted from (Huang and Johnson, 2000; Crough and Khanna, 2009). 
 
1.2.3 CMV evasion strategies, host responses and immunopathogenesis 
Human CMV is well adapted to its host as shown by the numerous immunomodulatory genes, 
which encode proteins that interfere with multiple innate and adaptive immune responses, allowing 
immune evasion and life long persistence (Noriega et al., 2012). Paradoxically, it is also among the 
most immunogenic of known viruses, eliciting high frequencies of CMV-specific T cells in healthy 
CMV-infected adults that continue to inflate throughout life. It has been estimated that on average 
10% of both the CD4 and CD8 memory T-cell compartments in blood are specific to CMV 
(Sylwester et al., 2005). Furthermore, high frequencies may be observed ex vivo against single 
epitopes, contributing to a substantial fraction of memory T cells in healthy seropositive individuals 
(Wills et al., 1996; Northfield et al., 2005). Periodic reactivation of latent virus may drive the 
expansion of CMV-specific T cells, which primarily target pp65 and the IE1 protein (Wills et al., 
1996), although responses to multiple other CMV antigens exist (Elkington et al., 2003; Li et al., 
2014).  
 
CD8 T cells take a central, although not exclusive, role in limiting CMV infection and reducing the 
burden of the latent genome (Hanley and Bollard, 2014). Early studies showed that adoptive 
transfer of CMV-specific CD8 T cells restored CMV-specific immunity and protected against clinical 
disease (Riddell et al., 1992; Walter et al., 1995). CMV-specific CD4 T cells (both as helper and 
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cytotoxic cells) and NK cells also play an important role in contributing to control of CMV 
(Sylwester et al., 2005; Wu et al., 2013). Recent studies have shown that the long-term protective 
role of CD8 T cells is dependent on the presence of CD4 T cells (Gabanti et al., 2014; Terrazzini 
and Kern, 2014).  
 
CMV has been implicated in inflammatory and age-related diseases including certain 
cardiovascular diseases (Eryol et al., 2005; Streblow et al., 2008; van de Berg et al., 2008; 
Simanek et al., 2011; Lichtner et al., 2015). An early study by Wikby and colleagues linked CMV 
seropositivity with an “immune risk profile” (IRP) that predicted increased mortality risks in the 
elderly (Wikby et al., 2002). This has also been described in later reports (Wang et al., 2010; 
Savva et al., 2013), although others have failed to find an association (Adler et al., 2011). The 
mechanisms behind the apparent contribution to increased mortality are not clear, although CMV 
could be accelerating an immunosenescent phenotype that is frequently observed in elderly. 
Healthy CMV-infected individuals have lower CD4/CD8 ratios, lower naïve T-cell numbers and 
some studies have described a smaller T-cell repertoire, compared to uninfected subjects (Hadrup 
et al., 2006; Chidrawar et al., 2009). The immunogenic nature of CMV is associated with an 
oligoclonal expansion of memory CD8+CD28- T cells (described as a late or terminally 
differentiated phenotype) during latency (Appay et al., 2002; Lee et al., 2014), which eventually 
may contribute substantially to the T-cell pool. These cells have low proliferative potential but retain 
their cytotoxic functions (perforin, granzyme A) (Appay et al., 2002). Recently it was reported that 
terminally differentiated CMV-specific CD8 T cells with low avidity accumulated with increasing 
age, suggesting that these cells may be less responsive in the elderly (Griffiths et al., 2013).  
 
CMV infection has also been associated with increased immune activation (van de Berg et al., 
2010; Hunt et al., 2011b), which may be associated with age-related frailty and increased 
incidence of cardiovascular diseases (Wikby et al., 2002; Simanek et al., 2011). Recent findings 
suggest that a novel CMV-induced regulatory-type CD4 T-cell subset may also be involved in 
enhancing CMV-associated vascular pathology (Terrazzini et al., 2014a). Moreover, highly 
differentiated CMV-specific T cells express elevated levels of chemokine receptors CX3CR1 and 
CXCR3, which allow them to migrate to activated endothelial cells expressing the ligands for these 
receptors (fractalkine and CXCL10) and induce apoptosis of the cells (Hertoghs et al., 2010; van 
de Berg et al., 2012). These studies suggest that CMV infection may alter the local environment by 
producing cellular factors potentially causing endothelial damage and an inflammatory response. 
However, the mechanisms behind this remain unclear warranting further studies on CMV-specific 
responses. 
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1.2.4 CMV and IL-10 
CMV has several mechanisms of immune evasion and devotes a significant part of its coding 
potential to proteins that modulate host immunity. Specifically, the virus encodes a number of 
homologues of host-encoded cytokines and chemokines (McSharry et al., 2012), one of which is 
for human IL-10 (Moore et al., 2001). This cytokine is an important regulator of immune responses 
and several herpes- and poxviruses, including CMV and EBV, encode viral IL-10 homologues that 
have retained many of the immunosuppressive functions of human IL-10 (Slobedman et al., 2009). 
Human IL-10 is a pleiotropic cytokine but has primarily been described as suppressive. However, 
its stimulatory effects on B cells and in some instances CD8 T cells have also been reported, 
highlighting the cell-type-dependent properties of this cytokine (MacNeil et al., 1990; Rousset et al., 
1992; Kang and Allen, 2005).  
 
Monocytes are thought to be major producers of IL-10, but T cells, B cells, DCs and macrophages 
are all sources of IL-10 and may all contribute to its suppressive functions (Couper et al., 2008a; 
Maynard and Weaver, 2008). IL-10 has particularly strong inhibitory effects on APCs, which 
includes the suppression of pro-inflammatory cytokines (IL-1α and β, IL-6, IL-12, IL-18, TNF-α,) 
and chemokines (MCP1, MCP5, RANTES, IL-8, IP-10 and MIP2) (reviewed in (Moore et al., 2001; 
Couper et al., 2008a)). IL-10 signalling is mediated by engagement of IL-10 with its receptor (IL-10 
receptor; IL-10R), which activates down-stream signals that lead to the phosphorylation of STAT3 
(signal transducer and activator of transcription 3) and the induction of STAT3-dependent genes 
(Moore et al., 2001). Mutations in the genes that encode for IL-10R have been associated with 
increased expression of pro-inflammatory cytokines (including TNF-α), in a subset of patients with 
inflammatory bowel disease (IBD), emphasizing a role for IL-10 in mucosal tissues (Glocker et al., 
2009; Ouyang et al., 2011). IL-10 also downregulates MHC class II and co-stimulatory molecule 
(CD80 and CD86) expression on APCs, and this inhibitory function affects the their maturation and 
subsequent ability to activate T cells (Moore et al., 2001; Carbonneil et al., 2004).  
 
IL-10 can act directly on T cells by limiting their proliferation, differentiation and effector activity 
(Maynard and Weaver, 2008; Brooks et al., 2010). IL-10 has an important role in suppressing 
excessive Th1 and Th2 responses that lead to immunopathology in infections with Toxoplasma 
gondii (Wilson et al., 2005) and malaria (Couper et al., 2008b). However, the presence of IL-10 has 
also been shown to inhibit antigen-specific responses, resulting in immune escape and persistent 
chronic infection (Omer et al., 2003; Brooks et al., 2006; Ejrnaes et al., 2006; Brooks et al., 2008). 
Increased IL-10 production has been associated with disease pathology in HBV and HCV (Flynn et 
al., 2011; Das et al., 2012) and elevated levels of serum IL-10 have been detected in HIV-1-
infected individuals (Norris et al., 2006; Brockman et al., 2009). These studies demonstrate a 
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complex role for IL-10 in the modulation of immune responses, particularly in the context of 
persistent infections, where IL-10 acts as a “negative feedback” regulation to limit pro-inflammatory 
responses but may also contribute to persistence. In vitro blockade of IL-10 signalling restores T-
cell function in HIV-1-specific CD4 and CD8 T cells, which suggests that manipulation of IL-10 
signalling during persistent viral infections can improve T-cell responses (Brockman et al., 2009). 
However, the in vivo benefit is yet unknown.  
 
The CMV gene UL111A encodes two viral homologues of human IL-10; cmvIL-10 expressed 
primarily during the lytic phase of infection and latency-associated cmvIL-10 (LAcmvIL-10), both of 
which are splice variants of the UL111A transcript and make up CMV-encoded IL-10 (Kotenko et 
al., 2000; Jenkins et al., 2004). Despite only sharing 27% of sequence identity with human IL-10, 
cmvIL-10 binds strongly to its receptor IL-10R and maintains several inhibitory functions associated 
with human IL-10, including modulation of DC maturation and function, downregulation of MHC 
class II expression and co-stimulatory molecules as well as inhibition of pro-inflammatory cytokine 
expression (Chang et al., 2004; Jenkins et al., 2008; Slobedman et al., 2009; McSharry et al., 
2012). In contrast, the functions of LAcmvIL-10 seem to be more restrictive and primarily involve 
downregulation of MHC class II molecules (Jenkins et al., 2008). The preservation of several 
human IL-10 functions is indicative that CMV has evolved to manipulate the human IL-10 signalling 
pathway as an immune evasion strategy and to facilitate viral persistence. For instance, CD34+ 
myeloid progenitor cells infected with virus strains lacking the UL111A gene exhibit increased MHC 
class II expression and elicit stronger allogeneic and autologous CD4 T-cell responses compared 
to cells infected with wild type virus (Cheung et al., 2009). 
1.2.5 CMV and HIV-1 co-infection 
Initiation of ART leads to lower CMV titres in the blood (Deayton et al., 1999; Durier et al., 2013) 
due to improved CMV-specific CD4 and CD8 T-cell responses (Li et al., 1998). In the post-ART 
era, fewer patients progress to advanced disease (CD4 T-cell counts <200 cells/µl blood), and as a 
result, the risks for developing CMV EOD have significantly decreased. However, in the patients 
that do progress, detection and quantity of CMV viraemia in the blood are independent predictors 
of a higher risk of HIV-1 disease progression (Deayton et al., 2004; El Amari et al., 2011). This may 
be independent of plasma HIV-1 RNA levels and CD4 T-cell counts (Deayton et al., 2004). Recent 
findings also suggest that CMV seropositivity is linked to a higher risk of severe non-AIDS defining 
events even in patients with higher CD4 T-cell counts (Lichtner et al., 2015). The underlying 
mechanisms behind this are not clear but CMV infection as a significant factor of HIV-1-associated 
immune activation has gained increasing interest in recent years (Haas et al., 2010). A small 
randomized study in 2011 demonstrated that patients who were not responding to ART (CD4 T-cell 
count <350 cells/µl blood) and were administered the anti-CMV drug valganciclovir for eight weeks, 
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exhibited significant reductions in total T-cell activation levels (Hunt et al., 2011b). A more recent 
study investigated the benefit of short-term (2 weeks) administration of valganciclovir to ART-naïve 
individuals with CD4 T-cell counts >400 cells/µl (Shin et al., 2014). A transient reduction of HIV-1 
RNA load in semen and peripheral blood was reported as well as a more durable reduction of CMV 
viraemia in semen. Phenotypic analysis further revealed reduced semen CD8 T-cell activation 
(CD38+CD69+) and increased frequencies of Tregs (CD4+CD25+FoxP3+). These studies confirm the 
contribution of CMV to immune activation, however the long-term clinical benefit that anti-CMV 
treatment may have on HIV-1-infected individuals in the context of ART is unclear.  
 
The high levels of CD4 and CD8 T-cell responses that CMV induces (TNF-α and IFN-γ) may be 
higher in HIV-1-infected individuals, and higher still in long-term treated patients, compared to 
uninfected CMV+ age-matched adults (Naeger et al., 2010; Appay et al., 2011). Appay and 
colleagues reported that the highest responses to CMV were detected in treated HIV-1-infected 
individuals >65 years of age (Appay et al., 2011). Thus, although CMV-specific immunity is 
improved with ART, there appears to be a continued expansion of CMV-specific T cells and the 
effect that this may have on other compartments of the immune system is unclear. Elevated 
frequencies of CMV-specific CD4 T cells expressing CX3CR1 may contribute to inflammatory 
responses (TNF-α and IFN-γ) and subsequent atherosclerosis in HIV-1-infected individuals (Hsue 
et al., 2006; Sacre et al., 2012). Moreover, higher CMV IgG antibody levels have been linked to 
subclinical cardiovascular disease in HIV-1-infected women (Parrinello et al., 2012). CMV co-
infection may also affect immune reconstitution in patients following ART initiation. Higher CMV-
specific T-cell responses have been linked to a reduction in total and naïve CD4 T-cell 
reconstitution in patients initiating ART (Appay et al., 2011).  
 
A suggested mechanism for the expansion of CMV-specific immune responses is that the transient 
low-level reactivation of CMV that occurs without clinical disease (McSharry et al., 2012), may 
drive continuous antigenic stimulation. However, it remains unclear how CMV-specific T cells are 
modulated during ART. Understanding the distinctions between immune responses to HIV-1 and 
co-pathogens such as CMV will be important to delineate how CMV induces such strong immune 
responses, whilst responses to HIV-1 remain dysfunctional during ART.  
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1.3 Aims & Hypothesis 
HIV-1 infection leads to an enormous modulation of host immune responses. The CD4 T-cell 
depletion that characterises this infection alters the behaviour of co-infections with other pathogens 
such as CMV. CMV is then maybe a driver of disease progression as it has been associated with 
HIV-1 immune activation. The mechanisms that underlie this relationship are not clear and the 
effects of ART initiation on CMV- and HIV-1-specific functional responses require further 
investigation. Furthermore, individuals who are able to control HIV-1 infection in the absence of 
ART represent an important group to investigate spontaneous immune control of HIV-1. 
Recognising mechanisms that distinguish ART-mediated immune reconstitution from spontaneous 
immune control will be important for identifying pathways that can be targeted in 
immunotherapeutic interventions.  
 
The overall hypothesis of this work is that CMV-specific responses contribute to HIV-1 
immunopathogenesis; CMV-specific responses increase immune activation by modifying cytokine 
responses. ART fails to reverse these deficiencies, resulting in distinct functional and phenotypic 
HIV-1- and CMV-specific responses. Additionally, it was hypothesised that reductions in viral 
fitness may determine HIV-1 immune control and reduce heterogeneity in these individuals.  
 
Thus, studies described in this thesis aim to characterise the phenotype and functional profiles of 
HIV-1 and CMV-specific responses in the context of ART, or divergent HIV-1 progression rates. 
Specific aims were as follows: 
 
Chapter 3 
i. To investigate the effects of ART on the reconstitution of HIV-1- and CMV-specific T-cell 
proliferative capacity.  
ii. Assess how cytokine profiles differ between ART-naïve and successfully treated HIV-1-
infected individuals, looking at IFN-γ and IL-2 known to be important for HIV-1 control as 
well as IL-10, a cytokine with immunomodulatory functions and a known immune-evasive 
mechanism used by CMV.  
 
Chapter 4 
i. To determine the differentiation, activation and exhaustion profiles of total CD4 and CD8 T 
cells in ART-naïve and treated HIV-1-infected individuals.  
ii. Identify and characterise HIV-1- and CMV-specific CD8 T cells for a better understanding of 
how these are altered with ART. 
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iii. Evaluate the effect of immunotherapy on the differentiation, activation and exhaustion of 
HIV-1- and CMV-specific CD8 T cells. 
 
Chapter 5 
i. To identify HIV-1-infected individuals with an atypical disease progression. 
ii. Characterise the phenotype and functional properties of their CD4 and CD8 T cells in order 
to identify immune profiles that may be shared between these individuals. 
iii. Elucidate whether viral fitness is one of the mechanisms behind viral control in these 
individuals. 
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Chapter 2 Materials and Methods 
2.1 Overview 
All work described herein was carried out in the Containment Level III Laboratory (CAT III), in the 
Section of Immunology, Department of Medicine, Chelsea and Westminster Hospital Campus, 
Imperial College London. All blood samples were processed immediately after collection and all 
functional assays carried out on fresh peripheral blood mononuclear cells (PBMC).  
2.2 Biocontainment Level III Training and Approval 
Training in the CAT III was completed before experiments were conducted on HIV-1+ blood 
samples. The specific training consisted of 30 hours observation in the laboratory, followed by 30 
hours supervised work by a registered user. Authorisation was granted by the resident containment 
level III manager once training hours were completed and upon successful completion of 
assessment. 
2.3 Seronegative Controls 
HIV-1 seronegative healthy control samples were kindly provided by laboratory volunteers from the 
Section of Immunology, Department of Medicine at Chelsea and Westminster Hospital and 
followed Imperial College London Occupational Health guidelines on sampling procedures. The 
average age was 33 years and the gender was mixed but predominantly female.  
2.4 Patient Cohorts and Ethical Approval 
Patients were recruited from the cohort of >5,000 HIV-1+ patients attending the St. Stephen’s 
centre at the Chelsea and Westminster Hospital NHS Foundation Trust (Mandalia et al., 2012). All 
work was carried out under ethical approval of the Riverside Research Ethics Committee 
(RREC1108) with informed written consent provided by all study participants. 
2.5 Plasma HIV-1 RNA Load Quantification 
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 (v2.0; Roche Molecular 
Diagnostics, Basel, Switzerland), was used to quantitate the copy number of HIV-1 RNA in patient 
plasma and was performed as part of the patients’ routine care by the Department of Virology at 
Bart’s and The London NHS Trust. The lower limit of detectability of this assay is 20 copies/ml and 
the upper limit of quantification of 10,000,000 copies/ml, with the reported results censored at <50.  
2.6 Lymphocyte Subsets 
Whole blood lymphocyte quantification was determined using murine anti-human monoclonal 
antibodies (mAb) to: CD3, CD4, CD8, CD56, CD19 and the pan-lymphocyte marker CD45 (Tetra 
One, Beckman Coulter, High Wycombe, UK), and were evaluated on a NAVIOS (Beckman 
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Coulter) flow-cytometer. This was performed at the Charing Cross Hospital in the Department of 
Infection and Immunity, Imperial College NHS Trust. 
2.7 Preparation of Human Male AB Plasma 
Frozen human male AB serum (Sigma-Aldrich, Poole, UK), previously screened for HIV-1 and -2, 
Hepatitis B and C, and CMV by the supplier, was heat inactivated by heating to 56°C in a water 
bath for 30 minutes, inverting every ten minutes. This procedure inactivated complement but did 
not affect other essential components within the AB serum required for in vitro PBMC culture. The 
heat inactivated human male AB serum was subsequently separated into 2ml aliquots in a sterile 
environment and stored at -20°C until required.  
2.8 Preparation of Media and Solutions 
• Standard tissue culture medium (TCM) was made up of Roswell Park Memorial Institute 
(RPMI)-1640 solution supplemented with L-glutamine and Penicillin/Streptomycin (GluPS; 
final concentrations of 2mM, 100 U/ml, 100 µg/ml respectively; all Sigma-Aldrich) and 10% 
heat inactivated human male AB serum (Sigma-Aldrich). 
• Freezing medium was prepared by supplementing Fetal Bovine Serum (FBS; PAA 
Laboratories, Pasching, Austria) with 10% sterile dimethyl sulfoxide (DMSO; Sigma-
Aldrich). 
• MACS buffer was prepared by supplementing sterile phosphate buffered saline (PBS) with 
2mM ethylenediaminetetraacetic acid (EDTA; both Sigma-Aldrich), and 2% FBS (PAA 
Laboratories). 
2.9 Collection of Blood Samples 
Whole blood from HIV-1 seropositive and seronegative adults was collected into heparinised and 
EDTA lined VacutainersTM (Becton Dickinson, Oxford, UK), for functional and phenotypic analysis 
respectively. 
2.10 Separation of Plasma 
Blood samples collected in heparinised or EDTA Vacutainers™ were centrifuged at 652 x g for 10 
minutes to separate the plasma. Aliquots of 1ml plasma were stored in sterile 1.5ml eppendorf 
tubes (Alpha Laboratories, Eastleigh, UK) at -80 ̊C for future use. 
2.11 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Fresh PBMC were isolated by density gradient centrifugation. Briefly, whole blood was diluted in a 
1:1 ratio with PBS (Sigma-Aldrich) and layered over 20ml of Lymphocyte Separation Medium 
(LSM; PAA Laboratories) at a 1:1 ratio in a 50ml tube (Greiner Bio-One, Stonehouse, UK). Tubes 
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were centrifuged at 800 x g for 20 minutes at room temperature (RT) without the use of centrifuge 
brakes. A sterile Pasteur pipette (Alpha Laboratories) was utilised to aspirate the resulting interface 
layer of PBMC into a new sterile 50ml tube (Greiner Bio-One), PBMC were resuspended with 
sterile PBS and centrifuged at 652 x g for 10 minutes with brakes set to 9 (1st wash). The 
supernatant was discarded and the pellet resuspended in 50ml of sterile PBS for enumeration and 
determination of PBMC viability using the KOVA method described below (Section 2.12). Cell 
suspension was centrifuged at 452 x g for 10 minutes at RT with brakes set to 9 (2nd wash). The 
supernatant was discarded and the cell pellet resuspended in 50ml RPMI-1640 + GluPS (for 
functional experiments) or 50ml sterile PBS and centrifuged at 452 x g for 10 min at RT with brakes 
set to 9 (3rd wash). Following removal of supernatant, PBMC were resuspended at an appropriate 
concentration for functional or phenotypical assays detailed below. 
2.12 Counting and Viability of Cells Using the KOVA Method 
Viability and cell count of PBMC was measured using the Trypan Blue exclusion method. In brief, 
20µl aliquot of cell suspension was stained with 20µl of 0.4% Trypan Blue (Sigma-Aldrich). Dead 
cells incorporate Trypan Blue and are thus stained blue. Viable PBMC were counted on a KOVA 
Glasstic® slide (Hycor Biomedical Inc, Edinburgh, UK) using an inverted microscope with 
magnification x40. Two large squares were counted and the average number of cells between the 
two was used. 
The formula used to determine total number of cells in sample was as follows: 
Average number of cells in 2 large squares x chamber factor (2) x dilution factor (104) x total 
volume → Average number of cells x 2 x 104 x 50ml = Total number of cells 
2.13 Cryopreservation and Thawing of PBMC 
Reagents and equipment were kept as cool as possible to ensure optimum freezing conditions. 
Cryotubes (Corning Incorporated, New York, USA) were labelled with marker pen and placed in a 
Nalgene® “Mr Frosty” box (Nalge Nunc International, Hereford, UK) filled with isopropanol (Sigma-
Aldrich). The Mr Frosty box was then cooled to 4°C. PBMC were resuspended in cold (4°C) 
freezing medium to give a concentration of 1x107 cells/ml. One ml of the cell suspension was 
transferred immediately to each cold cryotube and the Mr Frosty box containing the cryotubes was 
then placed at -80°C.  
 
Cells were thawed as rapidly as possible using a 37°C water bath and resuspended in 50ml ice 
cold PBS (Sigma-Aldrich), added drop-wise initially, then at a quicker rate. They were then 
immediately centrifuged at 652 x g for 10 minutes, the supernatant discarded and another 
centrifugation carried out to wash the cells. Thawed cell number and viability was then determined 
using the same method as detailed above (Section 2.12). 
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2.14 Preparation of Antigens, Peptide Pools and Individual Peptides 
The peptide pools and antigens used in the studies described in this thesis are all commercially 
available, and summarised in Table 2.1 and Table 2.2. 
Table 2.1. Antigens, peptide pools and mitogens used in both ELISpot and LPR assays. 
 
 
Table 2.2. Individual peptides used in both ELISpot and LPR assays. 
 
 
2.14.1 HIV-1 Antigens and Peptide Pools 
HIV-1 Gag p24 9mer and Nef 9mer peptide pools 
A pool of 36 HIV-1 Gag peptides (Table 2.3) and a pool of 13 HIV-1 Nef peptides (Table 2.4), 
restricted to MHC class I alleles common in the population (Sigma-Aldrich), were made up in 
RPMI-1640 + GluPS at a concentration of 10µg/ml, to give a final concentration of 5µg/ml of each 
peptide in culture. HIV-1 Gag p24 and Nef MHC class I pools for optimal stimulation of CD8 T cells.  
 
HIV-1 Gag p24 and Nef 20mer peptide pools 
HIV-1 capsid Gag p24 (ARP788.1-.22) and Nef (ARP7074.1-.20) peptides are mostly twenty amino 
acids (aa) long, overlapping by 10 aa (all from National Institute for Biological Standards and 
Control (NIBSC), Potters Bar, UK). Tables 2.5 and 2.6 detail the overlapping peptides, which were 
all made up in RPMI-1640 + GluPS to a concentration of 10µg/ml, to give a final concentration of 
5µg/ml in culture for each peptide in the pool.  
 
Recombinant HIV-1 Gag and Nef p24 pools 
Recombinant (r)HIV-1 Gag protein p24 (EVA620) and Nef (EVA650; both NIBSC and detailed in 
Table 2.7) were each made up in RPMI-1640 + GluPS to a concentration of 10µg/ml. 
Antigen Final concentration (µg/ml) Supplier
HIV-1 Gag p24 9mer peptide pool 5 Sigma-Genosys
HIV-1 Nef 9mer peptide pool 5 Sigma-Genosys
HIV-1 Gag p24 20mer peptide pool 5 NIBSC
HIV-1 Nef 20mer peptide pool 5 NIBSC
HIV-1 Gag recombinant p24 pool 5 NIBSC
HIV-1 Nef recombinant pool 5 NIBSC
CMV pp65 peptide pool 5 Miltenyi
CMV whole lysate (WL) 5 Virion
FEC peptide pool 1.5 NIBSC
HSV 5 Virion
EBV 5 Virion
PHA 5 Sigma
PMA 0.005 Sigma
Ionomycin (I) 0.0001 (M) Sigma
Peptide Restricting HLA allele Sequence Length
Final 
concentration 
(µg/ml)
Supplier
HIV-1 KK10 B*27:05 KRWIILGLNK 10 5 Proimmune
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All recombinant HIV-1 antigens and peptides were provided through the Centre for AIDS 
Reagents, NIBSC, supported by the EU Programme EVA and the UK Medical Research Council 
(HIV-1 Gag p24, rGag, AIDS Vaccine Initiative Programme (AVIP) contract number QLK2-CT-
1999-00609, and HIV-1 BRU Nef peptides; AVIP contract number LSHP-CT-2004-503487). 
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Table 2.3. HIV-1 p24 Gag single peptides included in the Gag 9mer peptide pool.  
The sequences, position and MHC class I restrictions of the 36 HIV-1 p24 Gag single peptides used as a 
pool to stimulate CD8 T cells from HIV-1-infected individuals. 
 
Peptides were identified from the NIH HIV Molecular Immunology Database website 
(http://www.hiv.lanl.gov). References for each peptide are available at this website. 
 
 
 
 
 
 
Peptide 
number Protein (amino acid number)
HLA-
restriction Peptide
Amino acid 
sequence Length
1 p17 (14-22) B*1401 DR9 DRWEKIRLR 9
2 p17 (20-28) A*0301 RK9 RLRPGGKKK 9
3 p17 (24-31) B*0801 GL9 GGKKKKYKL 9
4 p17 (26-34) B*8 KI9 KKKYKLKHI 9
5 p17 (28-36) A*2402 KW9 KYKLKHIVW 9
6 p17 (36-44) B*3501 WF9 WASRELERF 9
7 p17 (71-79) A*1 GY9 GSEELRSLY 9
8 p17 (74-82) B*0801 EV9 ELRSLYNTV 9
9 p17 (77-85) A*0201 SL9 SLYNTVATL 9
10 p17 (84-92) A*1101 TI9 TLYCVHQRI 9
11 p17 (92-101) B*4001 IL10 IEIKDTKEAL 10
12 p17 (93-101) B*8, B*60 EL9 EIKDTKEAL 9
13 p24 (13-23) A*25 QW11 QAISPRTLNAW 11
14 p24 (15-23) B*5701 IW9 ISPRTLNAW 9
15 p24 (16-24) B*7 SW8 SPRTLNAW 8
16 p24 (30-40) B*57 KF11 KAFSPEVIPMF 11
17 p24 (32-40) B*57 FF9 FSPEVIPMF 9
18 p24 (35-43) A*2601 EL9 EVIPMFSAL 9
19 p24 (44-52) B*4001 SL9 SEGATPQDL 9
20 p24 (61-69) B*3901 GL9 GHQAAMQML 9
21 p24 (71-80) A*25 EW10 ETINEEAAEW 10
22 p24 (83-92) B*55 VA10 VHPVHAGPIA 10
23 p24 (84-92) B*35 HA9 HPVHAGPIA 9
24 p24 (108-117) B*5701 TW10 TSTLQEQIGW 10
25 p24 (108-117) B*5701 TN10 TSTLQEQIGN 10
26 p24 (122-130) B*3501 PY9 PPIPVGDIY 9
27 p24 (127-135) B*8 GI9 GEIYKRWII 9
28 p24 (128-136) B*8 EL9 EIYKRWIIL 9
29 p24 (131-140) B*2705 KK10 KRWIILGLNK 10
30 p24 (174-184) B*44 AW11 AEQASQDVKNW 11
31 p24 (176-184) B*57 QW9 QASQEVKNW 9
32 p24 (197-205) B*8 DL9 DCKTILKAL 9
33 p24 (217-227) A*1101 AK11 ACQGVGGPGHK 11
34 p24 (230-231) p2p7p1p6 (1-7) A*02 VV9 VLAEAMSQV 9
35 p6 (36-44) B*35/B*8 YL9 YPLTSLRSL 9
36 p7 (52-55)  p1(1-5) B*2705 RI9 RQANFLGKI 9
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Table 2.4. HIV-1 Nef single peptides included in the Nef 9mer peptide pool.  
 
Peptides were identified from the NIH HIV Molecular Immunology Database website 
(http://www.hiv.lanl.gov). References for each peptide are available at this website. 
 
Table 2.5. HIV-1 Gag p24 20mer peptides used as a pool to stimulate PBMC. 
 
  
 
 
 
 
 
 
 
Peptide 
number
Protein (amino acid 
number) HLA-restriction Peptide
Amino acid 
sequence Length
1 Nef (13-20) B*0801 WM9 WPTVRERM 9
2 Nef (73-82) A*0301/A*1101    QK10 QVPLRPMTYK 10
3 Nef (74-81) B*3501 VY8 VPLRPMTY 8
4 Nef (75-82) A*1101 PK8 PLRPMTYK 8
5 Nef (84-92) A*0301/A*1101    AK9 AVDLSHFLK 9
6 Nef (90-97) B*0801 FL8 FLKEKGGL 8
7 Nef (92-100) B*4001/B*4002 KL9 KEKGGLEGL 9
8 Nef (116-125) B*5701 HQ10 HTQGYFPDWQ 10
9 Nef (128-137) B*0702 TL9 TPGPGVRYPL 9
10 Nef (134-141) B*2402 RW8 RYPLTFGW 8
11 Nef (135-143) B*1801/B*5301 YY9 YPLTFGWCY 9
12 Nef (180-189) A*0201 VL9 VLEWRFDSRL 9
13 Nef (186-193) B*35 DH8 DSRLAFHH 8
Protein Virus Strain Peptide Sequence Length Reference
Gag p24 1SF2 1 PIVQNLQGQMVHQAISPRTL 20 ARP788.1
Gag p24 1SF2 2 VHQAISPRTLNAWVKVVEEK 20 ARP788.2
Gag p24 1SF2 3 NAWVKVVEEKAFSPEVIPMF 20 ARP788.3
Gag p24 1SF2 4 AFSPEVIPMFSALSEGATPQ 20 ARP788.4
Gag p24 1SF2 5 SALSEGATPQDLNTMLNTVG 20 ARP788.5
Gag p24 1SF2 6 DLNTMLNTVGGHQAAMQMLK 20 ARP788.6
Gag p24 1SF2 7 GHQAAMQMLKETINEEAAEW 20 ARP788.7
Gag p24 1SF2 8 ETINEEAAEWDRVHPVHAGP 20 ARP788.8
Gag p24 1SF2 9 DRVHPVHAGPIAPGQMREPR 20 ARP788.9
Gag p24 1SF2 10 IAPGQMREPRGSDIAGTTST 20 ARP788.10
Gag p24 1SF2 11 GSDIAGTTSTLQEQIGWMTN 20 ARP788.11
Gag p24 1SF2 12 LQEQIGWMTNNPPIPVGEIY 20 ARP788.12
Gag p24 1SF2 13 NPPIPVGEIYKRWIILGLNK 20 ARP788.13
Gag p24 1SF2 14 KRWIILGLNKIVRMYSPTSI 20 ARP788.14
Gag p24 1SF2 15 IVRMYSPTSILDIRQGPKEP 20 ARP788.15
Gag p24 1SF2 16 LDIRQGPKEPFRDYVDRFYK 20 ARP788.16
Gag p24 1SF2 17 FRDYVDRFYKTLRAEQASQD 20 ARP788.17
Gag p24 1SF2 18 TLRAEQASQDVKNWMTETLL 20 ARP788.18
Gag p24 1SF2 19 VKNWMTETLLVQNANPDCKT 20 ARP788.19
Gag p24 1SF2 20 VQNANPDCKTILKALGPAAT 20 ARP788.20
Gag p24 1SF2 21 ILKALGPAATLEEMMTACQG 20 ARP788.21
Gag p24 1SF2 22 LEEMMTACQGVGGPGHKARV 20 ARP788.22
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Table 2.6. HIV-1 Nef 20mer peptides used as pools to stimulate PBMC.  
 
 
 Table 2.7. Details of the NIBSC recombinant HIV-1 proteins used to stimulate PBMC. 
 
2.14.2 Additional Peptide Pools, Antigens and Mitogens 
CMV peptide pool (pp65 sequence, strain AD169; BD Biosciences, Oxford, UK) consisting of 138 
individual peptides (15mers overlapping by 11 aa) was diluted in RPMI-1640 + GluPS to give a 
final concentration of 5µg/ml. CMV whole lysate (WL) was processed through virus infection on 
HEL 299 cells. These cells were harvested, pelleted and purified through ultracentrifugation. 
Inactivation was performed by heat treatment for 30 min at 56°C and 0.01% Thiomersal was used 
as a preservation. It is expected that the preparation consists of a high concentration of virus and 
viral components and also contains residual host cell material. CMV, HSV, EBV and Flu whole 
lysate (WL; all Virion/Serion, Würzburg, Germany) were prepared according to manufacturer’s 
instructions. FEC peptides (NIBSC), consisting of 33 peptides of CMV, EBV and Flu A WL (the 
sequences of which and references are shown in Table 2.8) were made up in RPMI-1640 + GluPS 
as a peptide pool to a concentration of 3µg/ml (to give a final concentration of 1.5µg/ml in culture) 
for each peptide. These peptides were between 9 and 12 aa in length, an optimal size for 
presentation by MHC class I molecules to CD8 T cells. Phytohaemagglutinin (PHA; Sigma-Aldrich) 
was diluted in RPMI-1640 + GluPS to a concentration of 10µg/ml, to give a final concentration of 
5µg/ml in culture, and used as a mitogen positive control in ELISpot and proliferation assays. 
Phorbol 12-myristate 13-acetate (PMA) and Ionomycin calcium salt (both Sigma-Aldrich) were 
diluted in RPMI-1640 + GluPS to give final concentrations of 50ng and 1µM respectively in culture 
Protein Virus Strain Peptide Sequence Length Reference
Nef BRU n1 GGKWSKSSVVGWPTVRERMR 20 ARP7074.1
Nef BRU n2 GWPTVRERMRRAEPAADGVG 20 ARP7074.2
Nef BRU n3 RAEPAADGVGAASRDLEKHG 20 ARP7074.3
Nef BRU n4 AASRDLEKHGAITSSNTAAT 20 ARP7074.4
Nef BRU n5 AITSSNTAATNAACAWLEAQ 20 ARP7074.5
Nef BRU n6 NAACAWLEAQEEEEVGFPVT 20 ARP7074.6
Nef BRU n7 EEEEVGFPVTPQVPLRPMTY 20 ARP7074.7
Nef BRU n8 PQVPLRPMTYKAAVDLSHFL 20 ARP7074.8
Nef BRU n9 KAAVDLSHFLKEKGGLEGLI 20 ARP7074.9
Nef BRU n10 KEKGGLEGLIHSQRRQDILD 20 ARP7074.10
Nef BRU n11 HSQRRQDILDLWIYHTQGYF 20 ARP7074.11
Nef BRU n12 LWIYHTQGYFPDWQNYTPGP 20 ARP7074.12
Nef BRU n13 PDWQNYTPGPGVRYPLTFGW 20 ARP7074.13
Nef BRU n14 GVRYPLTFGWCYKLVPVEPD 20 ARP7074.14
Nef BRU n15 CYKLVPVEPDKVEEANKGEN 20 ARP7074.15
Nef BRU n16 KVEEANKGENTSLLHPVSLH 20 ARP7074.16
Nef BRU n17 TSLLHPVSLHGMDDPEREVL 20 ARP7074.17
Nef BRU n18 GMDDPEREVLEWRFDSRLAF 20 ARP7074.18
Nef BRU n19 EWRFDSRLAFHHVARELHPE 20 ARP7074.19
Nef BRU n20 HHVARELHPEYFKNC 15 ARP7074.20
Repository 
Reference
Recombinant 
Protein Details
EVA620 Gag p24 A cytosolic protein produced in the baculovirus 
expression system.
EVA650 Nef From Bru strain expressed as E.coli.
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and were used as mitogen positive control in intracellular cytokine staining (ICCS) assays as 
detailed below. 
 
Table 2.8. List of individual peptides included in the FEC peptide pool.  
The peptide number, restricting HLA allele, sequences and antigenic origin of the 33 HLA-matched FEC 
peptides used as a pool (Currier et al., 2002) to stimulate CD8 T cells from both seronegative and HIV-1 
seropositive individuals. 
 
*The sequence of peptide 8 was checked against the original reference (Bowness et al., 1993) and a 
discrepancy discovered. Therefore peptide FEC 13 was synthesised with the correct sequence and added to 
the pool. Prior to this, the pool did not contain a FEC 13. 
#In the reference, the sequence is LPFDRTTVM. 
2.15 Enzyme-Linked Immunosorbent Spot (ELISpot) Assay  
HIV-1-specific cellular responses were quantified by IFN-γ, IL-2, IL-10 and granzyme B enzyme-
linked immunosorbent spot (ELISpot) assay as recommended by the manufacturer (Mabtech, 
Nacka Strand, Sweden). Coating step: Polyvinylidene diflouride (PVDF)-bottomed plates (Merck 
Millipore, Billerica, Massachusetts, USA) were coated with 100 µl/well of the corresponding capture 
antibody (Mabtech); diluted at 10µg/ml for IFN-γ, IL-2 and IL-10. Plates were then incubated 
overnight at 4°C, after which six sterile washes were carried out on the plate with 200µl of sterile 
Antigen Restricting HLA allele Peptide Sequence Reference
Flu A M A2 FEC 1 GILGFVFTL (Lalvani et al., 1997)
Flu A A2 FEC 2 FMYSDFHFI (Gianfrani et al., 2000)
Flu A M A3/11/6081 FEC 3 SIIPSGPLK (Gianfrani et al., 2000)
Flu A NP A3 FEC 4 RVLSFIKGTK (Gianfrani et al., 2000)
Flu A NP A68 FEC 5 KTGGPIYKR (Cerundolo et al., 1991)
Flu A NP B7 FEC 6 LPFDK#TTVM (Gianfrani et al., 2000)
Flu A NP B8 FEC 7 ELRSRYWAI (Suhrbier et al., 1993)
control B27 FEC 8* SRYWAIRTE
Flu A M B27 FEC 9 ASCMGLIY (Lalvani et al., 1997)
EBV A2 FEC 10 CLGGLLTMV (Lee et al., 1993)
EBV A2 FEC 11 GLCTLVAML (Rickinson and Moss 1997)
EBV A11 FEC 12 AVFDRKSDAK (de Campos-Lima et al., 1994)
Flu A NP B27 FEC 13* SRYWAIRTR (Bowness et al., 1993)
EBV A24 FEC 14 DYCNVLNKEF (Rickinson and Moss 1997)
EBV B8 FEC 15 RAKFKQLL (Rickinson and Moss 1997)
EBV B8 FEC 16 FLRGRAYGL (Rickinson and Moss 1997)
EBV B8 FEC 17 QAKWRLQTL (Rickinson and Moss 1997)
EBV B27 FEC 18 RRIYDLIEL (Rickinson and Moss 1997)
EBV B35 FEC 19 YPLHEQHGM (Rickinson and Moss 1997)
CMV A0201 FEC 20 NLVPMVATV (Wills et al., 1996)
CMV B0702 FEC 21 TPRVTGGGAM (Wills et al., 1996)
CMV B18 FEC 22 SDEEEAIVAYTL (Gavin et al., 1993)
CMV B35 FEC 23 IPSINVHHY (Gavin et al., 1993)
Flu A PB1 A1 FEC 24 VSDGGPNLY (DiBrino et al., 1993)
Flu A NP A1 FEC 25 CTELKLSDY (DiBrino et al., 1993)
Flu A A3 FEC 26 ILRGSVAHK (DiBrino et al., 1993)
EBV A3 FEC 27 RVRAYTYSK (Rickinson and Moss 1997)
EBV A3 FEC 28 RLRAEAQVK (Rickinson and Moss 1997)
EBV A11 FEC 29 IVTDFSVIK (Rickinson and Moss 1997)
EBV A11 FEC 30 ATIGTAMYK (Rickinson and Moss 1997)
EBV B7 FEC 31 RPPIFIRRL (Rickinson and Moss 1997)
EBV B44 FEC 32 EENLLDFVRF (Rickinson and Moss 1997)
CMV B44 FEC 33 EFFWDANDIY (Wills et al., 1996)
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PBS. The last wash was left on to avoid drying out of the wells and removed immediately before 
adding the blocking buffer.  
Blocking step: 100µl of blocking buffer (sterile PBS supplemented with 10% heat inactivated 
screened human male AB serum; Sigma-Aldrich) was dispensed into each well, the plate was 
covered and incubated at RT for 1 hour, after which the wells were emptied immediately before 
adding cell suspensions and appropriate antigens by flicking the plate and tapping it on absorbent 
paper. PBS was used instead of RPMI-1640 + GluPS to prevent fluctuations in pH. Stimulation 
step: Fresh PBMC were resuspended in RPMI-1640 + GluPS supplemented with 20% heat 
inactivated human male AB serum (Sigma-Aldrich), at a concentration of 2x106 cells/ml. 100µl of 
fresh cell suspension (2x105 cells) were added to each well in duplicate. 100µl of relevant antigen 
or peptide pool was added to each well according to plate layout below (Figure 2.1). Negative 
control wells (cells and tissue culture medium only) were run in duplicate on each plate, along with 
positive control wells (PHA, at a final concentration of 5µg/ml) to ensure that the cells were 
responsive and that experiments had worked. Plates were incubated for either 48 hours (IFN-γ, IL-
10 and granzyme B) or 72 hours (IL-2) at 37°C in a 5% CO2 incubator to capture the peak kinetics. 
Following the incubation period the plate was washed six times with PBS using the MultiWash III 
automated plate washer (Tricontinent, California, USA).  
 
Detection step: 100µl biotinylated detection antibody for each cytokine (all Mabtech) was added 
as appropriate at 1µg/ml in PBS to each well, and plates were incubated for 3 hours at RT after 
which another set of washes was carried out. 100µl streptavidin-ALP antibody (Mabtech) was 
added at 1:1000 dilution in PBS to each well for a final incubation at room temperature for 1 hour. 
Plates were washed six times with sterile PBS leaving the last wash on the plates to prevent any 
drying out. Plates were developed using a BioRad AP development kit dye which was freshly 
prepared by adding 400µl development BufferTM to 9.6ml deionised water and then 50µl of both 
reagents A and B (Bio Rad Life Science Research, Hemel Hempstead, UK) were added to the 
diluted buffer. Immediately after preparing the chromogen the PBS left from the last wash was 
removed from the plate and 100µl of chromogen was added to each well. Plates were washed 
under the tap when clear blue/purple spots appeared and left to dry overnight. All plates were 
decontaminated and removed from the containment III lab according to local safety rules. Spots 
resulting from the production of IFN-γ, IL-2, IL-10 and granzyme B were read using an automated 
AID ELISpot reader (ELR07; AID GmbH, Strassberg, Germany). Validation of the ELISpot assay is 
defined by a PHA response of at least 50 times the background (TCM alone). A negative response 
is defined as less than 20 SFC per million PBMC for IFN-γ, IL-2, L-10 and granzyme B. A positive 
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response was defined as greater than or equal to 20 SFC/million PBMC for IFN-γ, IL-2, IL-10 and 
granzyme B and at least twice the background. 
 
 
Figure 2.1 ELISpot plate layout.  
Representative layout used to evaluate secretion of IFN-γ, IL-2, IL-10 and granzyme B by PBMC after 
stimulation with the antigens and/or peptide pools shown. This plate layout was also used for the lymphocyte 
proliferation assay described below (Section 2.16). 
 
2.16 Lymphoproliferative Response (LPR) Assay 
Fresh PBMC were resuspended in tissue culture medium at a concentration of 1x106 cells/ml. 
100µl (1x105 cells per well) of cell suspension was subsequently transferred into a 96-well round-
bottomed tissue culture plate in triplicate (Griener Bio-One, Stonehouse, UK). Antigens and/or 
peptides were prepared at an appropriate concentration for each antigen (Table 2.1) in tissue 
culture medium, and 100µl of antigen/peptide was dispensed in triplicates to each well. Cells were 
incubated for 5 days at 37°C in 5% CO2 and then pulsed on the morning of day 5 with 50µl of 
[methyl-3H] thymidine (Amersham International, Amersham, UK) per well, giving a final radioactive 
dosage of 1µCi per well, followed by a further incubation period of 8 hours. Proliferation of PBMC 
was measured by [methyl-3H] thymidine incorporation into DNA. The DNA was subsequently 
harvested onto scintillation glass fibre filter mats using a Micro96™ cell harvester (Wallac, Oy, 
Turku, Finland), and allowed to dry overnight on a foil inside the hood before the mat was sealed 
into a sample bag with 10ml of OptiPhase ‘Hisafe’ 2 liquid scintillant completely covering the mat 
with no air bubbles (Wallac). The mat was then evaluated by liquid scintillation spectroscopy using 
a 1205 Betaplate counter (Wallac). Control wells, for calculation of background activity, contained 
PBMC only. Results are expressed as stimulation index (SI); calculated by dividing the 
experimental triplicate mean result by the background (TCM) mean result. A positive response is 
defined as an SI score of five or more.  
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2.17 Surface Staining of PBMC for Flow Cytometric Analysis 
PBMC (2x106) were allocated to labelled FACS tubes (Greiner Bio-One) and washed using 2ml 
BSA stain buffer (BD Biosciences). Tubes were centrifuged at 652 x g for 5 minutes, after which 
the supernatant was discarded and cells resuspended in the residual volume of stain buffer 
(~50µl). Antibodies to cell-surface molecules (Table 2.9) were aliquoted to the tubes in optimal 
amounts according to the two antibody panels listed in Table 2.10 and Table 2.11. Isotype controls 
were included to eliminate non-specific binding. Tubes were then incubated in the dark, on ice, for 
20 minutes. Stained cells were washed two times with 2ml BSA stain buffer (BD Biosciences), 
centrifuged at 652 x g for 5 minutes, the supernatant discarded and resuspended in the residual 
volume. Cells were fixed with 200µl of 2% paraformaldehyde diluted 2:1 with deionised water. 
Tubes were vortexed to avoid clumping and stored in the dark at 4ºC until acquisition within 2 
hours using an LSR II flow cytometer and FACSDiva™ v.6.1.2. acquisition software (Becton 
Dickinson Immunocytometry Systems, v5.0.1). At least 100,000 events were acquired within a 
lymphocyte gate.  
 
Table 2.9 List of monoclonal antibodies used for eight-colour flow cytometry staining. 
 
 
Table 2.10. Antibody panel used for surface phenotyping of differentiation and activation in T cells. 
 
 
 
 
Fluorochrome Antibody Isotype Clone Reference nr Supplier
FITC CD8 Ms IgG1, κ LT8 A003-3A ProImmune Ltd., UK
FITC PD-1 (CD279) Ms IgG1, κ MIH4 557860 BD Pharmingen™, UK
FITC IFN-γ Ms IgG2b, κ 25723.11 340449 BD Pharmingen™, UK
PerCP CD3 Ms IgG1, κ SK7 345766 BD Pharmingen™, UK
PerCP TIM-3 Rat IgG2a, κ 344823 FAB2365C R&D Systems Europe Ltd 
PE-Cy7 CD45RA Ms IgG1, κ L48 337186 BD Pharmingen™, UK
PE-Cy7 CD4 Ms IgG1, κ SK3 348809 BD Pharmingen™, UK
APC CD3 Ms IgG1, κ SK7 345767 BD Pharmingen™, UK
APC CCR7 Ms IgG2a, κ 150503 FAB197A R&D Systems Europe Ltd 
APC IL-10 Rat IgG2a JES3-19F1 562036 BD Pharmingen™, UK
APC-H7 CD8 Ms IgG1, κ SK1 560179 BD Pharmingen™, UK
APC-H7 CD4 Ms IgG1, κ SK3 641398 BD Pharmingen™, UK
V450 CD38 Ms IgG1, κ HB7 646851 BD Horizon™
V500 HLA-DR Ms IgG2a, κ G46-6 561224 BD Horizon™
FITC Mouse IgG1, κ Ms IgG1, κ MOPC-21 555748 BD Pharmingen™, UK
PerCP Rat IgG2a,  κ Rat IgG2a 54447 IC006C R&D Systems Europe Ltd 
PE-Cy7 Mouse IgG1, κ Ms IgG1, κ MOPC-21 557872 BD Pharmingen™, UK
APC Mouse IgG2a, κ Ms IgG2a, κ 20102 IC003A R&D Systems Europe Ltd 
V450 Mouse 1gG1,  κ Ms IgG1, κ X40 642268 BD Horizon™
V500 Mouse IgG2a, κ Ms IgG2a, κ G155-178 561221 BD Horizon™
Tube PE-Cy7 APC V450 V500 PerCP FITC APC-H7
Isotype IgG1 IgG2 IgG1 IgG2 CD3 CD8 CD4
Experimental CD45RA  CCR7 CD38 HLA-DR CD3 CD8 CD4
Volume 2 µl 5 µl 5 µl 5 µl 5µl 1µl 5µl
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Table 2.11. Antibody panel used for surface phenotyping of exhaustion and activation in T cells. 
 
 
2.17.1 Gating strategy and controls 
Cells were gated based on forward scatter height (FSC-H) and forward scatter area (FSC-A) to 
exclude doublets (Figure 2.2 A). The side scatter area (SSC-A) versus the FSC-A was used to 
identify lymphocytes based on their size and granularity. After gating on CD3+, CD3+CD4+ and 
CD3+CD8+ cells, further quadrant gates were set for each of the respective populations based on 
isotype controls for each marker. Lineage differentiation markers CD45RA and CCR7 were used to 
subdivide CD4+ T cells and CD8+ T cells into subpopulations of naïve (CD45RA+CCR7+), central 
memory (TCM, CD45RA
-CCR7+), effector memory (TEM, CD45RA
-CCR7-), and terminally 
differentiated effector memory (TEMRA, CD45RA+CCR7
-) subsets (Sallusto et al., 1999) (Figure 2.2 
B). In addition, activation markers HLA-DR and CD38 were used to subdivide CD4+ and CD8+ T 
cells into HLA-DR-CD38-, HLA-DR-CD38+, HLA-DR+CD38- and HLA-DR+ CD38+, as indication of 
cell activation status. The markers T-cell immunoglobulin and mucin protein-3 (TIM-3) and 
Programmed death-1 (PD-1) were used to examine exhaustion levels in CD4+ T cells and CD8+ T 
cells (TIM-3-PD-1-, TIM-3-PD-1+, TIM-3+PD-1- and TIM-3+PD-1+). Histograms were also plotted for 
each activation and exhaustion marker to examine the frequency distribution of the data, as a 
function of median fluorescence intensity (MFI; Figure 2.2 C).  
 
 
 
 
 
Tube FITC PerCP V450 V500 APC APC-H7 PE-Cy7
Isotype IgG1 IgG2 IgG1 IgG2 CD3 CD8 CD4
Experimental PD-1 TIM-3 CD38 HLA-DR CD3 CD8 CD4
Volume 2µl 10µl 5 µl 5 µl 5 µl 2µl 2 µl
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Figure 2.2 Gating strategy for flow cytometric analysis.  
Singlets and lymphocytes were gated based on forward scatter height (FSC-H), forward scatter area (FSC-
A) and side scatter area (SSC-A) (A). Gating on CD3+ cells was followed by identification of CD3+CD4+ and 
CD3+CD8+ T cells. Quadrant gates were set based on isotype control for CD45RA and CCR7 
(differentiation), HLA-DR and CD38 (activation), TIM-3 and PD-1 (exhaustion) on the CD3+CD4+ T-cell 
population (B). Overlapping histograms from the isotype (grey) and the experimental tubes (red and blue) 
were plotted for each activation and exhaustion marker to examine the frequency distribution of the data, as 
a function of median fluorescence intensity (MFI) on CD3+CD4+ T cells (C). The same gating strategy was 
carried out on CD3+CD8+ T cells. Representative data from one HIV-1-uninfected healthy control is shown. 
 
To verify that the gating strategy using isotype controls accurately defined a positive population 
from a negative one, a fluorescence-minus-one (FMO) analysis was carried out to determine the 
background fluorescence staining. This was carried out on two HIV-1 seronegative individuals in 
parallel with the isotype staining shown above. The procedure of FMO involved alternating the 
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exclusion of one surface marker antibody from the panels listed in Table 2.10 and Table 2.11. As 
listed in Table 2.12 below, PBMC added to Tube 1 were stained with monoclonal antibodies 
against CCR7, CD38, HLA-DR, CD3, CD8 and CD4 whilst anti-CD45RA was excluded from the 
panel. Tubes 2, 3 and 4 contained all antibodies except for anti-CCR7, anti-CD38 and anti-HLA-DR 
respectively. Finally, PBMC in Tube 5 were stained with the entire antibody panel. The same 
analysis was carried out for the exhaustion/activation panel as listed in Table 2.13. 
 
Table 2.12. Differentiation/activation panel used for Fluorescence-minus-one (FMO) staining.  
PBMC were stained in four different tubes alternating the exclusion of one antibody. Antibody left out is 
indicated by (-). Tube 5 contained all antibodies. 
 
 
Table 2.13. Exhaustion/activation panel used for Fluorescence-minus-one (FMO) staining. 
PBMC were stained in four different tubes leaving out one antibody. Antibody left out is indicated by (-). Tube 
5 contained all antibodies. 
 
 
For clarification, an insert of Table 2.12 is shown in Figure 2.3 (A). CD3+CD4+ T cells (Figure 2.3 B) 
were identified as depicted above and the gates were set based on background staining for each 
tube (Figure 2.3 C and D). The gates set based on FMO staining were not notably different to the 
quadrant gates set based on isotype controls (Figure 2.3 E), suggesting that the two staining 
controls were compatible for the two antibody panels. Isotype controls were used for all 
subsequent experiments. 
Tube nr PE-Cy7 APC V450 V500 PerCP FITC APC-H7
1 - CCR7 CD38 HLA-DR CD3 CD8 CD4
2 CD45RA - CD38 HLA-DR CD3 CD8 CD4
3 CD45RA CCR7 - HLA-DR CD3 CD8 CD4
4 CD45RA CCR7 CD38 - CD3 CD8 CD4
5 CD45RA CCR7 CD38 HLA-DR CD3 CD8 CD4
Volume 2 µl 5 µl 5 µl 5 µl 5µl 1µl 5µl
Tube nr FITC PerCP V450 V500 APC APC-H7 PE-Cy7
1 - TIM-3 CD38 HLA-DR CD3 CD8 CD4
2 PD-1 - CD38 HLA-DR CD3 CD8 CD4
3 PD-1 TIM-3 - HLA-DR CD3 CD8 CD4
4 PD-1 TIM-3 CD38 - CD3 CD8 CD4
5 PD-1 TIM-3 CD38 HLA-DR CD3 CD8 CD4
Volume 1µl 10 µl 5 µl 5 µl 5 µl 2 µl 2 µl
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Figure 2.3 Fluorescence-minus-one (FMO) staining.  
Representative staining of one HIV-1-uninfected control. PBMC were stained with various surface markers in 
five different tubes as listed in the table (A). CD3+CD4+ T cells were identified based on the gating strategy 
outlined in Figure 2.2 (B). Alternative exclusion of anti-CD45RA (Tube 1) and anti-CCR7 (Tube 2) from the 
antibody panel defined a positive staining result from a negative one based on background fluorescence 
staining (C). This was also carried out for anti-CD38 (Tube 3) and anti-HLA-DR (Tube 4) (D). Gates were set 
based on background staining in Tubes 1 and 2 to identify the four differentiation subsets and Tubes 3 and 4 
to assess activation levels (E). The gates that were set based on FMO staining (Tube 5) were not notably 
different compared to the gates that were set based on isotypes, leading to similar frequencies (E). The 
same analysis was carried out for CD3+CD8+ T cells. 
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2.18 Detection of Antigen-Specific CD8+ T Cells with ProImmune Pro5® 
Pentamers 
The Pro5® Pentamers used to detect antigen-specific CD8+ T cells are detailed in Table 2.14. 
PBMC (2x106) were allocated to labelled FACS tubes (Greiner Bio-One) and washed with 2ml BSA 
stain buffer (BD Biosciences), centrifuged at 652 x g for 5 minutes, supernatant discarded and 
resuspended in residual liquid (~50µl). Pro5® Pentamers (ProImmune Ltd) were centrifuged at 4ºC 
in a microcentrifuge at 14,000 x g for 3 minutes to pellet any protein aggregates and prevent 
interference with staining. 10µl of appropriate Pro5® Pentamer conjugated to R-phycoerythrin (PE), 
at a concentration of 50µg/ml in PBS stabilized with 1% BSA and 0.01% sodium azide, were added 
to the cells and mixed by pipetting. After 10 minutes of incubation at RT in the dark the cells were 
washed with 2ml BSA stain buffer (BD Biosciences), centrifuged at 652 x g for 5 minutes, the 
supernatant discarded and resuspended in the residual volume of stain buffer (~50µl). Antibodies 
to cell-surface molecules were added in optimal amounts according to the antibody panel (Table 
2.15), and incubated in the dark for 20 minutes at 4ºC. Stained cells were then washed two more 
times with 2ml BSA stain buffer (BD Biosciences) centrifuged at 652 x g for 5 minutes, the 
supernatant discarded and resuspended in the residual volume. Cells were fixed with 200µl of 2% 
paraformaldehyde diluted 2:1 with deionised water. Tubes were vortexed to avoid clumping and 
stored in the dark at 4ºC until acquisition using an LSR II flow cytometer and FACSDiva™ v.6.1.2. 
acquisition software (Becton Dickinson Immunocytometry Systems). The spectral overlap between 
all channels was calculated automatically by the BD FACSDiva software. At least 250,000 events 
were acquired within a lymphocyte gate. Data were analysed using FlowJo software (Tree Star). 
 
Table 2.14. List of Pro5® Pentamers from ProImmune used for multimer staining.  
The sequences, HLA-restriction and epitope origin of all Pro5® Pentamers are listed. 
 
 
 
 
 
 
 
Antigen Epitope origin Restricting HLA allele
Pentamer 
code
Peptide 
sequence
EBV BMLF-1 259-267 A*02:01 GL9 GLCTLVAML
EBV EBNA-3A 247-255 B*07:02 RL9 RPPIFIRRL
HCMV pp65 495-503 A*0201 NV9 NLVPMVATV
HCMV pp65 417-426 B*07:02 TM10 TPRVTGGGAM 
HIV-1 gag p17 76-84 A*0201 SL9 SLYNTVATL 
HIV-1 gag p24 223-231 B*07:02 GL9 GPGHKARVL
HIV-1 gag p24 265-274 B*27:05 KK10 KRWIILGLNK
HIV-1 nef 137-145 A*0201 LL9 LTFGWCFKL
HIV-1 nef 128-137 B*07:02 TL10 TPGPGVRYPL
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Table 2.15. Antibody panel for phenotypic analysis of antigen-specific CD8 T cells using Pro5® 
Pentamers. 
 
 
2.19 Detection of Antigen-Specific CD8 T Cells with MHC DextramerTM 
PBMC (2x106) were allocated to labelled FACS tubes (Greiner Bio-One) and washed with 2ml BSA 
stain buffer (BD Biosciences), centrifuged at 652 x g for 5 minutes, supernatant discarded and 
resuspended in residual liquid (~50µl). 10µl of appropriate MHC DextramerTM (Immudex, 
Copenhagen, Denmark) was added to the cells, tubes were mixed gently with a vortex mixer and 
incubated for 10 minutes at RT in the dark. Two ml of BSA stain buffer (BD Biosciences) was 
added, tubes were centrifuged at 652 x g for 5 minutes, the supernatant discarded and 
resuspended in the residual volume of stain buffer (~50µl). Antibodies to cell-surface molecules 
(Table 2.9) were added in optimal amounts according to the antibody panel detailed below (Table 
2.16). Stained cells were then washed two more times with 2ml BSA stain buffer (BD Biosciences) 
centrifuged at 652 x g for 5 minutes, the supernatant discarded and resuspended in the residual 
volume. Cells were fixed with 200µl of 2% paraformaldehyde diluted 2:1 with deionised water. 
Tubes were vortexed to avoid clumping and stored in the dark at 4ºC until acquisition using an LSR 
II flow cytometer and FACSDiva™ v.6.1.2. acquisition software (Becton Dickinson 
Immunocytometry Systems). At least 250,000 events were acquired within a lymphocyte gate.  
 
Table 2.16. Antibody panel for phenotypic analysis of antigen-specific CD8 T cells using MHC 
DextramerTM.  
 
 
2.20 Intracellular Cytokine Staining 
PBMC were resuspended in tissue culture medium at a concentration of 2x106 cells/ml. 1ml of cell 
suspension (2x106 cells) was transferred to labelled 15ml screw-cap polypropylene tubes (Alpha 
Laboratories) and appropriate concentrations of peptide, peptide pools and whole antigen were 
added as detailed in Table 2.1. TCM and PMA/Ionomycin were used as negative and positive 
control respectively. In addition, co-stimulatory antibodies CD28/CD49d (BD Biosciences) were 
Tube PE-Cy7 APC V450 V500 PE PerCP FITC APC-H7
Isotype IgG1 IgG2 IgG1 IgG2 Irrelevant Pro5® 
Pentamer
CD3 CD8 CD4
Diff/Act CD45RA  CCR7 CD38 HLA-DR Pro5® Pentamer CD3 CD8 CD4
Volume 2 µl 5 µl 5 µl 5 µl 10 µl 5µl 1µl 5µl
Tube PE-Cy7 APC V450 V500 PE PerCP FITC APC-H7
Isotype IgG1 IgG2 IgG1 IgG2 Irrelevant 
Dexramer™
CD3 CD8 CD4
Diff/Act CD45RA  CCR7 CD38 HLA-DR Dexramer™ CD3 CD8 CD4
Volume 2 µl 5 µl 5 µl 5 µl 10 µl 5µl 1µl 5µl
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added to all tubes (final concentration of 3µg/ml) and tubes were then incubated at 37°C for 1 hour 
at a 45° angle with tube lids slightly loosened to allow a greater surface area for CO2 incorporation. 
Following incubation, Brefeldin A (Sigma-Aldrich) was added to give a final concentration of 
10µg/ml, tubes vortexed briefly and then incubated a further 5 hours at 37°C. Following a total of 6 
hours incubation, tubes were washed with 10ml PBS, centrifuged at 652 x g for 5 minutes, after 
which supernatant was discarded and cells resuspended in the residual volume of PBS (~50µl). 
50µl of stain buffer multiplied by number of FACS tubes per staining condition was dispensed into 
each tube and the suspensions were split between FACS tubes. Antibodies to cell-surface 
molecules (Table 2.9) were added in optimal amounts according to the layout in Table 2.17 and 
tubes were incubated in the dark, on ice, for 20 minutes. Stained cells were then washed two times 
with 2ml BSA stain buffer (BD Biosciences), centrifuged at 652 x g for 5 minutes, the supernatant 
discarded and resuspended in the residual volume. 250µl of Fixation/Permeabilization solution was 
added to each tube followed by a brief vortex and subsequent incubation at 4°C for 20 minutes. 
Cells were washed with 2ml Perm/Wash buffer to keep cells permeabilized (BD Biosciences), 
centrifuged at 652 x g for 5 minutes, supernatant discarded and resuspended in residual volume of 
Perm/Wash buffer (~50µl). Antibodies to intracellular cytokines were added in optimal amounts 
(Table 2.17), tubes vortexed and incubated at 4°C for 30 minutes. Cells were subsequently 
washed with 2ml 1X Perm/Wash buffer, centrifuged at 652 x g for 5 minutes, supernatant 
discarded and resuspended in 200µl of Fixative (diluted 1:2 with distilled H20; BD Biosciences). 
Cells were vortexed briefly and stored at 4°C until acquisition on an LSR II flow cytometer and 
FACSDiva™ v.6.1.2. acquisition software (Becton Dickinson Immunocytometry Systems). At least 
250,000 events were acquired within a lymphocyte gate. The gating strategy is demonstrated in 
Chapter 3 (Figure 3.14; page 109). 
 
Table 2.17. Layout of antibody panel used in intracelluar cytokine staining. 
 
2.21 Depletion of CD8+ Cells from PBMC  
Fresh PBMC were resuspended in 50ml MACS buffer in a 50ml polypropylene tube (Greiner Bio-
One) and centrifuged at 425 x g for 10 minutes followed by complete aspiration of supernatant. 
Cell pellets were resuspended in 80µl of MACS buffer and 20µl of anti-CD8 MicroBeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany), per 107 total cells followed by a 15 minute incubation at 
4°C. Cells were washed by adding 2ml of MACS buffer per 107 and centrifuged at 425 x g for 10 
minutes followed by complete aspiration of supernatant. Cells were resuspended in 500µl of MACS 
Tube PE-Cy7 APC PerCP FITC APC-H7
Isotype CD4 IgG2a CD3 IgG2b CD8
Experimental CD4 IL-10 CD3 IFN-γ CD8
Volume 2 µl 3 µl 5µl 10µl 2µl
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buffer and CD8+ cells were isolated using MACS separation columns as per the manufacturer’s 
instructions (Miltenyi Biotec). The CD8- PBMC fraction was used in stimulation assays (Section 
2.22).  
2.22 Culture Stimulations for Viral Fitness Assay 
CD8- PBMC were resuspended at 1x106 cells/ml in tissue culture medium and 2ml (2x106 cells) 
were transferred to a 12-well plate. PHA was added at 10µg/ml to give a final concentration of 
5µg/ml and cells in tissue culture medium alone were run in parallel as a negative control. On day 
3 post-stimulation, 1ml of supernatant was carefully removed and divided in 500µl aliquots in 
sterile 1.5ml eppendorf tubes (Alpha Laboratories) and frozen at -80ºC. To replenish cultured cells, 
one ml of tissue culture medium supplemented with IL-2 (final concentration 40U/ml) was added to 
each well. On day 7 post-stimulation this procedure was repeated with the difference that IL-2 was 
added at 20U/ml). Supernatants for each time-point were stored at -80ºC until required for the 
Perkin Elmer p24 ELISA (section 2.23). Following preliminary analysis where little HIV-1 p24 was 
detected in initial experiments the concentration of PHA and IL-2 was increased to 10µg/ml and 
100U/ml respectively.  
 
An alternative approach tested co-cultured HIV-1+ patient PBMC or plasma with PBMC from an 
HIV-1 seronegative individual to provide fresh targets for viral replication (Karn, 1995). PBMC 
obtained from HIV-1 seronegative individuals are described in this section as donor cells/PBMC 
and were used in co-cultures with HIV-1+ patient PBMC or plasma. A summary of the assay is 
outlined below (Figure 2.4). Three days prior to co-culturing (Day -3), fresh donor PBMC were 
isolated and enumerated as detailed above. Donor PBMC were resuspended at a concentration of 
3x106 cells/ml in tissue culture medium and stimulated with PHA at a final concentration of 5µg/ml. 
The cell suspension was transferred to a 25 cm2 flask and incubated at 37°C in an upright position 
for three days. On the day of co-culturing (Day 0), donor PBMC were transferred to a 50ml tube 
(Greiner Bio-One) and centrifuged at 425 x g for 10 minutes with supernatant discarded. Donor 
PBMC were counted and resuspended at a concentration of 1x106 cells/ml in tissue culture 
medium supplemented with IL-2 (final concentration: 2U/ml). Preparation of patient PBMC were as 
follows: frozen PBMC were thawed and counted according to protocols previously detailed 
(Sections 2.12 and 2.13) and resuspended at a concentration of 1x106 cells/ml in tissue culture 
medium supplemented with IL-2 (final concentration: 2U/ml). For co-culturing, 3ml (3x106 cells) of 
patient PBMC or 1ml thawed patient plasma was mixed with 5ml (5x106 cells) of donor PBMC. The 
co-culture mix was centrifuged at 425 x g for 10 min and, without disturbing the cell pellet, tubes 
were incubated in a 37°C water bath for 1 h before transferring the cells to a 25cm2 culture flask 
and incubating at 37°C. On day 4 after co-culture, the cell suspension was transferred to labelled 
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15ml screw-cap polypropylene tubes (Alpha Laboratories) and centrifuged at 425 x g for 10 
minutes. Three ml of supernatant was collected and frozen in 1.5ml screw top tubes at -80°C until 
needed. Three ml of fresh tissue culture medium supplemented with IL-2 at a final concentration of 
2U/ml was added and cells transferred to a new 25 cm2 culture flask and incubated at 37°C. On 
the same day at day 4, fresh PBMC from a new HIV-1-uninfected donor were isolated and 
resuspended at a concentration of 3x106 cells/ml in tissue culture medium supplemented with IL-2 
(final concentration: 2U/ml) and stimulated with PHA (final concentration: 5µg/ml) as detailed 
above. The cell suspension was transferred to a 25 cm2 flask and incubated at 37°C in an upright 
position for three days. On day 7, PHA-stimulated donor PBMC suspension was transferred to a 
50ml tube (Greiner Bio-One), centrifuged at 425 x g for 10 min and resuspended in tissue culture 
medium supplemented with IL-2 at 2U/ml at a concentration of 1x106 cells/ml. The previously co-
cultured patient/donor cell suspension was transferred to a 15ml screw-cap polypropylene tube 
(Alpha Laboratories), centrifuged at 425 x g for 10 min and 3ml supernatant collected in 500µl 
aliquots in sterile 1.5ml eppendorf tubes (Alpha Laboratories) and frozen at -80°C until needed. 
Patient/donor co-culture cells were resuspended and half of the cell suspension was mixed with 
5ml (5x106 cells) of the PHA-stimulated donor PBMC to give a total volume of 8ml. The co-culture 
mix was centrifuged at 425 x g for 10 minutes and without disturbing the cell pellet tubes were 
incubated in a 37°C water bath for 1 hr before transferring the cells to a 25cm2 tissue culture flask 
and incubating at 37°C. The steps on day 4 and day 7 were repeated on day 11, 18 and 14, 21 
respectively. On day 25 after co-culture, supernatants were collected and the cell culture 
supplemented with fresh tissue culture medium and IL-2 (at 2U/ml) and incubated another three 
days as detailed above for day 4. On day 28 after co-culture, collection of supernatants was carried 
out for the last time and the cell culture disposed of according to local safety rules.  
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Figure 2.4 Schematic plan of co-culture of donor PBMC and patient PBMC/plasma.  
HC – HIV-1-uninfected control, PBMC – peripheral blood mononuclear cells, PHA – Phytohaemaglutinin. 
 
2.23 Detection of HIV-1 p24 Core Antigen in Culture Supernatants  
The Alliance HIV-1 p24 Antigen ELISA kit was used to detect HIV-1 p24 core antigen in culture 
supernatants as recommended by the manufacturer (Perkin-Elmer Life Sciences, Waltham, MA, 
USA). Frozen supernatants collected at different time-points were thawed to RT and treated with 
Triton X-100 (Perkin-Elmer Life Sciences) at 1 in10 for 20 minutes to inactivate the virus. Samples 
were diluted to 1/10 in addition to using neat sample. A p24 standard curve was prepared as 
follows: 20µl of p24 positive control (Perkin-Elmer Life Sciences) was added to 980µL of tissue 
culture medium in a sterile 1.5ml eppendorf tube (Alpha Laboratories) to make a 4000pg/ml 
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previous co-culture 
Incubate 
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Incubate 
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dilution. 800µl of the 4000pg/ml solution was then added to 3.2ml tissue culture medium in a 15ml 
screw-cap polypropylene tube (Alpha Laboratories) to make an 800pg/ml solution. This solution 
was subsequently used to prepare a 2-fold serial dilution as shown in Figure 2.5 always ensuring 
that the tip was replaced between each dilution. 100µl of standard curve dilutions were added in 
duplicate to the appropriate wells of an anti-HIV-1 p24 antibody-coated Microplate (Perkin-Elmer 
Life Sciences) according to the plate layout below (Figure 2.6). 100µl of supernatant were added to 
each well in duplicate. 100µl of tissue culture medium was included as a negative control. 
 
Figure 2.5 Preparation of 2-fold dilutions for p24 standard curve. 
 
 
Figure 2.6 Example of plate layout used in ELISA. 
 
The plate was sealed and incubated at 37° for 2 hours, after which six washes were carried out on 
the plate with 200µl wash buffer, gently decanting and blotting onto paper between washes. The 
last wash was left on to prevent the plate from drying out. 100µl detector antibody (Perkin-Elmer 
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Life Sciences) was added to all wells, the plate sealed and incubated for 1 hour at 37°C. Plate was 
washed six times with 200µl wash buffer, gently decanting and blotting onto paper between 
washes. The last wash was left to avoid drying out the wells and removed immediately before 
adding 100µl of Streptavidin-HRP solution (Perkin-Elmer Life Sciences) to all wells and the plate 
was incubated at RT for 30 minutes. Plate was washed six times with 200µl 1x wash buffer 
(Perkin-Elmer Life Sciences), gently decanting and blotting onto paper between washes. Just prior 
to use, 1OPD tablet (Perkin-Elmer Life Sciences) was added to 11ml of substrate diluent (Perkin-
Elmer Life Sciences) in a 15ml screw-cap polypropylene tube (Alpha Laboratories) and left to fully 
dissolve. 100µl of this was dispensed to each well and incubated for 20 minutes at RT. 100µl stop 
solution (4M sulphuric acid) (Perkin-Elmer Life Sciences) was added to all wells. The plate was 
read at 492 nm against a reference of 620 nm using the Infinite® 200 PRO Microplate reader 
(Tecan Group, Switzerland).  
2.24 PBMC Stimulations for Detection of IL-10 
PBMC were resuspended at 1x106 cells/ml in tissue culture medium and 2ml (2x106 cells) were 
transferred to a 12-well plate. Antigens including CMV WL and HIV-1 Nef 20mer peptide pool were 
added at appropriate concentrations (Table 2.1) and PBMC in tissue culture medium alone were 
run in parallel as a negative control. One ml of supernatant was carefully removed at 12 hrs, 24 hrs 
and 48 hrs post stimulation, divided in 500µl aliquots in sterile 1.5ml eppendorf tubes (Alpha 
Laboratories) and frozen at -80ºC until required for detection of IL-10 in the IL-10 Quantikine assay 
(Section 2.25).  
2.25 Detection of IL-10 by Enzyme-Linked Immunosorbent Assay 
(ELISA) 
The presence of IL-10 in plasma and culture supernatants was quantified using the IL-10 
Quantikine ELISA as recommended by the manufacturer (R&D Systems, Abingdon, UK). This 
assay has a lower level of threshold sensitivity of 3.9 pg/ml. Plasma and supernatants were 
collected according to protocols previously described (Sections 2.10 and 2.24) and thawed to RT 
prior to use. Fifty µl of Assay Diluent (R&D Systems) (plasma samples only) was added to each 
well in a 96 well polystyrene Microplate pre-coated with a mouse anti-IL-10 monoclonal antibody 
(R&D Systems). In parallel, 5000pg of IL-10 standard (R&D Systems) was reconstituted with 1ml of 
deionised water and 100µl (500pg) of this stock solution was used to produce a two-fold serial 
dilution (500, 250, 125, 62.5, 31.2, 15.6 and 7.8 pg/ml) with the Calibrator Diluent (R&D Systems) 
serving as the zero standard (0 pg/ml) ensuring that every tube was mixed thoroughly and a new 
tip used between each transfer. 200µl of Standard, control and samples was added to each well, 
the plate covered with an adhesive strip and then incubated for 2 hours at RT. The plate was 
subsequently washed 4 times with 400µl of wash buffer (R&D Systems) per well ensuring a 
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complete removal of liquid between each wash for good performance. 200µl of conjugate IL-10 
(R&D Systems) was added to each well, the plate covered with an adhesive strip and incubated for 
2 hours or 1 hour if plasma or culture supernatants were assayed respectively. The plate was 
subsequently washed 4 times with wash buffer (R&D Systems) and 200µl of Substrate solution 
(stabilised hydrogen peroxide and chromogen) (R&D Systems), which was made up within 15 
minutes of use was added to each well. The plate was protected from light and stored at RT for 
approximately 30 minutes before 50µl of Stop Solution (R&D Systems) was added to stop the 
reaction. The Infinite® 200 PRO Microplate reader (Tecan Group) set to 450nm was used to 
determine the optical density of each well within 20 minutes of adding the Stop Solution. 
2.26 Genomic DNA Extraction for HLA-Genotype Analysis 
The Nucleon™ BACC2 Genomic DNA Extraction kit (GE Healthcare Life Sciences, 
Buckinghamshire, UK) was used to extract genomic DNA from cryopreserved PBMC. Following 
thawing, 1x106 cells were aliquoted into 50ml polypropylene tubes and collected by centrifugation 
at 600 x g for 5 minutes at 4°C. Cell lysis and RNA digestion: Supernatant was discarded and 
cells were resuspended in 1ml of Reagent A (GE Healthcare Life Sciences) and subsequently left 
for 5 minutes on ice. Tubes were centrifuged at 1300 x g for 5 minutes at 4°C and supernatant was 
discarded. 2ml of Reagent B (GE Healthcare Life Sciences) was added to the pellet and tubes 
were vortexed briefly to resuspend the pellet. Suspension was then transferred to a 15ml screw-
cap polypropylene tube (Alpha Laboratories). 15µl of 50µl/ml RNAse A solution (GE Healthcare 
Life Sciences) was added to the tubes for digestion of RNA that may be present in the sample and 
tubes were incubated for 30 minutes at 37°C. Deproteinisation: Following the incubation period, 
500µl of sodium perchlorate (GE Healthcare Life Sciences) was added to the cells and tubes were 
inverted slowly 10 times by hand. 2ml chloroform was added and tubes were inverted slowly an 
additional 10 times by hand. Tubes were centrifuged for 1 minute at 1300 x g and 300µl of fully 
suspended Nucleon resin (GE Healthcare Life Sciences) was added to each tube without re-mixing 
the phases. Tubes were centrifuged at 1300 x g for 4 minutes. DNA precipitation: The upper 
phase was subsequently transferred to a fresh 15ml screw-cap polypropylene tube (Alpha 
Laboratories) without disturbing the Nucleon resin layer. Two volumes of cold (-20°C) absolute 
ethanol were added to each tube, which were then inverted several times to precipitate the DNA. 
The precipitated DNA was subsequently “hooked out” using a sterile pipette tip and placed into a 
sterile 1.5ml eppendorf tube (Alpha Laboratories) containing 200µl cold (-20°C) 70% ethanol for 2 
minutes to eliminate any salts that were still present due to EDTA in the blood collection tube or 
sodium perchlorate used in the deproteinisation step of this protocol. The pipette tip was then 
removed from the ethanol and left to allow the ethanol to evaporate for 3 minutes. The dried DNA 
was then placed into a sterile 1.5ml eppendorf tube (Alpha Laboratories), containing 200µl of 
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RNAse/DNAse free water. If hooking out was not possible an additional DNA washing step was 
performed: tubes were centrifuged at 5000 x g for 5 minutes to pellet the DNA. Supernatant was 
discarded and 2ml of cold (-20°C) 70% ethanol was added to the tubes and these were inverted 
several times to wash. Tubes were then centrifuged at 5000 x g for 5 minutes. Supernatant was 
discarded and tubes placed upside down at a 35° angle to allow the pellet to air dry for 10 minutes 
to ensure all the ethanol had evaporated. 100µl RNAse/DNAse free water was added to each tube 
and left for 20 minutes to dissolve the pellet after which the 100µl was transferred into a sterile 
1.5ml eppendorf tube (Alpha Laboratories) and stored at -20°C until required.  
2.27 HLA-Typing 
HLA-typing was carried out at the Clinical Immunology Laboratory, Department of 
Histocompatibility and Immunogenetics, Hammersmith Hospital, and details on the methodology 
were kindly provided by Ruhena Sergeant. Sequencing of HLA was performed using Invitrogen 
SeCore® kits. The class I (A, B & Cw Locus) kits use primers that sequence exons 2, 3 & 4, whilst 
the DRB1 locus kit uses primers that sequence exon 2 only as these are significant sites of HLA 
polymorphism. The sequencing involves locus specific amplification for class I and group specific 
amplification for class II, in conjunction with the use of Taq DNA Polymerase and sample genomic 
DNA. Prior to carrying out sequencing reaction all unincorporated primers and free nucleotides are 
treated with ExoSAP-ITTM. The nucleotides and resulting HLA subtype is determined using 
multicolour sequence analyser. Based on the sequence data the HLA type is assigned using SBT 
software.	
2.28 Statistical Analysis 
Data was collated using Microsoft Excel version 14.4.7 for Mac 2011 (Microsoft, Redmond, WA) 
and the software GraphPad Prism version 5.0f for Mac OS X (Graphpad Software, San Diego, 
California USA) was used for all statistical calculations. Statistical analysis was performed using 
the Mann-Whitney U test for comparisons between two sets of nonparametric unpaired 
observations or the Kruskall Wallis test (when multiple sets of nonparametric unpaired 
observations were compared) with Dunns multiple test as post-hoc analysis. The Wilcoxon 
matched pairs test was used to compare statistical difference between two sets of paired 
nonparametric data. The results are presented as p values, where values less than p=0.05 were 
considered to be of statistical significance. The Spearman’s rho test was used to study possible 
correlation between two sets of nonparametric data; correlations were statistically significant when 
p values signified a 95% probability of rejection of the null hypothesis. Any variability between 
patients was assumed to be random.  
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Chapter 3 Discordant Reconstitution of HIV-1- and CMV-
specific Responses in ART-treated HIV-1+ Patients – What Can 
We Learn From Co-infection? 
3.1 Background and Aims 
The development of ART has revolutionised HIV-1 care by reversing many of the immunological 
deficiencies associated with untreated HIV-1 infection, leading to significant improvements in the 
clinical outcome of infected individuals (Deeks et al., 2013). Despite this, HIV-1-infected individuals 
on fully suppressive ART continue to be at risk of non-AIDS-related morbidities such as 
cardiovascular disease, cancer, kidney disease and neurocognitive disorders (Deeks, 2011; 
Guaraldi et al., 2011). The initiation of ART results in most cases in a suppressed plasma HIV-1 
RNA load (Volberding and Deeks, 2010), allowing for an increase of peripheral CD4 T-cell counts 
(Mocroft et al., 2007). The extent of this reconstitution depends on various factors at the start of 
ART such as: nadir CD4 T-cell count levels (Robbins et al., 2009; Lifson et al., 2011), thymic 
function (Douek et al., 2001) and immune activation (Hunt et al., 2003b; Corbeau and Reynes, 
2011). Together, these factors may affect both the quantitative immune recovery; in terms of innate 
and adaptive cell type frequencies, as well as the qualitative response to HIV-1 and other co-
morbidities.  
 
Although certain immune parameters are improved with ART, other facets of the immune system 
are only partially restored and the degree to which ART can “normalise” functional immune 
responses continue to be the focus of current research. T-cell responses to HIV-1 remain impaired 
following ART, exhibiting decreased proliferative capacity and cytolytic function (Burton et al., 
2006; Migueles et al., 2009). Cytokine profiles are also skewed with only a partial recovery of IL-2 
expression, yet IFN-γ expression is often retained (Betts et al., 2001; Harari et al., 2004). Although 
ART is inefficient at restoring qualitative responses to HIV-1 it does result in improved responses to 
opportunistic infections such as CMV (Li et al., 1998). In patients co-infected with CMV, ART-
mediated suppression of plasma HIV-1 RNA load and the resulting CD4 T-cell increase, results in 
a reduction of CMV viraemia (Deayton et al., 1999; Durier et al., 2013), as well as a decrease in 
the risk of clinical CMV disease (Palella et al., 1998; Wohl et al., 2009).  
 
CMV seropositivity has been associated with an immune risk profile in the elderly population 
(Wikby et al., 2002; Hadrup et al., 2006), which may be attributed to increased frequencies of 
CMV-specific T cells with an immunosenescent phenotype and contracted T-cell repertoire 
(Hadrup et al., 2006; Deeks, 2011). Elevated CMV-specific CD4 T-cell responses are strongly 
associated with atherosclerosis in HIV-1-infected individuals (Hsue et al., 2006; Sacre et al., 2012) 
and higher CMV IgG antibody levels have been linked to subclinical cardiovascular disease in HIV-
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1-infected women (Parrinello et al., 2012). The increased levels of T-cell activation in HIV-1-
infected individuals, which remain higher despite ART (Funderburg et al., 2013; Zhang et al., 
2013), decrease even more with the addition of an anti-CMV drug valganciclovir (Hunt et al., 
2011b).  
 
These studies highlight the importance of better understanding immune responses to CMV, not 
only in the context of its strong stimulatory responses but also for its continued association with 
increased immune activation and HIV-1 disease progression. The detection of CMV viraemia in the 
semen of ART-naïve and treated individuals with CD4 T-cell counts >200 cells/µl blood has 
recently been associated with increased levels of HIV-1 proviral DNA and CD4 T-cell activation 
(Gianella et al., 2013; Gianella et al., 2014), indicating that the replication dynamics of these are 
likely to affect each other. A large proportion of the human CMV genome is devoted to immune 
evasion strategies that facilitate the persistence and dissemination of CMV in the host (Noriega et 
al., 2012). Among these is the CMV homologue for human IL-10 (McSharry et al., 2012). 
Described mainly as suppressive in the context of chronic infection, human IL-10 has been linked 
to impaired proliferative and cytokine responses during HIV-1 infection (Brockman et al., 2009). 
However, its production in response to HIV-1 or CMV has not been fully elucidated in HIV-1-
infected individuals. Considering the link between CMV and immune activation and the role of IL-
10 as an immunosuppressive cytokine, it will be important to understand how IL-10 production to 
CMV and HIV-1 may change with ART. The recent development of SIV protein-encoding vectors 
based on rhesus cytomegalovirus (RhCMV) suggests that the immunogenic nature of CMV, and its 
ability to persist in the immune system, could potentially be harnessed in vaccine development 
(Hansen et al., 2009; Hansen et al., 2011; Hansen et al., 2013). This warrants a better 
understanding of CMV-specific responses during HIV-1 infection. 
 
The work presented here aimed to explore the magnitude and functional characteristics of both 
HIV-1- and CMV-specific T-cell responses to better understand the underlying mechanism as to 
why ART reconstitutes CMV- but not HIV-1-specific responses.  
Particular aims were:  
i. To investigate the effects of ART on the reconstitution of HIV-1- and CMV-specific T-cell 
proliferative capacity.  
ii. To assess how cytokine profiles differ between ART-naïve and successfully treated HIV-1-
infected individuals, looking at IFN-γ and IL-2 known to be important for HIV-1 control as 
well as IL-10, a cytokine with immunomodulatory functions and a known immune-evasive 
mechanism used by CMV. 
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3.1.1 Hypothesis 
The main hypothesis that underlined this work is that the functional characteristics of CMV-specific 
responses are altered during HIV-1 infection and as such impact on HIV-1-specific responses and 
the ensuing ART-mediated immune reconstitution.  
 
3.2 Results 
3.2.1 Longitudinal assessment of proliferative responses in HIV-1+ 
individuals initiating ART  
Proliferative capacity of T cells as part of a polyfunctional response is one of the strongest factors 
associated with HIV-1 control (Migueles et al., 2002; Day et al., 2007; McKinnon et al., 2012; 
Imami et al., 2013). In the majority of HIV-1-infected individuals this is lost during early HIV-1 
infection (Migueles et al., 2002; Streeck and Nixon, 2010) and not fully restored even after fully 
suppressive ART (Migueles et al., 2009). On the other hand, responses to co-infections such as 
CMV are restored and long-term successfully treated HIV-1-infected patients have high levels of 
IFN-γ anti-CMV T-cell responses (Naeger et al., 2010). Despite this, the effect of ART on CMV-
specific proliferative responses is less clear. Herein is a case study of a 32-year old HIV-1+ 
individual co-infected with CMV and presenting with late stage HIV-1 disease. The patient was 
initially diagnosed with Pneumocystis carinii (or jiroveci) pneumonia, and had a nadir CD4 T-cell 
count and plasma HIV-1 RNA load of 23 cells/µl blood and 848,985 RNA copies/ml, respectively. 
Both colon and rectum biopsies isolated from this individual tested positive for CMV. Initiation of 
ART with stavudine, lamivudine, ritonavir and saquinavir resulted in a rebound of CD4 T-cell count 
to >200 cells/µl blood and a decrease of HIV-1 RNA load to below the level of detection (<50 
copies/ml plasma) in the space of two months, with no further trace of CMV end-organ disease 6 
months after initiation of ART. To better understand the effect of ART on the induction of 
proliferative HIV-1- and CMV-specific T-cell responses, a longitudinal analysis was carried out on 
this individual. Blood samples were collected at baseline before initiation of ART (week 0), at week 
12 and week 52. PBMC were isolated and stimulated with recombinant HIV-1 Gag p24 antigen and 
CMV WL, and assessed for proliferative responses using the lymphoproliferative response (LPR) 
assay. The patient had no proliferative responses to either HIV-1 Gag or CMV WL prior to initiation 
of ART (SI=3 for both; Figure 3.1). However, within 12 weeks of initiating ART there was a modest 
increase in proliferative responses to CMV (SI=4) but not to HIV-1 Gag (SI=3). Fifty-two weeks 
after initiation of ART the proliferative responses to CMV showed an almost eight-fold increase to a 
value of SI=33, yet HIV-1-specific responses to Gag remained unchanged (SI=3).  
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Figure 3.1 Longitudinal analysis of proliferative responses to antigens in one HIV-1+ patient. 
Proliferative responses to recombinant HIV-1 Gag p24 protein (red bars) and CMV WL (blue bars) (with error 
of the mean) were examined using the LPR assay on one HIV-1+ CMV+ case study initiating ART. Samples 
were taken before (Week 0) initiating ART and at Week 12 and 52 after initiating ART, to examine the effect 
of ART on viral-specific proliferative responses. Results are expressed as stimulation index (SI) derived from 
dividing the experimental triplicate mean result by background control (tissue culture medium, TCM) mean 
result. A positive response was defined as an SI score of ≥5 (dotted horizontal line). 
 
Although CMV-specific responses were improved in the case study, the follow-up period of 52 
weeks might not have been long enough for HIV-1-specific responses to recover and could have 
contributed to the lack of observable HIV-1-specific proliferative responses. To this end, six 
chronically HIV-1-infected patients initiating ART, with median CD4 T-cell counts of 198 
(interquartile range, IQR, 80-328) cells/µl blood and median plasma HIV-1 RNA load 4.99 (IQR 
4.56-5.49) log10 copies/ml plasma, were assessed for their proliferative responses to HIV-1 and 
CMV WL over a period of 96 weeks. The study (INITIO Immunology Substudy), which was part of 
a larger research programme called the INITIO study (comparing virological and immunological 
outcomes at three years after starting ART with regimens containing non-nucleoside reverse 
transcriptase inhibitor, protease inhibitor, or both), was carried out as a collaborative study in Dr 
Nesrina Imami’s group by Dr Catherine Burton (Burton, 2003; Yeni et al., 2006; Samri et al., 2007; 
Burton et al., 2008). Detailed analysis was performed with the principal aim of investigating the 
effect of ART initiation on CMV- and HIV-1- specific proliferative responses over this 96-week 
study period. Similar to the case study presented above, prior to initiation of ART, five of the six 
HIV-1+ individuals had no positive proliferative responses to either HIV-1 or CMV (median SI=1 and 
SI=2 respectively; Figure 3.2). Patient (Pt) 3 exhibited a positive proliferative response to CMV 
both before ART and in all subsequent study visits. The other five patients had variable but 
nonetheless increasing proliferative responses to CMV. Specifically, Pt 6 had a positive 
proliferative response after 24 weeks on ART (SI=12), Pt 4 after 48 weeks on ART and Pt 2 and Pt 
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5 exhibited positive proliferative responses after 72 weeks of ART (SI=11 and 25 respectively). 
After 96 weeks of treatment all 6 patients exhibited positive proliferative responses to CMV 
(median SI=25). In contrast, proliferative responses to HIV-1 remained absent throughout the study 
and were after 96 weeks of treatment still negative (median SI=2). 
 
Figure 3.2 Effect of ART initiation on CMV- and HIV-1-specific proliferative responses.  
Six chronically HIV-1-infected patients were evaluated for their proliferative responses to recombinant HIV-1 
Gag p24 antigen (red symbols and lines) and CMV WL (blue symbols and lines) over a period of 96 weeks, 
to examine the effect of initiation of ART on viral-specific responses. Samples were taken before (Week 0) 
initiating ART and at 24, 48, 72 and 96 weeks after initiating ART and examined using the LPR assay. 
Results are expressed as stimulation index (SI) derived from dividing the experimental triplicate mean result 
by background control (tissue culture medium, TCM) mean result. A positive response was defined as an SI 
score of ≥5 (dotted horizontal line). PHA responses were >5 SI for all experiments.  
 
3.2.2 Cross-sectional comparison of HIV-1 and CMV proliferative responses  
To further delineate the observed difference in reconstitution of HIV-1- and CMV-specific 
responses I next carried out detailed analysis on a cross-sectional study with the main purpose to 
further assess proliferative responses to HIV-1 and CMV in two cohorts of HIV-1+CMV+ patients: 
chronically infected ART-naïve progressors (ART-naïve; n=54) and elite controllers (EC; n=10). 
HIV-1 seronegative CMV+ healthy control individuals (HC, n=16) were included for comparison. 
Fresh PBMC were stimulated with recombinant HIV-1 Gag p24 and CMV WL and the proliferation 
responses assessed using the LPR assay. Available clinical parameters for all patients included in 
this part of the study such as CD4 and CD8 T-cell count as well as ART status, were obtained from 
the St Stephen’s Centre and detailed in table below (Table 3.1).  
 
As illustrated in Figure 3.3, proliferative responses to recombinant HIV-1 Gag p24 were negative in 
all healthy controls as would be expected (median SI=1). Equally, although five healthy controls 
exhibited positive proliferative responses to CMV WL, the majority lacked any proliferative 
responses to CMV WL (median SI=3). Of the HIV-1-infected individuals who were ART-naïve with 
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high plasma HIV-1 RNA loads, 12 responded to both HIV-1 and CMV WL, eight to CMV WL only 
and three to HIV-1 only. The median response to CMV WL was not significantly different between 
ART-naïve HIV-1-infected patients and healthy controls (median SI=2 and 3 respectively; 
p=0.7577). The highest magnitude of proliferative responses to both HIV-1 Gag and CMV WL was 
observed in EC (median SI=54 and 30). Specifically, EC exhibited significantly higher proliferative 
responses to CMV compared to both ART-naïve and HIV-1 seronegative healthy controls (p<0.001 
for both). Furthermore, responses to HIV-1 were also significantly higher in EC compared to both 
ART-naïve patients and healthy control subjects (p<0.0001).  
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Table 3.1 Clinical characteristics of HIV-1+ individuals assessed for proliferative responses. 
T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and copies/ml respectively. Age 
and HIV-1 infection are expressed in years. (IQR – interquartile range, n/a – not available). 
 
Continued on the following page. 
 
 
 
 
ID Gender Age HIV-1 infection
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
ART 
regimen
EC 1 M 53 >8 >500 n/a n/a <50 None
EC 2 M 45 >8 >500 n/a n/a <50 None
EC 3 M 58 >8 >500 n/a n/a <50 None
EC 4 M 36 >8 >500 n/a n/a <50 None
EC 5 M 50 >8 >500 n/a n/a <50 None
EC 6 M 47 >8 >500 n/a n/a <50 None
EC 7 M 52 >8 850 n/a n/a <50 None
EC 8 M 36 >8 693 n/a n/a <50 None
EC 9 M 41 >8 879 n/a n/a 92 None
EC 10 M 37 >8 722 n/a n/a <50 None
Median 46 n/a n/a n.a n/a n/a
IQR (38 to 52) n/a n/a n/a n/a n/a
ART-naïve 1 M 54 n/a 223 663 0.34 229772 None
ART-naïve 2 M 33 n/a 139 1217 0.11 94151 None
ART-naïve 3 M n/a n/a 195 n/a n/a n/a None
ART-naïve 4 M 57 n/a 257 949 0.27 24590 None
ART-naïve 5 M 35 n/a 83 498 0.17 100801 None
ART-naïve 6 M 33 n/a 627 731 0.86 1784 None
ART-naïve 7 M 40 n/a 474 1096 0.43 21382 None
ART-naïve 8 M 31 n/a 89 369 0.24 779254 None
ART-naïve 9 M 48 n/a 256 777 0.33 357436 None
ART-naïve 10 M 37 n/a 151 412 0.37 21004 None
ART-naïve 11 M 27 n/a 397 2479 0.16 138244 None
ART-naïve 12 M 38 n/a 278 629 0.44 141169 None
ART-naïve 13 M 28 n/a 551 1437 0.38 39917 None
ART-naïve 14 M 41 n/a 496 745 0.67 24753 None
ART-naïve 15 M 28 n/a 516 1177 0.44 69395 None
ART-naïve 16 M 47 n/a 415 546 0.76 27248 None
ART-naïve 17 M 43 n/a 323 999 0.32 n/a None
ART-naïve 18 M 42 n/a 509 1153 0.44 179290 None
ART-naïve 19 M 30 n/a 13 169 0.08 514975 None
ART-naïve 20 M 45 n/a 486 6143 0.08 331292 None
ART-naïve 21 M 31 n/a 420 1251 0.34 182718 None
ART-naïve 22 M 36 n/a 471 912 0.52 22706 None
ART-naïve 23 M 27 n/a 358 521 0.69 144979 None
ART-naïve 24 M 31 n/a 209 502 0.42 64004 None
ART-naïve 25 M 21 n/a 233 1041 0.22 10133 None
ART-naïve 26 M 24 n/a 179 537 0.33 202760 None
ART-naïve 27 M 30 n/a 355 981 0.36 45780 None
ART-naïve 28 M 46 n/a 340 1558 0.22 123088 None
ART-naïve 29 M 29 n/a 205 339 0.60 21634 None
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Table 3.1 continued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ID Gender Age HIV-1 infection
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
ART 
regimen
ART-naïve 30 M 26 n/a 503 1367 0.37 17621 None
ART-naïve 31 M 27 n/a 284 925 0.31 228941 None
ART-naïve 32 M 43 n/a 337 794 0.42 115439 None
ART-naïve 33 M 34 n/a n/a n/a n/a n/a None
ART-naïve 34 M 39 n/a 333 1145 0.29 165378 None
ART-naïve 35 M 32 n/a 279 826 0.34 76430 None
ART-naïve 36 M 31 n/a 290 1240 0.23 475018 None
ART-naïve 37 M 41 n/a 8 330 0.02 169423 None
ART-naïve 38 M 36 n/a n/a n/a n/a n/a None
ART-naïve 39 F 35 n/a 83 730 0.11 71707 None
ART-naïve 40 M 34 n/a 123 793 0.16 38914 None
ART-naïve 41 M 31 n/a 127 949 0.13 109235 None
ART-naïve 42 M 35 n/a 128 877 0.15 1020096 None
ART-naïve 43 M 57 n/a 230 768 0.30 17878 None
ART-naïve 44 M 30 n/a n/a n/a n/a n/a None
ART-naïve 45 F 50 n/a n/a n/a n/a n/a None
ART-naïve 46 M 29 n/a 441 552 0.80 25,280 None
ART-naïve 47 M 31 n/a 465 1192 0.39 90,823 None
ART-naïve 48 M 43 n/a 123 649 0.19 274943 None
ART-naïve 49 M 40 n/a n/a n/a n/a n/a None
ART-naïve 50 F 30 n/a 300 765 0.39 11,381 None
ART-naïve 51 M 41 n/a n/a n/a n/a n/a None
ART-naïve 52 M 40 n/a 149 1702 0.09 184496 None
ART-naïve 53 M 26 n/a 397 892 0.45 134818 None
ART-naïve 54 M 33 n/a 239 1538 0.16 92795 None
Median 34 n/a 282 877 0.33 97476
IQR (30 to 41) n/a (172 to 416) (639 to 1165) (0.18 to 0.43) (25772 to 181861)
CHAPTER 3 
FUNCTIONAL RESPONSES 
94 
 
Figure 3.3 Assessment of proliferative responses to HIV-1 Gag p24 and CMV antigens 
Proliferative responses to HIV-1 Gag p24 (red bars) and CMV WL (blue bars) antigens were evaluated in EC 
(n=10), ART-naïve (n=54) and healthy controls (HC; n=16) using the LPR assay. Results are expressed as 
stimulation index (SI) derived from dividing the experimental triplicate mean result by background control 
(tissue culture medium, TCM) mean result. A positive response was defined as an SI score of ≥5 (dotted 
horizontal line). Statistical analysis was performed using the Mann-Whitney U test. Where responses 
between stimuli or groups are significantly different this will be indicated by: *= p<0.05, **= p<0.01, ***= 
p<0.001, ****= p<0.0001. 
 
In summary, untreated HIV-1 infection was associated with low HIV-1 and CMV-specific 
proliferative responses. In the longitudinal study, five of six patients who initiated ART exhibited an 
increase in CMV-specific responses, however responses to HIV-1 remained absent. HIV-1+ 
individuals who were controlling HIV-1 infection in the absence of antiretroviral therapy (termed 
EC) maintained high HIV-1- and CMV-specific proliferative responses, whereas HIV-uninfected 
controls exhibited low proliferative responses to CMV WL.  
3.2.3 Assessment of CMV- and HIV-1-specific cytokine responses 
An important aspect of the immune response involves the production of cytokines, which mediate 
the appropriate responses to different pathogens. Cytokines are important mediators of CD4 and 
CD8 T-cell homeostasis and function during antiviral immunity and changes in various cytokine 
profiles occur during HIV-1 infection with detrimental consequences to both the phenotype and 
functional properties of various T-cell subsets. For example, although IFN-γ production is readily 
detected in patients at all stages of HIV-1 infection, HIV-1-specific T cells exhibit reduced IL-2 
expression (Betts et al., 2001; Harari et al., 2004) and this has been associated with diminished 
proliferative responses (Imami et al., 2002). Moreover, studies indicate increased plasma levels of 
IL-10 during both acute and chronic untreated HIV-1 infection (Norris et al., 2006; Brockman et al., 
2009) with levels reduced upon ART initiation (Brockman et al., 2009). The nature and 
consequence of this upregulation and how it contributes to immunopathology are less clear. To 
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reconcile the differences in HIV-1 and CMV-specific T-cell responses, IFN-γ, IL-2 and IL-10 
cytokine production was evaluated in 66 chronically HIV-1-infected patients belonging to the 
Chelsea and Westminster Hospital cohort. Fresh PBMC were isolated and stimulated with CMV 
WL, HIV-1 Gag p24 and Nef 20mer peptide pools and FEC MHC class I-restricted 9mer peptide 
pool, and assessed for cytokine release using the ELISpot assay. CMV pp65 pool was included to 
assess both CD4 and CD8 T-cell responses in a subset of the individuals (n=47).  
As CMV is manifested as an asymptomatic latent infection in the majority of individuals, the 
diagnosis of this virus is generally only carried out in transplantation settings. Around 50-90% of 
HIV-1-uninfected individuals are co-infected with CMV and the majority of HIV-1-infected patients 
will be seropositive with CMV (Kim et al., 2006; Staras et al., 2006; Cannon et al., 2010). This is 
likely to be reflected in the Chelsea and Westminster Hospital cohort, where ~90% of patients are 
CMV+ (Professor Mark Nelson, personal communication). CMV induces a strong host response, in 
particular with regards to IFN-γ production (Naeger et al., 2010), and CMV-specific CD4 T cells 
may persist longer due to increased resistance to HIV-1 infection (Casazza et al., 2009; Hu et al., 
2013). Previous studies have therefore used IFN-γ production as a marker for CMV seropositivity 
and this identification of CMV+ individuals correlates well when compared to CMV serology (Appay 
et al., 2011). With this in mind, as CMV serology was unknown for the majority of patients included 
in this part of the study, IFN-γ production in response to CMV antigen stimulation was used as a 
surrogate marker for CMV seropositivity. Individuals with positive IFN-γ responses (≥20 spot-
forming cells (SFC)/million PBMC), to either or both CMV WL and CMV pp65 peptide pool were 
grouped as CMV responders, and individuals who showed no positive IFN-γ response (<20 
SFC/million PBMC) to either CMV WL or CMV pp65 peptide pool were considered CMV non-
responders. By these criteria, 58/66 HIV-1-infected patients (87.9%) were categorised as CMV-
responders and eight patients (12.1%) as CMV non-responders. The clinical characteristics for 
both groups, including CD4 and CD8 T-cell count and ART regimen, were obtained from the St 
Stephen’s Centre and detailed in Table 3.2 and Table 3.3. Nine patients had previously tested 
positive for CMV (by detection of anti-CMV IgG antibodies in their plasma) and all showed positive 
IFN-γ responses in the ELISpot assay, indicating a good correlation between CMV serology and 
ELISpot (Table 3.4). Of note, patient M105 who was CMV+, although exhibiting a positive IFN-γ 
response to CMV WL produced no IFN-γ in response to CMV pp65 peptide pool, indicating 
perhaps that the CMV WL is a better antigen/stimulus to utilise in such assessments. 
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Table 3.2 Clinical characteristics of HIV-1+ individuals classified as CMV responders.  
T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and copies/ml respectively. Age 
and HIV-1 infection are expressed in years. (IQR – interquartile range, n/a – not available). 
 
Continued on the following page. 
 
 
 
 
ID Gender Age HIV-1 infection
Nadir     
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma 
HIV-1 
RNA load
ART regimen
L352 M 37 3 136 252 231 1.09 <50 TFV+FTC+ETR
R674 M 55 18 199 975 1154 0.84 <50 ETR+TFV+FTC
H255 M 40 5 250 374 996 0.38 <50 RAL+TFV+FTC
K814 M 57 24 20 492 1003 0.49 <50 n/a+AZT
G707 M 45 3 120 461 1321 0.35 <50 DRV+RTV
G012 M 59 9 204 634 838 0.76 <50 AZT+3TC+EFV
G591 F 55 25 3 428 391 1.09 <50 TFV+FTC+EFV
M529 M 47 14 149 436 529 0.82 <50 TFV+FTC+EFV
C861 M 37 10 215 314 322 0.98 <50 3TC+TFV+DRV+RTV
K110 F 52 11 117 1131 746 1.52 <50 TFV+FTC+NVP
H374 M 49 13 205 464 836 0.56 <50 3TC+ABC+NVP
M451 M 53 21 64 219 428 0.51 <50 TFV+FTC+EFV
R394 M 60 7 154 423 394 1.07 <50 TFV+FTC+EFV
M105 M 34 7 137 360 581 0.62 <50 TFV+FTC+DRV+RTV
H973 M 39 2 214 352 352 1.00 <50 TFV+FTC+DRV+RTV
M390 M 47 17 32 368 1140 0.32 <50 TFV+FTC+EFV
E827 M 74 26 91 296 978 0.30 <50 EFV+TFV+FTC
S399 M 42 0 374 481 364 1.32 <50 FTC+TFV+EVG+n/a
V334 M 47 14 106 595 567 1.05 <50 TFV+FTC+EFV
L115 F 31 11 195 610 482 1.27 <50 TFV+FTC+DRV+RTV
C989 F 50 5 201 654 568 1.15 <50 TFV+FTC+EFV
J316 M 36 7 40 367 520 0.71 <50 TFV+FTC+EFV
J670 F 46 20 82 518 510 1.02 <50 TFV+FTC+DRV+RTV
I689 M 50 3 504 529 663 0.80 <50 TFV+FTC+NVP
M196 M 52 13 10 382 592 0.65 <50 TFV+FTC+EFV
M269 M 59 25 120 486 350 1.39 <50 TFV+FTC+RTV
O723 M 44 8 210 325 750 0.43 <50 TFV+FTC+ATZ+RTV
Z071 M 51 18 80 966 399 2.42 <50 TFV+FTC+DRV+RTV
E690 M 46 6 5 321 641 0.50 <50 FTC+TFV+EFV
C674 M 35 12 865 1112 434 2.56 <50 TFV+FTC+NVP
H479 M 36 12 94 444 966 0.46 <50 TFV+FTC+DRV+RTV
M593 M 46 9 175 503 1142 0.44 477 DRV+RTV
A983 M 56 27 241 876 562 1.56 58 TFV+FTC+EFV
W210 M 53 22 121 637 331 1.92 54 TFV+FTC+DRV+RTV
S081 M 30 7 327 346 695 0.50 7489 Art-naïve
D170 M 24 n/a 378 484 1005 0.48 6418 Art-naïve
L420 M 42 13 17 56 493 0.11 113132 Art-naïve
T041 M 48 14 246 502 963 0.52 2138529 Art-naïve
D676 M 34 0 491 491 720 0.68 43200 Art-naïve
B817 M 42 0 183 183 303 0.60 47261 Art-naïve
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Table 3.2 continued. 
 
Type of ART: Nucleoside Reverse Transcriptase Inhibitor (NRTI): Lamivudine (3TC), Abacavir (ABC), 
Azidothymidine (AZT), Emtricitabine (FTC), Tenofovir (TFV). Non-Nucleoside Reverse Transcriptase Inhibitor 
(NNRTI): Efavirenz (EFV), Etravirine (ETR). Protease Inhibitor (PI): Atazanavir (ATZ), Darunavir (DRV), Nevirapine 
(NVP), Ritonavir (RTV). Integrase Inhibitor (INSTI): Raltegravir (RAL), Elvitegravir (EVG). 
 
 
Table 3.3 Clinical characteristics of HIV-1+ individuals classified as CMV non-responders.  
T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and copies/ml respectively. Age 
and HIV-1 infection are expressed in years. (IQR – interquartile range). 
 
Type of ART: Nucleoside Reverse Transcriptase Inhibitor (NRTI): Lamivudine (3TC), Abacavir (ABC), Emtricitabine 
(FTC), Tenofovir (TFV). Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): Efavirenz (EFV). Protease 
Inhibitor (PI): Atazanavir (ATZ), Nevirapine (NVP), Ritonavir (RTV). 
 
 
 
 
ID Gender Age HIV-1 infection
Nadir     
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-
1 RNA load ART regimen
B277 M 58 0 235 348 2291 0.15 1077366 Art-naïve
H207 M 38 2 464 498 1122 0.44 33322 Art-naïve
L989 M 33 0 263 274 811 0.34 102922 Art-naïve
C295 M 29 1 414 507 1387 0.37 44217 Art-naïve
J063 M 52 20 36 127 670 0.19 209872 Art-naïve
H577 M 34 11 301 356 1466 0.24 91942 Art-naïve
C571 M 43 0 255 255 1077 0.24 53250000 Art-naïve
B288 M 47 26 337 367 1719 0.21 86878 Art-naïve
E806 M 26 1 590 751 1204 0.62 271549 Art-naïve
S476 M 26 0 670 675 556 1.21 1145 Art-naïve
C336 M 29 6 216 313 919 0.34 41085 Art-naïve
B103 M 44 9 356 421 1101 0.38 368802 Art-naïve
F383 M 43 1 472 472 1832 0.26 1581806 Art-naïve
S612 M 38 0 297 297 1113 0.27 54907 Art-naïve
B013 F 38 4 333 333 470 0.71 10567 Art-naïve
I091 M 57 10 314 314 556 0.56 78414 Art-naïve
P918 M 23 3 686 977 1272 0.77 1225 Art-naïve
P462 M 58 16 237 592 2288 0.26 10924 Art-naïve
Median 45 9 208 394 984 0.58 49
IQR (36 to 52) (3 to 14) (118 to 334) (309 to 504) (561 to 1221) (0.37 to 1.01)(49 to 43963)
ID Gender Age HIV-1 infection
Nadir     
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load ART regimen
T155 M 46 7 351 436 699 0.62 200294 Art-naïve
P498 M 23 0 384 384 896 0.43 11654 Art-naïve
E300 M 51 0 620 620 312 1.99 1282 Art-naïve
O686 M 23 1 312 312 581 0.54 107471 Art-naïve
B599 M 30 0 303 460 992 0.46 167691 Art-naïve
S326 M 23 0 252 673 942 0.71 704 TFV+FTC+ATZ+RTV
D786 M 46 9 131 399 683 0.58 <50 FTC + TFV+ EFV
M808 M 53 9 61 365 493 0.74 <50 ABC+3TC+NVP
Median 38 1 308 410 798 0.6 6468
IQR (23 to 47) (0 to 8) (222 to 359)(397 to 423) (748 to 847) (0.52 to 0.72) (540 to 122526)
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Table 3.4 Comparison of CMV serology and functional responses in a subset of HIV-1+ patients. 
Where CMV serology was known this was compared with IFN-γ, IL-2 and IL-10 functional responses 
assessed by ELISpot assays (data expressed as SFC/million PBMC).  
 
 
3.2.4 Cytokine responses to CMV and HIV-1 in HIV-1+ CMV responders and 
CMV non-responders 
The majority of HIV-1+ CMV responders produced IFN-γ in response to both CMV WL and CMV 
pp65 peptide pool, indicating a good correlation between the two CMV stimuli (Figure 3.4 A). Only 
two patients exhibited differential responses to these, producing IFN-γ in response to either antigen 
or peptide pool, not both. The median magnitude of response was slightly lower for CMV pp65 
peptide pool however, this was not significantly different compared to the response to CMV WL 
(median 197 and 269 SFC/million PBMC respectively) or the FEC peptide pool (median 225 
SFC/million PBMC). In contrast, IFN-γ responses to both HIV-1 Gag and Nef peptide pools were 
significantly lower (median 43 and 59 SFC/million PBMC; p<0.0001 for all). The majority who 
responded to HIV-1 peptide pools did so to both Gag and Nef (n=31). Seven patients responded 
only to Gag, whilst eight produced IFN-γ to Nef peptide pool only. Finally, twelve patients had no 
measurable IFN-γ response to either of the HIV-1 peptide pools. 
 
Out of 66 patients, eight (13.1 %) had no positive IFN-γ responses to either the CMV WL or CMV 
pp65 peptide pool (Figure 3.4 B). In addition, of these eight CMV non-responders, few produced 
IFN-γ in response to HIV-1 Gag and Nef peptide pool or FEC peptide pool. 
CMV       
WL
CMV 
pool
CMV     
WL
CMV 
pool
CMV    
WL
CMV 
pool
L352 POSITIVE 23/09/2009 221 304 58 25 7 2
H255 POSITIVE 03/01/2006 151 552 0 42 9 2
K110 POSITIVE 21/09/1999 352 865 9 16 2 3
M105 POSITIVE 07/07/2009 140 16 2 1 16 29
H973 POSITIVE 02/01/2009 46 83 0 1 8 119
E827 POSITIVE 07/03/2005 603 88 0 1 6 39
L115 POSITIVE 26/06/2007 463 671 55 55 110 73
M196 POSITIVE 15/11/2004 482 497 0 5 48 30
M269 POSITIVE 17/06/2008 453 1047 41 118 7 10
IFN-γ IL-2 IL-10
ID CMV IgG Date of test
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Figure 3.4 Defining CMV responsiveness by IFN-γ  production in HIV-1+ individuals.  
IFN-γ responses to CMV WL and peptide pools of CMV pp65, HIV-1 Gag p24, HIV-1 Nef and FEC were 
evaluated in 66 HIV-1+ patients using the ELISpot assay. Median and interquartile ranges are shown. PHA 
was used as a positive control and values of >250 SFC/million PBMC were obtained in all assays. A 
threshold of ≥20 SFC/million PBMC was used to determine a positive response (indicated by a dashed line). 
Patients were categorised into CMV responders (≥20 SFC/million PBMC; A) and CMV non-responders (<20 
SFC/million PBMC) based on their IFN-γ response to CMV WL and CMV peptide pool. Statistical analysis 
was performed using the Wilcoxon matched pairs test. Where responses between antigens are significantly 
different this is indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001.  
 
In contrast to that observed for IFN-γ, IL-2 production in response to either HIV-1 or CMV was 
generally low for both CMV responders and non-responders (Figure 3.5 A and B). In CMV 
responders, median IL-2 production to both CMV WL and CMV pp65 peptide pool was below the 
threshold (median 3 and 4 SFC/million PBMC respectively) but was still significantly higher 
compared to the levels observed for HIV-1 Gag p24 and Nef peptide pools (median 2 and 1 
SFC/million PBMC; p<0.01 for all). Only four CMV responders out of 58 produced IL-2 in response 
to Gag p24 peptide pool and out of these two also responded to Nef peptide pool. Furthermore, 
two patients responded to Nef peptide pool but not to Gag p24 peptide pool. Responses to FEC 
peptide pool were similar to that for CMV WL and CMV pp65 peptide pool. Only one CMV non-
responder produced measurable IL-2 responses and this was in response to HIV-1 Nef peptide 
pool (29 SFC/million PBMC; Figure 3.5 B).  
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Figure 3.5 IL-2 production in response to HIV-1 and CMV in HIV-1+ individuals.  
IL-2 ELISpot responses to CMV WL and peptide pools of CMV pp65, HIV-1 Gag p24, HIV-1 Nef and FEC 
were evaluated in 58 CMV responders (A) and eight CMV non-responders (B) identified based on their IFN-γ 
response to CMV. Median and interquartile ranges are shown. PHA was used as a positive control and 
values of >100 SFC/million PBMC were obtained in all assays. A threshold of ≥20 SFC/million PBMC was 
used to determine a positive response (indicated by a dashed line). Statistical analysis was performed using 
the Wilcoxon matched pairs test. Where responses between antigens are significantly different this is 
indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. 
 
IL-10 production in response to HIV-1 and CMV was readily observed in CMV responders (Figure 
3.6 A), albeit at a slightly lower magnitude compared to that observed for IFN-γ. PBMC stimulated 
with CMV WL or CMV pp65 peptide pool generated a positive IL-10 response in the majority of 
individuals (median 45 and 47 SFC/million PBMC). This was significantly higher in magnitude 
compared to IL-10 production following stimulation with HIV-1 Gag and Nef peptide pools (median 
4 and 9 SFC/million PBMC; p<0.001 for all). Responses to HIV-1 Nef peptide pool, although 
significantly lower compared to CMV WL and CMV pp65 peptide pool, were observed in at least 
40% of the patients studied. In contrast, few patients produced IL-10 in response to HIV-1 Gag 
peptide pool, which suggests a protein-specific IL-10 response in HIV-1-infected individuals. Of the 
ten patients who did produce IL-10 in response to Gag peptide pool, they also produced IL-10 to 
Nef peptide pool. Responses to FEC peptide pool were only observed in four individuals and these 
were just above the threshold of 20 SFC/million PBMC (median 1 SFC/million PBMC). The 
composition of the FEC peptide pool (consisting of 33 9mer peptides) results in an optimal 
stimulation of CD8 T cells, suggesting that the source of IL-10 might not be this particular cell-type 
in the HIV-1-infected patients studied.  
 
Parallel to the observations for IFN-γ and IL-2 responses, there was little IL-10 production in the 
eight CMV non-responders to either of the antigens and peptide pools tested (Figure 3.6 B). 
However, two CMV non-responders (D786 and O686) did mount a positive, albeit low, IL-10 
response to CMV pp65 peptide pool even though no IFN-γ response was observed for either of the 
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CMV forms (Figure 3.4 B). CMV non-responder E300 exhibited the only positive IL-10 responses 
to HIV-1 Gag and Nef peptide pools in these patients (33 and 38 SFC/million PBMC respectively).  
 
Figure 3.6 IL-10 production in response to HIV-1 and CMV in HIV-1+ individuals.  
IL-10 responses to CMV WL and peptide pools of CMV pp65, HIV-1 Gag p24, HIV-1 Nef and FEC were 
evaluated in 58 CMV responders (A) and 8 CMV non-responders (B), identified based on their IFN-γ 
response to CMV. Median and interquartile ranges are shown. PHA was used as a positive control and 
values of >250 SFC/million PBMC were obtained in all assays. A threshold of ≥20 SFC/million PBMC was 
used to determine a positive response (indicated by a dashed line). Statistical analysis was performed using 
the Wilcoxon matched pairs test. Where responses between antigens are significantly different this is 
indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. 
 
3.2.5 Effect of plasma HIV-1 RNA load on HIV-1- and CMV-specific responses 
Plasma HIV-1 RNA load is an important indicator of disease progression (Mellors et al., 1996), with 
strong correlations shown between viral set point and mortality during HIV-1 infection (Lavreys et 
al., 2006). To determine the effect of plasma HIV-1 RNA load on the observed HIV-1- and CMV-
specific responses, CMV responders (n=58), were subdivided into two groups based on their 
treatment status and plasma HIV-1 RNA load. HIV-1+ patients that were on ART and successfully 
responding to their treatment (having a plasma HIV-1 RNA load <50 copies/ml) were categorised 
as treated. Thirty-one patients were included in this group (n=31). In turn, CMV responders that 
had never been on treatment and exhibited plasma HIV RNA load >10,000 copies/ml plasma) 
(Hunt et al., 2011a) were referred to as ART-naϊve (n=20). The threshold of >10,000 copies/ml 
plasma was chosen to eliminate patients that were either not responding to ART (virologic non-
responders) or patients who exhibit a low plasma HIV-1 RNA load without the need for treatment 
(HIV controllers) (Emu et al., 2008). Seven patients with plasma HIV-1 RNA load between these 
two cut-offs (51-10 000 copies/ml plasma) were excluded from this analysis for the purpose of 
taking the two extremes of each side. The summary of clinical characteristics of the patients is 
listed below (Table 3.5).  
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When grouping the patients based on their treatment status, some significant differences in their 
clinical characteristics were observed. Although age was not significantly different between the 
groups (median 47 and 42 years for treated and ART-naϊve individuals respectively), treated 
patients had been diagnosed with HIV-1 for a longer period of time compared to ART-naϊve 
individuals (median 12 and 3 years respectively; p=0.0105; Table 3.5). In addition, treated patients 
had significantly higher CD4 T-cell counts compared to ART-naϊve individuals (median 444 and 
352 cells/µl blood respectively; p=0.0418), but had a history of lower nadir CD4 T-cell counts 
(median 136 and 299 respectively; p=0002). In terms of CD8 T-cell counts, these were significantly 
higher in ART-naϊve patients (median 1089 and 568 cells/µl blood; p=0.0016), which resulted in a 
significantly lower CD4/CD8 ratio, compared to patients on treatment (median 0.34 and 0.82 
respectively; p<0.0001), the latter reflecting the effect of ART towards normalisation of CD4/CD8 
ratio. 
 
Table 3.5 Clinical characteristics of ART-naϊve and treated HIV-1+ individuals.  
T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and copies/ml respectively. Age 
and HIV-1 infection are expressed in years. (IQR – Interquartile range). 
 
 
 
 
Figure 3.7 illustrates how IFN-γ production to CMV and HIV-1 varied between the two groups. 
Responses to CMV WL, CMV pp65 and FEC peptide pool were not significantly different between 
HIV-1 treated and ART-naϊve individuals. In contrast, ART-naϊve patients produced significantly 
higher IFN-γ responses to HIV-1 Gag and Nef peptide pools (median 81 and 297 SFC/million 
PBMC respectively) compared to treated individuals (median 24 and 26 SFC/million PBMC; 
p=0.0014 and p<0.0001). These results confirm the previously observed decrease of HIV-1-
specific responses in treated individuals due to loss/reduction of antigenic stimulation (Ogg et al., 
1999; Casazza et al., 2001). 
 
 
 
 
 
Age HIV-1 infection
Nadir        
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 RNA 
load
Median 42 3 299 352 1089 0.34 89410
(IQR)  (34 to 47) (0 to 12) (237 to 371) (391 to 493) (708 to 1407) (0.24 to 0.53) (43963 to 295862)
Median 47 12 136 444 568 0.82 <50
(IQR) (40 to 53) (7 to 18) (81 to 205)  (364 to 562) (414 to 837) (0.51 to 1.09) -
p value 0.0535 0.0105 0.0002 0.0418 0.0016 <0.0001 <0.0001
ART-naïve 
Treated
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Figure 3.7 IFN-γ  production in treated and ART-naϊve CMV responders. 
CMV responders (defined by positive IFN-γ responses to CMV) were further categorised into treated (n=31; 
black dots) and ART-naϊve (n=20; red dots) based on their plasma HIV-1 RNA load (<50 copies/ml and 
>10,000 copies/ml respectively). Fresh PBMC were isolated and stimulated with CMV WL and peptide pools 
of CMV pp65, HIV-1 Gag p24, HIV-1 Nef and FEC and evaluated for IFN-γ production using the ELISpot 
assay. A threshold of ≥20 SFC/million PBMC was used to determine a positive response (indicated by a 
dashed line). Statistical analysis was performed using the Mann-Whitney U test. Where responses between 
stimuli are significantly different this is indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001.  
 
Considering that IL-2 production was in general low for all patients studied, there were little 
differences observed between treated and ART-naϊve CMV responders (Figure 3.8). However, of 
the patients that did produce IL-2, the vast majority were on ART and responded to CMV WL 
and/or CMV pp65 peptide pool (median 4 and 5 SFC/million PBMC). Of these, six produced IL-2 in 
response to both CMV stimuli, two responded to CMV WL only and another two to CMV pp65 
peptide pool only. Measurable IL-2 production in response to CMV was observed in only two ART-
naϊve patients. No significant difference was observed between the two groups in terms of 
responses to FEC, HIV-1 Gag and Nef peptide pools. 
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Figure 3.8 IL-2 production in treated and ART-naϊve CMV responders.  
CMV responders (defined by positive IFN-γ responses to CMV) were further categorised into treated (n=31; 
black dots) and ART-naϊve (n=20; red dots) based on their plasma HIV-1 RNA load (<50 copies/ml and 
>10,000 copies/ml respectively). Fresh PBMC were isolated and stimulated with CMV WL and peptide pools 
of CMV, HIV-1 Gag p24, HIV-1 Nef and FEC and evaluated for IL-2 production using the ELISpot assay. A 
threshold of ≥20 SFC/million PBMC was used to determine a positive response (indicated by a dashed line). 
Statistical analysis was performed using the Mann-Whitney U test. Where responses between stimuli are 
significantly different this is indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001.  
 
With regards to IL-10 production and its expression relative to plasma HIV-1 RNA load in the two 
groups, ART-naϊve patients with high viral load exhibited the highest magnitude of IL-10 production 
in response to both CMV and HIV-1 (Figure 3.9). Indeed, of the few individuals that exhibited HIV-1 
Gag-specific IL-10 production (Figure 3.6 A), the majority of these were ART-naϊve (median 11 
SFC/million PBMC; p<0.0001). Responses to HIV-1 Nef were also significantly higher in ART-
naϊve individuals compared to treated patients (median 52 and 1 SFC/million PBMC respectively; 
p=0.0004), although at least eight treated individuals exhibited positive IL-10 production to this 
protein. In contrast, IL-10-specific responses to CMV were observed in both treated and ART-naϊve 
individuals. However, there were some notable differences depending on whether whole lysate or 
peptide pool was used as ART-naϊve patients produced significantly higher IL-10 responses to 
CMV WL compared to treated patients (median 60 and 23 SFC/million PBMC; p=0.0121), but this 
did not reach statistical significance for the CMV pp65 peptide pool (median 97 and 39; p=0.0887). 
These results suggest that the association between higher plasma HIV-1 RNA load and IL-10 
production (Brockman et al., 2009) is not specific to HIV-1-specific responses but can also be 
observed for CMV-specific IL-10 production. Finally, although only three ART-naϊve patients 
produced IL-10 in response to FEC peptide pool, this was significantly higher compared to the 
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responses observed in treated patients (p=0.0018). However, as the majority of FEC responses 
were below the threshold, the biological relevance might not be appropriate. 
 
Figure 3.9 IL-10 production in treated and ART-naϊve CMV responders. 
CMV responders (defined by positive IFN-γ responses to CMV) were further categorised into treated (n=31; 
black dots) and ART-naϊve (n=20; red dots) based on their plasma HIV-1 RNA load (<50 copies/ml and 
>10,000 copies/ml respectively). Fresh PBMC were isolated and stimulated with CMV WL and peptide pools 
of CMV, HIV-1 Gag p24, HIV-1 Nef and FEC and evaluated for IL-10 production using the ELISpot assay. A 
threshold of ≥20 SFC/million PBMC was used to determine a positive response (indicated by a dashed line). 
Statistical analysis was performed using the Mann-Whitney U test. Where responses between stimuli are 
significantly different this is indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. 
 
For an extensive evaluation of CMV-specific responses, the next analysis included 16 HIV-1-
uninfected healthy controls (HC) for comparison. PBMC were isolated and stimulated with CMV 
WL and FEC peptide pool and assessed for IFN-γ, IL-2 and IL-10 responses as described above. 
Moreover, CMV responsiveness was determined as for HIV-1+ individuals. The results obtained 
were compared to the results observed for the 31 treated and 20 ART-naϊve HIV-1+ individuals 
(Figure 3.7 to Figure 3.9). Healthy controls exhibited similar levels of IFN-γ-producing PBMC in 
response to both CMV WL and FEC peptide pool, compared to the two HIV-1-infected patient 
groups (Figure 3.10 A). In contrast, IL-2 responses to CMV WL and FEC peptide pool were almost 
absent in healthy controls (Figure 3.10 B), with measurable responses to CMV WL only detected in 
one out of 16 healthy controls. Instead, the majority of individuals who produced IL-2 in response 
to CMV WL were treated HIV-1+ individuals. In the end, the main difference observed between the 
groups was in IL-10 production (Figure 3.10 C). Interestingly, healthy control subjects exhibited the 
highest magnitude of CMV-specific IL-10 responses (median 119 SFC/million PBMC). These were 
significantly higher compared to treated patients (median 23 SFC/million; p=0.0189), but not 
compared to the ART-naϊve group (median 56 SFC/million PBMC; p>0.05). Five healthy controls 
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also had detectable IL-10 responses to FEC peptide pool, which was significantly higher compared 
to the levels observed in treated patients (p=0.0004), indicating that IL-10 responses in HIV-1-
uninfected individuals may involve CD8 T cells. 
 
 
Figure 3.10 CMV-specific responses in HIV-1+ individuals and healthy controls (HC).  
CMV responders (as defined by IFN-γ responses to CMV) were further categorised into HIV-1 treated (n=31; 
black dots) and ART-naϊve (n=20; red dots) patients based on their HIV-1 plasma load (<50 copies/ml and 
>10,000 copies/ml respectively). HIV-1-uninfected individuals were included for comparison (n=16; blue 
dots). PBMC were stimulated with CMV WL and FEC peptide pool and evaluated for IFN-γ (A), IL-2 (B) and 
IL-10 (C) production using the ELISpot assay. A threshold of ≥20 SFC/million PBMC was used to determine 
a positive response (indicated by a dashed line). Statistical analysis was performed using the Kruskal-Wallis 
Test for multiple group comparisons. Where responses between stimuli are significantly different this is 
indicated by: *= p<0.05, **= p<0.01, ***= p<0.001, ****= p<0.0001. 
 
To determine whether responses to CMV WL, HIV-1 Gag and HIV-1 Nef peptide pools were 
associated with absolute CD4 and CD8 T-cell counts, a correlations analysis was carried out in all 
58 CMV responders as well as in treated and ART-naϊve CMV responders separately. CMV WL-
specific IFN-γ production was not significantly associated with CD8 T-cell count regardless of 
whether all patients were assessed or depending on plasma HIV-1 RNA load (data not shown). In 
contrast, IFN-γ production to CMV WL significantly correlated with CD4 T-cell count when all 
patients were assessed together (p=0.0140; Figure 3.11 A), as well as in treated individuals 
(p=0.0416; Figure 3.11B), but was not significant when ART-naϊve individuals were examined 
(p=0.1929; Figure 3.11 C). IL-10 responses to CMV WL were also associated with CD4 T-cell 
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counts rather than CD8 T-cell count, however this was only significant when treated patients were 
assessed (p=0.0475; Figure 3.11 E) and not when all individuals (Figure 3.11 D) or ART-naϊve 
patients were assessed (Figure 3.11 F) (data not shown for CD8 T-cell counts). Together these 
results suggest that higher CMV WL-specific IFN-γ and IL-10 production correlates with levels of 
CD4 but not CD8 T-cell counts primarily in treated individuals.  
 
In contrast to CMV WL, HIV-1 Gag-specific IFN-γ production did not show any correlation with 
levels of CD4 T cells in any of the three groups (data not shown). Instead, HIV-1 Gag-specific IFN-
γ production significantly correlated with CD8 T-cell count when all patients were examined 
(p=0.0037; Figure 3.12 A), although this was not significant when treated and ART-naϊve patients 
were analysed separately (p=0.5485 and p=0.0780; Figure 3.12 B and C).  
 
Finally, IFN-γ responses to HIV-1 Nef were significantly associated with CD4 T-cell counts in 
treated individuals (p=0.0002; Figure 3.13 B), but this did not reach statistical significance when all 
patients were grouped (p=0.0639; Figure 3.13 A) or when only ART-naϊve individuals were 
assessed (data not shown). CD8 T-cell counts were associated with HIV-1 Nef-specific IFN-γ 
production when all patients were grouped (p=0.0011; Figure 3.13 C), but not when patients were 
stratified by plasma HIV-1 RNA load (Figure 3.13 D; data not shown for ART-naϊve individuals). 
These results were echoed in IL-10 production as there was a correlation between HIV-1 Nef-
specific IL-10 responses and CD4 T-cell counts in treated individuals (p=0.0342; Figure 3.13 F) but 
not in ART-naϊve individuals (data not shown). Moreover, CD8 T-cell counts were significantly 
associated with HIV-1 Nef-specific IL-10 responses when all patients were assessed (Figure 3.13 
G; p=0.0098). Together these results suggest that both IFN-γ and IL-10 responses to HIV-1 Nef 
correlate with CD4 T-cell responses in treated individuals (as observed for CMV WL) but they also 
correlate with CD8 T-cell counts in HIV-1-infected individuals regardless of plasma HIV-1 RNA 
load.  
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Figure 3.11 Correlation between CMV-specific cytokine responses and CD4 T-cell counts. 
The frequency of IFN-γ producing PBMC stimulated with CMV WL was correlated with absolute CD4 T-cell 
count in all patients (n=58; A), treated (n=31; B) and ART-naϊve (n=20 C) HIV-1+ individuals. Moreover, the 
frequency of IL-10 producing PBMC stimulated with CMV WL was correlated with absolute CD4 T-cell count 
in all patients (n=58; D), treated (n=31; E) and ART-naϊve (n=20; F) HIV-1+ individuals. Spearman’s 
correlation was used for correlation analysis. 
 
 
Figure 3.12 Correlation between HIV-1 Gag-specific IFN-γ production and CD8 T-cell count.  
The frequency of IFN-γ producing PBMC stimulated with HIV-1 Gag peptide pool was correlated with 
absolute CD8 T-cell count in all patients (n=58; A), treated (n=31; B) and ART-naϊve (n=20; C) HIV-1+ 
individuals. Spearman’s correlation was used for correlation analysis. 
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Figure 3.13 Correlation between HIV-1 Nef-specific cytokine responses and CD4 and CD8 T-cell 
counts. 
The frequency of IFN-γ-producing PBMC stimulated with HIV-1 Nef peptide pool was correlated with 
absolute CD4 T-cell count (A-B) and absolute CD8 T-cell count (C-D) in all patients (n=58) and treated 
(n=31) HIV-1+ individuals. The frequency of IL-10-producing PBMC stimulated with HIV-1 Nef peptide pool 
was correlated with absolute CD4 T-cell count (E-F) and absolute CD8 T-cell count (G-H) in all patients 
(n=58) and treated (n=31) HIV-1+ individuals. Spearman’s correlation was used for correlation analysis. 
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In summary, the magnitude of IFN-γ responses to both HIV-1 peptide pools and CMV WL and pp65 peptide 
pool were high in HIV-1+ individuals, with significantly greater responses detected against CMV in HIV-1+ 
individuals. Responses to HIV-1 and CMV were of a significantly higher magnitude in ART-naïve patients 
compared to patients that were on ART, whereas IL-2-producing PBMC were detected at a very low level in 
all groups studied. IL-10 production was readily detectable in HIV-1+ individuals, and similar to IFN-γ 
responses the magnitude of IL-10-producing PBMC was significantly higher in response to CMV WL and 
CMV pp65 peptide pool compared to HIV-1 peptide pools. In addition, elevated plasma HIV-1 RNA load in 
ART-naïve individuals was associated with significantly higher IL-10 responses to CMV WL as well as HIV-1 
Gag and Ned peptide pools. Still, uninfected healthy controls exhibited the highest magnitude of IL-10 
responses to CMV WL and CMV pp65 peptide pool. IFN-γ and IL-10 responses to CMV WL and HIV-1 Nef 
peptide pool were associated with higher CD4 T-cell counts in treated patients, whilst IFN-γ responses to 
HIV-1 Gag peptide pools were associated with higher CD8 T-cell counts in viraemic patients.  
 
3.2.6 Assessment of IL-10 production in CD4 and CD8 T-cell populations 
Production of IL-10 has been detected in a wide range of cells including monocytes, macrophages, 
DC subsets and B cells, but also in several T-cell subpopulations including Th2 and Tregs (Couper 
et al., 2008a; Maynard and Weaver, 2008). IL-10 has also been reported to be upregulated in 
several of these cell types during untreated HIV-1 infection (Brockman et al., 2009). However, the 
authors measured IL-10 mRNA expression using quantitative RT-PCR and this might not reflect 
the final abundance and release of IL-10 protein as various post-translational regulatory pathways 
are likely to take place (Powell et al., 2000; Vogel and Marcotte, 2012). Having observed high IL-10 
responses in HIV-1-infected and uninfected individuals, preliminary intracellular staining was 
carried out on three healthy controls, two ART-naïve and two treated HIV-1+ patients to assess 
whether CD4 or CD8 T cells were the source of IL-10 production in these individuals. PBMC were 
isolated and stimulated with CMV WL, HIV-1 Gag and Nef 20mer peptide pools and the 
intracellular assay was used to detect IFN-γ and IL-10 cytokine levels in CD4 and CD8 T cells. 
Tissue culture medium alone and PMA/I were used as negative and positive controls respectively. 
 
Figure 3.14 A illustrates the gating strategy used to identify IFN-γ+, IL-10+ as well as IFN-γ and IL-
10 double-positive CD4+ and CD8+ T cells in one HIV-1-uninfected healthy subject (Figure 3.14 B), 
one ART-naïve ART-naϊve (Figure 3.14 C) and one treated HIV-1-infected individual (Figure 3.14 
D). IFN-γ expression in response to PMA/I was readily detected in both CD4 and CD8 T cells of all 
three individuals, whilst a more clear population of IL-10 producing T cells was detected in CD4 T 
cells from the uninfected healthy individual only (0.249% for CD4+IL-10+IFN-γ- and 0.326% for 
CD4+IL-10+IFN-γ+; Figure 3.14 B). CMV WL-specific IFN-γ responses were detected in both CD4 
and CD8 T cells of the two HIV-1-infected individuals, whilst the uninfected healthy subject 
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exhibited low CMV WL-specific IFN-γ responses in both T-cell compartments. IL-10 production in 
response to HIV-1 Gag and Nef peptide pool stimulation was not readily detected in the two HIV-1-
infected individuals. IFN-γ production was more readily detected, however it was mainly the CD8 T-
cell population which produced IFN-γ in response to HIV-1 Gag and Nef peptide pools in the two 
HIV-1-infected individuals. 
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Figure 3.14 Detection of IFN-γ and IL-10 production in CD4 and CD8 T cells.  
Gating strategy used for identification of ex vivo IFN-γ and IL-10 producing CD4+ and CD8+ T cells in PBMC 
(A). Flow cytometry dot plots of IL-10- and IFN-γ-producing CD4+ and CD8+ T cells in unstimulated PBMC 
(TCM) and in PBMC stimulated with PMA/I and CMV WL from one representative healthy control (HC) (B). 
Dot plots of IL-10- and IFN-γ-producing CD4+ and CD8+ T cells in unstimulated PBMC (TCM) and in PBMC 
stimulated with PMA/I, CMV WL, HIV-1 Gag and HIV-1 Nef peptide pools from one representative ART-naïve 
HIV-1+ individual (C) and one representative HIV-1+ individual on ART with an undetectable plasma HIV-1 
RNA load (D). Gates for the discrimination of positive and negative cytokine events were set on unstimulated 
PBMC (TCM).  
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3.3 Discussion 
Immunologic reconstitution in response to ART is routinely defined as an increase of CD4 T-cell 
count, however, the degree to which ART can fully restore immune function remains less clear 
(Guihot et al., 2011). The results of the present study provide some important insights regarding 
features of HIV-1- and CMV-specific T-cell responses in chronic progressors and how plasma HIV-
1 RNA load and its ART-mediated suppression may affect these responses.  
 
Although HIV-1-specific proliferative responses following ART initiation have been extensively 
studied, less is known about the kinetics of CMV-specific proliferative responses. One study 
reported the increase of CMV-specific CD4 T-cell proliferation in a small proportion of patients 
given ART for >3 months, but this was partial, decreasing at 6 months post-ART initiation (Autran 
et al., 1997). A cross-sectional analysis of patients with different lengths of treatment revealed that 
CD4 T-cell proliferative responses to CMV WL increased by year one post-ART initiation but 
subsequently declined after 3 years (Keane et al., 2004). An earlier study found a similar decrease 
between years three and four post-ART, which were the earliest and latest time points studied 
(Gerna et al., 2001). Variability in time points and length of follow-up are likely behind the different 
outcomes in these studies. The case study presented here, showing a decline in CMV end-organ 
disease with concomitant increase of CMV-specific T-cell proliferation, indicates an early ART-
mediated reconstitution of CMV-specific responses that was not observed for HIV-1. Discordance 
in proliferative ability to both viruses was further shown in six HIV-1-infected individuals with higher 
CD4 T-cell counts, all exhibiting strong T-cell proliferative responses to CMV WL by 96 weeks. 
There was no observed decline such as that reported for previous studies, which might be 
explained by differences in cohort characteristics (studies described above all included late stage 
disease patients) and it cannot be ruled out that this occurred post follow-up. Proliferative 
responses to CMV WL were absent in the majority of HIV-1-uninfected CMV seropositive 
individuals assessed here and this has also been observed in HIV-1-infected individuals with high 
CD4 T-cell counts (~700 cells/µl blood) (Plana et al., 2002). This suggests that proliferative 
capacity may not always be required for protective CMV-specific responses in immunocompetent 
individuals, supporting previous observations of a decline in CMV-specific proliferative responses 
(Gerna et al., 2001; Keane et al., 2004). However, CMV-specific proliferation has been detected in 
CMV seropositive healthy individuals and therefore seems to be variable (Keane et al., 2000; 
Sinclair et al., 2004). Further studies are required in which patients initiating ART can be stratified 
according to CD4 T-cell count and followed for a longer period of time. This will be important in 
order to delineate the role that pre-ART CD4 T-cell count plays in the distinct proliferative 
responses to CMV and how HIV-1 disease progression and timing of ART might affect these 
responses. 
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Interestingly, elite controllers (EC) exhibited the highest proliferative responses to HIV-1, 
concurring with previous reports (Migueles et al., 2002; Westrop et al., 2009; Imami et al., 2013). 
EC also exhibited the strongest proliferative responses to CMV. This might reflect an enhanced 
capacity of EC, compared to both chronic progressors and HIV-1-uninfected individuals, to respond 
to a wide range of pathogens including CMV (Imami et al., 2013). The demonstration that HIV 
controller status is independently associated with better control of HCV in co-infected individuals 
further supports this (Ruiz-Mateos et al., 2011), although the mechanisms behind this are not clear.  
 
In contrast to controllers, proliferative responses to HIV-1 quickly disappear in both the CD4 and 
CD8 T-cell compartments of untreated chronic progressors (Migueles et al., 2002; Streeck and 
Nixon, 2010) and initiation of ART may only partially restore this function. For instance, CD4 T-cell 
proliferation can be detected in some but not all treated individuals (Palmer et al., 2002; Migueles 
et al., 2009), whereas ART appears to have less of an effect on the HIV-1-specific CD8 T-cell 
compartment (Migueles et al., 2009). This suggests that certain aspects of T cells remain impaired 
despite ART, perhaps due to a disruption in the intracellular signalling pathways, which leads to 
poor responsiveness to stimulation with IL-2 and CD3/CD28 (both important for proliferative 
capacity) (Downey et al., 2011). In the current study, initiation of treatment had no effect on HIV-1-
specific proliferative T-cell responses despite up to two years of follow-up. As CD4 T-cell recovery 
and HIV-1-specific responses are greater when ART is initiated as early as possible (Jain et al., 
2013; Le et al., 2013), the median CD4 T-cell count of 198 cell/µl blood may be behind the 
persistent impairment of HIV-1-specific proliferative responses in these individuals. Nevertheless, 
these results demonstrate that CMV-specific proliferative capacity is readily detected in patients 
initiating ART, suggesting distinctive kinetics of reconstitution between CMV and HIV-1-specific T 
cells.  
 
The initial increase of CD4 T cells following ART initiation is due to a redistribution of memory CD4 
T cells from the lymphoid tissues toward the blood compartment (Autran et al., 1999; Bucy et al., 
1999) with naïve cells appearing after 6 months of treatment (Autran et al., 1999). CMV-specific 
immunity is often maintained during progressive HIV-1 infection, which may be due to CMV-
specific CD4 T cells persisting for longer compared to CD4 T cells with other antigen-specificities. 
CMV-specific CD4 T cells are relatively resistant to HIV-1 infection as they release β-chemokines 
(capable of binding to the CCR5 co-receptor and blocking HIV-1 entry) and upregulate innate anti-
viral responses that restricts HIV-1 post-entry (Casazza et al., 2009; Hu et al., 2013). Thus, 
following ART initiation, CMV-specific memory populations may be selectively expanded, 
consistent with the expansion of CMV-specific T cells observed here. Age-driven changes in T-cell 
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immunity that are associated with CMV infection have been linked to impaired responses to 
several infections including influenza, EBV-co-infection and mycobacterial infections in middle-
aged and elderly persons (Khan et al., 2004; Terrazzini et al., 2014b).  
 
CMV has been postulated to indirectly or directly affect HIV-1-specific responses. For example, the 
establishment of strong immune responses to CMV has been associated with a significant 
reduction in naïve T-cell levels and CD4 T-cell counts in HIV-1-uninfected young adults with 
compromised T-cell renewal capacity (Sauce et al., 2009). HIV-1-infected individuals also 
experience diminished T-cell renewal capacity due to reduced thymic output (Douek et al., 2001) 
and so in this context, a strong expansion of CMV-specific cells may influence T-cell reconstitution 
to HIV-1 after ART is initiated, particularly if CMV-specific responses are restored earlier. Previous 
studies suggest that strong anti-CMV-specific CD4 and CD8 T-cell responses are associated with 
significantly lower CD4 T-cell count recovery (in particular regarding the naïve subset) in treated 
patients (Appay et al., 2011). Lower levels of pre-ART CD4 T cells correlate with a greater CMV-
specific reconstitution (Hsu et al., 2013). Although Hsu and colleagues did not assess proliferative 
responses, the results indicate that the more advanced immunodeficiency the greater the need for 
proliferative responses to restore the pool of CMV-specific cells. Thus, starting treatment at a later 
stage of HIV-1 infection results in loss of primarily HIV-1-specific responses to a degree that is not 
readily restored in a qualitative fashion. The late initiation of ART may also result in a rapid 
expansion of CMV-specific responses, which may drive T-cell population turnover and overpower 
T-cell reconstitution for other antigens such as HIV-1.  
 
A possible mechanism for the role of CMV-specific responses in ART-mediated immune 
reconstitution may be due to its high induction of IL-10-specific responses as observed in the 
present study. The complex role of IL-10 as an immunomodulatory cytokine is shown by its 
importance in balancing protective responses and immunopathology in various infectious diseases 
(Moore et al., 2001; Couper et al., 2008a). During untreated HIV-1 infection, blockade of the IL-
10/IL-10R pathway leads to improved HIV-1-specific proliferation and IFN-γ production from CD4 
and CD8 T cells (Brockman et al., 2009; Kwon et al., 2012; Porichis et al., 2014b). CMV-specific 
CD4 T-cell proliferation following IL-10R blockade has also been detected (Brockman et al., 2009), 
but few studies have directly assessed IL-10 responses to CMV and HIV-1 in HIV-1+ individuals. 
Here it was demonstrated that IL-10 production and release is readily detected in the majority of 
HIV-1-infected individuals, concurring with previous studies (Brockman et al., 2009). A novel 
finding however, is the observation that the majority of these responses were directed against CMV 
WL and CMV pp65 peptide pool at a significantly higher magnitude compared to HIV-1-specific 
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responses, where IL-10 production was observed for HIV-1 Nef and only detected in a few subjects 
for HIV-1 Gag.  
 
Interestingly, HIV-1-uninfected individuals exhibited the highest CMV-specific IL-10 responses, 
suggesting that IL-10 is readily upregulated in response to CMV and not exclusive to CMV+ HIV-1+ 
individuals. This concurs with a recent study by Mason and colleagues in which several latency-
associated CMV genes elicited IL-10-producing CD4 T-cell responses in healthy CMV+ subjects 
(Mason et al., 2013). CMV-induced IL-10 may play a role in limiting CMV-associated immune 
activation, which has been described in both HIV-1-infected and uninfected healthy individuals (van 
de Berg et al., 2010; Hunt et al., 2011b). However, considering the described role of IL-10 in HIV-1 
immune dysfunction (Brockman et al., 2009), it is also possible that increasingly higher IL-10 
production to CMV may contribute to the accumulated levels of plasma IL-10 that is observed in 
untreated HIV-1 infection. Indeed, CMV WL stimulated a greater IL-10 response in ART-naϊve 
individuals and there was a trend for a similar observation in the CMV pp65 peptide pool. As CMV-
specific T cells may persist during advanced HIV-1 infection (Casazza et al., 2009; Hu et al., 2013), 
these cells may be a source of IL-10, thereby contributing to its accumulation. Moreover, HIV-1-
specific T-cell responses could indirectly be affected by alterations in APC function modulated by 
CMV-specific IL-10 production. Still, it is noteworthy that the highest IL-10 responses to CMV were 
observed in HIV-1-uninfected healthy controls. This raises the question of whether IL-10 is 
beneficial in some instances, yet its immunosuppressive role becomes unfavourable in the context 
of increasing immunodeficiency. Understanding the pathways that lead to IL-10 expression, its link 
with activation and whether its role is altered in the context of CMV and HIV-1 co-infection will be 
essential. ART-naϊve individuals exhibited higher IL-10 responses compared to treated individuals, 
yet higher CD4 T-cell count correlated with CMV-specific IL-10 production in the latter group only. 
Multivariate analysis will be important to correct for confounding factors including age, length of 
HIV-1 infection and length of treatment that may be behind these results.  
 
The presence of IL-10-producing HIV-1 Nef-specific T cells in ART-naϊve and to a lesser extent 
treated patients is consistent with the suppressive role that has been described for this protein 
(Landi et al., 2011). HIV-1 Nef shares at least one of the immunomodulatory functions of cellular 
IL-10, the downregulation of MHC class II. However, whilst Nef interferes with MHC class II 
expression on the cell surface by inhibiting its maturation (Stumptner-Cuvelette et al., 2001; Landi 
et al., 2011), cellular IL-10 down-regulates MHC class II expression through the induction of 
MARCH1, an ubiquitin ligase family member that promotes the degradation of MHC class II 
molecules (Thibodeau et al., 2008). Thus, Nef may on its own and via the induction of cellular IL-10 
(as described here) downmodulate MHC class II expression. CMV appears to share this function 
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via its own ability to induce cellular IL-10 and express an IL-10 homologue. Human CD34+ myeloid 
progenitor cells infected with CMV strains lacking the UL111A gene (which encodes the IL-10 
homologue) exhibit increased MHC class II expression and elicit stronger allogeneic and 
autologous CD4 T-cell responses compared to cells infected with wild type virus (Cheung et al., 
2009). In the mouse model of CMV infection, blocking cellular IL-10 (either by deleting the IL-10 
gene or blocking IL-10R) results in the expansion of mouse CMV-specific memory CD4 T cells and 
reduced latent viral load (Jones et al., 2010). Collectively, these studies suggest that cellular and 
viral IL-10 promotes the long-term maintenance of CMV by limiting the expansion of CMV-specific 
memory T cells via downmodulated MHC class II expression.  
 
The strong HIV-1 Nef-specific IL-10 production observed here suggests a similar mechanism 
employed by this protein to limit expansion of Nef-specific T cells, although this requires further 
investigation in future work. The absence of IL-10 production in response to HIV-1 Gag may be 
due to differences in the HIV-1 Gag stimulus used (recombinant versus peptide pool) or the 
method used to detect these responses compared to previous studies (Brockman et al., 2009). 
Brockman and colleagues measured Gag p24-induced T-cell proliferation and IFN-γ production 
following IL-10R blockade (Brockman et al., 2009), whereas the ELISpot assay used here 
measured IL-10 directly and detected the magnitude of IL-10 that was produced in response to 
HIV-1 Gag peptide pool. It could be that HIV-1 Gag stimulates very little IL-10 production compared 
to CMV and HIV-1 Nef but instead, Gag-specific T cells may be more sensitive to IL-10 
suppression and blockade. This would suggest differences in the expression of IL-10 receptor (IL-
10R) between different antigen-specific T cells, warranting further studies that examine its role in 
HIV-1- and CMV-specific responses. These results highlight the importance of understanding both 
the cell type that is the main producer of IL-10 during different stages of HIV-1 infection as well as 
identifying the targets of this cytokine.  
 
Upregulation of IL-10 mRNA and protein levels during HIV-1 infection have been detected in a 
wide range of cells including CD4 and CD8 T cells (Brockman et al., 2009), B cells (Siewe et al., 
2014) and NK cells (Brockman et al., 2009). In the preliminary intracellular cytokine staining 
results, although IL-10 production was above the threshold of 0.01% for some of the antigens, little 
IL-10 was detected in CD4 and CD8 T cells in response to HIV-1 peptide pools or CMV WL. 
However, few individuals were assessed, which is a limitation of the study and needs to be 
addressed in the future. A previous study found that HIV-1-specific IL-10 was produced primarily 
by CD14+ monocytes and that Tregs regulated this (Kwon et al., 2012), which may be more 
relevant to examine in future work. Positive IL-10 responses to FEC peptide pool in a few healthy 
controls does indicate that IL-10-producing CD8 T cells can be detected, although this could be to 
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EBV, Influenza or CMV, which make up the FEC peptide pool. Understanding the dynamics of IL-
10 production and uptake will shed some more light into the distinct IL-10 responses to CMV and 
HIV-1 and how these are affected by blockade of this pathway. 
 
The upregulation of plasma IL-10 that occurs during HIV-1 infection reflects an overall change in 
the cytokine network of HIV-1+ individuals compared to uninfected controls. In particular, 
diminished capacity to produce multiple cytokines is a key hallmark of HIV-1-specific T-cell 
dysfunction (Almeida et al., 2007). The use of IFN-γ as a marker for identifying HIV-1-infected 
individuals who are also co-infected with CMV (CMV responders) has been well reported and 
shown to correlate with CMV serology (Naeger et al., 2010; Loeth et al., 2012). Two more patients, 
who produced IL-10 but not IFN-γ, could have been included as CMV responders, however, re-
analysis with these two patients did not significantly change the results. The vast majority of HIV-1+ 
individuals were CMV responders and exhibited significantly higher IFN-γ responses to CMV when 
compared to HIV-1, concurring with the high incidence (Kim et al., 2006) and immunogenicity 
previously reported for CMV (Sylwester et al., 2005). However, although CMV seropositive status 
can be inferred from responses to CMV antigens, this does not preclude the possibility of the eight 
non-responsive patients also being CMV seropositive. A study in 2010 reported the highest CMV-
specific CD8 (and to a lesser extent CD4) T-cell responses (IFN-γ and/or IL-2) to be found in long-
term treated HIV-1-infected individuals compared to both untreated patients and uninfected healthy 
controls (Naeger et al., 2010). This was not observed in the current study where IFN-γ responses 
were similar between all three groups however, differences in clinical characteristics of cohorts 
need to be taken into consideration. Length of treatment was not available and will have varied 
between the patients, which might have contributed to the different results obtained to Naeger and 
colleagues. Nevertheless, higher CMV WL-specific IFN-γ production was associated with higher 
CD4 T-cell count in treated patients only, indicating that treated individuals do indeed exhibit 
increasing CMV-specific IFN-γ responses as their CD4 T-cell counts improve.  
 
The effects of ART on HIV-1-specific IFN-γ responses were more discernable. Treated patients 
exhibited a lower median IFN-γ response to both Gag and Nef peptide pools compared to ART-
naϊve individuals, in line with previous studies (Ogg et al., 1999; Casazza et al., 2001). It appears 
that although ART-mediated suppression of HIV-1 RNA load results in restoration of CMV-specific 
proliferative responses, the loss of antigenic stimulation from HIV-1 also results in loss of HIV-1-
specific IFN-γ responses. Interestingly, higher CD8 but not CD4 T-cell counts correlated with 
higher IFN-γ T-cell response to Gag and Nef, suggesting that increasing CD8 T-cell responses are 
needed to respond to HIV-1 during chronic infection. This is in stark contrast to elite and HIV 
controllers, who exhibit high IFN-γ and proliferative responses despite very low to undetectable 
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HIV-1 RNA levels (Migueles et al., 2002; Betts et al., 2006; Imami et al., 2013). The enhanced 
responses may reflect increased avidity of HIV-1-specific T cells in these individuals (Almeida et 
al., 2007). In addition, although ART-naϊve responders exhibit higher HIV-1-specific responses 
initially, the continuous antigen stimulation eventually leads to impaired T-cell responses and 
immunodeficiency that is not readily improved with ART, as observed in the longitudinal study and 
in previous studies (Migueles et al., 2009).	 In contrast to IFN-γ, HIV-1 Gag and Nef induced very 
little IL-2 responses in HIV-1-infected individuals (Harari et al., 2004), consistent with the low 
proliferative capacity displayed by HIV-1-specific T cells during chronic infection. This was also 
observed for CMV-specific IL-2 responses, which were low both in HIV-1-infected and uninfected 
healthy controls. The mechanisms behind low T-cell proliferation and IL-2 production to CMV in 
HIV-1-uninfected controls assessed here are not clear. Previous reports have described CMV-
specific IL-2 dysfunction predominantly as a feature of primary or reactivated CMV infection. CMV-
specific CD4 and CD8 T cells in pregnant women with primary infection have decreased capacity 
to proliferate and produce IL-2 in response to antigen presentation from CMV-infected DCs (Lilleri 
et al., 2008) and stimulation with CMV WL and pp65 peptide pool (Antoine et al., 2012). In addition, 
HIV-1+ patients with ART-induced elimination of active CMV retinitis experience increased CD4 
and CD8 T-cell IL-2 production (Sinclair et al., 2006). Collectively these studies suggest that active 
CMV disease down-regulates IL-2 production. The improvement of proliferative responses 
following ART-induced elimination of CMV retinitis in the case study presented here is indicative of 
an improved IL-2 response. Thus, both IL-2 and proliferative responses may be more pronounced 
in individuals with active reconstitution of CMV-specific T cells. Indeed, IL-2 responses to CMV WL 
and CMV pp65 peptide pool were present in a number of treated patients. The absence of Gag 
and Nef-specific IL-2 responses, however, demonstrates a continued impairment of HIV-1-specific 
T-cell responses despite ART, as described previously (Migueles et al., 2009). This impairment is 
consistent with the continued dysfunction of proliferative HIV-1-specific responses following ART 
initiation in the longitudinal study here.  
 
For future evaluation, it will be useful to assess CMV viraemia in order to investigate how this might 
affect CMV-specific responses. Higher CMV DNA levels have been associated with higher 
mortality among HIV-1+ patients with advanced disease (Deayton et al., 2004; El Amari et al., 
2011; Mayaphi et al., 2014). However, CMV viraemia is not readily detected in the majority of 
patients with advanced HIV-1 infection even when using an ultrasensitive PCR technique (El Amari 
et al., 2011). Out of 1128 HIV-1+ samples (from individuals with a CD4 T-cell count ≤100 cells/µl 
blood), 368 (34% of samples) had detectable CMV DNA at baseline (El Amari et al., 2011). 
Another study detected just four out of 50 samples (Hsu et al., 2013). The majority of the patients 
in this study had CD4 T-cell count >200 cells/µl decreasing the likelihood of detecting CMV DNA. 
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Thus, future studies will need to include larger number of study subjects to be able to obtain 
significant results. CMV viraemia has been linked to increased activation in the semen of HIV-1-
infected individuals (Gianella et al., 2014; Shin et al., 2014). Therefore, detection of CMV DNA in 
tissues or seminal fluids may be more relevant to examine, although this presents more challenges 
in terms of obtaining samples.  
 
This study provides some insights into the underlying mechanisms of the observed discordant 
reconstitution to HIV-1 and CMV in HIV-1+ individuals. Through analysis of proliferative and 
cytokine profiles it is demonstrated that HIV-1+ patients on ART exhibit distinct increases of 
proliferative and cytokine responses to CMV compared to HIV-1. In addition, high IL-10 production 
in both HIV-1-infected individuals and healthy control subjects suggests an important role for this 
cytokine in regulating CMV-specific responses. During untreated HIV-1 infection, CMV-specific IL-
10 may contribute to the accumulation of plasma IL-10 and impaired T-cell function described in 
previous studies. Moreover, perturbations in IL-10 production in the context of untreated and 
treated HIV-1 infection may affect the regulation of CMV-specific and HIV-1 Nef-specific 
responses. Considering the described link between CMV-associated expansion of T cells and 
compromised HIV-1 immune reconstitution, this warrants further investigation. HIV-1 studies with 
greater focus on the impact of co-infections such as CMV will help delineate to what extent CMV 
contributes to HIV-1-associated immune dysfunction. Increased bystander activation of T cells 
specific for herpesviruses such as CMV has been reported in HIV-1-infected individuals, but 
whether these are completely reduced in treated individuals is not clear. Furthermore, whether the 
discordant proliferative responses to the two viruses can be attributed to differences in exhaustion 
levels in antigen-specific T cells requires further evaluation. Investigating the distinct phenotypes of 
CMV- and HIV-1-specific T cells will help delineate the underlying mechanisms behind the 
disparate functional responses to each virus. Moreover, examination of the distribution of T-cell 
subset profiles in the context of ART may also explain the persistent impairment in the HIV-1-
specific response despite full virologic control. This may lead to new ideas and developments on 
how we can go from ART-mediated control of HIV-1 to successful elimination of the virus and 
achieve a functional cure. One of the main challenges will be to induce a qualitative restoration of 
HIV-1-specific immune responses, such as those found in individuals who control HIV-1 infection in 
the absence of ART (Walker and Yu, 2013).   
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Chapter 4 Phenotypic Characterisation of Virus-specific T 
cells in HIV-1 Infection: Profiling Total and Multimer-specific 
CD8 T cells  
4.1 Background and Aims 
HIV-1 infection has a direct impact on the immune system by depleting CD4 T cells, thereby 
preventing the generation and maintenance of antigen-specific T- and B-cell responses against 
pathogens. Continuous antigen stimulation from uncontrolled HIV-1 replication also drives 
increased levels of CD8 T cells (Margolick et al., 1995), resulting in a low CD4/CD8 T-cell ratio 
(Serrano-Villar et al., 2014). One of the key research questions to date is thus how to improve HIV-
1-specific T-cell responses in treated individuals. Although the importance of CD8 T-cell specificity 
and functionality has been underscored, further understanding of the link between phenotype of 
CD4 and CD8 T cells and viral control is needed. Previous studies have asserted the importance of 
quality, rather than quantity of the CD4 and CD8 T-cell response (Wilson et al., 2000; Migueles et 
al., 2002; Almeida et al., 2007; Deeks and Walker, 2007; Walker and Yu, 2013). Although ART-
mediated increase of CD4 T cells may help restore these functions it is only partial with many 
functions and phenotypes of both CD4 and CD8 T cells remaining altered even after years of 
treatment (Emu et al., 2014).  
 
Functional ability is tightly linked to the phenotype of responding cells and therefore the maturation 
and differentiation stage of antigen-specific CD4 and CD8 T cells is likely to affect the response 
and overall immune control of HIV-1. Amongst loss of proliferative capacity and diminished release 
of IL-2 (Wilson et al., 2000; Imami et al., 2002; Migueles et al., 2002), HIV-1-infected individuals 
also exhibit a skewed differentiation profile, suggesting HIV-1-mediated alterations in the 
differentiation pathway of various T-cell subset populations. This is often described as an abnormal 
maturation block from effector memory phenotype (TEM) to terminally differentiated phenotype 
(TEMRA) based on the differentiation model using lineage markers CCR7 and CD45RA (Sallusto et 
al., 1999; Champagne et al., 2001). Inability to mature into fully differentiated effector cells could 
result in dysfunctional effector functions and affect the capacity of HIV-1-specific CD8 T cells to 
control viraemia (Champagne et al., 2001). However, studies also describe an accumulation of 
HIV-1-specific T cells with a late differentiated phenotype (CD45RO-CD27-) and reduced 
polyfunctionality (Riou et al., 2012), indicating that further understanding of the T-cell differentiation 
subsets and their phenotype is needed.  
 
Differentiation is closely linked to activation, as this is necessary for efficient effector responses 
(resting CD8 T cells usually lack effector functions but can become cytotoxic when activated) 
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(Kaech et al., 2002), whereas excessive activation may lead to functional inefficiency (Trautmann 
et al., 2006). High T-cell immune activation (defined by expression of HLA-DR and CD38) during 
HIV-1 infection is one of the strongest predictors of disease progression (Douek et al., 2009), 
however the mechanisms behind this are not clear (Douek et al., 2009; Klatt et al., 2013). 
Destruction of mucosal surfaces and translocation of microbial products (Brenchley et al., 2006), 
irreversible tissue fibrosis due to collagen deposition (Estes et al., 2008) and bystander activation 
of co-pathogens (Hunt et al., 2011b; Smith et al., 2013) may all contribute to the persistent immune 
activation during ART. Persistent viruses in particular, have been associated with increased 
immune activation (Haas et al., 2010). Human CMV is one of these persistent viruses, which has 
been implicated in playing a role in inflammatory and age-related diseases including certain 
cardiovascular diseases (Eryol et al., 2005; Streblow et al., 2008; van de Berg et al., 2008; 
Simanek et al., 2011; Lichtner et al., 2015). It is a highly immunogenic virus and may therefore 
cause a distortion of the T-cell repertoire, skewing it in favour of a few antigen specificities (Naeger 
et al., 2010), which in turn may affect HIV-1-specific responses. Thus, understanding the CMV-
specific phenotype is warranted to understand the complex interplay between HIV-1 and CMV. 
 
Excessive immune activation and HIV-1 replication are known factors that lead to upregulation of 
co-inhibitory receptors, which act to dampen the immune response (Sachdeva et al., 2010; 
Kuchroo et al., 2014). In the absence of ART, high levels of co-inhibitory receptors gradually leads 
to the accumulation of exhausted T cells, which are characterised by altered differentiation, 
impaired function and compromised proliferation/survival (Day et al., 2006; Trautmann et al., 
2006). Several receptors have been identified including CTLA-4 (mainly found on CD4 T cells), 
LAG-3, PD-1 and TIM-3, and the complexities of the simultaneous expression of these are still 
under focus (Workman and Vignali, 2005; Day et al., 2006; Kaufmann et al., 2007; Jones et al., 
2008). The suppressive role of PD-1 on antigen-specific CD8 T cells is particularly reflected in the 
success of PD-1 inhibitors driving regression of various different types of tumours in clinical trials 
(Flemming, 2012; Errico, 2014). In addition, it plays an immunoregulatory role in various different 
viral diseases such as HBV (Maier et al., 2007), and HCV (Golden-Mason et al., 2007).  
 
In the context of HIV-1 infection, in vitro blockade of the interaction between PD-1 and one of its 
ligands PD-L1, leads to enhanced proliferation and cytotoxic function of HIV-1-specific CD8 T cells 
(Rosignoli et al., 2009; Porichis et al., 2011). Although PD-1 has been studied to a great extent, it 
is not the only negative regulator and it is likely that various regulators are involved in the 
dysfunction of HIV-1-specific CD8 T cells. TIM-3 is a relatively newly described exhaustion marker 
initially identified as a specific cell surface marker on mouse Th1 CD4 T cells (Monney et al., 
2002). Interaction of mouse TIM-3 with its ligand, galectin-9, regulates Th1 responses by 
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promoting the death of IFN-γ–producing Th1 cells (Zhu et al., 2005; Dardalhon et al., 2010). This 
may depend on the presence of the carcinoembryonic antigen cell adhesion molecule 1 
(CEACAM1), which has recently been described to be important for the inhibitory function of TIM-3 
(Huang et al., 2015). In the context of HIV-1, TIM-3 has been found to be upregulated on HIV-1-
specific CD8 T cells and blocking this marker leads to increased proliferation on HIV-1-specific 
CD8 T cells (Jones et al., 2008). However, most of the studies on TIM-3 have been performed in 
mice or in a cancer setting (Jin et al., 2010; Cao et al., 2013). During chronic LCMV infection TIM-
3+PD-1+ CD8 T cells were shown to have reduced proliferation compared to those with a TIM-3-
PD-1+ phenotype (Jin et al., 2010). Few studies have focused on human HIV-1 infection and fewer 
still on its co-expression with PD-1 in HIV-1 infection.  
 
The current study aimed to carry out a comprehensive immunophenotypic analysis where the 
magnitude and characteristics of total CD4 and CD8 T cells were evaluated. HIV-1- and CMV-
specific CD8 T cells were identified in ART-naïve and treated individuals and assessed for their 
phenotypic characteristics to further evaluate the effect of ART on virus-specific T-cell 
differentiation, activation and exhaustion. In addition, HIV-1 and CMV-specific CD8 T cells from 
treated HIV-1+ patients, who had previously taken part in an immunotherapy trial, were also 
evaluated to assess if administration of growth hormone, IL-2 and GM-CSF has an impact on the 
phenotype of these cells. 
 
Particular aims were: 
i. To determine the differentiation, activation and exhaustion profiles of total CD4 and CD8 T 
cells in ART-naïve and treated HIV-1-infected individuals.  
ii. Identify and characterise HIV-1- and CMV-specific CD8 T cells for a better understanding of 
how these are altered with ART. 
iii. Evaluate the effect of immunotherapy on the differentiation, activation and exhaustion of 
HIV-1- and CMV-specific CD8 T cells. 
4.1.1 Hypothesis 
HIV-1 infection results in profound modulation of both CD4 and CD8 T cells that are not fully 
stabilised with ART. In addition, although HIV-1 infection results in significant phenotypic changes 
of HIV-1-specific CD8 T cells, these changes also occur in CMV-specific CD8 T cells and ART-
mediated reconstitution may have differential effects on the differentiation, activation and 
exhaustion profiles of these two virus-specific CD8 T cell populations. 
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4.2  Results 
4.2.1 Immunophenotyping in HIV-1+ Individuals and Healthy Controls 
The study presented here involves a comprehensive flow cytometric analysis of the differentiation, 
activation and exhaustion profiles of CD4 and CD8 T cells in up to 64 HIV-1+ patients from the 
Chelsea & Westminster cohort and 14 HIV-1-uninfected controls (HC), for comparison. An 
established differentiation model from naïve to antigen-specific memory T cells based on the 
lineage markers CCR7 (lymph node homing receptor) and CD45RA (expressed on naïve cells and 
re-expressed at the fully mature stage of differentiation) was used to identify the T-cell 
differentiation subsets: naïve T cells (characterised by expression of both markers 
(CCR7+CD45RA+), central memory T cells (TCM) with lymph node homing capabilities characterised 
by expression of CCR7 but not CD45RA (CCR7+CD45RA
-), effector memory T cells (TEM) are 
negative for both (CCR7-CD45RA-) and terminally differentiated cells (TEMRA) by expression of 
CD45RA and not CCR7 (CCR7-CD45RA+) (Sallusto et al., 1999). Activation levels were also 
assessed using CD38 and HLA-DR to identify highly activated (HLA-DR+CD38+) CD4 and CD8 T 
cells as well as subsets expressing either of them or none (HLA-DR+CD38-, HLA-DR-CD38+ and 
HLA-DR-CD38-). Finally, co-expression of PD-1 and TIM-3 was examined to identify hyper 
exhausted CD4 and CD8 T cells (TIM-3+PD-1+) as well as T-cell subsets with other expression 
patterns of PD-1 and TIM-3 (TIM-3-PD-1-, TIM-3-PD-1+ and TIM-3+PD-1-). The gating strategy 
used to identify the different T-cell subsets is illustrated in Figure 4.1. 
 
The clinical characteristics of all patients participating in this study, including CD4 and CD8 T-cell 
counts and ART regimens, were obtained from St Stephen’s Centre and are summarized below in 
Table 4.1. It should be noted that in the 64 HIV-1+ patients, there was a wide range of the plasma 
HIV-1 RNA load and CD4 T-cell counts amongst other factors.  
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Figure 4.1 Gating strategy used to assess phenotypic profiles in CD4 and CD8 T cells.  
PBMC from one HIV-1-uninfected control (HC) were isolated and stained with various monoclonal antibodies 
for flow cytometric analysis. Doublets were gated out followed by gating on live lymphocytes (A). CD3+ cells 
were then selected followed by identification of CD3+CD8+ and CD3+CD4+ T cells. The percentage 
expression of surface markers CD45RA and CCR7 were subsequently used to identify the four differentiation 
subsets (naïve, TCM, TEM, and TEMRA; B) whilst co-expression of HLA-DR and CD38 was assessed to 
determine immune activation status (HLA-DR-CD38+, HLA-DR+CD38+, HLA-DR-CD38- and HLA-DR+CD38-; 
C). Co-expression of PD-1 and TIM-3 was examined to determine exhaustion status (TIM-3-PD-1-, TIM-3-
PD-1+, TIM-3+PD-1- and TIM-3+PD-1+; D). Expression of either marker alone was also assessed (HLA-DR+, 
CD38+, TIM-3+ and PD-1+; E). Quadrants and histogram gates were based on isotype controls. 
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Table 4.1 Clinical characteristics of HIV-1+ individuals. 
T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and copies/ml respectively. Age 
and HIV-1 infection are expressed in years. (IQR – interquartile range, n/a – not available). 
 
Continued on the following page. 
 
 
 
 
 
 
ID Gender Age HIV-1 infection
Nadir     
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load ART regimen
M898 M 50 21 230 511 470 1.09 <50 DRV+TDF+FTC
F652 M 28 6 321 485 1614 0.30 <50 AZT+3TC+EFV
S387 M 42 17 249 350 1126 0.31 <50 ETR+TPV+FTC
C696 M 37 11 67 208 821 0.25 <50 TDF+FTC+EFV
S662 M 37 5 366 503 818 0.61 <50 DRV+RTV+ETR
M380 M 44 3 296 889 559 1.59 <50 TDF+FTC+EFV
N381 F 29 1 850 902 579 1.56 <50 AZT+3TC+SQV+RTV
S276 M 49 2 206 603 546 1.10 <50 TDF+FTC+EFV
E957 M 45 9 86 277 1058 0.26 <50 TDF+ETR+DRV+RTV
H109 M 49 10 154 215 543 0.40 <50 TDF+FTC+ATV+RTV
H149 M 43 15 429 869 767 1.13 <50 TDF+FTC+EFV
P479 M 32 4 508 602 769 0.78 <50 TDF+FTC+EFV
S134 M 44 4 272 519 665 0.78 <50 TDF+FTC+EFV
H730 M 40 2 389 389 632 0.62 <50 TDF+FTC+DRV+RTV
F577 M 32 1 412 477 753 0.63 57 n/a
W524 M 57 0 220 247 522 0.47 <50 AZT+3TC+EFV
M653 M 51 14 600 850 1312 0.65 <50 EFV+TFV+FTC
M476 M 47 8 621 621 648 0.96 <50 EFV+TFV+FTC
F204 M 46 5 343 635 963 0.66 <50 ABC+3TC+ETR
R740 M 49 20 657 769 1185 0.65 <50 TFV+3TC+NVP
W291 M 37 9 640 635 493 1.29 <50 FTC+TDF+NVP
B039 M 49 16 411 411 755 0.54 <50 DRV+RTV+TFV
L040 M 50 13 273 341 891 0.38 <50 AZT+3TC+NVP
M012 M 53 19 139 208 263 0.79 <50 n/a
R805 M 64 n/a 48 435 799 0.54 54 ABC+AZT+3TC
E629 M 66 n/a 8 367 1167 0.31 <50 3TC+ABC+NVP+RAL
K740 F 24 n/a 290 517 806 0.64 <50 RPV+FTC+TFV
M907 M 58 14 59 97 944 0.10 32914 none
I950 M 22 0 374 374 688 0.54 77710 none
M321 M 29 0 645 688 1271 0.54 522022 none
H140 M 57 8 257 323 821 0.39 17093 none
B624 M 40 16 29 29 834 0.03 500000 none
R429 M 32 14 219 404 647 0.62 54998 none
S612 M 38 0 297 297 1113 0.27 54907 none
C618 M 36 2 210 210 1019 0.21 17913 none
O255 M 57 0 827 827 1769 0.47 71310 none
B013 F 38 4 380 333 470 0.71 10567 none
F383 M 43 1 472 472 1832 0.26 1581806 none
I091 M 57 10 314 253 556 0.46 78414 none
B972 M 42 2 350 441 1775 0.25 30696 none
F110 F 39 11 233 262 1228 0.21 121736 none
B288 M 47 26 337 367 1719 0.21 86878 none
B356 M 41 1 544 544 751 0.72 185410 none
P462 M 58 16 237 592 2288 0.26 10924 none
B355 M 51 3 485 485 1599 0.30 49334 none
E806 M 26 1 590 751 1204 0.62 271549 none
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Table 4.1 continued. 
 
Type of ART: Nucleoside Reverse Transcriptase Inhibitor (NRTI): Lamivudine (3TC), Abacavir (ABC), 
Azidothymidine (AZT), Emtricitabine (FTC), Tenofovir (TFV, TDF). Non-Nucleoside Reverse Transcriptase Inhibitor 
(NNRTI): Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV). Protease Inhibitor (PI): Tipranavir (TPV), Saquinavir 
(SQV), Darunavir (DRV), Nevirapine (NVP), Ritonavir (RTV). Integrase Inhibitor (INSTI): Raltegravir (RAL). 
 
4.2.2 Assessment of Differentiation/Maturation Profile 
The T-cell differentiation subsets naïve, TCM, TEM and TEMRA have diverse functions, which are all 
essential for delivery of an effective immune response. CD4 and CD8 T cells with a TCM phenotype 
produce IL-2 but have little or no effector function, and readily proliferate and differentiate to 
effector cells in response to antigenic stimulation (Sallusto et al., 1999; Sallusto et al., 2004). In 
contrast, TEM exhibit lower proliferative ability, but are able to migrate to inflamed peripheral tissues 
and display immediate effector function by producing IFN-γ and in the case of CD8 T cells cytolytic 
activity (Sallusto et al., 2004; Mueller et al., 2013). CD8 T cells of the TEMRA phenotype have a 
similar gene-expression profile of TEM cells (Willinger et al., 2005) but display an even lower 
replication potential (Geginat et al., 2003) and have increased potential to release perforin 
(Sallusto et al., 1999). Chronic HIV-1 infection has been linked to a maturation block from effector 
memory phenotype TEM to terminally differentiated phenotype (TEMRA) (Champagne et al., 2001). 
To further understand this link and to examine the effect of ART, a comprehensive assessment of 
the differentiation profiles of CD4 and CD8 T cells was carried out on 59 of the 64 HIV-1+ 
individuals and 14 healthy controls for comparison (Figure 4.2 A and B). Based on the expression 
of CCR7 and CD45RA, it was possible to detect significant alterations in the differentiation 
phenotype of CD4 and CD8 T cells between the two groups. In particular, HIV-1-infected 
individuals exhibited significantly lower frequencies of both naïve CD4 and CD8 T cells (median 
ID Gender Age HIV-1 infection
Nadir     
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load ART regimen
H573 M 33 0 181 299 1495 0.20 180 AZT+3TC+NVP
D267 M 42 8 374 786 781 1.01 <125 DRV+RTV
N494 M 36 2 262 397 452 0.88 267 TDF+FTC+EFV
D201 M 22 0 187 387 920 0.42 2918 TDF+FTC+EFV
G154 M 38 0 579 579 961 0.60 130 none
J085 F 40 2 449 449 566 0.79 8442 none
S929 M 47 14 187 250 650 0.38 7372 TDF+FTC+DRV+RTV
W510 n/a n/a n/a n/a n/a n/a n/a n/a n/a
K235 M 43 5 191 241 381 0.63 3399 none
R899 M 28 0 344 494 724 0.68 2870 none
S476 M 26 0 670 675 556 1.21 1145 none
B318 M 26 0 397 443 729 0.61 149 AZT+3TC+EFV
P918 M 23 3 686 977 1272 0.77 1225 none
B207 M 41 2 577 645 960 0.67 2375 none
L323 n/a n/a n/a n/a n/a n/a n/a n/a n/a
C21H F 27 111 n/a 329 305 1.08 n/a n/a
C897 n/a n/a n/a n/a n/a n/a n/a n/a n/a
S01H F 71 111 n/a 375 70 5.36 n/a n/a
42 5 337 443 799 0.61 140
(33 to 49) (1 to 14) (220 to 479) (329 to 603) (579 to 1126) (0.31 to 0.78) (49 to 17708)
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23% and 9% respectively; B), compared to healthy controls (median 35 and 32%; p=0.0003 and 
p=0.0033). HIV-1-infected individuals also exhibited significantly lower levels of CD4 and CD8 TCM 
cells (median 19% and 2%), compared to healthy controls (median 26%; p=0.0029 and median 
3%; p=0.0388). The most striking difference in subset frequencies was the high frequencies of TEM 
cells found in HIV-1-infected individuals, observed both in CD4 T cells (median 36%) as well as in 
CD8 T cells (median 45%). Healthy control subjects displayed significantly lower levels of this 
subset both in CD4 T cells (median 25%) and in CD8 T cells (median 26%) compared to HIV-1-
infected individuals (p=0.0013 and p=0.0046 respectively). Levels of the TEMRA subset did not differ 
significantly between HIV-1-infected and uninfected healthy control subjects for either T-cell type 
although there was a trend for higher frequencies of CD4 TEMRA cells in the latter group (p=0.0696).  
 
HIV-1-infected individuals were further divided into two groups based on their treatment status to 
assess the effect of HIV-1 RNA load on subset frequencies and whether ART results in normalised 
levels. This was defined based on the threshold described in Chapter 3, section 3.2.5. Treated 
patients with undetectable plasma HIV-1 RNA load (<50 copies/ml) were classified as treated 
(n=26) and ART-naïve patients with an HIV-1 RNA load of more than 10,000 copies/ml were 
classified as ART-naϊve (n=19) (Hunt et al., 2011a). Fourteen patients with plasma HIV-1 RNA load 
between these two cut offs were excluded from this analysis. The median frequencies including 
interquartile range (IQR) of different clinical parameters are summarised in Table 4.2 for the two 
groups. CD8 T-cell counts and CD4/CD8 ratio were significantly different between the two groups 
and there was a trend for treated individuals having higher CD4 T-cell counts (p=0.0749). ART-
naϊve and treated patients had significantly lower levels of naïve CD4 T cells (median 31% and 
21% respectively) compared to healthy controls (median 35%; p=0.0003 and p=0.0432 
respectively), indicating a failure of ART to fully reconstitute the levels of naïve CD4 T cells to 
those observed in uninfected individuals (Figure 4.2 C). Furthermore, the two HIV-1-infected 
groups also had higher frequencies of CD4 T cells that were of the TEM subset (median 35% and 
36%) compared to healthy controls (25%), although it only reached statistical significance for the 
ART-naϊve group (p=0.0018). Although healthy controls had an overall higher frequency of CD4 
TCM cells compared to all HIV-1-infected individuals (Figure 4.2 A), when looking at treated and 
ART-naϊve patients individually, this difference was no longer observed with similar medians 
observed for both patient groups (19 and 18% respectively; Figure 4.2 C). However, a few treated 
patients had considerable levels of CD4 TCM cells, indicating an ART-mediated reconstitution of 
this subset in some individuals.  
 
The effect of ART on the distribution of CD8 differentiation subsets was most apparent when 
assessing levels of CD8 naïve and TEM cells (Figure 4.2 D). Specifically, ART-naϊve individuals had 
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significantly lower levels of naïve CD8 T cells (median 7%) and significantly higher levels of CD8 
TEM cells (median 50%), compared to healthy controls (median 32% for the naïve subset and 26% 
for the TEM subset; p=0.0021 and p=0.0021 respectively). A subset of treated individuals exhibited 
higher levels of naïve CD8 T cells, however the majority of subjects had persistently low levels of 
this subset (median 13%), consistent with previous reports (Emu et al., 2014). In addition, treated 
patients had a more variable distribution of the CD8 TEM subset (median 40%) with some 
individuals having particularly high frequencies, whilst others exhibited levels resembling those of 
healthy controls. This suggests a variable effect of ART on this subset. The frequencies of CD8 
TCM were low in all three groups, whilst frequencies of CD8 TEMRA varied considerably in treated 
individuals and healthy controls with no significant differences observed between the three groups. 
In summary, the results presented here suggest a shift in the distribution of CD4 and CD8 T-cell 
subsets during untreated HIV-1 infection, from naïve to a more differentiated TEM phenotype. 
Furthermore, ART has limited effects on this altered distribution of T-cell subpopulations. 
 
Figure 4.2 CD4 and CD8 T-cell differentiation levels in HIV-1+ individuals and HC. 
Flow cytometric analysis was carried out on PBMC of 59 HIV-1+ individuals (red bars) and 14 HIV-1-
uninfected controls (HC) (grey bars; A and B), using CCR7 and CD45RA co-expression to identify CD4 and 
CD8 T-cell differentiation subsets: naïve, TCM, TEM and TEMRA. The 59 HIV-1+ patients were then grouped into 
26 treated and 19 ART-naïve patients (light and dark red bars respectively) and were compared with the 14 
HC (grey bars; C and D). All individual data points are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10th and 90th percentile range. P values are shown where 
there are statistically significant differences between the two groups (p≤0.05). Statistical analysis was 
performed using the Mann-Whitney U test for two group comparisons and the Kruskal-Wallis Test for multiple 
group comparisons. 
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Table 4.2 Clinical characteristics of ART-naϊve and treated HIV-1+ individuals. 
T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and copies/ml respectively. Age 
and HIV-1 infection are expressed in years. 
 
 
To explore the relationship between frequencies of the differentiation subsets (naïve, TCM, TEM and 
TEMRA) and absolute T-cell count in both CD4 and CD8 T cells, a correlation was undertaken 
involving the 19 ART-naïve and 26 treated HIV-1-infected individuals (n=45). There was no 
observed association between frequencies of TCM or TEMRA and absolute T-cell counts for either of 
the T-cell types (data not shown). Frequencies of the naïve CD4 T-cell subset were weakly 
associated with absolute CD4 T-cell count but not with CD8 T-cell count or CD4/CD8 ratio 
(p=0.0798, p=0.9312 and p=0.1958 respectively; Figure 4.3 A, C and E). In contrast, frequencies 
of naïve CD8 T cells were significantly associated with absolute CD4 T-cell count and CD4/CD8 
ratio and inversely associated with absolute CD8 T-cell count (p=0.0170, p<0.0001 and p=0.0051 
respectively; Figure 4.3 B, D and F). The same analysis applied to the TEM subset revealed a 
strong inverse association between frequencies of CD8 TEM and two clinical parameters: absolute 
CD4 T-cell count and CD4/CD8 ratio (p=0.0080 and 0.0088; Figure 4.4 B and F). No correlation 
was observed between levels of CD8 TEM and absolute CD8 T-cell count (p=0.2736; Figure 4.4 D). 
Similar to that observed for the CD4 naïve subset, no association was observed between CD4 TEM 
levels and absolute CD4 or CD8 T-cell counts (p=0.1412 and 0.4807; Figure 4.4 A and C). A weak 
inverse association was however associated between CD4 TEM frequencies and CD4/CD8 ratio 
(p=0.0568; Figure 4.4 E). Differentiation subsets were further correlated with activation levels 
(defined as HLA-DR and CD38 co-expression; HLA-DR+CD38+). No significant correlation was 
observed when TCM and TEMRA subsets were analysed (data not shown). Levels of CD8 but not 
CD4 T cells with a naïve phenotype were inversely associated with activation levels (p=0.0029 and 
0.3632; Figure 4.5 A and B). Both CD4 and CD8 TEM frequencies correlated with HLA-DR and 
CD38 co-expression, however it only reached statistical significance for the CD4 T-cell subset 
(p=0.0244 and 0.0788; Figure 4.5 C and D).  
 
Age HIV-1 infection
Nadir        
CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
Median 41 3 337 374 1113 0.3 71310
(IQR)  (36 to 57) (1 to 14) (233 to 485) (262 to 544) (751 to 1719) (0.21 to 0.54) (30696 to 185410)
Median 45 9 309 507 768 0.65 <50
(IQR) (37 to 50) (4 to 15) (193 to 449) (363 to 635) (574 to 987) (0.40 to 0.99)
p value 0.7387 0.0897 0.7739 0.0749 0.0119 0.0006 <0.0001
Treated
ART-naïve 
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Figure 4.3 The relationship between naïve T cells and CD4 and CD8 T-cell counts.  
Absolute CD4 (A and B) and CD8 (C and D) T-cell counts as well as CD4/CD8 ratio (E and F) was correlated 
with the frequencies of naïve CD4 and CD8 cells in 45 HIV-1+ individuals. Spearman’s correlation was used 
for correlation analysis.  
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Figure 4.4 The relationship between CD4 and CD8 TEM and CD4 and CD8 T-cell counts.  
Absolute CD4 (A and B) and CD8 (C and D) T-cell count as well as CD4/CD8 ratio (E and F) was correlated 
with the frequencies of CD4 and CD8 TEM cells in 45 HIV-1+ individuals. Spearman’s correlation was used for 
correlation analysis.  
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Figure 4.5 The relationship between naïve and TEM subsets and activation levels.  
The frequencies of CD4 (A) and CD8 (B) naïve cells were correlated with HLA-DR and CD38 co-expression 
on CD4 and CD8 T cells in 45 HIV-1+ individuals. Frequencies of CD4 TEM (C) and CD8 TEM (D) were also 
correlated with HLA-DR and CD38 co-expression on CD4 and CD8 T cells. Spearman’s correlation was used 
for correlation analysis. 
 
In summary, ART-naϊve HIV-1+ individuals exhibited reduced levels of naϊve CD4 and CD8 T cells 
and increased levels of CD4 and CD8 T cells of a TEM phenotype when compared to healthy 
controls. For treated individuals, the main difference observed was in the naϊve CD4 T-cell subset, 
which remained significantly lower in this group compared to healthy controls. When assessing the 
relationship between frequencies of CD4 T-cell subsets with different immune parameters there 
were some noticeable differences observed between CD4 and CD8 T cells. Frequencies of naïve 
CD8 T cells were associated with improved immune function (including higher CD4 T-cell count 
and CD4/CD8 ratio). In contrast, both for CD4 and CD8 T cells, frequencies of TEM levels were 
associated with markers of disease progession including lower CD4 T-cell count, lower CD4/CD8 
ratio and higher activation levels. 
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4.2.3 Assessment of Immune Activation Levels 
The immune activation status and the effect of ART on this phenotype were next assessed on CD4 
and CD8 T cells based on the expression of CD38 and HLA-DR. This analysis was performed on 
57 of the 64 patients and compared to 14 HIV-1-uninfected healthy controls. HIV-1-infected 
individuals were subsequently grouped into ART-naϊve (n=19) and treated (n=23) individuals as 
described in the previous section. In healthy control subjects, CD38 expression was detected in a 
large percentage of CD4 and CD8 T cells (median 60 and 41%) whilst expression of HLA-DR was 
generally low (median 5 and 12% respectively; Figure 4.6). ART-naϊve patients exhibited similar 
levels of CD38+ CD4 T cells compared to healthy controls (median 61%) as well as significantly 
higher frequencies of CD38+ CD8 T cells (median 68%; p<0.0001; Figure 4.6 A and C). In addition, 
a significantly higher proportion of CD4 and CD8 T cells were positive for HLA-DR in this group 
(median 19 and 51%) compared to healthy controls (both p<0.0001; Figure 4.6 B and D). In treated 
individuals, frequencies of both CD4 and CD8 T cells expressing CD38 were significantly lower 
compared to the levels observed in ART-naϊve individuals (median 36 and 25%; both p<0.0001), 
indicating an ART-mediated reduction of this marker (Benito et al., 2005). Interestingly, the levels 
were even lower than that observed for healthy controls, reaching statistical significance for the 
CD4 T-cell compartment (p=0.0009). In contrast, HLA-DR expression on both CD4 and CD8 T 
cells remained elevated in treated individuals as evidenced by the significantly higher frequencies 
of HLA-DR+ CD4 and CD8 T cells (median 15 and 33%) compared to healthy controls (median 5 
and 12%; both p<0.0001).  
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Figure 4.6 Expression of HLA-DR and CD38 on CD4 and CD8 T cells.  
Flow cytometric analysis was carried out on PBMC of 19 ART-naϊve and 23 treated HIV-1+ individuals (dark 
and light red bars respectively) as well as 14 HIV-1-uninfected controls (HC) (grey bars). HLA-DR and CD38 
were analysed for their expression on CD4 (A and B) and CD8 (C and D) T cells. All individual data points 
are shown with box plots representing the median and interquartile range, and whiskers representing the 10th 
and 90th percentile range. P values are shown where there are statistically significant differences between 
the two groups (p≤0.05). Statistical analysis was performed using the Kruskal-Wallis Test. 
 
Different expression patterns of CD38 and HLA-DR were further explored in 57 of the 64 HIV-1-
infected individuals as a whole group, and as ART-naϊve and treated groups. In line with results 
presented above, a high frequency of CD4 and CD8 T cells from uninfected healthy controls 
expressed CD38 only (HLA-DR-CD38+) but frequencies of CD4 and CD8 T cells that were negative 
for both CD38 and HLA-DR (HLA-DR-CD38-) were also very high in this group (Figure 4.7 A and 
B). In contrast, a higher proportion of CD4 and CD8 T cells from HIV-1-infected individuals 
expressed HLA-DR only (HLA-DR+CD38-; p<0.0001 and p=0.0005) or both HLA-DR and CD38 
(CD38+HLA-DR+; p<0.0001 for both). Activation levels were particularly high in the CD8 T-cell 
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compartment with several individuals having more than 50% of highly activated CD8 T cells, in line 
with previous reports (Giorgi et al., 1999; Zheng et al., 2014).  
 
When HIV-1-infected individuals were grouped based on their treatment and plasma HIV-1 RNA 
status this revealed key differences between the ART-naϊve and treated group. Treated individuals 
had the highest frequencies of HLA-DR-CD38- CD4 T cells with the median value of 52%, 
significantly surpassing levels observed in ART-naϊve individuals and even HIV-1-uninfected 
individuals (median 28 and 35%; p<0.0001 and p=0.0056 respectively; Figure 4.7 C). Treated 
individuals also had the lowest proportion of CD4 T cells expressing CD38 only (median 35%; 
HLA-DR-CD38+), compared to ART-naϊve patients and healthy controls (median 51 and 57%; 
p=0.0024 and p<0.0001). In contrast, both treated and ART-naϊve individuals had significantly 
higher levels of HLA-DR+CD38- CD4 T cells (median 10 and 8%) compared to healthy controls 
(median 3%; p=0.0003 and p<0.0001). Finally, frequencies of highly activated CD4 T cells (HLA-
DR+CD38+) were significantly higher in ART-naϊve individuals (median 10%) compared to treated 
and HIV-1-uninfected individuals (median 4 and 2%; p<0.0001 for both). However, although levels 
in treated patients were lower, these were still significantly higher compared to the levels observed 
in healthy controls (p=0.0010).  
 
In terms of activation levels on CD8 T cells, the greatest difference was observed in ART-naϊve 
individuals who exhibited significantly lower levels of HLA-DR-CD38- CD8 T cells (median 23%) 
compared to healthy controls (median 51%; p<0.0001), whilst having significantly higher levels of 
highly activated CD8 T cells (median 39 and 5%; p<0.0001; Figure 4.7 D). Treated patients 
exhibited frequencies of these two subsets that approached those observed in healthy controls 
(median 51 and 12%), however, a majority of individuals continued to exhibit higher levels of highly 
activated CD8 T cells compared to healthy controls. Interestingly, ART-naϊve individuals did not 
exhibit any changes in CD8 T cells that expressed either of the two activation makers compared to 
healthy controls. This was instead observed in treated individuals who exhibited a notable shift 
from CD8 T cells that expressed CD38 only (HLA-DR-CD38+; median 13%), to CD8 T cells that 
expressed HLA-DR only (median 19%; HLA-DR+CD38-) compared to healthy controls (median 31 
and 5%; p=0.0001 and p<0.0001). Thus, treated individuals stood out for having lower levels of 
HLA-DR-CD38+ and higher levels of HLA-DR+CD38- CD8 T cell compared to both ART-naϊve 
patients and healthy control subjects. 
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Figure 4.7 CD4 and CD8 T-cell activation in HIV-1+ individuals and healthy controls.  
Percentage expression of HLA-DR and CD38 was determined on CD4 and CD8 T cells from 57 HIV-1+ 
patients (dark blue bars) and compared to 14 healthy controls (HC) (grey bars; A and B). The 57 HIV-1+ 
patients were then grouped into 23 treated and 19 ART-naϊve patients (light and dark blue bars respectively) 
to be compared with the 14 HC (grey bars; C and D). All individual data points are shown with box plots 
representing the median and interquartile range, and whiskers representing the 10th and 90th percentile 
range. P values are shown where there are statistically significant differences between the two groups 
(p≤0.05). Statistical analysis was performed using the Mann-Whitney U test for two group comparisons and 
the Kruskal-Wallis Test for multiple group comparisons. 
 
4.2.4 Activation Levels on Differentiation Subsets 
Overall immune activation is generally assessed on total CD4 and CD8 T cells, however it is 
important to understand whether the activation levels are altered between differentiation subsets 
as this might lead to changes in the dynamics of the different memory cell compartments. To this 
end, activation levels were next assessed on CD4 and CD8 naïve, TCM, TEM and TEMRA subsets. For 
CD4 T cells, the high levels of CD38 expression detected in healthy controls and to a lesser extent 
HIV-1-infected individuals, were predominantly observed in the CD4 naïve and TEMRA subsets 
concurring with an early study (Dianzani et al., 1994) (Figure 4.8 A). Healthy controls exhibited the 
highest levels of CD38+ CD4 naïve and TEMRA cells (median 91 and 81% respectively) whilst 
treated individuals exhibited significantly lower levels (median 82 and 50%; p=0.0047 and 
p=0.0016). In contrast, ART-naϊve patients exhibited increased levels of CD38+ CD4 TEM cells 
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(median 43%) compared to both treated patients and healthy control subjects (median 20 and 
17%; p=0.0001 and p=0.0027).  
 
In healthy controls, the levels of HLA-DR+ CD4 T cells were low across all four differentiation 
subsets (Figure 4.8 B), particularly when assessing the levels of HLA-DR+CD38- CD4 T cells 
(Figure 4.8 C). The observed increase of HLA-DR expression in ART-naϊve HIV-1-infected 
individuals was detected across all four subsets (Figure 4.8 B). Specifically, ART-naϊve individuals 
exhibited significantly higher levels of HLA-DR+ CD4 naïve, TCM, TEM and TEMRA cells (median 2, 19, 
34 and 20% respectively) compared to healthy controls (median 1, 5, 12 and 2% respectively; 
p=0.0047, p<0.0001, p<0.0001 and p=0.0007). This was observed when examining HLA-DR 
expression together with CD38 (Figure 4.8 D) or on its own (Figure 4.8 C).  
 
Treated individuals continued to exhibit high levels of HLA-DR+ CD4 T cells and this became more 
prevalent with increasing differentiation. For example, although levels of HLA-DR+ TCM were slightly 
lower in treated individuals (median 10%), they were still significantly higher compared to healthy 
controls (median 5%; p=0.0109). For the TEM and TEMRA subsets, this difference became even 
higher as treated individuals continued to have high levels of HLA-DR+ CD4 TEM and TEMRA cells 
(median 35 and 29%) as observed in ART-naϊve individuals. These frequencies were significantly 
higher compared to the low frequencies observed in healthy controls (median 12 and 2%; 
p=0.0011 and p=0.0004).  
 
The co-expression of HLA-DR and CD38 was next assessed on the differentiation subsets, 
revealing low frequencies of highly activated (HLA-DR+CD38+) CD4 T cells across all differentiation 
subsets in healthy controls. All three groups had particularly low levels of naïve CD4 T cells that 
were positive for both markers (Figure 4.8 C), although ART-naϊve individuals nevertheless had 
significantly higher levels compared to healthy controls (p=0.0049). ART-naϊve individuals also had 
significantly higher frequencies of highly activated CD4 TCM, TEM and TEMRA (median 10, 19 and 
12%) compared to healthy controls (median 2, 3 and 1%; p<0.0001, p<0.001 and p=0.0002). 
Treated individuals exhibited a decrease in the levels of highly activated CD4 T-cell subsets, 
although these did not always reach the levels observed in healthy control subjects, particularly for 
the TEM and TEMRA subsets (median 8 and 7%). The median levels of highly activated CD4 TEMRA 
cells in treated individuals were similar to those observed for ART-naϊve individuals and both 
groups had significantly higher frequencies of these cells compared to healthy controls (p=0.0003 
and p=0.0032 respectively). 
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Figure 4.8 Assessment of CD38 and HLA-DR expression on CD4 T-cell differentiation subsets. 
Percentage co-expression of CCR7 and CD45RA was determined on CD4 T cells for the identification of 
differentiation subsets: naïve, TCM, TEM and TEMRA as previously described (section 4.2.2). Expression of 
CD38 (A) and HLA-DR (B) was subsequently assessed on differentiation subsets of 14 HIV-1-uninfected 
controls (HC; grey bars), 15 ART-naïve ART-naϊve HIV-1+ individuals (dark red bars) and 12 treated HIV-1+ 
individuals on ART (light red bars). CD4 T-cell differentiation subsets expressing HLA-DR but not CD38 
(HLA-DR+CD38-; C) or both CD38 and HLA-DR (CD38+HLA-DR+; D) were analysed and shown for each 
subset. All individual data points are shown with box plots representing the median and interquartile range, 
and whiskers representing the 10th and 90th percentile range. P values are shown where there are 
statistically significant differences between the two groups (p≤0.05). Statistical analysis was performed using 
Kruskal-Wallis Test. 
 
In contrast to CD4 T cells, ART-naϊve individuals exhibited high levels of CD38+ CD8 T cells across 
all four differentiation subsets (Figure 4.9 A). For the naïve subset, median expression in ART-
naϊve patients was 60% with slightly lower levels found in healthy controls (median 51%) and 
significantly lower still in treated individuals (median 29%; p=0.0078). Although not significant, 
quite a few of the treated patients had lower frequencies of CD38+ naïve CD8 T cells compared to 
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healthy controls. For all three other memory subsets (TCM, TEM and TEMRA), the highest CD38 
expression was consistently observed in ART-naϊve individuals (median 60, 68 and 70% 
respectively). These were significantly higher when compared to healthy controls but also 
compared to treated patients (p<0.05 for all), whose levels approached those observed in healthy 
controls.  
 
Results presented in previous sections revealed low levels of HLA-DR+ CD8 T cells in HIV-1-
uninfected individuals and this was observed across all four differentiation subsets (Figure 4.9 B). 
In contrast, both ART-naϊve and treated individuals had significantly higher frequencies of HLA-
DR+ CD8 naïve cells (median 21 and 8%) compared to the median 3% observed in healthy 
controls (p=0.0012 and p=0.0168). In addition, across all three memory subsets (TCM, TEM and 
TEMRA), both ART-naϊve and treated individuals had significantly higher frequencies of HLA-DR+ 
CD8 T cells, compared to the low levels observed in healthy controls (p<0.05 for all). Although 
there were no statistically significant differences between ART-naϊve and treated individuals in 
terms of HLA-DR expression, treated individuals showed a trend towards having reduced levels of 
HLA-DR+ CD8 TCM cells compared to ART-naϊve individuals. This was also observed in the TEM 
subset albeit to a lesser degree and not at all for the TEMRA subset, indicating no effect of ART on 
reducing HLA-DR expression on this subset. When assessing HLA-DR expression in the absence 
of CD38 expression (HLA-DR+CD38-), it was mainly the treated group who exhibited higher levels 
of this subset compared to both uninfected controls and ART-naïve patients (Figure 4.9 C). 
Specifically, treated individuals had significantly higher levels of HLA-DR+CD38- CD8 T cells with a 
naïve, TEM and TEMRA phenotype (median 5, 22 and 21%), compared to uninfected healthy controls 
(median 1, 8 and 6%; p=0.0022, 0.0026 and 0.0022 respectively). In addition, the levels of this 
phenotype were also higher in the TCM, TEM and TEMRA subsets of treated individuals when 
compared to the levels observed in ART-naïve individuals (median 6, 8 and 7% respectively; 
p=0.0264, 0.0090 and 0.0016). 
 
Highly activated CD8 T cells (HLA-DR+CD38+) were detected in low frequencies across the four 
subsets in healthy controls (median ≤8% for all; Figure 4.9 C). In contrast, ART-naϊve individuals 
exhibited significantly higher levels of highly activated CD8 T cells across all four differentiation 
subsets (median 18, 43, 45 and 35% for naïve, TCM, TEM and TEMRA respectively, p<0.0001 for all). 
Treated individuals exhibited decreased levels of highly activated CD8 T cells, although these did 
not always approach the levels observed in healthy controls, particularly for the TEM and TEMRA 
subsets. Specifically, the frequencies of highly activated CD8 TEM and TEMRA in treated patients 
(median 19 and 21%) were still significantly higher compared to the levels observed in healthy 
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controls (median 8 and 6%; p=0.0003 and p=0.0006), suggesting a failure of ART to completely 
reduce activation levels on these subsets.  
 
Figure 4.9 Assessment of CD38 and HLA-DR expression on CD8 T-cell differentiation subsets.  
Percentage co-expression of CCR7 and CD45RA was determined on CD8 T cells leading to the identification 
of differentiation subsets: naïve, TCM, TEM and TEMRA as previously described (section 4.2.2). Expression of 
CD38 (A) and HLA-DR (B) was subsequently assessed on differentiation subsets of 14 HIV-1-uninfected 
controls (HC; grey bars), 15 ART-naïve HIV-1+ individuals (dark red bars) and 12 treated HIV-1+ individuals 
(light red bars). CD8 T-cell differentiation subsets expressing only HLA-DR but not CD38 (HLADR+CD38-; C) 
or expressing both CD38 and HLA-DR (CD38+HLA-DR+; D) were analysed and shown for each subset. All 
individual data points are shown with box plots representing the median and interquartile range, and 
whiskers representing the 10th and 90th percentile range. P values are shown where there are statistically 
significant differences between the two groups (p≤0.05). Statistical analysis was performed using the 
Kruskal-Wallis Test.  
 
In summary, HIV-1-uninfected individuals exhibited high levels of CD38+ CD4 T cells of the naïve 
and TEMRA subset, whilst having low levels of HLA-DR expression across all four CD4 and CD8 T-
cell differentiation subsets. Untreated HIV-1 infection was associated with increased levels of 
CD38+ CD4 T cells of a TEM phenotype, whereas levels of CD38+ CD8 T cells were increased 
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across the three memory subsets TCM, TEM and TEMRA. ART-naïve individuals also had significantly 
higher levels of HLA-DR+ CD4 and CD8 T cells across all four differentiation subsets when 
compared to healthy controls. Treated individuals exhibited decreased levels of CD38+ CD4 and 
CD8 T cells, however levels of HLA-DR+ CD4 and CD8 T cells remained high in this group, 
suggesting a failure to lower expression of this activation marker on T cells.  
 
Examination of the two markers together revealed increased levels of highly activated (CD38+HLA-
DR+) CD4 and CD8 T cells in ART-naïve individuals when compared to healthy controls. Treated 
individuals had significantly lower levels of HLA-DR-CD38+ CD4 and CD8 T cells compared to both 
healthy controls and ART-naϊve individuals, but instead had significantly higher levels of CD8 T 
cells expressing HLA-DR but not CD38 when compared to both groups.   
 
4.2.5 Assessment of Exhaustion Phenotype 
Elevated levels of activation on T cells during untreated HIV-1 and SIV infection have been 
associated with an exhaustive phenotype (Sachdeva et al., 2010; Dyavar Shetty et al., 2012), 
defined by reduced capacity to proliferate and release cytokines (Trautmann et al., 2006). The 
upregulation of PD-1 in exhausted T cells has consistently been linked to disease progression (Day 
et al., 2006), whereas less is known about TIM-3 and its role is still under debate with conflicting 
results reported (Jones et al., 2008; Leitner et al., 2013; Huang et al., 2015).  
 
PD-1 and TIM-3 expression was evaluated in 11 ART-naϊve and 12 treated HIV-1-infected 
individuals as well as eight healthy controls for comparison. PD-1 expression on CD4 T cells was 
consistently high in ART-naϊve individuals both in terms of frequency and Median Fluorescence 
Intensity (MFI) (median 19% and 471 respectively; Figure 4.10 A and B). In treated patients this 
was markedly reduced where the levels of PD-1+ CD4 T cells were similar to those of healthy 
controls (median 4% for both), demonstrating an ART- mediated reduction of PD-1 expression on 
CD4 T cells. PD-1 expression was also higher on CD8 T cells of ART-naϊve individuals (median 
27%), in particular when compared to treated patients (median 3%; p=0.0106), but not healthy 
controls (median 10%; Figure 4.10 C). The MFI of PD-1 on CD8 T cells was also higher in ART-
naϊve patients compared to healthy controls (p=0.0098), and treated patients had PD-1 MFI levels 
approaching those observed in healthy controls. Thus, ART was linked to lower PD-1 levels on 
both CD4 and CD8 T cells.  
 
TIM-3 expression on CD4 and CD8 T cells was low across all three groups, with median 
frequencies below 1% observed (Figure 4.11 A and C). Both its expression and MFI on CD4 T 
cells was not significantly different between the three groups (Figure 4.11 A and B). Healthy 
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controls did express significantly higher levels of TIM-3 on CD8 T cells compared to treated 
individuals; p=0.0057; Figure 4.11 C) although this may not be biologically relevant in vivo.  
 
 
Figure 4.10 Analysis of PD-1 expression on CD4 and CD8 T cells.  
Percentage expression of PD-1 and its Median Fluorescence Intensity (MFI) were analysed on CD4 (A and 
B) and CD8 (C and D) T cells from ART-naïve (dark red bars; n=11) and treated (light red bars; n=12) HIV-1+ 
individuals as well as HIV-1-uninfected controls (HC; grey bars; n=8). All individual data points are shown 
with box plots representing the median and interquartile range, and whiskers representing the 10th and 90th 
percentile range. P values are shown where there are statistically significant differences between the two 
groups (p≤0.05). Statistical analysis was performed using the Kruskal-Wallis Test.  
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Figure 4.11 Analysis of TIM-3 expression on CD4 and CD8 T cells.  
Percentage expression of TIM-3 and its Median Fluorescence Intensity (MFI) were analysed on CD4 (A and 
B) and CD8 (C and D) T cells from ART-naïve (dark red bars; n=11) and treated (light red bars; n=12) HIV-1+ 
individuals as well as HIV-1-uninfected controls (HC; grey bars; n=8). All individual data points are shown 
with box plots representing the median and interquartile range, and whiskers representing the 10th and 90th 
percentile range. P values are shown where there are statistically significant differences between the two 
groups (p≤0.05). Statistical analysis was performed using the Kruskal-Wallis Test.  
 
When PD-1 and TIM-3 were analysed for their co-expression it became clear that the main 
differences observed between HIV-1-infected and uninfected healthy control subjects was driven 
by PD-1 (Figure 4.12 A). Specifically, the majority of CD4 T cells in healthy controls and treated 
patients were negative for both PD-1 and TIM-3 (median 95 and 96%; TIM-3-PD-1-). In addition, 
ART-naϊve individuals exhibited a clear shift from the TIM-3-PD-1- to TIM-3-PD-1+ subset on CD4 T 
cells (median 81 and 19%), confirming a role for PD-1 but not TIM-3 upregulation in untreated HIV-
1 infection (Day et al., 2006; Trautmann et al., 2006).  
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Similar to that observed for CD4 T cells, the majority of CD8 T cells from all three groups did not 
express PD-1 or TIM-3 (TIM-3-PD-1-; Figure 4.12 B). Although TIM-3 expression was low there 
were some significant differences observed between the three groups. Treated individuals had 
significantly lower levels of CD8 T cells that were of the TIM-3+PD-1- phenotype compared to 
healthy controls (median 0.08 and 0.37%; p=0.0149) as well as lower levels of TIM-3-PD-1+ CD8 T 
cells compared to ART-naϊve individuals (median 3 and 27%; p=0.0106). Levels of hyper 
exhausted (TIM-3+PD-1+) CD8 T cells were similar between healthy control subjects and ART-
naϊve patients and were both higher compared to treated individuals (p=0.0026 and 0.0074 
respectively). 
 
 
Figure 4.12 PD-1 and TIM-3 co-expression on CD4 and CD8 T cells.  
Percentage co-expression of PD-1 and TIM-3 was determined on CD4 (A) and CD8 (B) T cells from 11 ART-
naïve HIV-1+ patients (dark red bars), 12 treated HIV-1+ patients (light red bars) and compared to 8 HIV-1-
uninfected controls (HC; grey bars). All individual data points are shown with box plots representing the 
median and interquartile range, and whiskers representing the 10th and 90th percentile range. P values are 
shown where there are statistically significant differences between the two groups (p≤0.05). Statistical 
analysis was performed using the Kruskal-Wallis Test.  
 
As frequencies of both CD38+ and PD-1+ CD4 and CD8 T cells were significantly elevated in ART-
naϊve individuals and have been closely linked, the relationship between these two markers was 
further analysed. This analysis was undertaken on 29 of the 64 HIV-1-infected patients and 
revealed a significant correlation between the frequencies of PD-1+ and CD38+ CD4 T cells 
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(p=0.0247; Figure 4.13 A), but not between PD-1 and HLA-DR expression (Figure 4.13 B). 
Moreover, there was a similar association for the CD8 T-cell compartment (p=0.0094; Figure 4.13 
B). Expression of PD-1 on CD4 and CD8 T cells was also associated with levels of highly activated 
T cells (HLA-DR+CD38+; p=0.0199 and 0.0319 respectively; Figure 4.13 C and F). Finally, 
frequencies of PD-1+ CD4 and CD8 T cells were not associated with absolute CD4 and CD8 T-cell 
counts respectively (data not shown), nor was the MFI of PD-1 associated with absolute T-cell 
counts or plasma HIV-1 RNA load (data not shown). Thus, PD-1 expression is more closely 
associated with CD38 but not HLA-DR expression or absolute T-cell counts in HIV-1-infected 
individuals.  
 
 
Figure 4.13 The relationship between PD-1 and CD38 and HLA-DR expression.  
The expression of PD-1 on CD4 T cells (A, B and C) and CD8 T cells (D, E and F) was correlated with 
CD38+, HLA-DR+ or HLA-DR+CD38+ CD4 and CD8 T cells in 29 HIV-1+ individuals. Spearman’s correlation 
was used for correlation analysis. 
 
Although PD-1 and CD38 have been closely linked, few studies have examined the co-expression 
of these two markers on T cells. A previous study reported higher levels of HIV-1-specific 
CD38+PD-1+ CD8 T cells in ART-naïve individuals compared to HIV controllers, a group of 
individuals who are able to maintain low plasma HIV-1 RNA levels in the absence of ART 
(Vollbrecht et al., 2010). However, other combinations of PD-1 and CD38 as well as PD-1 and 
HLA-DR co-expression have not been studied in great depth. To this end, PD-1 expression was 
evaluated with CD38 as well as with HLA-DR for comparison. In line with Vollbrecht and 
colleagues, ART-naϊve individuals exhibited increased levels of CD4 and CD8 T cells that were 
positive for both CD38 and PD-1 (median 11 and 18%; CD38+PD-1+; Figure 4.14 A and C). For 
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CD4 T cells these frequencies were significantly higher compared to the levels observed in healthy 
controls and treated patients (median 2 and 1%; p=0.0023 and p=0.0012). For CD8 T cells this 
only reached statistical significance when compared to treated individuals (median 1%; p=0.0015). 
These results indicate that ART reduces levels of CD38+PD-1+ on CD4 and CD8 T cells. PD-1 
expression on its own was not readily detected as evidenced by the low frequencies of CD38-PD-
1+ CD4 and CD8 T cells (median <9% for all groups). Across the three groups, the predominant 
phenotypes on CD4 and CD8 T cells were instead CD38-PD-1- and CD38+PD-1-, with some 
notable differences observed between the groups. ART-naϊve individuals exhibited slight increases 
in the levels of CD8 T cells expressing CD38 only (median 42%), but this was significantly reduced 
in treated patients to levels detected in healthy controls (median 26 and 27%; p=0.0210; Figure 
4.14 C). On the other hand, as demonstrated above, treated patients exhibited significant 
reductions in CD38 expression on CD4 T cells relative to healthy controls (and to a lesser extent 
ART-naϊve patients), having the lowest levels of CD38+PD-1- CD4 T cells (median 38%) whilst 
having the highest levels of CD38-PD-1- CD4 T cells (median 56%; Figure 4.14 A). Taken together 
these results suggest that upregulation of PD-1 during untreated HIV-1 infection occurs 
concomitant with CD38 expression on both CD4 and CD8 T cells.  
 
The majority of CD4 and CD8 T cells from healthy controls were negative for both HLA-DR and 
PD-1 (median 92 and 81% respectively; Figure 4.14 B and D). In contrast, ART-naϊve and treated 
individuals had significantly higher frequencies of CD4 and CD8 T cells that were HLA-DR+PD-1- 
(p<0.05 for all), indicating that ART has no effect in reducing the levels of this subset. The levels of 
CD4 T cells that were of an HLA-DR-PD-1+ phenotype were also higher in ART-naϊve individuals 
(median 11%), compared to healthy controls and treated subjects although statistical significance 
was only reached for the latter group (median 4 and 2%; 0.0062). Frequencies of CD4 and CD8 T 
cells expressing both HLA-DR and PD-1 were the highest in ART-naϊve individuals (median 8 and 
20%), and were significantly reduced in treated individuals (median 1 and 2%; p=0.0028 and 
p=0.0035) reaching levels observed in healthy controls (median 1 and 3%). These results suggest 
that whilst ART reduces levels of HLA-DR and PD-1 co-expression on CD4 and CD8 T cells, it has 
no effect on diminishing levels of HLA-DR+PD-1- T cells. Two subsets of CD8 T cells: PD-1+CD38- 
and PD-1+HLA-DR- were low across all three groups (p>0.05 for all), indicating that during 
untreated HIV-1 infection the expression of PD-1 is closely linked to CD38 and HLA-DR expression 
on CD8 T cells.  
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Figure 4.14 PD-1 and its co-expression with either CD38 or HLA-DR on CD4 and CD8 T cells.  
Percentage co-expression of PD-1 and CD38 as well as PD-1 and HLA-DR was determined on CD4 (A) and 
CD8 (B) T cells from 11 ART-naïve HIV-1+ patients (dark red bars), 12 treated HIV-1+ patients and compared 
to 8 healthy control subjects (HC; grey bars). All individual data points are shown with box plots representing 
the median and interquartile range, and whiskers representing the 10th and 90th percentile range. P values 
are shown where there are statistically significant differences between the two groups (p≤0.05). Statistical 
analysis was performed using the Kruskal-Wallis Test.  
 
With regards to TIM-3 and its expression with CD38, as TIM-3 expression was very low in general 
the majority of CD4 and CD8 T cells were either negative for both TIM-3 and CD38 or expressed 
CD38 only (CD38-TIM-3- and CD38+TIM-3-; Figure 4.15 A and C). Levels of the other two subsets 
CD38-TIM-3+ and CD38+TIM-3+ were below 1% for both CD4 and CD8 T cells, therefore these 
phenotypes may not be relevant in vivo. This was also the case for TIM-3 and HLA-DR co-
expression (Figure 4.15 B and D). Thus the main differences observed were in regards to changes 
in CD38 or HLA-DR expression as already reported above.  
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Figure 4.15 TIM-3 and its co-expression with CD38 or HLA-DR on CD4 and CD8 T cells.  
Percentage co-expression of TIM-3 and CD38 as well as TIM-3 and HLA-DR was determined on CD4 (A) 
and CD8 (B) T cells from 11 ART-naïve HIV-1+ patients (dark red bars), 12 treated HIV-1+ patients (light red 
bars) and compared to 8 HIV-1-uninfected controls (HC; grey bars). All individual data points are shown with 
box plots representing the median and interquartile range, and whiskers representing the 10th and 90th 
percentile range. P values are shown where there are statistically significant differences between the two 
groups (p≤0.05). Statistical analysis was performed using the Kruskal-Wallis Test.  
 
 
In summary, ART-naïve individuals exhibited increased levels of PD-1+ CD4 T cells compared to 
HIV-1-uninfected healthy controls. In addition, the MFI of PD1 was significantly higher in both CD4 
and CD8 T cells of this group. Treated individuals exhibited similar levels of PD-1+ CD4 and CD8 T 
cells when compared to healthy controls, indicating an ART-associated reduction of this marker in 
this group. CD38 and PD-1 co-expression as well as HLA-DR and PD-1 co-expression was rarely 
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observed in CD4 and CD8 T cells of healthy controls. However, ART-naïve individuals had 
increased levels of CD38+PD-1+ CD4 T cells and HLA-DR+PD-1+ CD4 and CD8 T cells compared 
to healthy controls. This association between PD-1 and activation levels on both CD4 and CD8 T 
cells was further confirmed during correlation analysis. There was no significant difference in the 
TIM-3 expression between the three groups. 
 
Table 4.3. Summary table of differentiation, activation and exhaustion markers on CD4 and CD8 T 
cells. 
The median and interquartile ranges (in brackets) are listed for each parameter between the three groups. 
Boxes are in red when the median value is significantly higher compared to the value observed in HIV-1-
uninfected individuals. Grey boxes indicate that the median frequency was significantly lower compared to 
those observed in healthy controls (Healthy control: HC; Central memory T-cell: TCM; Effector Memory T-cell: 
TEM; Terminally Differentiated Effector Memory T-cell: TEMRA).  
 
Differentiation 
T-cell type Marker HC ART-naïve Treated 
CD4 
Naïve 35 (31-43) 31 (25-40) 21 (13-29) 
TCM 26 (25-29) 19 (19-27) 18 (9-39) 
TEM 25 (23-27) 35 (29-47) 36 (24-47) 
TEMRA 5 (4-13) 8 (4-13) 13 (4-22) 
CD8 
Naïve 32 (18-43) 7 (5-11) 13 (6-24) 
TCM 3 (1-7) 2 (1-2) 2 (1-3) 
TEM 26 (25-35) 50 (44-58) 40 (30-49) 
TEMRA 28 (20-46) 39 (34-43) 41 (23-51) 
Activation 
T-cell type Marker HC ART-naïve Treated 
CD4 
CD38+ 60 (46-67) 61 (54-68) 36 (28-46) 
HLA-DR+ 5 (4-7) 19 (17-25) 15 (9-19) 
CD8 
CD38+ 41 (23-44) 68 (55-75) 25 (11-33) 
HLA-DR+ 12 (6-16) 51 (41-60) 33 (22-57) 
CD4 
HLA-DR-CD38- 35 (27-46) 28 (24-37) 52 (-44-58) 
HLA-DR-CD38+ 57 (45-70) 51 (37-58) 35 (26-44) 
HLA-DR+CD38- 3 (2-5) 8 (5-10) 10 (7-15) 
HLA-DR+CD38+ 2 (1-3) 10 (9-14) 4 (3-7) 
CD8 
HLA-DR-CD38- 51 (49-67) 51 (37-56) 23 (18-26) 
HLA-DR-CD38+ 31 (20-40) 13 (5-21) 31 (19-38) 
HLA-DR+CD38- 5 (3-10) 19 (12-38) 9 (5-13) 
HLA-DR+CD38+ 5 (3-8) 12 (6-19) 39 (32-47) 
 
Table continued on the following page. 
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Table 4.3. Summary table of differentiation, activation and exhaustion markers on CD4 and CD8 T 
cells. 
Activation on T-cell subsets 
T-cell type Marker HC ART-naïve Treated 
CD4 CD38+ 
Naïve 91 (87-93) 90 (84-92) 82 (79-88) 
TCM 36 (33-53) 52 (44-62) 30 (23-36) 
TEM 20 (13-27) 43 (35-49) 17 (11-27) 
TEMRA 81 (80-88) 72 (66-84) 50 (39-71) 
CD4 HLA-DR+ 
Naïve 0.64 (0.54-1.35) 2 (1-12) 2 (0.60-9) 
TCM 5 (3-7) 19 (13-23) 10 (7-15) 
TEM 12 (8-18) 34 (32-43) 35 (21-45) 
TEMRA 2 (0.93-6) 20 (12-34) 29 (14-43) 
CD4             
HLA-DR+CD38- 
Naïve 0.08 (0.05-0.16) 0.41 (0.13-1) 0.49 (0.18-1) 
TCM 3 (2-4) 7 (5-9) 8 (4-10) 
TEM 10 (6-13) 15 (14-20) 24 (13-32) 
TEMRA 0.80 (0.25-2) 5 (2-12) 16 (8-27) 
CD4 
HLA-DR+CD38+ 
Naïve 0.69 (0.58-1) 2 (1-9) 2 (0.55-7) 
TCM 2 (1-4) 10 (8-18) 4 (3-8) 
TEM 3 (2-6) 19 (16-23) 8 (5-14) 
TEMRA 1 (0.82-3) 12 (8-21) 7 (4-28) 
CD8 CD38+ 
Naïve 51 (41-55) 63 (51-69) 29 (20-52) 
TCM 24 (14-31) 60 (53-72) 15 (12-30) 
TEM 21 (12-26) 68 (53-80) 24 (13-32) 
TEMRA 43 (26 (47) 70 (64-77) 33 (19-47) 
CD8 HLA-DR+ 
Naïve 3 (1-6) 21 (7-36) 8 (4-37) 
TCM 15 (12-18) 53 (42-64) 29 (16-37) 
TEM 15 (11-23) 57 (50-69) 37 (31-59) 
TEMRA 12 (7-22) 48 (36-56) 40 (31-60) 
CD8            
  HLA-DR+CD38- 
Naïve 1 (0.52-3) 2 (0.88-4) 5 (2-9) 
TCM 7 (6-11) 6 (4-19) 17 (8-24) 
TEM 8 (6-14) 8 (5-20) 22 (14-29) 
TEMRA 6 (4-12) 7 (4-12) 21 (12-28) 
CD8             
 HLA-DR+CD38+ 
Naïve 2 (0.9-4) 18 (4-27) 4 (2-18) 
TCM 8 (4-11) 43 (30-50) 10 (8-18) 
TEM 8 (6-13) 45 (40-49) 19 (13-22) 
TEMRA 6 (2-10) 35 (26-47) 21 (16-36) 
Exhaustion 
T-cell type Marker HC ART-naïve Treated 
CD4 
PD-1+ 4 (2-9) 19 (12-30) 4 (1-11) 
PD-1 MFI 347 (337-406) 471 (458 (501) 389 (348-448) 
TIM-3+ 0.20 (0.08-0.26) 0.25 (0.16-0.44) 0.19 (0.06-0.38) 
TIM-3 MFI 304 (278-348) 354 (296-399) 309 (266-354) 
CD8 
PD-1+ 10 (7-25) 27 (14-39) 3 (2-24) 
PD-1 MFI 364 (326-483) 547 (446-600) 422 (406-481) 
TIM-3+ 0.54 (0.43-0.73) 0.40 (0.15-0.58) 0.09 (0.07-0.22) 
TIM-3 MFI 285 (259-389) 408 (246-546) 338 (262-383) 
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Table continued on the following page. 
Table 4.3. continued. 
Exhaustion 
T-cell type Marker HC ART-naïve Treated 
CD4 
TIM-3-PD-1- 95 (91-97) 81 (70-88) 96 (93-98) 
TIM-3+PD-1- 0.18 (0.061-0.24) 0.19 (0.13-0.31) 0.19 (0.069-0.28) 
TIM-3-PD-1+ 5 (3-9) 19 (12-30) 4 (2-7) 
TIM-3+PD-1+ 0.02 (0.014-0.024) 0.072 (0.04-0.10) 0.019 (0.0060-0.067) 
CD8 
TIM-3-PD-1- 89 (74-92) 73 (60-86) 3 (2-24) 
TIM-3+PD-1- 0.37 (0.21-0.56) 0.23 (0.10-0.46) 0.08 (0.061-0.15) 
TIM-3-PD-1+ 10 (7-25) 27 (14-39) 3 (2-24) 
TIM-3+PD-1+ 0.16 (0.11-0.23) 0.12 (0.06-0.31) 0.028 (0.015-0.040) 
Exhaustion and Activation 
T-cell type Marker HC ART-naïve Treated 
CD4 
CD38-PD-1- 39 (31-49) 32 (20-43) 56 (45-68) 
CD38+PD-1- 57 (45-63) 49 (44-52) 38 (30-46) 
CD38-PD-1+ 2 (1-3) 8 (3-11) 3 (0.4-6) 
CD38+PD-1+ 2 (1-4) 11 (6-22) 1 (0.5-3) 
CD8 
CD38-PD-1- 48 (44-67) 23 (-18-46) 63 (-55-71) 
CD38+PD-1- 27 (22-44) 42 (34-55) 26 (-20-40) 
CD38-PD-1+ 3 (1-8) 6 (2-13) 3 (1-8) 
CD38+PD-1+ 4 (3-10) 18 (6-31) 1 (0.92-6) 
CD4 
HLA-DR-PD-1- 92 (87-93) 65 (58-72) 83 (74-86) 
HLA-DR+PD-1- 4 (3-6) 12 (9-19) 13 (10-20) 
HLA-DR-PD-1+ 4 (2-6) 11 (4-18) 2 (0.5-4) 
HLA-DR+PD-1+ 1 (0.8-2) 8 (6-11) 1 (0.5-2) 
CD8 
HLA-DR-PD-1- 81 (69-83) 42 (34-51) 55 (44-67) 
HLA-DR+PD-1- 8 (5-11) 33 (17-39) 34 (25-47) 
HLA-DR-PD-1+ 7 (3-20) 6 (4-17) 0.8 (0.4-10) 
HLA-DR+PD-1+ 3 (2-6) 20 (9-23) 2 (1-10) 
CD4 
CD38-TIM-3- 41 (34-52) 37 (32-49) 60 (51-73) 
CD38+TIM-3- 59 (48-66) 63 (51-67) 40 (27-49) 
CD38-TIM-3+ 0.05 (0.03-0.1) 0.05 (0.03-0.1) 0.09 (0.04-0.2) 
CD38+TIM-3+ 0.07 (0.03-0.1) 0.2 (0.08-0.2) 0.07 (0.05-0.1) 
CD4 
HLA-DR-TIM-3- 95 (94-95) 79 (74-85) 84 (77-89) 
HLA-DR+TIM-3- 5 (5-6) 20 (14-25) 16 (11-23) 
HLA-DR-TIM-3+ 0.09 (0.06-0.2) 0.2 (0.08-0.3) 0.07 (0.05-0.2) 
HLA-DR+TIM-3+ 0.01 (0.01-0.02) 0.08 (0.07-0.1) 0.03 (0.02-0.07) 
CD8 
CD38-TIM-3- 62 (54-75) 32 (25-51) 73 (59-78) 
CD38+TIM-3- 37 (25-46) 67 (48-74) 27 (22-41) 
CD38-TIM-3+ 0.13 (0.10-0.47) 0.08 (0.02-0.34) 0.08 (0.03-0.11) 
CD38+TIM-3+ 0.18 (0.12-0.27) 0.23 (0.11-0.31) 0.04 (0.04-0.06) 
CD8 
HLA-DR-TIM-3- 88 (84-93) 55 (42-64) 61 (45-73) 
HLA-DR+TIM-3- 12 (7-15) 45 (35-57) 39 (27-55) 
HLA-DR-TIM-3+ 0.28 (0.22-0.43) 0.12 (0.05-0.36) 0.054 (0.02-0.13) 
HLA-DR+TIM-3+ 0.049 (0.04-0.06) 0.19 (0.11-0.30) 0.038 (0.02-0.06) 
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4.2.6 Identification of Antigen-Specific CD8+ T cells Using Multimers 
To further explore the dynamics of differentiation, activation and exhaustion profiles of virus-
specific CD8 T cells, PBMC were stained with multimers specific for various HIV-1- and CMV-
specific epitopes before staining with additional phenotypic markers. Two commercially available 
multimer staining technologies were used to identify antigen-specific CD8 T cells, Pro5® Pentamer 
and MHC Dextramer (Proimmune and Immudex respectively). 
 
In general, similar frequencies of antigen-specific CD8 T cells were obtained when the two 
multimer technologies were used in parallel (data not shown). However, to rule out that they might 
result in disparate frequencies of differentiation subsets, a preliminary experiment was performed 
on one healthy control subject. Comparison of the two multimer technologies showed no significant 
difference in the memory subset frequencies (Figure 4.16). Although with the MHC Dextramer 
there were a slightly higher proportion of CD8 T cells that were of the TCM subset, statistical 
analysis with a 95% confidence interval showed that this difference was not statistically significant. 
Either multimer technology was subsequently used.  
 
Figure 4.16 Comparison of multimer staining according to differentiation profile.  
PBMC from one HIV-1-uninfected healthy control were simultaneously stained with CMV TM10-specific MHC 
Dextramer (black dots) or CMV TM10-specific Pro5® Pentamer (red dots), to assess for any difference in 
staining profile between the two, according to maturation/differentiation profile. CMV TM10-specific CD8 T 
cells were identified and subsequently analysed for co-expression of CD45RA and CCR7. Symbols 
represent percentage distribution for each multimer+ CD8+ and error bars indicate 95% confidence intervals. 
 
As the CMV serology or the HLA-genotype was not known for some individuals, a screen was 
carried out on 50 HIV-1+ blood samples by staining PBMC with Pro5® Pentamers and/or MHC 
Dextramers specific for CMV B*07:02 TPRVTGGGAM (TM10). PBMC were also screened using 
Pro5® Pentamers specific for CMV A*02:01 NLVPMVATV (NV9), HIV-1 Gag A*02:01 SLYNTVATL 
(SL9), HIV-1 Gag B*07:02 GPGHKARVL (GL9), HIV-1 Nef A*02:01 LTFGWCFKL (LL9) and HIV-1 
CHAPTER 4 
PHENOTYPIC PROFILES 
155 
Nef B*07:02 TPGPGVRYPL (TL10). Two Pro5® Pentamers EBV A*02:01 GLCTLVAML (GL9) and 
EBV B*07:02 RPPIFIRRL (RL9) were also included for a subset of the individuals assessed, 
however no positive staining was detected. The gating strategy used to identify virus-specific CD8 
T cells and the different subsets is shown in Figure 4.17. Doublets were first excluded and a gate 
was set on live lymphocytes, then on CD3+ T cells and finally on CD8+CD4- T cells. Cells were 
subsequently analysed for co-expression of CD8 and either MHC Dextramer or Pro5® Pentamer 
(both defined as multimers; Figure 4.17). Where possible, a positive multimer staining was 
confirmed with ELISpot and HLA-genotyping to demonstrate that the sensitivity and specificity of 
these multimer technologies is high. In addition, when HLA-type was known, a negative control 
was included to show that no cross-reactivity occurred (Figure 4.18). Gating next proceeded to 
general phenotyping as previously described (Figure 4.1). Table 4.4 summarises the median 
characteristics of the HIV-1-infected individuals where a positive multimer staining was detected.  
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Figure 4.17 Gating strategy used to identify antigen-specific CD8 T cells.  
A staining example of 8 colour flow cytometric analysis, showing the gating strategy whereby singlets were 
first gated followed by live lymphocytes. Anti-CD3, anti-CD4 and anti-CD8 antibodies were subsequently 
used to define CD8+ T cells (A). MHC Dextramers or Pro5® Pentamers (both defined as multimers) were 
used to identify antigen-specific CD8+ T cells (B). The percentage expression of surface markers CD45RA 
and CCR7, CD38 and HLA-DR as well as PD-1 and TIM-3 were subsequently used to characterise the 
phenotype of antigen-specific CD8+ T cells.  
 
Figure 4.18 Multimer staining with negative control.  
PBMC from an HLA-B*27:05+ HIV-1-infected individual were stained with Pro5® Pentamers loaded with a 
peptide specific for B*2705 KRWIILGLNK (KK10; A) or A*02:01 SLYNTVATL (SL9; B) to demonstrate that no 
cross-reactivity occurs. 
 
 
Table 4.4 Clinical characteristics of HIV-1+ individuals where virus-specific CD8 T cells were detected.  
Median levels are shown with interquartile ranges (IQR) in brackets. Statistical analysis was performed using 
the Kruskal-Wallis Test. T-cell counts and plasma HIV-1 RNA load are expressed as: cells/µl blood and 
copies/ml respectively. Age and HIV-1 infection are expressed in years. 
 
 
 
4.2.7 Phenotypic Comparison of Total and Antigen-Specific CD8 T cells  
CMV-specific CD8 T cells can constitute approximately 10% of total CD8 T cells in one individual 
(Sylwester et al., 2005), therefore the phenotype and function of these cells may play a role in the 
overall dynamics of CD8 T cells (Naeger et al., 2010). To further delineate the phenotypic profile of 
CD8 T cells in HIV-1-infected individuals an analysis was carried out on the differentiation, 
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activation and exhaustion profiles of CMV- and HIV-1-specific CD8 T cells and compared that to 
the rest of the CD8 T-cell pool (designated bulk CD8 T cells).  
 
Frequencies of both CMV- and HIV-1-specific CD8 T cells displaying a naïve phenotype were very 
low compared to bulk CD8 T cells and reached statistical significance in all but one group (p<0.05; 
Figure 4.19 A, B, C and D). Although some intra-individual differences were observed, overall the 
differentiation profile of CMV-specific CD8 T cells in ART-naïve individuals was not significantly 
different to that of the rest of the CD8 T-cell pool (Figure 4.19 A). In contrast, treated individuals 
had significantly higher proportions of CMV-specific CD8 T cells that were of the TEM subset 
compared to bulk CD8 T cells (median 76 and 37% respectively; p=0.0156; Figure 4.19 B). No 
difference was observed for both the TCM and TEMRA subsets between CMV-specific CD8 T cells 
and the rest of the CD8 T-cell pool.  
 
The differentiation profile of HIV-1-specific CD8 T cells showed a clear shift from the TEMRA subset 
to the TEM subset in ART-naïve individuals (Figure 4.19 C). Thus, compared to the rest of the CD8 
T-cell pool, a significantly higher proportion of HIV-1-specific CD8 T cells were of the TEM subset 
(median 87%; p=0.0313), and a significantly lower proportion were of the TEMRA subset (median 
10%; p=0.0313), implying a block in the maturation pathway of HIV-1-specific CD8 T cells in line 
with previous studies (Champagne et al., 2001). Treated patients showed similar differentiation 
profiles of HIV-1-specific CD8 T cells as those observed for ART-naïve individuals (Figure 4.19 D). 
Specifically, whilst 48% of bulk CD8 T cells were of the TEM subset, the percentage observed for 
HIV-1-specific CD8 T cells was significantly higher (median 86%; p=0.0313). Although median 
levels of HIV-1-specific CD8 TEMRA cells were lower compared to the rest of the CD8 T-cell pool (10 
and 33% respectively), this did not reach statistical significance.  
 
 
 
CHAPTER 4 
PHENOTYPIC PROFILES 
158 
 
Figure 4.19 Differentiation profiles of bulk CD8+ T cells and multimer+ CD8+ T cells.  
PBMC were stained with CMV TPRVTGGGAM (TM10)-specific multimer or CMV NLVPMVATV (NV9)-
specific multimer (A-B) and HIV-1-specific Gag SL9 multimer (C and D) (mult+ CD8+ T cells; grey bars), to 
assess for any difference in maturation/differentiation profile compared to the rest of the CD8 T-cell 
population (bulk CD8+ T cells; white bars). Antigen-specific CD8+ T cells were identified and analysed for co-
expression of CD45RA and CCR7. All individual data points and lines are shown with box plots representing 
the median and interquartile range, and whiskers representing the 10th and 90th percentile range. P values 
are shown where there are statistically significant differences between the two groups (p≤0.05). Statistical 
analysis was performed using the Wilcoxon matched pairs test. 
  
Low levels of CMV- and HIV-1-specific CD8 T cells of a naïve phenotype were detected. This is 
expected, as naïve T cells for a particular specificity exist in peripheral blood at a very low 
precursor rate compared to antigen-experienced effector and memory T cells (Neller et al., 2015). 
Therefore, analysis with the naïve subset as well as the TCM subset, which were both low, might be 
misleading. To address this and further explore the relative TEM and TEMRA levels, the ratio of TEM to 
TEMRA was calculated (Figure 4.20). This further demonstrated that CMV-specific TEM levels in 
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treated patients but not in ART-naïve individuals were higher compared to bulk CD8 T cells 
(p=0.0078; Figure 4.20 A and B). For HIV-1-specific CD8 T cells this was observed in both ART-
naïve and treated individuals, although it did not reach statistical significance in the latter group 
(p=0.0313 and 1.00 respectively; Figure 4.20 C and D).  
 
Figure 4.20 Comparison of TEM to TEMRA ratio.  
Data are shown for CMV-specific multimer+ CD8+ T cells (multimers loaded with peptides TM10 or NV9) (A-
B) and HIV-1-specific Gag SL9 multimer+ CD8+ T cells (C and D) (mult+ CD8+; grey bars). Bulk CD8+ T cells 
(excluding mult+ CD8+ T cells) are shown in white bars. Bulk and mult+ CD8+ T cells were identified and 
analysed for co-expression of CD45RA and CCR7 to identify TEM (CCR7
-CD45RA-) and TEMRA (CCR7
-
CD45RA+). The TEM to TEMRA ratios for mult+ CD8+ and bulk CD8+ were derived by dividing the percentage 
distribution of TEM by (TEM + TEMRA) and TEMRA by (TEM + TEMRA). Values obtained for TEM were subsequently 
divided by values obtained for TEMRA and this value was plotted for ART-naïve and treated HIV-1-infected 
individuals. All individual data points and lines are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10th and 90th percentile range. P values are shown where 
there are statistically significant differences between the two groups (p≤0.05). Statistical analysis was 
performed using the Wilcoxon matched pairs test.  
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The effect of ART was next evaluated on the differentiation, activation and exhaustion profiles of 
HIV-1- and CMV-specific CD8 T cells (Figure 4.21). Both CMV- and HIV-1-specific CD8 T cells 
were primarily of either a TEM or TEMRA subset in line with previous studies (Chen et al., 2001) 
(Figure 4.21 A and B). The differentiation profiles of HIV-1-specific CD8 T cells in ART-naïve 
individuals were not significantly different from those observed in treated individuals (Figure 4.21 
A). However, treated individuals exhibited significantly higher levels of CMV-specific CD8 T cells 
that were of a TEM phenotype compared to ART-naïve individuals (median 76 and 24% 
respectively; p=0.0109; Figure 4.21 B). Moreover, there was a trend for lower frequencies of CMV-
specific CD8 T cells displaying the TEMRA phenotype in treated individuals but this did not reach 
statistical significance.  
 
ART had a more substantial effect on the activation levels of both HIV-1- and CMV-specific CD8 T 
cells (Figure 4.21 C and D). In ART-naïve individuals, approximately half of HIV-1-specific CD8 T 
cells were highly activated (median 48%; HLA-DR+CD38+). This was significantly higher compared 
to the median 22% observed in treated individuals (p=0.0087). Another common HIV-1-specific 
CD8 T-cell phenotype was the HLA-DR-CD38+ phenotype, the levels of which were significantly 
higher in ART-naϊve individuals compared to the levels observed in treated patients (median 26 
and 8%; p=0.0173). The lower frequencies of HLA-DR-CD38+ and highly activated CD8 T cells in 
treated individuals concurs with the effect of ART on lowering activation levels (Hunt et al., 2003b; 
Benito et al., 2005; Hunt et al., 2008). As demonstrated in total CD8 T cells above, treated 
individuals exhibited increased levels of HIV-1-specific CD8 T cells that expressed HLA-DR only 
(HLA-DR+CD38-) compared to the levels observed in ART-naïve patients (median 35 and 8%; 
p=0.0441). CMV-specific CD8 T cells displayed similar shifts in activation levels to those observed 
for HIV-1-specific CD8 T cells (Figure 4.21 D). Significantly higher frequencies of HLA-DR-CD38+ 
and HLA-DR+CD38+ CMV-specific CD8 T cells were observed in ART-naïve individuals (p=0.0303 
and p=0.0173). Treated individuals on the other hand had significantly higher levels of CMV-
specific CD8 T cells that were either negative for both markers (HLA-DR-CD38-) or expressed 
HLA-DR only (HLA-DR+CD38-; p=0.0303 and p=0.0173). The frequencies of CMV-specific CD8 T 
cells that were highly activated were significantly lower in treated patients compared to ART-naïve 
subjecs (median 7 and 38%; p=0.0173), although one individual exhibited higher levels. Thus, the 
phenotype HLA-DR+CD38- was increased in both HIV-1- and CMV-specific CD8 T cells from 
treated individuals. TIM-3 and PD-1 co-expression on HIV-1-specific CD8 T cells was highly 
variable between individuals and was therefore not significantly different between the two groups 
(Figure 4.21 E).  
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Figure 4.21 Assessment of phenotypic profiles of antigen-specific CD8 T cells. 
Percentage co-expression of CCR7 and CD45RA (differentiation; A and B), HLA-DR and CD38 (activation; C 
and D) and PD-1 and TIM-3 (exhaustion; E) was determined on CMV-specific (blue bars) and HIV-1-specific 
(red bars) CD8 T cells in ART-naïve (darker bars) and treated HIV-1+ individuals (lighter bars). Percentage 
distribution of multimer+ CD8+ T cells is shown for all four subsets: differentiation: naïve (CCR7+CD45RA+), 
TCM (CCR7+CD45RA
-), TEM (CCR7
-CD45RA-) and TEMRA (CCR7
-CD45RA+), activation: HLA-DR-CD38-, HLA-
DR-CD38+, HLA-DR+CD38-, HLA-DR+CD38+, exhaustion: TIM-3-PD-1-, TIM-3-PD-1+, TIM-3+PD-1-, TIM-
3+PD-1+. All individual data points are shown with box plots representing the median and interquartile range, 
and whiskers representing the 10th and 90th percentile range. P values are shown where there are 
statistically significant differences between the two groups (p≤0.05). Statistical analysis was performed using 
the Mann-Whitney U test. 
 
The phenotype of HIV-1-specific CD8 T cells was subsequently compared with CMV-specific CD8 
T cells to assess whether the observed ART-mediated changes lead to distinct antigen-specific 
profiles in the two groups (Figure 4.22). In ART-naïve individuals, significantly higher frequencies 
of HIV-1-specific CD8 T cells were of the TEM subset (median 87%), compared to the 24% 
observed for CMV-specific CD8 T cells (p=0.0043). This difference was not observed in treated 
CHAPTER 4 
PHENOTYPIC PROFILES 
162 
patients with both CMV- and HIV-1-specific CD8 T cells comprising comparable TEM frequencies 
(median 76 and 86% respectively; Figure 4.22 B). The activation levels were not significantly 
different between CMV- and HIV-1-specific CD8 T cells in either patient group (Figure 4.22 C and 
D). High levels of highly activated (HLA-DR+CD38+) CMV- and HIV-1-specific CD8 T cells were 
detected in ART-naïve individuals (although it was more variable for CMV-specific CD8 T cells). 
Treated patients still seemed to have a higher frequency of highly activated (HLA-DR+CD38+) HIV-
1-specific CD8 T cells compared to CMV-specific CD8 T cells, although this did not reach statistical 
significance (Figure 4.22 D). The exhaustion profile was also assessed in ART-naïve individuals 
and this was not significantly different between the two antigen-specific CD8 T-cell populations 
(Figure 4.22 E). 
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Figure 4.22 Comparison of phenotypic profiles of CMV- and HIV-1-specific CD8 T cells. 
Percentage co-expression of markers CCR7 and CD45RA (differentiation; A and B), HLA-DR and CD38 
(activation; C and D) and PD-1 and TIM-3 (exhaustion; E) was determined on CMV-specific (blue bars) and 
HIV-1-specific (red bars) CD8 T cells in ART-naïve (darker bars) and treated HIV-1+ individuals (lighter bars). 
Percentage distribution of multimer+ CD8+ T cells is shown for all four subsets: differentiation: naïve 
(CCR7+CD45RA+), TCM (CCR7+CD45RA
-), TEM (CCR7
-CD45RA-) and TEMRA (CCR7
-CD45RA+), activation: 
HLA-DR-CD38-, HLA-DR-CD38+, HLA-DR+CD38-, HLA-DR+CD38+, exhaustion: TIM-3-PD-1-, TIM-3-PD-1+, 
TIM-3+PD-1-, TIM-3+PD-1+. All individual data points are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10th and 90th percentile range. P values are shown where 
there are statistically significant differences between the two groups (p≤0.05). Statistical analysis was 
performed using the Mann-Whitney U test.  
 
In one treated HIV-1-infected individual who was HLA-A*02:01+, both HIV-1- and CMV-specific 
CD8 T cells were identified allowing a comparison (Figure 4.23). The majority of HIV-1 SL9-specific 
CD8 T cells in the HIV-1-infected individual were primarily TEM (79%), whereas CMV NV9-specific 
CD8 T cells displayed a TEM (55.9%) but also a TEMRA phenotype (26.1%; Figure 4.23 A and B). 
Interestingly, a higher percentage of the CMV NV9-specific CD8 T cells in this individual were 
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highly activated (44.4%) compared to the 26% observed for HIV-1-specific CD8 T cells. HIV-1 SL9- 
specific CD8 T cells were instead more likely to be HLA-DR+CD38- (54%) confirming previous 
findings that showed an accumulation of this subset in treated patients. The majority of HIV-1 SL9-
specific CD8 T cells expressed PD-1 either on its own (55.9%) or with TIM-3 (10.8%). In contrast, 
CMV-specific CD8 T cells were primarily negative for PD-1 and TIM-3, although at least 13.4% 
expressed TIM-3 alone.  
 
Figure 4.23 Comparison of HIV-1 and CMV-specific CD8 T cells in the same HIV-1+ individual.  
Analysis of differentiation, activation and exhaustion profiles of HIV-1- and CMV-specific CD8 T cells in one 
HIV-1+ individual on ART (M160; HLA-A*02:01+). Frozen PBMC were thawed and stained with Pro5® 
Pentamers specific for HLA-A*02:01-restricted HIV-1 Gag SL9 or CMV NV9 peptide and additional 
monoclonal antibodies: anti-CD3, anti-CD8 and anti-CD4. For phenotypic analysis the following were 
included: differentiation markers CCR7 and CD45RA; HLA-DR and CD38 to assess activation levels and 
TIM-3 and PD-1 for exhaustion. Gating frequencies are shown in all plots. 
 
In summary, the CMV-specific CD8 T cells detected in ART-naïve individuals varied in memory 
phenotype between TEM and TEMRA subsets. However, in treated individuals, the percentage of 
CMV-specific CD8 T cells that were of a TEM phenotype was significantly higher compared to the 
levels observed in ART-naïve individuals. This was not observed when examining HIV-1-specific 
CD8 T cells, which were predominantly skewed toward a TEM phenotype in both ART-naïve and 
treated individuals. Assessment of activation levels on antigen-specific CD8 T cells revealed two 
predominant phenotypes (HLA-DR+CD38+ and HLA-DR-CD38+) in HIV-1-specific CD8 T cells of 
ART-naïve individuals. In contrast, treated individuals exhibited significantly lower levels of these 
two subsets, whilst having significantly higher levels of HLA-DR+CD38- HIV-1-specific CD8 T cells. 
CMV-specific CD8 T cells followed the same pattern and consequently, when comparing the two 
antigen-specific populations, there was no significant difference between them.  
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4.2.8 Assessment of Growth Hormone, IL-2 and GM-CSF on Antigen-Specific 
CD8+ T cells  
An immunotherapy trial was previously carried out by Dr Nesrina Imami and Dr Anna 
Herasimtschuk (IMIRC 1003 clinical trial; clinicaltrials.gov identifier: NCT01130376), which 
comprised administering a GTU-Multi-HIV B clade vaccine, Interleukin-2, GM-CSF and Growth 
Hormone to treated HIV-1+ individuals. Amongst other important findings, the results from that 
study showed a decrease in activation levels of total CD4 and CD8 T cells (Herasimtschuk et al., 
2014). To further examine the effect of immunotherapy on the phenotype of antigen-specific CD8 T 
cells, available cryopreserved samples from the trial participants were thawed and stained with 
Pro5® Pentamers specific for CMV TM10 B*07:02, CMV NV9 A*02:01, HIV-1 SL9 A*02:01 and 
HIV-1 TL10 B*07:02. This part of the study was performed in collaboration with Dr Anna 
Herasimtschuk and Mr Ali Hamidi (MSc student), with details of the trial published (Herasimtschuk 
et al., 2014). CMV-specific CD8 T cells were identified in six treated patients: C319, P054, P087, 
S648 (all of which were HLA-B*07:02+), C789 and R771 (both of which were HLA-A*02:01+). HIV-
1-specific CD8 T cells were however only detected in two patients. All subsequent analysis was 
therefore carried out on the patients where CMV-specific CD8 T cells were detected (Pro5® 
Pentamer CMV TM10 for HLA-B*07:02+ patients and Pro5® Pentamer CMV NV9 for HLA-A*02:01+ 
patients). The median age for these six patients was 49 years (IQR 37 to 52 years). All were male 
and all had nadir ≥200 CD4 T cells/µl blood (median 219, IQR 203 to 289 cells/µl blood). The 
median CD4 T-cell count at baseline was 786 cells/µl (IQR 616 to 783 cells/µl blood).  
 
Figure 4.24 details the frequencies of CMV-specific CD8 T cells at baseline and after 12 weeks of 
immunotherapy. The overall frequency did not change, indicating that immunotherapy has no effect 
on the frequency of CMV-specific CD8 T cells. Variability between individuals was however 
detected. 
 
Immunotherapy did not have any overall effect on the differentiation profile of CMV-specific CD8 T 
cells (Figure 4.25). In terms of activation and exhaustion profiles, although variable levels were 
observed intra-individually, there were no significant differences before and after 12 weeks of 
immunotherapy in these individuals (Figure 4.26). Interestingly, PD-1 expression and HLA-
DR+CD38+ co-expression was particularly high in patients with detectable CD8 T cells specific for 
HLA-A*02:01-restricted CMV NV9 epitope, which might indicate epitope-specific differences 
(Figure 4.26 C and E, light and dark green lines). No significant differences were observed before 
and after immunotherapy when PD-1 co-expression with HLA-DR or CD38 was analysed (data not 
shown). 
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Figure 4.24 Effect of immunotherapy on CMV-specific CD8 T-cell frequencies.  
CMV-specific CD8 T cells were identified in six treated HIV-1+ individuals (with HLA-type B*07:02 or A*02:01 
using Pro5® Pentamer CMV TM10 and CMV NV9 respectively), receiving immunotherapy. Cryopreserved 
PBMC from baseline (white bars) and 12 weeks of receiving immunotherapy (Time point 12; grey bars), were 
thawed and stained with anti-CD3, anti-CD8 and anti-CD4 monoclonal antibodies as well as CMV TM10- or 
CMV NV9-specific Pro5® Pentamers. All individual data points with connecting lines are shown with box 
plots representing the median and interquartile range, and whiskers representing the 10th and 90th percentile 
range. Each colour and line represents one individual. Statistical analysis was performed using the Mann-
Whitney U test. 
 
 
 
Figure 4.25 Effect of immunotherapy on CMV-specific CD8 T-cell differentiation subsets.  
CMV-specific CD8+ T cells were identified in six HIV-1+ individuals (with HLA-type A*02:01 or B*07:02), 
receiving immunotherapy. Cryopreserved PBMC from baseline (white bars) and 12 weeks of receiving 
immunotherapy (Time point 12; grey bars), were thawed and stained with CMV TM10- or CMV NV9-specific 
Pro5® Pentamers, anti-CD3, anti-CD8 and anti-CD4 monoclonal antibodies as well as differentiation 
markers CCR7 and CD45RA to identify the four differentiation subsets naïve, TCM, TEM and TEMRA. All 
individual data points with connecting lines are shown with box plots representing the median and 
interquartile range, and whiskers representing the 10th and 90th percentile range. Each colour represents one 
individual. P values are shown where there are statistically significant differences between the two groups 
(p≤0.05). Statistical analysis was performed using the Mann-Whitney U test. 
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Figure 4.26 Effect of immunotherapy on activation and exhaustion profiles of CMV-specific CD8 T 
cells. 
CMV-specific CD8+ T cells were identified in six HIV-1+ individuals (with HLA-type A*02:01 or B*07:02), 
receiving immunotherapy. Cryopreserved PBMC from baseline and 12 weeks of receiving immunotherapy 
(Time point 12), were thawed and stained with CMV TM10- or CMV NV9-specific Pro5® Pentamers and 
additional monoclonal antibodies: anti-CD3, anti-CD8 and anti-CD4. For phenotypic analysis the following 
were included: CD38 and HLA-DR to assess activation levels as well as PD-1 and TIM-3 to assess 
exhaustion profiles. All individual data points with connecting lines are shown with each colour representing 
one individual.  
 
HIV-1-specific CD8 T cells were detected in two individuals and differentiation, activation and 
exhaustion profiles were assessed with the results shown for the one with the highest frequencies 
(Figure 4.27). The frequency of identified HIV-1 SL9-specific CD8 T cells decreased at time point 
12 from 0.601 to 0.294% of total CD8 T cells. Moreover, the frequencies of HIV-1 SL9-specific CD8 
TEMRA cells increased from 0.99% at baseline to 10% at time point 12, suggesting a role for 
immunotherapy in the increase of this subset. Alternatively, the effect of an additional 12 weeks of 
CHAPTER 4 
PHENOTYPIC PROFILES 
168 
ART may also be behind the increase. The percentage of highly activated HIV-1 SL9-specific CD8 
T cells also increased after 12 weeks of immunotherapy (27.7 at baseline to 45.7%). There were 
no notable differences observed for exhaustion levels.  
 
 
Figure 4.27 Effect of immunotherapy on HIV-1-specific CD8 T cells.  
Representative analysis of differentiation, activation and exhaustion profiles of HIV-1-specific CD8 T cells in 
one HIV-1+ individual (O523; HLA-B*07:02+) receiving immunotherapy. Cryopreserved PBMC from baseline 
and 12 weeks of receiving immunotherapy (Time point 12), were thawed and stained with Pro5® Pentamers 
specific for HIV-1 Nef TL10 peptide and additional monoclonal antibodies: anti-CD3, anti-CD8 and anti-CD4. 
For phenotypic analysis the following were included: differentiation markers CCR7 and CD45RA; HLA-DR 
and CD38 to assess activation levels and TIM-3 and PD-1 for exhaustion.  
0 102 103 104 105
CD8
0
103
104
105
H
IV
-1
 N
ef
 T
L1
0
99.3
0.601
0 102 103 104 105
CD8
0
103
104
105
H
IV
-1
 N
ef
 T
L1
0
99.4
0.294
Baseline Time-point 12 
0 102 103 104 105
0
103
104
105
0.99 0
8.9190.1
0 102 103 104 105
0
103
104
105
10 1.43
088.6
C
D
45
R
A
 
CCR7 
0 103 104 105
0
102
103
104
105
10.9 27.7
30.730.7
0 103 104 105
0
102
103
104
105
11.4 45.7
17.125.7
C
D
38
 
HLA-DR 
0 102 103 104 105
0
102
103
104
105
14.4 51.1
22.212.2
0 102 103 104 105
0
102
103
104
105
19.2 55.9
15.39.6
P
D
-1
 
TIM-3 
Differentiation 
Activation 
Exhaustion 
CHAPTER 4 
PHENOTYPIC PROFILES 
169 
4.3 Discussion 
Changes in the generation and maintenance of T cells due to compromised thymic output (Haynes 
et al., 2000; Douek et al., 2001), T-cell homeostasis (Douek et al., 2001; Douek et al., 2003) and 
survival (Yan et al., 2013) ultimately result in the accumulation of impaired CD4 and CD8 T cells in 
HIV-1-infected individuals (Papagno et al., 2004; Morou et al., 2014). Understanding the phenotype 
of these dysfunctional T cells will be important for highlighting how and why they occur. To this 
end, a comprehensive analysis of total T-cell phenotype was carried out to further explore the 
differentiation, activation and exhaustion profiles of both total CD4 and CD8 T cells as well as 
antigen-specific CD8 T cells.  
 
The previously described reduction of the naïve CD4 and CD8 T-cell compartment in HIV-1-
infected individuals, which was also observed here, has been attributed to several factors including 
reduced thymic output and recruitment of naïve T cells into the memory/effector cell compartments 
through antigen-specific stimulation (Champagne et al., 2001; Imami et al., 2001; Li et al., 2011b; 
Sauce et al., 2011). Moreover, nadir CD4 T-cell count upon ART initiation can significantly affect 
naïve T-cell recovery as well as naïve/cell memory ratio (Robbins et al., 2009). These factors may 
have contributed to the lower frequencies of naïve CD4 and CD8 T cells that persisted in treated 
HIV-1 individuals despite being on effective ART (Appay et al., 2011). Treated patients even 
displayed a trend for having lower levels of naïve CD4 T cells, which may be due to them 
presenting with a longer HIV-1 infection compared to ART-naϊve ART-naïve individuals, or they 
might have initiated ART during advanced disease as reflected by a low nadir CD4 T-cell count in 
some of the subjects. In any case, this points to persistent deficiencies in both de novo production 
and in the peripheral homeostatic renewal capacity of existing CD4 T cells to generate naïve cells 
despite ART. This does not seem to be linked to the level of activation on CD4 T cells as shown 
here, but might depend more on reduced thymic output as described in previous studies (Sauce et 
al., 2011). Diminishing thymic function as a consequence of HIV-1 infection will be particularly 
important to address in the near future as an increasing population of HIV-1-infected individuals 
are growing older and thymic function decreases further with age (Haynes et al., 2000).  
 
In contrast to CD4 T cells, reduction in naïve CD8 T cells was tightly linked to higher activation 
levels and a lower ratio between CD4 and CD8 T-cell frequencies. This is indicative of a persistent 
expansion of effector/memory CD8 T cells and the CD4/CD8 ratio may be reflecting these 
changes. Indeed, a recent study investigated the relevance of CD4/CD8 ratio in HIV-1+ individuals 
(Serrano-Villar et al., 2014). The study reported that treated patients who achieved otherwise good 
CD4 T-cell count recovery (>500 cells/µl blood) but exhibited decreased CD4/CD8 ratio, had 
persistently lower levels of naïve CD8 T cells, higher levels of CD8 TEM and TEMRA cells and 
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increased levels of CD8 T-cell activation (Serrano-Villar et al., 2014). This suggests that low 
CD4/CD8 ratio may be useful as a clinical marker for increased risk of disease progression 
because it reflects ongoing activation levels, lower naïve CD8 T-cell frequencies and persistent 
expansion of highly differentiated CD8 T cells despite fully suppressive ART. Indeed, results 
presented here also point to a significant association between higher frequencies of CD8 TEM cells 
and lower CD4/CD8 ratio in HIV-1-infected individuals, as further discussed below. 
 
Apart from the naïve T-cell subset, the most striking change was in regards to the increased 
frequencies of total CD4 and CD8 TEM cells in HIV-1-infected individuals compared to uninfected 
controls. Moreover, a higher proportion of HIV-1-specific CD8 T cells in both ART-naïve and 
treated individuals were of the TEM subset compared to the rest of the CD8 T-cell pool, a finding 
that was substantiated by calculating the TEM to TEMRA ratio. This previously described maturation 
block from TEM to TEMRA phenotype in the CD8 T-cell compartment (Champagne et al., 2001), 
contrasts the higher levels of HIV-1-specific CD8 TEMRA cells observed in a group of HIV controllers 
(Addo et al., 2007). The detection of HIV-1-specific CD8 TEMRA cells during primary infection has 
also been associated with lower plasma viral load set point (Northfield et al., 2007). These studies 
suggest that the presence of highly differentiated cells, which produce large amounts of perforin 
(Sallusto et al., 1999), may be important for control of HIV-1 infection in a subset of individuals. In 
the current study, although frequencies of the TEMRA phenotype varied considerably in both HIV-1-
infected individuals and uninfected controls, the activation levels of this subset differed markedly 
between the three groups.  
 
Both ART-naïve and treated HIV-1-infected individuals exhibited significantly higher levels of highly 
activated CD4 and CD8 TEMRA cells compared to healthy controls. The highly activated phenotype 
may be indicative of impaired function in these cells, consistent with previous data reporting 
progressive loss of function on HIV-1-specific CD8 T cells of a late differentiated phenotype 
(CD45RO-CD27-) (Riou et al., 2012). It is further demonstrated here that ART has little effect in 
reducing activation levels on this subset, which may underlie continued impairment in cytotoxic 
activity in these cells. However, the use of different markers to detect T cells with a terminally 
differentiated phenotype makes comparisons between studies difficult. In hindsight, it would have 
been more informative to include other differentiation markers such as CD45RO, CD27 and CD28 
as well as the senescent marker CD57 for a more comprehensive assessment.  
 
Although treated individuals exhibited slightly lower levels of total CD4 and CD8 TEM cells, these 
did not approach the levels observed in HIV-1-uninfected individuals. Higher frequencies of CD8 
TEM cells were associated with lower CD4 T-cell count, lower CD4/CD8 ratio and a trend for higher 
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activation levels, indicating a role in HIV-1 disease progression (Serrano-Villar et al., 2014). In 
agreement with these results, a recent study found that higher proportions of total and HIV-1-
specific CD8 TEM cells correlated with higher activation levels and lower CD4 T-cell counts in 
subjects with early HIV-1 infection (Ghiglione et al., 2014). However, whether increased TEM levels 
are a consequence or factor in HIV-1 immunopathology requires further studies into the functional 
capacity of these cells. Whereas TCM produce IL-2 and IFN-γ, TEM tend to produce exclusively IFN-
γ, particularly in the context of untreated HIV-1 infection (Younes et al., 2003). In a study published 
recently using an OX40/CD25 assay to detect activated HIV-1-specific T cells, initiation of ART 
lead to a shift in the HIV-1 Gag-specific CD4 T-cell functional responses from a TEM phenotype to a 
TCM phenotype (Phetsouphanh et al., 2014). This shift was not observed for CMV-specific CD4 T-
cell responses, suggesting that antigen exposure affects effector to central memory ratios 
(Phetsouphanh et al., 2014). Although the present data showed no significant difference in the 
frequencies of differentiation subsets in HIV-1-specific CD8 T cells between ART-naïve and treated 
patients, it cannot be excluded that the functional responses of these cells might have been 
different and is a limitation of the current study.  
 
Interestingly, treated patients had enhanced levels of CMV-specific CD8 T cells that were of the 
TEM phenotype and this was further shown by a clear shift of CMV-specific CD8 T cells towards the 
TEM phenotype compared to total CD8 T cells. This suggests that whilst ART may not reduce the 
frequencies of HIV-1-specific CD8 TEM cells, it may lead to increased levels of CD8 TEM cells 
specific for CMV. CMV-specific memory T cells have primarily been described to be of a late 
memory phenotype defined as TEM, TEMRA or CD28-CD27- (which encompasses both TEM and TEMRA) 
(Chen et al., 2001; Appay et al., 2002; Lee et al., 2014). The increase of CMV-specific CD8 TEM 
cells may therefore reflect an ART-mediated reconstitution of these levels. However, the rate at 
which this occurs might influence overall T-cell immune expansion, in particular since higher CMV-
specific responses in treated individuals have been linked to lower naïve T-cell recovery (Appay et 
al., 2011). The observation that up to 10% of CD4 and CD8 T-cell responses are specific for CMV 
in HIV-1 seronegative individuals is indicative of a significant contribution of this virus to the overall 
T-cell immune responses (Sylwester et al., 2005), and any changes in the dynamics of CMV-
specific CD4 and CD8 T-cell subsets may therefore impact the overall composition of the T-cell 
pool. It should be noted that the distinct outcomes may be due to different peptide specificities, as 
the multimers used to identify HIV-1- and CMV-specific CD8 T cells were loaded with peptides 
restricted to HLA-A*02:01 and HLA-B*07:02.  
 
Previous studies suggest that the differentiation status of antigen-specific CD8 T cells is 
independent of HLA-restriction (Addo et al., 2007), but whether it affects activation and exhaustion 
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is unclear. Ideally, different peptide specificities and HLA-types would have been assessed in a 
higher number of individuals, including HIV-1-uninfected individuals to provide a more general 
picture. However, obtaining a positive staining using multimers with other peptide specificities such 
as the HLA-B*27:05-restricted KK10 epitope proved to be more challenging due to lower frequency 
of this allele in the population. Future work that combines multimer staining with intracellular 
cytokine staining will allow for a more comprehensive assessment of the functional capacities of 
CD8 TEM and how these may impact on the overall T-cell response.  
 
A large proportion of CD4 and CD8 T cells from uninfected controls were either negative for both 
HLA-DR and CD38, or expressed CD38 only. ART-naϊve patients exhibited fluctuations of these 
frequencies in the CD4 T-cell compartment but there was a more discernable shift towards a highly 
activated phenotype (HLA-DR+CD38+) in the CD8 T cells from these patients. The shift was 
somewhat reversed in treated individuals but did not reach the frequencies detected in healthy 
controls, confirming the strong association between CD8 T-cell activation and disease progression 
despite ART (Hunt et al., 2003b; Funderburg et al., 2013). High activation levels on CD8 T cells 
have predicted lower CD4 T-cell gains upon ART-initiation in a longitudinal study (Zhang et al., 
2013). It is further demonstrated here that treated individuals exhibit considerable variation in the 
activation levels of CD4 and CD8 T-cell differentiation subsets. Specifically, it was the TEM and 
TEMRA subsets in treated individuals that remained highly activated despite effective ART. This 
might reflect an impairment in the homeostatic renewal capacity of these cells compared to TCM 
and naïve subsets or a propensity to travel to inflamed tissues and being exposed to antigen and 
an inflammatory environment (Sallusto et al., 1999; Mueller et al., 2013). Treated individuals also 
exhibited changes in activation phenotypes that were not observed in uninfected controls. Among 
these were CD38+HLA-DR- CD4 T cells, which were high in uninfected subjects, but significantly 
lower in treated individuals. Instead, treated individuals had significantly higher frequencies of CD4 
T cells that were negative for both CD38 and HLA-DR. The consequences of reduced CD38 
expression, which mainly concerned the naïve and TEMRA subsets, are not clear. Early studies have 
demonstrated that CD38 mediates a weak adhesion of CD45RA+ CD4 T cells to endothelial cells 
through a CD38/CD31 interaction (Dianzani et al., 1994; Deaglio et al., 1998). Low CD38 
expression could therefore affect the migration and cell-adhesion properties of these cells. The 
expression of other cell surface markers involved in migration (including selectins) could be 
evaluated on these subsets to determine if HIV-1 infection modifies the migratory pathways of 
naïve and TEMRA CD4 T cells.  
 
ART seemed to have less of an effect on the frequencies of HLA-DR+ CD4 and CD8 T cells and 
consequently a majority of treated patients continued to have elevated levels of HLA-DR 
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expression across all CD4 and CD8 T-cell differentiation subsets. The emergence of HLA-
DR+CD38- CD8 T cells in treated individuals is interesting because this was not observed in ART-
naϊve or uninfected controls. An early study linked this phenotype with slower disease progression 
and high CD4 T-cell counts (Giorgi et al., 1994). More recently, studies have found elevated 
frequencies of this phenotype on total and HIV-1-specific CD8 T cells of HIV controllers, compared 
to both treated HIV-1-infected and uninfected individuals (Saez-Cirion et al., 2007; Hua et al., 
2014). Hua and colleagues demonstrated that this phenotype was induced in the presence of low 
EBV antigen levels whereas high concentrations stimulated a predominantly highly activated (HLA-
DR+CD38+) phenotype. This would explain the induction of an HLA-DR+CD38- CD8 T-cell 
phenotype in the treated individuals assessed here. Low-level HIV-1 replication in the context of 
ART could be driving a shift from highly activated CD8 T cells in ART-naϊve individuals to an HLA-
DR+CD38- phenotype in treated patients. However, as this phenotype was detected in both HIV-1- 
and CMV-specific CD8 T cells, it will be important to determine if changes in CMV viraemia also 
affect the accumulation of this phenotype or whether this occurs regardless of antigen-specificity in 
treated individuals.  
 
Interestingly, HLA-DR was rarely co-expressed with PD-1 in CD8 T cells of treated individuals, 
suggesting improved effector functions in these cells. The induction of HLA-DR in the absence of 
CD38 needs further evaluation to clarify its role in antigen-specific T-cell responses. HLA-DR 
expression on CD8 T cells has been linked to higher telomerase activity (Speiser et al., 2001) and 
proliferation (Imamichi et al., 2012; Hua et al., 2014) and may therefore reflect a low level of 
activation needed for efficient responses (Saez-Cirion et al., 2007; Hua et al., 2014). Imamichi and 
colleagues reported that HLA-DR+ CD8 T cells from HIV-1-infected individuals were qualitatively 
the same as those observed in healthy controls (based on proliferation and survival), however 
although they also measured CD38 expression, they did not specifically assess HLA-DR+CD38- 
CD8 T cells (Imamichi et al., 2012). Therefore, the HLA-DR+ CD8 T cells that they detected would 
include both HLA-DR+CD38- and HLA-DR+CD38+ CD8 T cells. This emphasises the need for 
studies, which not only quantify HLA-DR and CD38 double positive cells but also measure different 
combinations of these markers. Hua and colleagues also demonstrated that the frequency of HIV-
1-specific HLA-DR+CD38- CD8 T cells correlated significantly with antigen sensitivity suggesting 
high avidity in CD8 T cells with this phenotype (Hua et al., 2014). This raises the question of 
whether antigen-specific CD8 T cells with this phenotype in treated individuals also exhibit high 
avidity and whether this leads to improved effector function in these cells as observed in HIV 
controllers.  
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The upregulation of negative cell surface receptors such as PD-1 and TIM-3 is a hallmark of 
untreated HIV-1 infection (Day et al., 2006; Trautmann et al., 2006; Jones et al., 2008), and this 
was confirmed here for PD-1 but not TIM-3. ART-naϊve HIV-1-infected individuals had high levels 
of PD-1 expression on both CD4 and CD8 T cells whilst an ART-mediated reduction was observed 
in treated individuals, confirming the effect of HIV-1 replication on this marker (Day et al., 2006; 
Trautmann et al., 2006). In contrast, TIM-3 expression was very low in both HIV-1-infected and 
uninfected healthy control subjects as demonstrated by the high frequencies of TIM-3-PD-1- and 
TIM-3-PD-1+ CD4 and CD8 T cells. Upregulation of TIM-3 might be less pronounced compared to 
PD-1 and therefore may be more relevant in antigen-specific T cells as shown by the higher 
percentages detected in HIV-1 and CMV-specific CD8 T cells. However, the expression patterns 
on HIV-1 and CMV-specific CD8 T cells were variable between individuals and would therefore 
require further evaluation with an increasing number of subjects. Future work should also explore 
whether PD-1 expression varies between CD8 T cells restricted for B*07:02 and A*02:02 as 
observed here. Considering that exhaustion is a multifaceted process with several negative 
receptors described, different markers may be involved in different stages of disease progression 
and contribute via different mechanisms (Kuchroo et al., 2014).  
 
PD-1 expression was strongly associated with CD4 and CD8 T-cell activation (both CD38+ and 
HLA-DR+CD38+), and this was also demonstrated in a recently published study (Cockerham et al., 
2014). However, the association between CD4 PD-1 MFI and CD4 T-cell count or CD8 PD-1 MFI 
and plasma HIV-1 RNA load, as reported by Cockerham and colleagues, was not observed here. 
The discrepancies between these two studies may be due to different clinical characteristics 
between the two patient groups investigated. Alternatively, the number of subjects included here 
might not have been enough to detect a significant correlation. However, the link between PD-1 
expression and T-cell activation does appear to be more strongly associated, particularly on CD8 T 
cells. The upregulation of PD-1 in ART-naϊve individuals occurred concomitant with upregulation of 
CD38 expression, suggesting a close link between these two markers. On the other hand, the 
increased levels of HLA-DR+PD-1- CD4 and CD8 T cells in both ART-naϊve and treated HIV-1-
infected individuals suggests that different mechanisms may lead to the upregulation of HLA-DR 
and PD-1. The simultaneous expression of PD-1 and CD38 or HLA-DR has not been investigated 
in great detail and future studies should aim to further assess the functional capacities of these 
cells, and determine whether they display a more dysfunctional response. To further explore the 
role of PD-1, further studies should look at PD-1 expression on differentiation subsets. Although 
the present study did not explore this, previous studies have described an upregulation of PD-1 on 
memory T cells and to a lesser extent naïve T cells (Rosignoli et al., 2009; Breton et al., 2013). 
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Two recent studies did however find that the highest PD-1 expression was on TEM cells both when 
looking at total CD8 T cells (Cockerham et al., 2014) and HIV-1-specific CD8 T cells (Kloverpris et 
al., 2014), perhaps providing a mechanism for the role of TEM cells in HIV-1 immunopathogenesis.  
 
The specificity and sensitivity of the various different multimer technologies including tetramers, 
pentamers and streptamers (Wooldridge et al., 2009) have been compared and been found to 
detect similar frequencies of antigen-specific CD8 T cells (Yao et al., 2008). In line with this, 
although slight differences in the proportion of CD8 T-cell differentiation subsets were observed 
between the two multimer technologies, this was not statistically significant. Even so, further 
evaluation with an increased number of individuals is needed. HIV-1-specific CD8 T cells were 
difficult to identify in treated patients, which is most likely because ART-mediated suppression of 
antigen levels results in a contracted HIV-1-specific T-cell response as demonstrated in Chapter 3 
and in previous studies (Ogg et al., 1999; Casazza et al., 2001). This is in contrast to the high 
levels of CMV-specific CD8 T cells identified due to the high immunogenicity of CMV (Naeger et 
al., 2010). Further studies are required that include multimers specific for a variety of peptides 
enabling a more in-depth assessment of the phenotypic profiles of CMV-and HIV-1-specific CD8 T 
cells. Comparison with intracellular staining will also be necessary, however multimers are ideal for 
ex vivo analysis whereas intracellular staining relies on re-stimulation to identify antigen-specific 
CD8 T cells and therefore may lead to altered phenotypic profiles during stimulation.  
 
A previous study reported that CMV-seropositive HIV-1+ patients on ART, but with incomplete CD4 
T-cell recovery, experienced significant declines in the frequency of CD38+HLA-DR+ CD8 T cells 
when treated with the anti-CMV drug valganciclovir (Hunt et al., 2011b). The results presented 
here suggest that ART-naïve individuals exhibit similar upregulation of activation levels on CMV-
specific CD8 T cells as HIV-1-specific CD8 T cells. This is in line with the previously described 
bystander activation of T cells specific for herpesviruses during HIV-1 infection (Smith et al., 2013) 
as well as certain acute infections (Sandalova et al., 2010). These results point towards a role for 
herpesviruses, including CMV, in immune activation during HIV-1 infection, which is partially 
restored with ART as shown here. However, few individuals were assessed for HIV-1 and CMV-
specific CD8 T cells, a limitation that needs to be addressed in future studies. For instance, 
although treated individuals on the whole exhibited reduced frequencies of highly activated CMV-
specific CD8 T cells, in the one treated individual where both HIV-1- and CMV-specific CD8 T cells 
were detected simultaneously, higher frequencies of highly activated CMV-specific CD8 T cells 
were detected compared to the levels observed for highly actiaved HIV-1-specific CD8 T cells 
(Figure 4.23, page 164). Thus, whilst activation is reduced in the majority of individuals, some will 
continue to exhibit persistently high levels of highly activated CD8 T cells specific for HIV-1 but also 
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for CMV. This might be even more noticeable during advanced infection or in patients not 
responding to ART where CMV infection may be driving immune activation as shown by Hunt and 
colleagues (Hunt et al., 2011b). Administration of immunotherapy had no effect on CMV-specific 
CD8 T cells, perhaps because patients were on effective ART with high levels of CD4 T cells and a 
reconstitution of CMV-specific T cells had already occurred (Herasimtschuk et al., 2014). The 
higher frequencies of CMV-specific CD8 TEM cells do however suggest a role for CMV during ART-
mediated reconstitution and requires further studies with increased number of patients.  
 
This study has several limitations. It is challenging to compare individuals with HIV-1 versus those 
without HIV-1, as these groups almost certainly differ in ways that are difficult to control for and 
analyse. Ideally, HIV-1 seronegative healthy control samples would be age- and gender-matched, 
however as these were kindly provided by laboratory volunteers from the Section of Immunology 
this was not always possible but should be taken into consideration for future studies. The study 
was cross-sectional in design and may therefore not account for long-term variations in phenotypic 
profiles that are likely to occur between study visits. Longitudinal analysis of patients initiating ART 
will be key to further investigate the emergence of HLA-DR+CD38- CD8 T cells in treated patients 
as well as confirming what role CMV-specific CD8 TEM cells play in the persistent expansion of 
CD8 T cells despite ART. Information regarding duration of ART for the HIV-1-infected individuals 
assessed would have been advantageous to fully understand the effect of ART on immune 
reconstitution. Furthermore, results were based on phenotypic changes that occurred in the blood. 
For a comprehensive study it is important to take into account not only what is observed in 
peripheral blood but also at multiple other sites in the body including mucosal tissues and seminal 
fluids.  
 
In summary, a comprehensive analysis of the differentiation, activation and exhaustion phenotype 
of CD4 and CD8 T cells was carried out in the present study. This confirmed previous findings 
such as higher activation levels and increased PD-1 expression during untreated HIV-1 infection 
but further revealed distinctive activation levels on differentiation subsets, which may be more 
relevant to explore. In addition, by quantifying CD38 and HLA-DR individually it was possible to 
identify an ART-mediated increase of the HLA-DR+CD38- CD8 T-cell subset not observed in ART-
naïve ART-naϊve HIV-1-infected individuals and uninfected healthy control subjects. As this 
phenotype has previously been identified in a subset of controllers it will be important to investigate 
this in controllers of the Chelsea and Westminster cohort and will be discussed in Chapter 5. 
Individuals that spontaneously control HIV-1 infection in the absence of ART present an ideal 
opportunity to compare and contrast the activation, differentiation and exhaustion profiles observed 
here in chronic individuals. For example, investigating the levels of CD38 expression on CD4 naïve 
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and TEMRA cells will help deduce whether this is maintained in controllers similar to HIV-1-
uninfected individuals or whether reduced CD38 expression on these subsets is a consequence of 
HIV-1 infection. The inverse correlation between CD8 TEM levels and CD4 T-cell counts point to a 
potential role for TEM in faster disease progression. HIV-1-specific TEM levels remained high in 
treated individuals and there was an observed ART-mediated effect of higher proportions of CMV-
specific CD8 TEM cells. Therefore, although ART reduced the activation levels of CMV-specific CD8 
T cells in the majority of treated HIV-1-infected individuals, it may also lead to a persistent increase 
in CMV-specific CD8 TEM cells that may contribute to the overall skewing of the TEM phenotype. 
Longitudinal studies assessing antigen-specific CD8 TEM levels and their functional capacities in 
ART-naïve patients initiating treatment will be important in defining how the T-cell compartment is 
altered by immune reconstitution to HIV-1 and whether CMV plays an important role in this. This is 
particularly relevant as CMV-based vectors are being used in the development of HIV-1 vaccines 
(Hansen et al., 2009; Hansen et al., 2011).  
 
 178 
 
 
 
 
 
 
 
 
Chapter 5:  
Identification and Characterisation  
of Long-term Non-progressors  
and HIV Controllers 
 
CHAPTER 5 
SPONTANEOUS HIV-1 CONTROL 
179 
Chapter 5 Identification and Characterisation of Long-term 
Non-progressors and HIV Controllers 
5.1 Background and Aims  
HIV-1 infection is characterised by intense viral replication and progressive CD4 T-cell depletion 
with a typical progression to AIDS that is on average ten years (Pantaleo and Fauci, 1996). 
However in a defined subset of individuals, the disease course is slower and more benign. Long-
term non-progressors (LTNP) comprise a rare group of HIV-1-infected individuals who, in the 
absence of therapy, maintain stable peripheral CD4 T-cell counts for several years without AIDS-
defining symptoms (Okulicz et al., 2009; Westrop et al., 2009; Mandalia et al., 2012). This clinical 
definition is independent of HIV-1 RNA load, which has been shown to be heterogeneous in these 
individuals (Madec et al., 2009). Two other groups are defined primarily by their ability to control 
plasma HIV-1 RNA load, although stable CD4 T-cell count >500 cells/µl blood is a key criteria in 
most studies. HIV controllers (HIC) have detectable but low plasma HIV-1 RNA load (typically 
<2000 copies of HIV-1 RNA/ml plasma), and an even more rare group termed elite controllers (EC; 
about 3/1000 of HIV-1-infected individuals) are able to control plasma HIV-1 RNA levels to below 
the detection limit of currently used assays (<50 copies/ml) (Deeks and Walker, 2007; Migueles 
and Connors, 2010; Okulicz and Lambotte, 2011).  
 
The definitions of what characterises LTNP, HIC and EC status are not universal, however several 
host mechanisms have been implicated in the spontaneous control of HIV-1. One of the strongest 
factors studied to date is the over-representation of certain HLA-types such as HLA-B*57:01 and 
B*27:05 in these individuals, supporting the role of adaptive immunity and HIV-1-specific CD8 T 
cells in spontaneous control of viral replication (Migueles et al., 2000; Migueles and Connors, 
2010; Pereyra et al., 2010; Goulder and Walker, 2012). Specifically, these protective alleles have 
been linked to polyfunctional CD8 T-cell responses with increased clonal turnover and a greater 
breadth of response to different HIV-1 proteins, particularly the structural protein Gag (Almeida et 
al., 2007).  
 
Although protective alleles are important in the control of HIV-1 infection, it is still not clear why the 
majority of HIV-1-infected individuals who carry protective alleles still progress to AIDS in the 
absence of therapy and not all LTNP/HIC/EC (controllers) carry these protective alleles (Migueles 
et al., 2000; Theze et al., 2011). Furthermore, polyfunctional CD8 T-cell responses are not always 
detected in these individuals (Emu et al., 2008), indicating that several factors are necessary to 
achieve spontaneous HIV-1 control. A better understanding of the functional and phenotypic 
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profiles is therefore needed to identify correlates of immune control in HIV-1-infected individuals 
with an atypical disease progression.  
 
There is increasing evidence that at least a subset of controllers are infected with an attenuated 
HIV-1 strain, often described as reduced viral fitness. This has been reported for a subset of 
controllers and, in view of the association between in vitro HIV-1 replication capacity and levels of 
plasma virus with disease progression, is an important factor to consider (Campbell et al., 2003). 
One of the first studies investigating viral fitness showed that infection with a defective HIV-1 strain, 
lacking Nef and a portion of the long terminal repeat (LTR), could lead to a more benign clinical 
course (Deacon et al., 1995). HIV-1 isolates with reduced viral fitness have since been described 
in LTNP as well as EC (Blaak et al., 1998; Quinones-Mateu et al., 2000; Lassen et al., 2009). 
Furthermore, transmission of viral variants with a greater number of escape mutations to HIV-1-
specific CD8 T cell responses have been shown to correlate with lower viral loads in the newly 
infected partners (Goepfert et al., 2008), and lower replication capacity has been detected in the 
acute/early stages of infection of individuals that later went on to become HIV controllers (Miura et 
al., 2010). Taken together, these data suggest that reduced replicative capacity may contribute to 
viral suppression in a fraction of HIV controllers and understanding this contribution to the 
controller phenotype will reduce heterogeneity and better define host- and viral specific responses 
that can be targeted.  
 
The low activation levels observed in HIV-1-infected individuals with an atypical disease 
progression suggests the presence of regulatory mechanisms that effectively balance immune 
responses between an activated state (which is needed for viral control) and uncontrolled 
pathogenic immune activation that does more harm than good. The cytokine IL-10 is a key 
immunoregulator during infections with viruses, bacteria, fungi and helminths (reviewed in (Moore 
et al., 2001; Couper et al., 2008a)). Although it may have both stimulatory and suppressive 
functions on various cell types, it has primarily been described as an anti-inflammatory regulator 
and its suggested role in inflammatory bowel disease and other excessive inflammatory responses 
indicates that IL-10 maybe be critically involved in limiting deleterious inflammatory responses in 
vivo (Glocker et al., 2009; Ouyang et al., 2011).  
 
In HIV-1 infection, different promoter variants of IL-10 have been associated with different rates of 
disease progression (Shin et al., 2000; Vasilescu et al., 2003; Naicker et al., 2009; Oleksyk et al., 
2009; Naicker et al., 2012). Higher plasma IL-10 levels are found in ART-naϊve chronic progressors 
and blockade of the interaction between IL-10 and its receptor (IL-10R) has been shown to 
increase proliferative and cytokine HIV-1-specific responses (Brockman et al., 2009; Said et al., 
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2010; Porichis et al., 2014b), indicating a role for IL-10 in regulating HIV-1-specific immune 
responses. Results from Chapter 3 suggested high IL-10 responses to HIV-1 peptide pools as well 
as CMV WL in ART-naϊve HIV-1-infected patients and this is further explored in the current 
chapter. 
 
The work presented here may shed some light on the complex mechanism and interlink between 
the infecting strain and host response. Sustaining a balanced fully functional anti-HIV-1 T-cell 
response represents a future challenge for both prophylactic and therapeutic approaches. 
 
Specific aims of this part of my thesis were to: 
i. Identify HIV-1-infected individuals with an atypical disease progression. 
ii. Characterise the phenotype and functional properties of their CD4 and CD8 T cells in order 
to identify immune profiles that may be shared between these individuals. 
iii. Elucidate whether viral fitness is one of the mechanisms behind viral control in these 
individuals. 
iv. Measure IL-10 responses to HIV-1 and CMV to investigate whether the differences 
observed in Chapter 3, high HIV-1 and CMV-specific IL-10 responses, are also found in the 
identified LTNP and HIC. 
5.1.1 Hypothesis 
Individuals who exhibit spontaneous HIV-1 immune control are a heterogeneous group but are, 
despite this heterogeneity, collectively able to maintain a balanced phenotypic and functional T-cell 
response. Factors such as replicative fitness of the infecting strain and responses to other co-
pathogens, such as CMV, are important considerations as these may contribute to or impede HIV-
1-specific responses in a subset of these individuals. 
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5.2 Results 
5.2.1 Identification of HIV-1-infected patients with LTNP status  
From previous work carried out in the Imami group by the on-site biostatistician Dr Sundhiya 
Mandalia, who was also carrying out her PhD studies within the group, a process was undertaken 
to identify patients who maintained stable CD4 T-cell counts over a longer period of time without 
the need for treatment (Mandalia et al., 2012). To this end, data for each patient in the entire 
Chelsea and Westminster cohort from 1st January 1988 to 28th February 2010 was extracted from 
the local database and screened using a number of key criteria: recorded HIV-1 infection >7 years, 
no previous history of ART or opportunistic infections (OI) and a stable CD4 T-cell count (defined 
as a non-declining CD4 T-cell count slope of ≥0 cells/µl blood) from entry into cohort until the most 
recently available CD4 T-cell count (Mandalia et al., 2012). These criteria, together with criteria 
used in other studies, are outlined in Figure 5.1. Although the criteria thresholds vary between 
studies the central characteristic of EC and HIC is spontaneous viral control, whilst for LTNP it is 
the preservation of CD4 T-cell counts over a longer period of time, remaining clinically healthy but 
having consistently detectable viral load.  
 
Figure 5.1 Criteria used to define HIV-1+ individuals with atypical disease progression.  
Long term non-progressors (LTNP) from the Chelsea and Westminster cohort are defined as follows: HIV-1+ 
individuals with a recorded HIV-1 infection for more than 7 years with no history of ART or opportunistic 
infections and who have maintained stable CD4 T-cell count >450 cells/µl blood throughout this period (blue 
boxes). A random intercept model using MIXED procedure in SAS was used to determine stable CD4 T-cell 
counts (Mandalia et al., 2012). Criteria commonly used in the literature to identify LTNP, elite controllers (EC) 
and HIV controllers (HIC) are listed in light red. 1(Mandalia et al., 2012), 2(Grabar et al., 2009), 3(Okulicz and 
Lambotte, 2011; Ndhlovu et al., 2012; Genovese et al., 2013), 4(Emu et al., 2008; Okulicz et al., 2009).  
 
LTNP –  
Chelsea and 
Westminster (UK)1 
Length of 
HIV-1 infection 
ART 
Opportunistic 
Infection 
CD4+ T-cell 
count 
≥ 7 years 
None  
(current or past) 
None  
(current or past) 
Stable 
(non-declining slope 
from cohort entry)  
>450 cells/µl blood 
LTNP2 
≥ 7-10 years 
None  
(current or past) 
None  
(current or past) 
>500 cells/µl blood 
EC3 
≥ 1-2 years 
None  
(current or past) 
None  
(current or past) 
>500 cells/µl blood 
HIC4 
≥ 1-2 years 
None  
(current or past) 
None  
(current or past) 
>500 cells/µl blood 
HIV-1 plasma 
RNA load 
(copies/ml) 
Not defined Not defined <50 51 to <2000 
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Based on the criteria summarised in Figure 5.1, fifty individuals from a cohort of 14,227 patients 
were identified with long-term stable CD4 T-cell counts and Figure 5.2 outlines the process 
undertaken to identify these 50 individuals (Mandalia et al., 2012). Of the entire cohort of 14,227 
HIV-1+ patients, 1,204 had a recorded HIV-1 infection of over 7 years and no history of ART. Out of 
these, 312 had no previous history of opportunistic infection. Fifty individuals (0.35% of the entire 
cohort) were identified to also have stable CD4 T-cell counts from entry into cohort until the most 
recently available CD4 T-cell count (Mandalia et al., 2012). Thirteen subjects (0.09%) consistently 
had CD4 T-cell counts >450 cells/µl blood and were therefore identified as LTNP. Out of these one 
also had a history of undetectable plasma HIV-1 RNA levels and was identified as an HIC. The 
remaining 37 (0.3%) had at least one recorded CD4 T-cell count below 450 cells/µl blood and out 
of these three had a history of undetectable levels of plasma HIV-1 RNA. Although 13 patients 
were identified as LTNP, all 50 patients who were identified to have a stable CD4 T-cell count were 
investigated for the purpose of obtaining a blood sample for further immunological and functional 
studies described in this chapter. The reason for including all 50 was to not exclude patients who 
maintained high CD4 T-cell responses but presented with one uncharacteristic reading. 
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Figure 5.2 Identification of long-term non-progressors (LTNP).  
14,227 patients comprising the entire Chelsea and Westminster cohort were screened by Mandalia and 
colleagues to identify HIV-1+ individuals who: had a recorded HIV-1 infection for >7 years, no history of ART 
or opportunistic infections and retained stable CD4 T-cell count since first entry into cohort (Mandalia et al., 
2012). This facilitated the identification of 50 HIV-1+ individuals who met these criteria and were evaluated in 
the present study. Patients who met these criteria were further stratified into two different groups based on 
whether they had a recorded CD4 T-cell count below or above 450 cells/µl blood. History of plasma HIV-1 
RNA values below the limit of detection (BLD) was also assessed in these two groups to identify HIC. 
Provided with permission from (Mandalia et al., 2012). (n – number, OI – Opportunistic infections). 
 
Following the previous identification of 50 HIV-1+ individuals with stable CD4 T-cell counts by Dr 
Sundhiya Mandalia, an in-depth analysis was carried out on these patients to clearly define 
whether they still met the criteria a year after the study with the purpose of obtaining subsequent 
blood samples for future immunologic and virologic studies. Data of previous clinic visits were 
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obtained and continuous contact with staff and the caring physicians at the St Stephen’s Centre 
was established. A large majority of the fifty patients were excluded for reasons unrelated to the 
defined clinical characteristics criteria. Specifically, seven out of the 50 had attended clinic two 
times and were therefore deemed to have too little information to be included and were excluded 
from further investigations. There were no available contact details for two of the patients, four had 
moved and a further eleven had not attended clinic for >2 years and were ascribed as lost to follow 
up (Figure 5.3). Of the remaining 26, fifteen had commenced ART since the screen was carried 
out, due to declining CD4 T-cell counts or presentation of OI. In summary, out of 50 identified HIV-
1+ individuals, 11 were found to still meet the criteria. Six of these eleven had CD4 T-cell count 
>450 cells/µl and the remaining five had presented with at least one CD4 T-cell count <450 cells/µl 
blood. Blood samples were obtained from four subjects; three with a history of at least one CD4 T-
cell count <450 and one with CD4 T-cell counts always >450 cells/µl blood.  
 
 
Figure 5.3 Status of 50 HIV-1+ individuals with stable CD4 T-cell counts a year after initial screening.  
HIV-1+ individuals screened and identified from the Chelsea and Westminster cohort by Dr Sundhiya 
Mandalia were further assessed a year after the study to evaluate whether they still met the criteria and were 
available to participate.  
 
Phenotypic and functional analysis was carried out on these four individuals. The available patient 
characteristics for all clinic visits are listed in Table 5.1 with a further graphical presentation of the 
relationship between CD4 and CD8 T-cell counts as well as plasma HIV-1 RNA load in Figure 5.4. 
The age at the time of blood sample ranged from 38 to 69 years in the four individuals (L594, 
S219, R363 and T202) and length of infection ranged from 9 to 24 years (Table 5.1). All four had 
stable CD4 T-cell counts although two of them (L594 and S219) had recurring CD4 T-cell count 
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values <450 cells/µl blood (Table 5.1 and Figure 5.4), which would exclude them as LTNP. The 
majority of CD4 T-cell count values of R363 were considerably above 500 cells/µl blood with only 
one value of 378, indicating that this was an anomaly and the patient may be defined as LTNP. 
This demonstrates how important it was to include all 50 HIV-1+ individuals into this study, and not 
just the 13 with sustained CD4 T-cell counts >450 cells/µl blood.  
 
Plasma HIV-1 RNA load varied between visit points but were in general low for the two patients 
who maintained CD4 T-cell counts >450 cells/µl blood (T202 and R363). T202 had a history of 
consistently undetectable HIV-1 plasma RNA load values with occasional blips, however these 
would never go above 145 RNA copies/ml plasma, indicating that this individual would be classified 
as HIC as well as LTNP (Figure 5.4 B). The age of T202 (69 years) should be noted considering 
the changes in T-cell homeostasis that occur with increasing age (Haynes et al., 2000). The two 
other individuals, L594 and S219, did show some signs of increasing HIV-1 load, which might have 
an effect on the phenotype and functional responses of these two individuals. CD8 T-cell counts 
and CD4/CD8 ratio were variable with one individual (S219) having particularly high levels of CD8 
T cells and a low CD4/CD8 ratio (0.36) similar to that observed for ART-naϊve HIV-1-infected 
individuals in Chapter 4 (Table 4.2; page131). Two individuals (R363 and T202) had higher 
CD4/CD8 ratios that at the time of blood collection resembled more the levels observed in treated 
HIV-1-infected individuals in Chapter 4 (0.60-0.79). Finally, L594 had a CD4/CD8 ratio >1 which 
reflected the very low levels of CD8 T-cell counts in this individual, despite having plasma HIV-1 
RNA loads >10,000 copies/ml. 
 
In summary, two HIV-1-infected individuals (T202 and R363) were identified as LTNP and two 
(L594 and S219) were identified as having stable CD4 T-cell counts but did not meet the criteria of 
LTNP. However, all four will be denoted as LTNP for the purpose of comparing these with HIV 
controllers described below.  
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Table 5.1 Clinical characteristics of HIV-1+ individuals with stable CD4 T-cell counts.  
The available nadir CD4, CD4 and CD8 T-cell counts (cells/µl blood), plasma HIV-1 RNA load (copies/ml) 
and time since HIV-1 diagnosis are listed for each clinical attendance. Visits in bold indicate when a blood 
sample was obtained for the immunological studies presented here. (n/a – not available, IQR – interquartile 
range). 
 
Continued on the following page. 
ID Gender Age
Time since HIV-1+ 
diagnosis, 
months (years)
Nadir CD4 
T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
36 38 (3) 399 399 462 0.86 3829
36 42 (3) 399 434 570 0.76 11115
37 47 (3) 399 416 336 1.24 8601
37 50 (4) 399 460 453 1.02 6303
37 53 (4) 387 387 358 1.08 8353
37 56 (4) 387 996 2466 0.40 36699
38 59 (4) 387 404 332 1.22 8541
38 62 (5) 387 520 555 0.94 11469
38 68 (5) 387 418 384 1.09 5591
39 71 (5) 387 389 357 1.09 9717
39 74 (6) 387 400 368 1.09 56300
39 77 (6) 377 377 448 0.84 16979
40 82 (6) 377 532 434 1.23 3811
L594 M 40 85 (7) 377 589 467 1.26 5636
41 97 (8) 377 618 529 1.17 5724
41 100 (8) 377 518 407 1.27 5045
42 105 (8) 377 403 386 1.04 13910
43 119 (9) 377 457 424 1.08 2459
43 124 (10) 377 544 441 1.23 884
45 146 (12) 377 611 443 1.38 10241
46 160 (13) 377 513 496 1.03 35888
47 165 (13) 377 465 433 1.07 31393
47 165 (13) 377 465 433 1.07 31393
L594-1 47 167 (13) 377 511 449 1.14 38481
47 170 (14) 377 465 497 0.94 49969
L594-2 47 170 (14) 377 465 497 0.94 49969
48 181 (15) 377 607 585 1.04 30658
L594-3 48 186 (15) 377 466 349 1.34 28534
48 187 (15) 377 595 485 1.23 148
465 442 1.08 10678
(416 to 532) (386 to 488) (1.02 to 1.23) (5658 to 31393)
30 43 (3) 516 516 n/a 1056
31 44 (3) 506 506 1182 0.43 741
31 49 (4) 457 457 1200 0.38 4210
31 52 (4) 457 476 1086 0.44 2922
31 55 (4) 355 355 1035 0.34 350
32 58 (4) 355 532 1352 0.39 414
32 62 (5) 355 380 863 0.44 469
32 66 (5) 355 406 1285 0.32 448
33 74 (6) 355 509 1331 0.38 1424
S219 F 34 84 (7) 355 545 1489 0.37 269
35 94 (7) 355 473 1345 0.35 177
36 111 (9) 355 493 1341 0.37 5342
37 119 (9) 355 463 1337 0.35 6423
37 123 (10) 355 570 1542 0.37 12010
38 135 (11) 355 364 1028 0.35 14692
S219-1 38 136 (11) 355 510 1676 0.30 11750
39 140 (11) 355 545 1622 0.34 10819
40 152 (12) 355 591 1919 0.31 n/a
39 151 (12) 355 448 1462 0.31 85862
493 1339 0.36 2173
(453 to 524) (1187 to 1482) (0.34 to 0.38) (453 to 9720)
Median
IQR
Median
IQR
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Table 5.1 continued. 
 
 
 
 
ID Gender Age
Time since HIV-1+ 
diagnosis, 
months (years)
Nadir CD4 
T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
61 187 (15) 681 681 833 0.82 n/a
62 196 (16) 609 609 744 0.82 <50
62 207 (17) 583 583 775 0.75 <50
64 220 (18) 583 637 849 0.75 <50
65 232 (19) 583 647 651 0.99 < 50
65 242 (20) 583 688 1104 0.62 97
66 245 (20) 583 586 772 0.76 < 50
T202 M 66 252 (21) 583 707 1035 0.68 < 50
67 261 (21) 583 741 1222 0.61 < 50
68 273 (22) n/a n/a n/a n/a 145
68 274 (22) 548 548 886 0.62 n/a
T202-1 69 290 (24) 548 660 1045 0.63 52
T202-2 70 292 (24) 548 609 824 0.74 143
71 306 (25) 548 735 965 0.76 <50
T202-3 71 309 (25) 548 682 1109 0.61 <50
654 868 0.74 <50
(609 to 687) (787 to 1043) (0.63 to 0.76) (49 to 51)
39 3 (<1) 586 586 412 1.42 7905
40 12 (1) 586 695 625 1.11 1676
40 15 (1) 586 597 611 0.98 7730
41 18 (1) 586 677 521 1.30 9975
41 22 (1) 378 378 350 1.08 2195
41 25 (2) 378 586 557 1.05 1239
42 32 (2) 378 673 599 1.12 1569
42 36 (3) 378 625 559 1.12 822
42 40 (3) 378 789 779 1.01 1379
43 43 (3) 378 768 718 1.07 5372
43 50 (4) 378 627 585 1.07 2101
44 57 (4) 378 970 975 0.99 1014
44 61 (5) 378 692 625 1.11 907
44 64 (5) 378 573 578 0.99 269
R363 M 45 67 (5) 378 732 664 1.10 2492
45 70 (5) 378 n/a n/a n/a 1302
45 72 (6) 378 784 871 0.90 n/a
45 78 (6) 378 716 825 0.87 1313
46 81 (6) 378 643 779 0.83 116
46 85 (7) 378 682 763 0.89 2393
47 90 (7) 378 508 663 0.77 2046
47 93 (7) 378 657 758 0.87 6516
47 97 (8) 378 678 735 0.92 n/a
47 102 (8) 378 909 1020 0.89 n/a
48 107 (8) 378 722 916 0.79 1040
48 110 (9) 378 705 991 0.71 1776
R363-1 49 118 (9) 378 675 979 0.69 1776
49 122 (10) 378 922 1307 0.71 n/a
R363-2 50 129 (10) 378 782 996 0.79 n/a
680 727 0.98 1776
(627 to 741) (596 to 882) (0.86 to 1.09) (1239 to 2393)IQR
Median
IQR
Median
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Figure 5.4 Longitudinal characteristics of HIV-1+ individuals with stable CD4 T-cell counts.  
The available plasma HIV-1 RNA loads (red triangles), CD4 (blue dots) and CD8 T-cell counts (green 
crosses) are depicted for each individual. Each symbol represents a clinic visit. Vertical dashed lines 
represent visits where a blood sample was obtained for the studies described here and horizontal dashes 
depict the UK healthy range for CD4 T-cell count (450-1660 cells/µl blood).  
 
5.2.2 Identification of HIV controllers (HIC) 
The criteria used in the previous study included length of infection >7 years to identify LTNP. 
However, it has been demonstrated that spontaneous control of HIV-1 replication (as observed in 
HIC and EC) may occur at early stages of infection (Goujard et al., 2009; Okulicz et al., 2009) and 
several studies have set the threshold for length of infection in HIC and EC at >1 year (Pereyra et 
al., 2008; Ndhlovu et al., 2012). Therefore, in collaboration with Dr Sundhiya Mandalia, a further 
screening was carried out in 2013 to identify putative HIC and EC that might have been missed in 
the previous screening. The entire Chelsea and Westminster cohort from 1988 to 2010 were 
screened and the criteria included in this screen were: no history of ART and no history of OI 
providing there were three consecutive plasma HIV-1 RNA load values <500 copies/ml plasma for 
a period of >12 months. Details of the screening criteria and number of patients are shown in 
Figure 5.5. From a total of 14,227 patients, 102 (0.72%) individuals were identified to have 
presented with three consecutive plasma HIV-1 RNA load values <500 copies/ml and who were 
CHAPTER 5 
SPONTANEOUS HIV-1 CONTROL 
190 
not reported to be on treatment. An independent case notes review, in collaboration with onsite 
consultant (Dr Peter Kelleher), was carried out to further confirm the status of these patients. 
Seven also fulfilled LTNP status and had been identified in the first screen (50 LTNP list), 
indicating some overlap between groups as described elsewhere (Okulicz et al., 2009). Three of 
these seven had initiated ART; one was lost to follow up (LTFU) leaving three as potential HIC/EC. 
Out of the 95 individuals that were uniquely identified in the new screen the thorough case notes 
review revealed that 79 patients were on treatment and of those who were ART-naïve, nine had 
unstable CD4 T-cell counts leaving seven as potential HIC/EC. In summary, the screening 
identified seven unique HIV-1-infected individuals who were putative HIV-1 controllers. The 
difference between the two screens was mainly that the first one focused on stable CD4 T-cell 
counts and length of HIV-1 infection to identify putative LTNP, whilst the second one focused more 
on plasma HIV-1 RNA values to identify HIV controllers. Attempts to obtain blood samples were 
however unsuccessful as the identified patients rarely attended clinic. 
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Figure 5.5 Identification of HIV controllers in the Chelsea and Westminster cohort.  
Kindly provided by Dr S. Mandalia (Mandalia, 2014). 
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5.2.3 Identification of HIC through collaborations with clinicians 
In parallel to the screens, collaboration with a number of HIV caring physicians at the St Stephen’s 
Centre was established to identify patients that could potentially be LTNP, HIC or EC and might not 
have been picked up in these screens. This enabled the identification of 7 HIC who were ART-
naïve and controlled plasma HIV-1 RNA load to <2000 copies/ml with the occasional viral blip 
(Table 5.2 and Figure 5.6). In addition they all had CD4 T-cell counts above 450 cells/µl and no OI. 
M407 had one CD4 T-cell count below 450 (402) but was included as the plasma HIV-1 RNA load 
was undetectable (<50 copies/ml). Length of infection varied in these individuals, ranging from 1 
year and two months to 19 years. Three individuals (G993, T883 and A338) had a recorded HIV-1 
infection of >7 years and would also be classified as LTNP. A key feature was the relatively low 
CD8 T-cell counts in the majority of these individuals particularly in W757 and M407, who often 
had values below 300 and 500 cells/µl blood respectively (Figure 5.6 A and B). Patient P993 
started ART of own accord (Figure 5.6 E). Individual P918 presented once with plasma HIV-1 RNA 
load of 2967 copies/ml plasma but was included as the two latest values were <2000 copies/ml 
(Figure 5.6 G).  
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Table 5.2 Clinical characteristics of HIV controllers (HIC). 
The available nadir CD4, CD4 and CD8 T-cell counts (cells/µl blood), plasma HIV-1 RNA load (copies/ml) 
and time since HIV-1 diagnosis are listed for each clinical attendance. Visits in bold indicate when a blood 
sample was obtained for the immunological studies presented here. (n/a – not available, IQR – interquartile 
range). 
 
Continued on the following page. 
ID Gender Age
Time since HIV-1+ 
diagnosis, 
months (years)
Nadir CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
36 0 (0) 739 739 n/a n/a n/a
36 1 (0) 740 1009 339 2.98 <50
36 3 (0) 741 1374 393 3.50 <50
36 3 (0) 742 1053 340 3.10 <50
36 5 (0) 743 922 364 2.53 <50
36 8 (0) 744 934 263 3.55 <50
37 13 (1) 745 1135 414 2.74 1351
W757 F 37 18 (1) 746 987 330 2.99 688
37 21 (1) 747 927 336 2.76 403
38 27 (2) 748 974 386 2.52 n/a
38 31 (2) 749 939 356 2.64 226
W757-1 39 40 (3) 802 1213 574 2.11 1075
39 41 (3) 749 802 346 2.32 483
40 46 (3) 749 1342 594 2.26 153
40 48 (4) 749 999 343 2.91 560
987 351 2.75 226
(931 to 1094) (339 to 391) (253 to 299) (<50 to 560)
34 12 (1) 488 488 233 2.09 <50
34 12 (1) 459 459 216 2.13 <50
34 13 (1) 459 n/a n/a n/a <50
M407 F 34 14 (1) 459 520 269 1.93 <50
35 15 (1) 402 402 208 1.93 <50
M407-1 35 20 (1) 402 498 290 1.72 <50
M407-2 35 25 (2) 402 n/a n/a n/a <50
35 26 (2) 402 717 366 1.96 n/a
493 251 1.95 <50
(466 to 515) (220 to 285) (1.93 to 2.06) (<50 to <50)
23 0 (0) 409 409 448 0.91 n/a
23 1 (0) 409 577 545 1.06 129
23 1 (0) 409 610 527 1.16 <50
24 3 (0) 409 707 699 1.01 <50
24 4 (0) 409 562 522 1.08 <50
24 5 (0) 409 719 618 1.16 <50
24 5 (0) 409 967 751 1.29 <50
24 7 (0) 409 848 1039 0.82 125
24 8 (0) 409 726 788 0.92 <50
24 11 (0) 409 714 890 0.80 <50
25 15 (1) 409 704 796 0.88 <50
25 18 (1) 409 518 559 0.93 <50
25 21 (1) 409 633 636 1.00 <50
25 23 (1) 409 965 1428 0.68 <50
25 25 (2) 409 754 1017 0.74 <50
G993 F 26 28 (2) 409 714 959 0.74 <50
26 31 (2) 409 942 1033 0.91 <50
26 34 (2) 409 792 779 1.02 <50
26 37 (3) 409 1003 1027 0.98 <50
27 41 (3) 409 476 597 0.80 <50
27 45 (3) 409 718 833 0.86 <50
27 48 (4) 409 713 940 0.76 <50
28 53 (4) 409 512 789 0.65 <50
28 56 (4) 409 696 911 0.76 <50
28 60 (4) 409 799 992 0.81 <50
29 64 (5) 409 702 1090 0.64 <50
29 69 (5) 409 603 793 0.76 <50
30 76 (6) 409 674 710 0.95 253
30 85 (7) 409 812 1267 0.64 76
31 93 (7) 409 731 1288 0.57 454
32 100 (8) 409 609 1090 0.56 833
G993-1 32 104 (8) 409 1050 2146 0.49 249
33 113 (9) 409 837 1538 0.54 406
714 833 0.82 <50
(610 to 799) (699 to 1033) (0.74 to 0.98) (<50 to <50)
Median
IQR
Median
IQR
Median
IQR
CHAPTER 5 
SPONTANEOUS HIV-1 CONTROL 
194 
Table 5.2 continued. 
 
ID Gender Age
Time since HIV-1+ 
diagnosis, 
months (years)
Nadir CD4 T-cell 
count
CD4 T-cell 
count
CD8 T-cell 
count
CD4/CD8 
ratio
Plasma HIV-1 
RNA load
27 2 (0) 921 921 921 1.08 2208
29 24 (2) 921 1122 1122 1.17 1387
29 26 (2) 921 1098 1098 1.05 1995
29 29 (2) 921 1254 1254 1.10 897
30  31 (2) 921 1425 1425 0.64 72484
30 33 (2) 921 725 725 0.72 2627
30 34 (2) 921 1382 1382 1.02 647
30 39 (3) 921 1246 1246 0.75 252
31 43 (3) 921 1523 1523 0.77 336
T883 M 31 47 (3) 728 728 728 0.99 354
32 56 (4) 728 1475 1475 0.84 969
32 59 (4) 728 1282 1282 1.11 367
32 64 (5) 728 1262 1262 1.06 671
34 77 (6) 728 1626 1626 1.24 204
34 85 (7) 728 1083 1083 1.30 316
35 91 (7) 728 1497 1497 0.97 n/a
35 92 (7) 728 n/a n/a n/a 360
35 96 (7) 728 1531 1531 1.18 498
T883-1 36 101 (8) 728 1754 1754 1.17 360
36 107 (8) 728 1519 1519 1.29 245
1282 1190 1.06 498
(1110 to 1508) (1026 to 1517) (0.91 to 1.17) (345 to 1178)
47 0 (0) 800 800 535 1.50 232
47 4 (0) 800 1045 1014 1.03 100
47 7 (0) 621 621 615 1.01 <50
P993 M 48 12 (1) 621 785 710 1.11 95
48 13 (1) 621 963 785 1.23 111
P993-1 48 15 (1) 621 925 722 1.28 <50
48 17 (1) 621 856 622 1.38 <50
856 710 1.23 106
(796 to 944) (620 to 754) (1.09 to 1.33) (100 to 141)
29 0 (0) 1070 1070 n/a n/a n/a
30 5 (0) 880 880 n/a n/a n/a
30 7 (0) 880 990 n/a n/a n/a
31 15 (1) 840 840 n/a n/a n/a
31 18 (1) 840 960 n/a n/a n/a
31 21 (1) 740 740 n/a n/a n/a
31 24 (2) 740 740 n/a n/a n/a
32 28 (2) 600 600 n/a n/a n/a
32 32 (2) 600 950 n/a n/a n/a
33 46 (3) 600 950 n/a n/a n/a
34 50 (4) 600 760 n/a n/a n/a
34 52 (4) 600 1090 n/a n/a n/a
A338 M 34 56 (4) 600 916 791 1.16 191
34 60 (5) 600 851 829 1.03 100
35 70 (5) 600 822 911 0.90 49
36 73 (6) 600 n/a 82 0.18 49
36 74 (6) 600 793 667 1.19 100
36 78 (6) 600 700 812 0.86 49
36 81 (6) 600 762 701 1.09 49
37 89 (7) 600 606 504 1.20 973
38 98 (8) 600 633 738 0.86 < 50
42 150 (12) 600 1011 1230 0.82 < 50
43 161 (13) 600 1057 1041 1.02 < 50
44 180 (15) 600 855 985 0.87 <50
45 190 (15) 600 1060 1314 0.81 <50
46 202 (16) 600 998 1083 0.92 n/a
A338-1 49 233 (19) 600 1241 1263 0.98 <50
868 829 0.95 <50
(761 to 996) (720 to 1062) (0.86 to 1.07) (<50 to 100)
22 29 (2) 686 686 882 0.78 2967
P918 M 23 32 (2) 686 865 1061 0.82 n/a
23 37 (3) 686 1021 1379 0.74 n/a
P918-1 23 42 (3) 686 977 1272 0.77 1225
23 42 (3) 686 796 950 0.84 286
865 1061 0.78 1225
(796 to 977) (950 to 1272) (0.77 to 0.82) (756 to 2096)
Median
IQR
Median
IQR
Median
IQR
IQR
Median
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Figure 5.6 Longitudinal characteristics for HIV controllers (HIC).  
The available plasma HIV-1 RNA loads (red triangles), CD4 (blue dots) and CD8 T-cell counts (green 
crosses) are depicted for the seven HIC. Each symbol represents a clinic visit. Vertical dashed lines 
represent visits where a blood sample was obtained for the studies described here and horizontal dashes 
depict the UK healthy range for CD4 T-cell count (450-1660 cells/µl blood). A solid vertical line denotes 
commencement of ART, visits after which are shaded in grey (E).  
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Patients that after careful case note review did not meet the criteria were defined as progressing 
LTNP (pLTNP) (Figure 5.7). These individuals exhibited declining CD4 T cells and plasma HIV-1 
RNA load was typically >2000 copies/ml but varied from <50 to >50,000 copies/ml. Subject B288 
had been diagnosed for more than 26 years indicating some form of host immune control of HIV-1 
(Figure 5.7 A). However, declining CD4 T-cell counts and variable plasma HIV-1 RNA load 
(sometimes over 100,000 copies/ml) indicates progression in this individual. Patient N542 had 
been diagnosed with HIV-1 infection for >10 years when blood samples were acquired and had for 
the majority of time maintained CD4 T-cell counts >500 cells/µl blood (Figure 5.7 E). However, 
during the last visits the HIV-1 RNA load had risen from being predominantly <2000 to 41,258 and 
32,264 copies/ml in the visits where blood samples were obtained, indicating that the patient 
showed signs of progression (Okulicz et al., 2009). A sharp rise in CD8 T-cell count was also noted 
although CD4 T-cell levels remained stable. A similar pattern was observed for patient J785 who 
had been diagnosed >9 years previously, and although this subject had CD4 T-cell levels >500 
cells/µl blood, there was an observable decline with concomitant rise in plasma HIV-1 RNA load 
during the later clinical visits possibly indicating progression (Figure 5.7 B). Subject W609 had 
been diagnosed for more than 8 years and appeared to have a stable CD4 T-cell count although 
was on the border of the >450 cells/µl blood threshold (Figure 5.7 D). This patient started treatment 
after the second blood sample was acquired.  
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Figure 5.7 Longitudinal characteristics for progressing LTNP (pLTNP).  
The available plasma HIV-1 RNA loads (red triangles), CD4 (blue dots) and CD8 T-cell counts (green 
crosses) are depicted for the five pLTNP. Each symbol represents a clinic visit. Vertical dashed lines 
represent visits where a blood sample was obtained for the studies described here and horizontal dashes 
depict the UK healthy range for CD4 T-cell count (450-1660 cells/µl blood). A solid vertical line denotes 
commencement of ART, visits after which are shaded in grey (D).  
 
Amongst the strongest factors known to influence controller status is the genetic HLA haplotype of 
these individuals (Pereyra et al., 2010; Goulder and Walker, 2012). HLA-typing was therefore 
performed to assess whether some of these patients possessed any HLA-alleles previously 
described to be protective in HIV-1 infection. Genomic DNA was extracted from PBMC and sent for 
high resolution HLA-typing to Dr Ruhena Sergeant in the Clinical Immunology Laboratory in the 
Department of Histocompatibility and Immunogenetics (Hammersmith Hospital, London, UK). The 
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majority of individuals possessed protective HLA-alleles; HLA-B*27:05 was identified in two 
individuals (R363 and T883) and HLA-B*57:01 in one HIC (A338; Table 5.3). In addition, two 
individuals (G993 and M407) had the HLA-type B*58:01, a closely related HLA-type to B*57:01 that 
has been associated with lower viral loads in African ethnicities (Kiepiela et al., 2004). G993 also 
had the HLA-type B*14:02, which has been associated with protection (McLaren et al., 2012). 
N542 was HLA-B*81:01+ and HLA-C*18:01+, both of which are in strong linkage disequilibrium to 
each other, and have been associated with favourable disease progression in African ethnicities 
(Tang et al., 2010; McLaren et al., 2012). The HLA-type B*52:01, also associated with slow 
disease progression, was identified in two individuals (T202 and W609) (Pereyra et al., 2010). 
Finally, one HIC (W757) possessed an HLA-type previously associated with a more rapid disease 
progression; HLA-B*35:02 (Gao et al., 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
SPONTANEOUS HIV-1 CONTROL 
199 
Table 5.3. HLA-types and ethnicity of LTNP, HIC and pLTNP.  
HLA-types in bold have previously been associated with slow HIV-1 disease progression.  
 
HIC – HIV controller; HLA – human leukocyte antigen; LTNP – long-term non progressor; pLTNP – 
progressing LTNP; n/a – not available. 
 
 
 
 
 
ID Ethnicity HLA-A HLA-B HLA-C HLA-DRB1
L594 Caucasian *24:02        *31:01
*07:06         
*40:02
*15:02        
*15:05
*04:05        
*13:01
LTNP
T202 Caucasian n/a *18:01         *52:01
*05:01         
*12:02
*07:01        
*15:02
S219 Black *29:02         *74:01
*15:03        
*44:03
*02:02        
*07:01
*11:01         
*13:02
R363 Caucasian *01:01        *11:01    
*40:06          
*27:05 n/a
*01:01         
*16:02
ID Ethnicity HLA-A HLA-B HLA-C HLA-DRB1
W757 n/a *30:02               *53:01
*35:02         
*53:01
*04:01          
*06:02
*07:01         
*11:04
M407 n/a n/a *15:03         *58:01
*02:02              
*07:01
*07:01         
*11:03
G993 Black *03:01         *33:03
*14:02        
*58:01
*03:02         
*08:02
*07:01         
*13:02
HIC
T883 Caucasian *11:01                    n/a
*15:01        
*27:05
*01:02              
n/a
*01:01        
*08:01
P993 n/a n/a n/a n/a n/a
P918 n/a n/a n/a n/a n/a
A338 Caucasian *02:01         *31:01
*40:01         
*57:01
*03:04         
*06:02
*04:04         
*11:04
ID Ethnicity HLA-A HLA-B HLA-C HLA-DRB1
N542 Black *02:02         *23:01
*58:02         
*81:01/81:02
*06:02         
*18:01
*01:02          
*11:02
pLTNP
J785 Caucasian n/a n/a n/a n/a
M547 Caucasian n/a n/a n/a n/a
W609 Caucasian *01:01/36:04     *24:03/02
*08:01         
*52:01
*07:01         
*12:02
*12:01         
*15:02
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5.2.4  Assessment of viral fitness in LTNP and HIC 
To investigate whether the control of HIV-1 infection is due to reduced viral fitness in the infecting 
strain of these LTNP and HIC, a viral fitness assay was established in collaboration with Dr Peter 
Hayes from the International AIDS Vaccine Initiative (IAVI), and carried out on all four LTNP and a 
subset of HIC. PBMC from LTNP and ART-naïve HIV-1-infected individuals were isolated from 
fresh heparinized blood and depleted of CD8+ cells as these have been shown to be strong 
suppressors of HIV-1 replication ex vivo (Saez-Cirion et al., 2007). The CD8+-depleted PBMC were 
subsequently stimulated with PHA (final concentration 5µg/ml) in AB/RPMI supplemented with L-
Glut, Pen/Strep and IL-2 (40 U/ml) for a period of 7 days as detailed in Chapter 2 (section 2.22). 
Supernatants were collected on day 3, 5 and 7 and cultures were replaced with fresh AB/RPMI + 
IL-2, L-Glut and Pen/Strep. The collected supernatants were immediately frozen until required for 
detection of HIV-1 Gag p24 levels using the Alliance HIV-1 p24 antigen ELISA kit from Perkin 
Elmer. Following preliminary analysis where no HIV-1 p24 core antigen was detected in five 
chronically infected ART-naïve individuals the concentration of PHA and IL-2 was increased to 10 
µg/ml and 100 U/ml respectively. Increasing the PHA and IL-2 resulted in the detection of high p24 
levels (769 pg/ml) in an ART-naïve individual with high HIV-1 RNA load (>10,000 copies/ml 
plasma, data not shown). The four LTNP were assessed, however the levels of HIV-1 Gag p24 
were continously undetectable in three patients even after increasing the concentration of PHA and 
IL-2. One LTNP (L594) with the highest plasma HIV-1 RNA load (28,534 copies/ml) tested positive 
above the threshold and within the threshold of the assay (Figure 5.8 B). The values of the 
concentration of HIV-1 p24 core antigen in the supernatants were obtained based on the standard 
curve (Figure 5.8 A), and were 26 pg/ml for L594 on day 5 of PHA stimulation going down slightly 
to 17 pg/ml on day 7. 
 
Figure 5.8 Detection of HIV-1 p24 antigen in culture supernatants.  
PBMC of four LTNP, depleted of CD8+ cells, were stimulated with PHA and IL-2 and the supernatants were 
assessed for detection of HIV-1 p24 core antigen in a Perkin-Elmer ELISA. A representative standard curve 
(A) was used to calculate values (B). Each coloured symbol and line represents one individual.  
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To further examine whether the negative results in three of the LTNP were due to the sensitivity of 
the assay, a different approach was chosen. This approach was based on a previously described 
method (Karn, 1995) and involved a co-culture outgrowth assay using HIV-1-uninfected healthy 
donor PBMC as targets for infection and continued HIV-1 replication (described in Chapter 2 
section 2.22). Initial experiments were carried out to assess whether using HIV-1+ plasma or 
PBMC to co-culture with uninfected donor PBMC stimulated the highest HIV-1 p24 levels. Plasma 
or PBMC from three ART-naϊve HIV-1+ individuals (who all had plasma HIV-1 RNA load >10,000 
copies/ml) and one LTNP (L594) were co-cultured with PHA-stimulated PBMC from uninfected 
donors as detailed in Chapter 2, Figure 2.4. Supernatants were collected on days 4, 7, 11, 14, 18, 
21, 25 and 28 and were frozen until needed for detection of HIV-1 p24 levels using the Alliance 
HIV-1 p24 antigen ELISA kit. In addition, on days 7, 14 and 21, half of the cell culture was co-
cultured with a fresh batch of PBMC from a new uninfected donor. Using this revised method HIV-1 
p24 core antigen was detected in supernatants from all three ART-naϊve HIV-1+ individuals and 
LTNP L594.  
 
Using cells (PBMC) as opposed to plasma to co-culture with PHA-stimulated PBMC from 
uninfected donors generated the highest levels of HIV-1 p24 protein (Figure 5.9). Patients B103 
and C920 had detectable levels of HIV-1 p24 on days 7 and 4 respectively, when cells were used 
whereas HIV-1 p24 was detected on days 11 and 7 respectively, when plasma was used (Figure 
5.9 A and C). For individuals K455 and L594, no detectable levels of HIV-1 p24 were detected in 
supernatants when plasma was used (Figure 5.9 B and D). HIV-1+ PBMC were subsequently used 
in all co-cultures. In addition to the three ART-naϊve patients and one LTNP, five treated patients 
and four HIC were assessed using the same outgrowth assay. As shown in Figure 5.9 above, HIV-
1 p24 core antigen was detected in all three ART-naϊve patients (Figure 5.10 A). Two individuals 
had detectable HIV-1 p24 antigen by day 4 (K455 and C920; 395 and 248 pg/ml respectively) with 
levels going above the threshold of the assay at day 7 and staying up until day 28 when the culture 
was terminated. The third patient (B103) had detectable HIV-1 p24 core antigen on day 7 with 
levels above the threshold of the assay by day 11 and all subsequent time-points. In contrast, HIV-
1 p24 core antigen was detected in only one (K740) of the five treated HIV-1+ individuals at day 7 
(548 pg/ml), gradually increasing until it was above the threshold of the assay by D21 (Figure 5.10 
B). Of the four HIC assessed, HIV-1 p24 antigen was detected in two subjects (W757 and G993) 
as well as in LTNP L594 (Figure 5.10 C). G993 exhibited detectable HIV-1 p24 levels on day 4 of 
co-culture (29 pg/ml), however by day 7 and subsequent time points this was no longer observed. 
In contrast, for W757, detectable HIV-1 p24 core antigen was observed on D21 (9 pg/ml) after two 
co-cultures with PBMC from uninfected donors and this was increased by day 28 (56 pg/ml). LTNP 
L594 had detectable HIV-1 p24 core antigen on day 4 (37 pg/ml), which increased to 1294 pg/ml 
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on day 7 and was above the threshold of the assay by day 11. The two other HIC (M407 and 
A338) had negative p24 levels throughout the assay. In summary, whilst HIV-1 p24 core antigen 
was readily detectable in ART-naϊve patients, it was harder to detect in treated individuals with 
undetectable plasma HIV-1 RNA levels. Replication-competent virus was detected in one LTNP 
and two HIC, where differing lengths of time that it took to detect HIV-1 p24 core antigen (day 4 
versus day 21) may indicate lower replication capacity. 
 
Figure 5.9 PBMC versus plasma for detection of HIV-1 p24 antigen in culture supernatants using the 
co-culture outgrowth method.  
PHA stimulated-PBMC from HIV-1-uninfected donors were co-cultured with plasma (open grey circles and 
lines) or PBMC (black circles/diamond and lines) from three ART-naϊve (A, B and C) and one LTNP (D) and 
the supernatants were assessed for detection of HIV-1 p24 core antigen at different time points in a Perkin-
Elmer ELISA. Dotted horizontal line denotes the lower level of detection for the assay (6.25 pg/ml) based on 
negative controls. Black diamond shaped symbols represent values higher than the threshold of the assay 
(800 pg/ml). 
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Figure 5.10 Detection of HIV-1 p24 antigen in culture supernatants using the co-culture outgrowth 
method.  
PBMC were co-cultured with PHA-stimulated PBMC from HIV-1-uninfected donors and the supernatants 
were assessed for detection of HIV-1 p24 core antigen in a Perkin-Elmer ELISA. Supernatants from three 
ART-naϊve (A), five treated HIV-1+ individuals (B), four HIC (M407, W757, G993 and A338) and one LTNP 
(L594) were examined (C). Each coloured symbol and line represents one individual. Dotted horizontal line 
denotes the lower level of detection for the assay (6.25 pg/ml) based on negative controls. Black diamond 
shaped symbols represent values higher than the threshold of the assay (800 pg/ml). 
 
5.2.5 Phenotypic analysis of LTNP and HIC and pLTNP 
Phenotypic differences of CD4 and CD8 T cells are often observed between HIV-1-infected chronic 
progressors and uninfected healthy controls, which may contribute to the impaired responses to 
HIV-1 (Day et al., 2006; Deeks, 2011). Results from Chapter 4 suggested increased levels of CD4 
and CD8 TEM cells in HIV-1-infected individuals compared to HIV-1-uninfected controls and this 
was inversely associated with CD4 T-cell counts for the CD8 T-cell compartment (Chapter 4, 
section 4.2.2). Moreover, the activation levels on CD8 TEM and TEMRA cells remained elevated in 
treated patients compared to HIV-1-uninfected controls, which may substantially affect the 
functional responses in subsets (Chapter 4, section 4.2.4). The frequencies of TEM cells and other 
differentiation subsets as well as activation and exhaustion profiles were investigated in the LTNP, 
HIC and pLTNP groups to determine whether these subjects possessed certain phenotypes that 
were not observed in chronic progressors. Lineage markers CCR7 (lymph node homing receptor) 
and CD45RA were used to identify the T-cell differentiation subsets: Naïve (CCR7+CD45RA+), TCM 
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(CCR7+CD45RA-), TEM (CCR7
-CD45RA-) and TEMRA (CCR7
-CD45RA+) (Sallusto et al., 1999). 
Furthermore, activation levels were assessed using CD38 and HLA-DR to identify highly activated 
CD4 and CD8 T cells (HLA-DR+CD38+) as well as subsets expressing either of these markers or 
none (HLA-DR+CD38-, HLA-DR-CD38+ and HLA-DR-CD38-). Finally, co-expression of PD-1 and 
TIM-3 was examined to identify hyper exhausted CD4 and CD8 T cells (TIM-3+PD-1+) as well as 
other T-cell subsets (TIM-3-PD-1-, TIM-3-PD-1+ and TIM-3+PD-1-). The gating strategy used to 
identify the different populations was described in Chapter 4 section 4.2.1.  
 
Of the four identified HIV-1-infected individuals with stable CD4 T-cell counts, two (L594 and S219) 
had repeated CD4 T-cell counts <450 cells/µl blood and would therefore not be considered to meet 
the criteria for LTNP in the majority of studies. Previous reports have described a subset of 
individuals who exhibit spontaneous HIV-1 control despite having lower CD4 T-cell numbers as 
discord controllers and attributed this difference to higher viral DNA load, depletion of naïve CD4 T 
cells and higher activation in all CD4 T-cell subsets compared to typical controllers (Groves et al., 
2012). To investigate whether this was also observed in L594 and S219, the differentiation, 
activation and exhaustion profiles of CD4 and CD8 T cells was initially evaluated in these two 
individuals as well as R363 and T202.  
 
Overall, the phenotype of L594 and S219 did not stand out as different from R363 and T202 who 
maintained high CD4 T-cell counts (Figure 5.11). Specifically, CD4 T-cell differentiation was highly 
variable between the four individuals whilst similar frequencies of differentiation subsets were 
observed for CD8 T cells (Figure 5.11 A and B). Activation levels on CD4 T cells and exhaustion 
levels on both CD4 and CD8 T cells were also similar between all four individuals although S219 
exhibited somewhat higher levels of both CD4 and CD8 T cells that were TIM-3-PD-1+ (Figure 5.11 
C, E and F). L594 had very high levels of CD8 T cells that expressed CD38 only (70%; HLA-DR-
CD38+; Figure 5.11 D). T202, who had high levels of CD4 T-cell counts and exhibited spontaneous 
control of plasma HIV-1 RNA load to below 150 copies/ml, exhibited high levels of highly activated 
CD8 T cells (HLA-DR+CD38+; 47%; Figure 5.11 D). This profile concurs with previous reports of 
higher CD8 T-cell activation levels observed in some cohorts of HIV controllers compared to 
healthy controls (Hunt et al., 2011a). In addition, T202 as well as S219 and R363 had significant 
levels of CD8 T cells that produced HLA-DR only (HLA-DR+CD38-; 34%; Figure 5.11 D). In 
summary, although individual variability occurred, no phenotypic differences were observed 
between L594 and S219 who repeatedly had CD4 T-cell counts <450 cells/µl blood compared to 
T202 and R363 who had high levels of CD4 T cells. 
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Figure 5.11 Differentiation, activation and exhaustion profiles of T cells in LTNP.  
Flow cytometric analysis was carried out on PBMC from four LTNP; two had CD4 T-cell counts >450 cells/µl 
blood (L594 and S219; blue circle and diamond symbols) and two had CD4 T-cell counts <450 cells/µl blood 
(R363 and T202; black triangle and square symbols). Co-expression of surface markers CCR7 and CD45RA 
was used to identify CD4 (A, C and E) and CD8 (B, D and F) T-cell differentiation subsets: Naïve, TCM, TEM 
and TEMRA. Activation markers CD38 and HLA-DR were used to assess activation levels (defined as HLA-DR
-
CD38-, HLA-DR-CD38+, HLA-DR+CD38- and HLA-DR+CD38+) and PD-1 and TIM-3 to assess exhaustion 
profiles (TIM-3-PD-1-, TIM-3-PD-1+, TIM-3+PD-1- and TIM-3+PD-1+). All individual data points are shown.  
 
Phenotypic profiles were further evaluated in six HIC and compared with five pLTNP. The four 
LTNP were included as a group for comparison. The differentiation profile of CD4 T cells was 
highly variable in all three groups, particularly for the naïve and TEM subsets (Figure 5.12 A). 
Frequencies of CD4 TEMRA cells were consistently low in both HIC and pLTNP as well as two of the 
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LTNP. In the CD8 T-cell compartment, the main difference was observed in the TEM subset (Figure 
5.12 B) as pLTNP had significantly higher frequencies of CD8 TEM cells (median 60%) compared to 
both LTNP and HIC (median 41 and 37%; p=0.0317 and p=0.0303 respectively). pLTNP also had 
significantly lower levels of CD8 TEMRA cells compared to LTNP (median 33 and 52% respectively; 
p=0.0159). It is noteworthy that approximately 52% of the CD8 T cells in LTNP were of a TEMRA 
phenotype suggesting an enhanced ability to generate and maintain this subset in LTNP. The 
majority of HIC had higher levels of naïve CD8 T cells, compared to the other two groups although 
this did not reach statistical significance.  
 
Figure 5.12 CD4 and CD8 T-cell differentiation levels in HIV-1+ individuals with different progression 
rates.  
Flow cytometric analysis was carried out on PBMC of four LTNP (blue bars), six HIC (grey bars), and five 
pLTNP (light blue bars) using CCR7 and CD45RA co-expression to identify CD4 and CD8 T-cell 
differentiation subsets: naïve, TCM, TEM and TEMRA. All individual data points are shown with box plots 
representing the median and interquartile range, and whiskers representing the 10th and 90th percentile 
range. P values are shown where there are statistically significant differences between the two groups 
(p≤0.05). Statistical analysis was performed using the Kruskal-Wallis Test for multiple group comparisons.  
 
Frequencies of CD38+ and HLA-DR+ CD4 T cells did not vary significantly between the three 
groups (Figure 5.13 A and B). However, assessing CD38 and HLA-DR co-expression revealed that 
pLTNP exhibited a significant shift towards highly activated CD4 T cells (median 23%; HLA-
DR+CD38+), compared to HIC (median 4%), who in turn had high levels of non-activated CD4 T 
cells (HLA-DR-CD38-; median 46%; p=0.0303 and p=0.0173; Figure 5.13 E). The same trend was 
observed for the CD8 T-cell compartment, from a non-activated to a highly activated phenotype in 
pLTNP (median 22 and 40% respectively) compared to HIC (55 and 13% respectively; p=0.0043 
for both; Figure 5.13 F). This shift was also apparent when assessing each marker on its own. 
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pLTNP exhibited higher frequencies of both CD38+ and HLA-DR+ CD8 T cells (median 63 and 
64%) compared to HIC (median 26 and 28%; p=0.0174 and p=0.0303; Figure 5.13 C and D). 
LTNP had variable frequencies of CD8 T cells expressing CD38 and HLA-DR and no clear trend 
was observed for this group. 
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Figure 5.13 HLA-DR and CD38 co-expression on CD4 and CD8 T cells from HIV-1+ individuals with 
different progression rates.  
HLA-DR and CD38 were analysed for their expression on CD4 (A, B and E) and CD8 (C, D and F) T cells 
from four LTNP (blue bars), six HIC (grey bars), and five pLTNP (light blue bars). All individual data points 
are shown with box plots representing the median and interquartile range, and whiskers representing the 10th 
and 90th percentile range. P values are shown where there are statistically significant differences between 
the two groups (p≤0.05). Statistical analysis was performed using the Kruskal-Wallis Test.  
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Activation levels were next assessed on CD4 and CD8 naïve, TCM, TEM and TEMRA subsets. 
Interestingly, although the frequencies of total CD38+ and HLA-DR+ CD4 T cells were not 
significantly different between the three groups, there were some noticeable differences when 
measuring CD38 and HLA-DR expression on CD4 differentiation subsets. The main differences 
were observed in the TCM and TEM subsets with higher levels of activation detected in the pLTNP 
group overall. Specifically, pLTNP had significantly higher levels of CD38+ TCM and TEM subsets 
(median 48 and 37%) compared to HIC (median 22 and 14%; p=0.0173 and p=0.0303; Figure 5.14 
A). HLA-DR expression was also higher in CD4 TEM from pLTNP compared to HIC (median 55 and 
24%; p=0.0353; Figure 5.14 B). Finally, the frequencies of highly activated CD4 TCM and TEM cells 
were detected at higher levels in pLTNP (median 17 and 23%) compared to HIC (3 and 5%; 
p=0.0087 and p=0.0303; Figure 5.14 D). LTNP exhibited more variable levels of activation on the 
CD4 T-cell subpopulations, but the frequencies of highly activated CD4 TCM cells (median 9%) 
were significantly higher compared to the median 3% observed in HIC for this subset (p=0.0190; 
Figure 5.14 D). Thus, HIV controllers had particularly low activation levels on the CD4 TCM subset, 
which has previously been associated with HIV control (Potter et al., 2007). The high levels of 
CD38+ naïve CD4 T cells that were observed in chronic progressors and uninfected controls 
(medians >80%) in Chapter 4 (section 4.2.4), were more variable in the three groups assessed 
here with no significant differences observed between them (Figure 5.14 A). Moreover, frequencies 
of CD38+ TEMRA CD4 T cells were also similar between the groups. These results suggest that 
differences in plasma HIV-1 RNA load may not affect CD38 expression on CD4 naïve and TEMRA 
cells.  
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Figure 5.14 CD38 and HLA-DR expression on CD4 T-cell differentiation subsets.  
Percentage co-expression of CCR7 and CD45RA was determined on CD4 T cells for identification of 
differentiation subsets: naïve, TCM, TEM and TEMRA. Expression of CD38 (A) and HLA-DR (B) on all four 
differentiation subsets was subsequently assessed on four LTNP (dark blue bars), six HIC (grey bars) and 
five pLTNP (light blue bars). CD4 T-cell differentiation subsets expressing HLA-DR but not CD38 (HLA-
DR+CD38-; C) or both HLA-DR and CD38 (HLA-DR+CD38+; D) were analysed and shown for each subset. 
All individual data points are shown with box plots representing the median and interquartile range, and 
whiskers representing the 10th and 90th percentile range. P values are shown where there are statistically 
significant differences between the two groups (p≤0.05). Statistical analysis was performed using the 
Kruskal-Wallis Test.  
 
Assessment of activation levels on CD8 T-cell differentiation subsets revealed statistically 
significant differences between HIC and pLTNP, whilst LTNP had more variable profiles as 
observed for the CD4 T-cell compartment (Figure 5.15). Specifically, as previously demonstrated, 
HIC exhibited low CD38 expression on CD8 T cells and this was observed across all four 
differentiation subsets (medians 15-40% for all four subsets; Figure 5.15 A). In addition, the high 
frequencies of CD38+ CD8 T cells previously observed in pLTNP were detected in all subsets 
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(medians 57-66%), but were more prevalent in the TCM, TEM and TEMRA compartments when 
compared to HIC (p=00043, 0.0043 and 0.0303 respectively). LTNP exhibited variable levels of 
CD38 expression across all four subsets, but the frequency of CD38+ CD8 TEM cells was 
significantly lower compared to the high levels in pLTNP (median 30 and 66% respectively 
(p=0.0159). HLA-DR+ CD8 T-cell frequencies were high in the naïve, TCM and TEM subsets of 
pLTNP but only reached statistical significance when compared to HIC for the TCM and TEM subsets 
(p=0.0087 and 0.0303; Figure 5.15 B). There was no significant difference observed between the 
frequencies of HLA-DR+CD38- CD8 T-cell subsets in the three groups, although LTNP exhibited 
higher median levels of HLA-DR+CD38- TCM and TEM (median 27 and 31%) compared to pLTNP 
(median 11 and 16%; Figure 5.15 C). Finally, both LTNP and HIC had low median frequencies of 
highly activated CD8 T cells (HLA-DR+CD38+) across all subsets (median <20% for all), whilst the 
highest levels were detected in pLTNP across all subsets (Figure 5.15 D). Specifically, almost half 
of CD8 TCM and TEM cells were highly activated in pLTNP (median 48 and 50%) with somewhat 
lower frequencies observed in the TEMRA and naïve subsets (median 39 and 27%). These levels of 
activation in pLTNP were significantly higher compared to those observed in LTNP and HIC for the 
naïve, TCM and TEM subsets (p<0.05 for all) and compared to HIC for the TEMRA subset (p=0.0173). 
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Figure 5.15 CD38 and HLA-DR expression on CD8 T-cell differentiation subsets.  
Percentage co-expression of CCR7 and CD45RA was determined on CD8 T cells for identification of 
differentiation subsets: naïve, TCM, TEM and TEMRA. Expression of CD38 (A) and HLA-DR (B) on all four 
differentiation subsets was subsequently assessed on four LTNP (dark blue bars), six HIC (grey bars) and 
five pLTNP (light blue bars). CD8 T-cell differentiation subsets expressing HLA-DR but not CD38 (HLA-
DR+CD38-; C) or both HLA-DR and CD38 (HLA-DR+CD38+; D) were analysed and shown for each subset. 
All individual data points are shown with box plots representing the median and interquartile range, and 
whiskers representing the 10th and 90th percentile range. P values are shown where there are statistically 
significant differences between the two groups (p≤0.05). Statistical analysis was performed using the 
Kruskal-Wallis Test.  
 
The expression of TIM-3 was low in the three groups examined (<0.5%), with no significant 
differences observed between them (data not shown). When PD-1 expression was measured there 
was a trend for higher levels of PD-1+ CD4 T cells in HIC and lower levels of PD-1+ CD8 T cells in 
LTNP, however this did not reach statistical significance (Figure 5.16 A and B). The high PD-1 
expression with concomitant low TIM-3 expression was evident when looking at PD-1 and TIM-3 
co-expression as the majority of both CD4 and CD8 T cells were either of the TIM-3-PD-1- or TIM-
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3-PD-1+ phenotype (Figure 5.16 C and D). No significant difference was observed between the 
three groups.  
 
Figure 5.16 PD-1 and TIM-3 expression on CD4 and CD8 T cells from HIV-1+ individuals with different 
progression rates.  
Expression of PD-1 was determined on CD4 (A) and CD8 (B) T cells from four LTNP (blue bars), six HIC 
(grey bars), and five pLTNP (light blue bars). Percentage co-expression of PD-1 and TIM-3 was determined 
on CD4 (C) and CD8 (D) T cells. All individual data points are shown with box plots representing the median 
and interquartile range, and whiskers representing the 10th and 90th percentile range. P values are shown 
where there are statistically significant differences between the two groups (p≤0.05). Statistical analysis was 
performed using the Kruskal-Wallis Test.  
 
Previous studies suggest that CD38 and PD-1 expression is elevated in chronic progressors 
(Vollbrecht et al., 2010), and this was confirmed in Chapter 4 (sections 4.2.3 and 4.2.5). The 
relationship between PD-1 and CD38 as well as PD-1 and HLA-DR was next investigated (Figure 
5.17). All three groups had low levels of CD4 T cells expressing both CD38 and PD-1, despite high 
plasma HIV-1 RNA levels in pLTNP (median 4, 3 and 7% respectively; CD38+PD-1+; Figure 5.17 
A). Instead, the majority of individuals in the three groups had CD4 T cells that were either 
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negative for both CD38 and PD-1 (CD38-PD-1-) or expressed CD38 only (CD38+PD-1-; Figure 
5.17 A). This was similar for CD8 T cells, although there was a trend for pLTNP to have higher 
frequencies of CD8 T cells expressing both CD38 and PD-1 (median 20%; CD38+PD-1+) compared 
to LTNP (median 5%; p=0.0635; Figure 5.17 C). In terms of HLA-DR and PD-1 expression, the 
majority of individuals from all three groups had CD4 T cells that were negative for both markers 
(median 77, 73 and 64% for LTNP, HIC and pLTNP respectively; Figure 5.17 B). pLTNP did 
however have higher frequencies of CD4 T cells expressing HLA-DR in the absence of PD-1 
compared to the two other groups (median 31, 12 and 7% for pLTNP, LTNP and HIC respectively; 
HLA-DR+PD-1-), reaching statistical significance when compared with HIC (p=0.0173; Figure 5.17 
B). The distribution of PD-1 and HLA-DR expression on CD8 T cells was not significantly different 
between the three groups as frequencies were variable in LTNP and pLTNP (Figure 5.17 D).  
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Figure 5.17 PD-1 and its co-expression with either CD38 or HLA-DR on CD4 and CD8 T cells.  
Percentage co-expression of PD-1 and CD38 as well as PD-1 and HLA-DR was determined on CD4 (A and 
B) and CD8 (C and D) T cells from four LTNP (dark blue bars), six HIC (grey bars) and five pLTNP (light blue 
bars). All individual data points are shown with box plots representing the median and interquartile range, 
and whiskers representing the 10th and 90th percentile range. P values are shown where there are 
statistically significant differences between the two groups (p≤0.05). Statistical analysis was performed using 
the Kruskal-Wallis Test.  
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Table 5.4. Summary table of differentiation, activation and exhaustion markers on CD4 and CD8 T 
cells. 
The median and interquartile ranges (in brackets) are listed for each parameter between the three groups 
(Long-term nonprogressors: LTNP; HIV controllers: HIC and progressing LTNP: pLTNP). Boxes are in red 
when the median value is significantly higher compared to the value observed in pLTNP. Grey boxes 
indicate that the median frequency was significantly lower compared to that observed in pLTNP (Central 
memory T-cell: TCM; Effector Memory T-cell: TEM; Terminally Differentiated Effector Memory T-cell: TEMRA).  
Differentiation 
T-cell type Marker LTNP HIC pLTNP 
CD4 
Naïve 30	(14-64)	 21	(14-47)	 18	(10-36)	
TCM 19	(7-24)	 22	(20-32)	 28	(17-30)	
TEM 30	(6-47)	 44	(19-54)	 47	(33-66)	
TEMRA 16	(2-41)	 8	(4-11)	 6	(2-8)	
CD8 
Naïve 5	(2-13)	 24	(8-28)	 4	(4-10)	
TCM 2	(0.53-2)	 3	(0.78-5)	 4	(3-5)	
TEM 41	(27-44)	 37	(23-48)	 60	(49-73)	
TEMRA 52	(45-67)	 40	(32-47)	 33	(19-39)	
Activation 
T-cell type Marker LTNP HIC pLTNP 
CD4 
CD38+ 47 (44-67) 31 (23-55) 64 (40-69) 
HLA-DR+ 20 (12-24) 10 (8-24) 36 (16-45) 
CD8 
CD38+ 37 (14-67) 26 (21-37) 63 (52-84) 
HLA-DR+ 33 (12-69) 28 (14-46) 64 (47-75) 
CD4 
HLA-DR-CD38- 41 (26-48) 46 (38-65) 22 (18-34) 
HLA-DR-CD38+ 41 (37-51) 28 (16-55) 46 (28-54) 
HLA-DR+CD38- 8 (5-13) 10 (3-18) 11 (8-22) 
HLA-DR+CD38+ 9 (5-18) 4 (2-8) 23 (9-27) 
CD8 
HLA-DR-CD38- 39 (16-61) 55 (34-65) 22 (6-26) 
HLA-DR-CD38+ 10 (5-56) 17 (8-24) 23 (12-29) 
HLA-DR+CD38- 25 (8-32) 16 (8-31) 14 (5-21) 
HLA-DR+CD38+ 8 (4-38) 13 (7-19) 40 (35-67) 
Activation on T-cell subsets 
T-cell type Marker LTNP HIC pLTNP 
CD4 CD38+ 
Naïve 71 (61-87) 81 (64-83) 92 (70-94) 
TCM 40 (38-65) 22 (12-38) 48 (41-62) 
TEM 29 (21-49) 14 (7-27) 37 (29-62) 
TEMRA 60 (47-73) 61 (56-71) 67 (53-83) 
CD4 HLA-DR+ 
Naïve 5 (3-11) 1 (0.9-13) 3 (1-7) 
TCM 18 (12-50) 7 (6-16) 28 (12-40) 
TEM 31 (24-45) 24 (12-35) 55 (40-59) 
TEMRA 19 (10-43) 9 (5-27) 27 (12-49) 
Table continued on the following page. 
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Table 5.4. continued. 
Activation on T-cell subsets 
T-cell type Marker LTNP HIC pLTNP 
CD4             
HLA-DR+CD38- 
Naïve 1 (0.55-2) 0.64 (0.15-4) 0.27 (0.21-0.92) 
TCM 8 (7-11) 5 (4-15) 9 (5-19) 
TEM 16 (12-22) 13 (11-28) 20 (13-38) 
TEMRA 8 (5-14) 6 (1-15) 7 (2-18) 
CD4              
HLA-DR+CD38+ 
Naïve 4 (2-9) 1 (0.88-10) 3 (0.99-6) 
TCM 9 (5-41) 3 (2-4) 17 (7-24) 
TEM 12 (8-32) 5 (3-13) 23 (18-41) 
TEMRA 8 (5-33) 3 (0.98-17) 21 (7-36) 
CD8 CD38+ 
Naïve 44 (24-79) 40 (13-56) 57 (44-76) 
TCM 30 (21-66) 15 (13-24) 58 (54-84) 
TEM 30 (21-66) 21 (14-31) 66 (54-86) 
TEMRA 42 (15-80) 28 (18-42) 61 (48-82) 
CD8 HLA-DR+ 
Naïve 11 (4-15) 4 (3-17) 29 (13-41) 
TCM 49 (14-53) 22 (14-32) 67 (47-79) 
TEM 41 (18-71) 33 (22-51) 71 (55-82) 
TEMRA 31 (8-74) 29 (17-59) 56 (43-65) 
CD8            
  HLA-DR+CD38- 
Naïve 5 (1-8) 4 (1-9) 4 (1-13) 
TCM 27 (7-32) 15 (8-21) 11 (4-20) 
TEM 31 (13-36) 24 (15-36) 16 (6-22) 
TEMRA 23 (5-33) 18 (8-39) 15 (5-22) 
CD8              
HLA-DR+CD38+ 
Naïve 4 (3-9) 2 (1-7) 27 (11-29) 
TCM 19 (6-27) 10 (7-13) 48 (37-71) 
TEM 10 (5-35) 15 (9-26) 50 (39-74) 
TEMRA 8 (2-43) 16 (6-25) 39 (29-55) 
Exhaustion 
T-cell type Marker LTNP HIC pLTNP 
CD4 
PD-1 5 (1-12) 16 (6-29) 12 (7-15) 
TIM-3-PD-1- 90 (82-98) 82 (66-88) 78 (49-90) 
TIM-3+PD-1- 0.48 (0.15-3.1) 0.21 (0.10-0.30) 0.18 (0.13-0.24) 
TIM-3-PD-1+ 7 (1.3-17) 17 (12-33) 21 (10-50) 
TIM-3+PD-1+ 0.13 (0.02-1) 0.11 (0.07-0.41) 0.15 (0.06-0.25) 
CD8 
PD-1 10 (7-25) 27 (14-39) 3 (2-24) 
TIM-3-PD-1- 96 (88-99) 84 (71-94) 88 (85-93) 
TIM-3+PD-1- 0.21 (0.06-0.35) 0.21 (0.16-0.30) 0.13 (0.04-0.21) 
TIM-3-PD-1+ 3 (0.54-12) 16 (6-29) 12 (6-15) 
TIM-3+PD-1+ 0.06 (0.007-0.01) 0.07 (0.04-0.12) 0.05 (0.01-0.06) 
Table continued on the following page. 
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Table 5.4 continued. 
Exhaustion and Activation 
T-cell type Marker LTNP HIC pLTNP 
CD4 
CD38-PD-1- 32 (20-43) 49 (31-63) 31 (24-43) 
CD38+PD-1- 60 (37-78) 30 (16-52) 61 (43-66) 
CD38-PD-1+ 6 (0.26-13) 7 (6-28) 5 (2-6) 
CD38+PD-1+ 4 (0.34-7) 3 (2-7) 7 (4-11) 
CD8 
CD38-PD-1- 43 (30-63) 55 (37-66) 24 (12-40) 
CD38+PD-1- 41 (17-67) 27 (17-36) 49 (27-62) 
CD38-PD-1+ 8 (1-16) 15 (7-19) 6 (0.83-15) 
CD38+PD-1+ 5 (0.93-8) 7 (3-12) 20 (8-36) 
CD4 
HLA-DR-PD-1- 77 (69-89) 73 (64-88) 64 (53-77) 
HLA-DR+PD-1- 12 (8-18) 7 (4-11) 31 (13-35) 
HLA-DR-PD-1+ 6 (0.10-11) 8 (4-12) 5 (2-5) 
HLA-DR+PD-1+ 4 (0.57-6) 7 (2-18) 6 (3-9) 
CD8 
HLA-DR-PD-1- 51 (32-71) 51 (45-72) 31 (28-48) 
HLA-DR+PD-1- 34 (24-53) 17 (11-27) 39 (18-53) 
HLA-DR-PD-1+ 3 (0.45-8) 6 (3-13) 5 (2-15) 
HLA-DR+PD-1+ 10 (2-12) 14 (9-22) 15 (9-33) 
 
5.2.6 Functional responses 
Results from Chapter 3 demonstrated distinct induction of INF-γ, IL-2 and IL-10 responses in 
chronically HIV-1-infected individuals. Whilst IFN-γ responses were high in response to HIV-1 
peptide pools in ART-naïve patients, these appeared diminished in the context of ART (Casazza et 
al., 2001). Moreover, IL-2 responses were absent in both untreated and treated individuals, 
indicating a persistent absence of polyfunctional responses that are often associated with 
spontaneous HIV-1 control (Imami et al., 2002; Betts et al., 2006; Vingert et al., 2012). CMV was a 
strong inducer of IL-10 and induced significantly higher IL-10 levels compared to HIV-1 peptide 
pools. Still, HIV-1-uninfected individuals displayed the highest levels of CMV-induced IL-10, 
suggesting a strong immunomodulatory role of IL-10 in response to CMV. To investigate IL-10 
responses in controllers and whether polyfunctional T-cell responses were present in these 
individuals, functional ELISpot analysis was carried out. Fresh PBMC were isolated and stimulated 
with CMV WL, HIV-1 Gag 9mer and 20mer peptide pools as well as Nef 9mer and 20mer peptide 
pools, to assess IFN-γ, IL-2, IL-10 and granzyme B responses as detailed in Chapter 2 (section 
2.15). Granzyme B was examined because of its importance in mediating T-cell cytotoxicity 
(Chowdhury and Lieberman, 2008), a function that has been linked to spontaneous HIV-1 control 
(Migueles et al., 2008). Responses to HSV antigen (Ag), EBV Ag, FEC MHC class I-restricted 
9mer peptide pool and an HLA-B*27:05-restricted HIV-1 Gag 10mer peptide (KRWIILGLNK; KK10) 
were also evaluated. The KK10 peptide is immunodominant and has previously been associated 
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with HIV-1 control (Altfeld et al., 2006). Due to the 20 aa length of the peptides in the HIV-1 20mer 
peptide pools, it is expected that these pools would stimulate both CD4 and CD8 T-cell responses. 
However, it should be noted that preliminary intracellular cytokine staining in Chapter 3 hinted that 
CD8 T cells predominantly responded to these pools, whereas CD4 T cells responded to CMV WL. 
Although, this was not evaluated for the subjects included in this study, this should be taken into 
consideration. 
 
As expected, the most prevalent cytokine was IFN-γ and in the LTNP group; all four individuals 
produced IFN-γ in response to CMV WL and Nef 20mer peptide pool (Figure 5.18 A). Three LTNP 
(S219, T202 and R363) had detectable IFN-γ production to all four HIV-1 peptide pools. In 
contrast, L594 responded only to one of the HIV-1 peptide pools (Nef 20mer), whilst having low but 
detectable responses to CMV, EBV and HSV antigen. L594 also exhibited low but above the 
threshold IL-2 responses to Nef 9mer and 20mer peptide pools, indicating that this individual 
predominantly targeted the HIV-1 Nef and not Gag protein (Figure 5.18 B).  
 
R363 (who was HLA-B*27:05+) was the only LTNP who exhibited polyfunctional T-cell responses, 
as indicated by the strong IFN-γ, IL-2 and granzyme B production to CM WL and HIV-1 Gag 20mer 
and Nef 9mer peptide pools (Figure 5.18 A, B and D). The detection of granzyme B production to 
Gag and Nef 20mer pools in R363 may be indicative of a strong CD4 T-cell presence with cytolytic 
activity in this individual, a function that has previously been associated with HIV-1 control 
(Soghoian et al., 2012). However, this would have to be examined with intracellular cytokine 
staining in future studies, to determine whether it is CD4, CD8 T cells or both who respond to HIV-
1 Gag and Nef 20mer peptide pools in this individual. R363 did also exhibit strong IFN-γ and 
granzyme B responses to the HLA-B*27:05-restricted single HIV-1 Gag peptide KK10, suggesting 
a strong cytotoxic CD8 T-cell response directed against this epitope. Interestingly, although strong 
granzyme B responses to the KK10 peptide were observed in R363, these were absent towards 
the Gag 9mer peptide pool despite KK10 being included in this pool (Chapter 2 section 2.14 for list 
of peptides included in the Gag 9mer pool). This could be due to the composition of the peptide 
pool, which may inhibit the ability to accurately detect a positive response to one peptide, 
compared to when the peptide is tested individually (Precopio et al., 2008). IL-10 production was 
mainly observed in two patients; S219 responded to CMV WL, Nef 20mer pool and EBV, whilst 
R363 had detectable IL-10 responses to all four HIV-1 peptide pools, CMV WL, FEC peptide pool 
and the single peptide KK10.  
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In summary, polyfunctional CMV and HIV-1 Gag and Nef-specific responses defined by IFN-γ, IL-2 
and granzyme B release, were detected in one (R363) of the four LTNP. Moreover, IL-10 
production was observed to the same antigen and peptide pools, which stimulated a polyfunctional 
response in R363. 
 
Figure 5.18 Functional ELISpot responses to various antigens in four LTNP.  
PBMC were isolated and stimulated with whole lysates of CMV, HSV and EBV as well as HIV-1 Gag and Nef 
9mer and 20mer peptide pools and evaluated for IFN-γ (A), IL-2 (B), IL-10 (C) and granzyme B (D) 
production in the ELISpot assay. FEC peptide pool and a single HLA-B*27:05-restricted HIV-1 Gag 10mer 
peptide (KRWIILGLNK; KK10) was also evaluated. Tissue culture medium (TCM) and PHA were used as a 
negative and positive control respectively, and values of >250 SFC/million PBMC were obtained in all assays 
in response to PHA. A threshold of ≥20 SFC/million PBMC was used to determine a positive response 
(indicated by a dashed line).  
 
The same analysis was carried out on four of the pLTNP (N542, W609, J785 and B288). Similar to 
that observed for LTNP, the prevalent cytokine produced in this group was IFN-γ and all four 
pLTNP had positive IFN-γ T-cell responses to CMV WL, HIV-1 Gag and HIV-1 Nef 20mer peptide 
pools (Figure 5.19 A). HIV-1 Gag- and Nef-specific CD8 T cells directed against 9mer pools were 
also detected in B288 and W609 respectively, whilst N542 produced detectable IFN-γ responses to 
both HIV-1 9mer peptide pools. Of note, N542 produced IFN-γ, IL-10 and granzyme B in response 
to the HLA-B*27:05-restricted peptide KK10 despite being HLA-B*27:05-. Epitopes that bind 
diverse HLA alleles, referred to as an epitopes binding promiscuity, is controversial but has been 
previously reported (Frahm et al., 2005; Rao et al., 2011; Eisen et al., 2012).  
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Low, but over the threshold HIV-1-specific IL-2 responses were observed in one individual (N542) 
against Gag 9mer and Nef 20mer peptide pools (Figure 5.19 B). N542 also produced granzyme B 
against Nef 20mer peptide pool demonstrating the presence of polyfunctional Nef-specific T-cell 
responses in this individual (Figure 5.19 D). Moreover, granzyme B responses to CMV WL, three 
of the HIV-1-specific peptide pools, FEC, HSV and the KK10 peptide indicates strong cytotoxic 
activity in this individual. B288 also exhibited strong cytotoxic activity to several antigens, including 
CMV WL and three of the HIV-1-specific peptide pools. Low granzyme B responses to at least one 
HIV-1 peptide pool were detected in the other two pLTNP (W609 and J785).  
 
 IL-10 production was readily detected in all four pLTNP in response to CMV WL, HIV-1 Nef 20mer 
pool and HSV (Figure 5.19 C). N542, who exhibited polyfunctional Nef-specific responses, also 
produced IL-10 in response to Nef 20mer peptide pool. IL-10-producing CD8 T cells were also 
detected in N542 to both Gag and Nef 9mer peptide pools and the KK10 peptide. Gag-specific IL-
10 responses to 20mer peptide pool were detected in the three other individuals (W609, J785 and 
B288), although these were just above the threshold.  
 
In summary, polyfunctional Nef-specific responses were detected in one pLTNP (N542), however 
low granzyme B responses to at least one HIV-1 peptide pool were detected in the other three 
pLTNP. As observed for LTNP R363, IL-10 production was observed to the same peptide pool, 
which stimulated a polyfunctional response in N542. Finally, low Gag-specific IL-10 responses 
were detected in all four pLTNP. 
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Figure 5.19 Functional ELISpot responses to various antigens in four pLTNP.  
PBMC were isolated and stimulated with whole lysates of CMV, HSV and EBV as well as HIV-1 Gag and Nef 
9mer and 20mer peptide pools and evaluated for IFN-γ (A), IL-2 (B), IL-10 (C) and granzyme B (D) 
production in the ELISpot assay. FEC peptide pool and a single HLA-B*27:05-restricted HIV-1 Gag 10mer 
peptide (KRWIILGLNK; KK10) was also evaluated. Tissue culture medium (TCM) and PHA were used as a 
negative and positive control respectively, and values of >250 SFC/million PBMC were obtained in all assays 
in response to PHA. A threshold of ≥20 SFC/million PBMC was used to determine a positive response 
(indicated by a dashed line). 
 
The same analysis, when applied to the seven identified HIV controllers, revealed that strong IFN-γ 
T-cell responses to CMV WL, HSV, HIV-1 Gag and Nef 20mer peptide pools were readily detected 
in the majority of individuals with a few exceptions (Figure 5.20 A). In contrast, CD8 T-cell 
responses to HIV-1 Gag and Nef 9mer peptide pools were less frequent; HIC A338 and G993 had 
detectable IFN-γ-producing CD8 T cells to both Gag and Nef 9mer peptide pools, whilst P993 and 
W757 responded to the Gag 9mer peptide pool only. Of note, T883 (who was HLA-B*27:05+) had 
no detectable IFN-γ responses from CD8 T cells to HIV-1 Gag 9mer peptide pool even though 
these were observed to the HLA-B*27:05-restricted peptide KK10. This suggests a similar inability 
to detect positive responses when peptides are tested in pools rather than individually as observed 
in LTNP R363 (Figure 5.18 D). It will be important to investigate whether this is observed in other 
HLA-B*27:05+ subjects, in order to determine the reliability of the Gag 9mer pool in detecting HLA-
B*27:05-restricted responses. It should be noted that P918, whose HLA-type was unknown, was 
not assessed for cytokine responses to HIV-1 Gag or Nef 9mer peptide pools. However, strong 
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IFN-γ, IL-2, IL-10 and granzyme B responses to the KK10 peptide indicate that this individual may 
have been HLA-B*27:05+. Alternatively, P918 could have exhibited the same epitope binding 
promiscuity as N542. P918 also exhibited strong IFN-γ, IL-2 and Granzyme B responses to CMV 
WL, EBV Ag and HIV-1 Gag and Nef 20mer peptide pools, indicating strong polyfunctional 
responses in this individual. In addition to P918, only one more HIV controller had detectable IL-2 
responses: A338 (Figure 5.20 B). This individual responded primarily to one of the HIV-1 peptide 
pools (Gag 20mer) as well as CMV WL, FEC and HSV. A338 also produced low but detectable 
granzyme B responses to HIV-1 Gag 20mer peptide pool suggesting polyfunctional Gag-specific 
responses in this individual. Granzyme B responses were detected in a further three HIV 
controllers: G993, M407 and W757 (Figure 5.20 D). However, only G993 responded to stimulation 
with HIV-1 peptide pools (in this case it was Nef 9mer peptide pool). As mentioned above, P918 
produced granzyme B in response to HIV-1 Gag and Nef 20mer peptide pools. These results 
indicate the presence of HIV-1-specific CD4 T cells with a cytotoxic activity in P918 (and A338) as 
observed for LTNP R363. Yet as mentioned above, this will have to be confirmed with intracellular 
cytokine staining in future studies. Finally, IL-10 responses in HIC were in general detected at a 
lower magnitude compared to both LTNP and pLTNP (Figure 5.20 C). Four individuals exhibited 
strong IL-10 responses to HSV Ag (T883, P993, A338 and P918), three of which also produced 
high IL-10 responses to CMV WL (P993, A338 and P918). Two more responded to CMV WL but 
just above the threshold (25 and 23 SFC/million PBMC; G993 and T883). Responses to HIV-1 
peptide pools were variable; three individuals exhibited positive IL-10 responses to HIV-1 Nef 
20mer peptide pool (P918, A338 and T883), two of which also responded to one of the HIV-1 Gag 
peptide pools (P918 and T883). As described above for LTNP R363 and pLTNP N542, P918 
produced IL-10 in response to the two HIV-1 peptide pools (Gag and Nef 20mer), as well as CMV 
WL and EBV, which stimulated a polyfunctional response in this individual.  
 
In summary, whilst the majority of HIC exhibited strong IFN-γ responses to HIV-1 peptide pools, 
fewer produced IL-2, IL-10 and granzyme B. One individual (P918), exhibited polyfunctional 
responses to CMV WL, EBV and HIV-1 (Gag KK10 peptide, Gag and Nef 20mer peptide pools), 
whilst another (A338) exhibited a polyfunctional response to HIV-1 Gag 20mer peptide pool. 
Moreover, as observed for LTNP R363 and pLTNP N542 above, IL-10 production in P918 was 
detected to the same antigens and peptide pools (CMV WL, EBV and HIV-1), which stimulated a 
polyfunctional response. Granzyme B responses were also observed in three more HIC, although 
not necessarily to HIV-1.  
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Figure 5.20 Functional ELISpot responses to various antigens in seven HIV controllers (HIC).  
PBMC were isolated and stimulated with whole lysates of CMV, HSV and EBV as well as HIV-1 Gag and Nef 
9mer and 20mer peptide pools and evaluated for IFN-γ (A), IL-2 (B), IL-10 (C) and granzyme B (D) 
production in the ELISpot assay. FEC peptide pool and a single HLA-B*27:05-restricted HIV-1 Gag 10mer 
peptide (KRWIILGLNK; KK10) was also evaluated. Tissue culture medium (TCM) and PHA were used as a 
negative and positive control respectively, and values of >250 SFC/million PBMC were obtained in all assays 
in response to PHA. A threshold of ≥20 SFC/million PBMC was used to determine a positive response 
(indicated by a dashed line). 
 
HIV controllers T883 and R363 were identified through HLA-typing to be HLA-B*27:05+ and both 
exhibited strong IFN-γ responses to the HLA-B*27:05-restricted peptide KK10 in the ELISpot 
assay. However, R363 also produced granzyme B to this peptide indicating a strong cytotoxic CD8 
T-cell activity. Moreover, functional responses in R363 were polyfunctional to both HIV-1 Gag and 
Nef whilst these responses were absent in T883. The phenotypic profile of KK10-specific CD8 T 
cells in these two individuals was further evaluated to see whether the differentiation, activation or 
exhaustion profiles could account for the different functional responses. Pro5® Pentamers loaded 
with the KK10 peptide were used to stain PBMC and identify KK10-specific CD8 T cells in R363 
and T883 as detailed in Chapter 2, section 2.18. KK10-specific CD8 T cells were also identified in 
the HIV controller P993 (who did not show any polyfunctional responses to HIV-1 peptide pools) 
and the staining profile is shown for all three individuals (Figure 5.21). KK10-specific CD8 T cells 
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constituted 9.73% of total CD8 T cells in R363 indicating a highly immunogenic peptide as 
previously described (Altfeld et al., 2006) (Figure 2.1 A). The frequencies of KK10-specific CD8 T 
cells were considerably lower in T883 and P993 (0.232 and 0.114% respectively; Figure 2.1 B and 
C). The differentiation profiles of KK10-specific CD8 T cells were predominantly of a TEMRA and TEM 
phenotype with higher levels observed for the latter in all three individuals. When looking at the rest 
of the CD8 T-cell pool, T883 and R363 had higher frequencies of CD8 T cells that were of TEMRA 
subset (54.1 and 43.5%) compared to TEM (15.8 and 37.7%), whilst P993 had twice as many CD8 
T cells of the TEM phenotype compared to the TEMRA phenotype (64.3 and 31.7% respectively). 
Interestingly, P993 also had very low levels of markers associated with naïve CD8 T cells (3.25%; 
CD45RA+CCR7+). The three HIV controllers had in general low levels of highly activated bulk CD8 
T cells (HLA-DR+CD38+), which was mainly due to low CD38 expression. T883 did however exhibit 
an increase of highly activated KK10-specific CD8 T cells (24.2%) despite only 10% of the rest of 
the CD8 T-cell pool being highly activated. P993 and R363 had similar levels of HLA-DR+CD38- in 
total CD8 T cells (18.2 and 21.1% respectively) whilst levels in T883 were low (6.49%). However, 
when looking at antigen-specific CD8 T cells, a greater proportion of KK10-specific CD8 T cells 
from R363 were HLA-DR+CD38-, compared to KK10-specific CD8 T cells from P993 (39.4 and 
12.4% respectively).  
 
PD-1 levels were low on bulk CD8 T cells in all three HIC (<14%) and higher on KK10-specific CD8 
T cells. Although TIM-3 levels on both CD4 and CD8 T cells were very low in these individuals, 
when looking at KK10-specific CD8 T cells it was found that a high percentage of them expressed 
TIM-3. In particular, when looking at TIM-3 and PD-1 co-expression, P993 had high frequencies of 
TIM-3+PD-1+ KK10-specific CD8 T cells (42.5%), whilst lower frequencies were observed for T883 
and R363 (17.4 and 13.8% respectively). In R363, the subset TIM-3+PD-1- was the more 
predominant phenotype (39.7%), which appeared to be primarily due to lower PD-1 expression in 
these antigen-specific CD8 T cells. Thus, in R363, a large proportion of KK10-specific CD8 T cells 
were HLA-DR+CD38- and TIM-3+PD-1- compared to T883 who had increased levels of highly 
activated HIV-1-specific CD8 T cells.  
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Figure 5.21 Phenotypic profiles of HIV-1 Gag KK10+-specific CD8 T cells in HIC.  
PBMC were stained with Pro5® Pentamers loaded with HIV-1 Gag KK10 (KRWIILGLNK) peptide to identify 
KK10-specific CD8 T cells in R363 (A), T883 (B) and P993 (C). In addition, CD45RA and CCR7; HLA-DR 
and CD38; TIM-3 and PD-1 were used to examine the differentiation, activation and exhaustion profiles of 
KK10-specific CD8 T cells as well as the rest of the CD8 T-cell pool. Gates were set based on isotype 
controls. 
 
5.2.7 Assessment of IL-10 in plasma and supernatants 
Results presented in Chapter 3 (sections 3.2.4 and 3.2.5) demonstrated high IL-10 responses to 
CMV WL and HIV-1 Nef peptide pools. Here it was shown that the production of this cytokine was 
variable in controllers with some patients exhibiting it and others not. The ELISpot assay will detect 
the magnitude of responses but will not say anything about the kinetics of release and uptake of IL-
10. The ELISA assay was therefore carried out to better understand the kinetics of IL-10 plasma 
levels and its secretion in response to HIV-1 and CMV in individuals with an atypical HIV-1 disease 
progression. The levels of IL-10 in plasma were evaluated using the IL-10 Quantikine ELISA 
assay, which has a lower level of threshold sensitivity of 3.9 pg/ml. This was carried out on seven 
healthy controls, eleven ART-naïve HIV-1+ individuals, four LTNP, three HIC and three pLTNP, all 
who had previously been identified as CMV responders in the ELISpot assay. Of the ones who had 
detectable plasma IL-10 (three ART-naïve and one pLTNP), all were ART-naïve individuals, 
concurring with previous findings (Brockman et al., 2009) (Figure 5.22 A). In contrast, none of the 
healthy controls, LTNP or HIC had detectable plasma IL-10 levels. Next, PBMC from one ART-
naïve HIV-1+ individual (F383), two LTNP (T202 and S219) and two HIC (P993 and A338) were 
stimulated with CMV WL as well as HIV-1 Nef 20mer peptide pool for 12h, 24h and 48h to 
investigate the kinetics of IL-10 production. Supernatants were taken at each time point and stored 
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until assessed in the IL-10 Quantikine ELISA assay. PBMC from one HIV-1-uninfected individual 
were stimulated with CMV WL for comparison. No detectable IL-10 was observed above the 
threshold in response to HIV-1 Nef 20mer pools (data not shown), despite three of them (F383, 
S219 and A338) exhibiting positive IL-10 responses to HIV-1 Nef peptide pool in the ELISpot assay 
(Figure 5.18 and Figure 5.20 for S219 and A338). CMV-specific IL-10 production was observed in 
the supernatant of one LTNP (S219; 12 pg/ml) and one HIC (P993; 14 pg/ml) after 24h of 
stimulation and was still detectable 48h after stimulation (Figure 5.22 B). LTNP T202 had 
detectable CMV-specific IL-10 production after 48 hours of stimulation and this time point was 
therefore chosen for subsequent stimulations. To investigate whether IL-10 levels in the plasma 
were linked to CMV-specific IL-10 levels in the supernatant following stimulation of PBMC, results 
for these two were compared for each individual. A total of six ART-naϊve patients, one HIV-1-
uninfected individual, three LTNP, two HIC and five pLTNP were included (Figure 5.22 C). In 
general, IL-10 levels were either undetectable both in the plasma and in the supernatant following 
CMV stimulation or observed in one of the conditions. In the one HIV-1-uninfected individual it was 
not detected either in the plasma or after 48h of CMV-stimulation on PBMC. Two of the ART-naïve 
patients had detectable levels of IL-10 in the plasma but none had detectable levels in 
supernatants following CMV WL stimulation. In contrast, none of the three LTNP tested had 
detectable IL-10 levels in the plasma but all three did produce IL-10 following CMV stimulation of 
PBMC (14.7, 14 and 6 pg/ml for R363, S219 and T202 respectively). One HIC and two pLTNP also 
exhibited CMV WL-induced IL-10 responses in the supernatant (6, 28.9 and 11.6 pg/ml for P918, 
J785 and B288 respectively). 
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Figure 5.22 Detection of IL-10 in HIV-1+ plasma and supernatants.  
The IL-10 Quantikine ELISA was used to detect IL-10 in plasma of seven HIV-1-uninfected healthy controls 
(HC; grey circles), 11 ART-naïve (red circles), four LTNP (black open circles), three HIC (light red circles) 
and five pLTNP (black circles; A). PBMC were stimulated with CMV WL for 12, 24 and 48 hours and 
supernatants were assessed for IL-10 levels in five HIV-1+ individuals and one HC (B). IL-10 levels in plasma 
and supernatants are shown for one HC, six ART-naïve progressors, three LTNP, two HIC and five pLTNP.  
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5.3 Discussion 
High viral load, depletion of immune cells and resultant immunodeficiency characterises the natural 
course of HIV-1 infection ultimately leading to AIDS. Understanding the mechanistic role that host 
and viral factors play in determining disease progression will likely provide clues for the design of 
therapeutic vaccines and functional cure strategies (Genovese et al., 2013; Walker and Yu, 2013).  
 
A thorough case-by-case assessment of the previously identified 50 HIV-1-infected individuals with 
stable CD4 T-cell counts for >7 years (Mandalia et al., 2012), revealed that a significant proportion 
had eventually initiated ART. Considering that the majority of these individuals had a history of at 
least one CD4 T-cell count <450 cells/µl blood, this is to be expected. Out of the 13 patients 
identified to have stable CD4 T-cell counts >450 cells/µl blood, only one had initiated ART. Still, the 
majority of these individuals were lost to follow up due to sporadic clinic attendance, demonstrating 
the importance of having well-documented cohorts and established collaborations with clinicians 
for effective retention of such patients in ongoing care despite being asymptomatic.  
 
The low numbers that were identifiable is a limitation of this study, however, some important 
characteristics of a controller status were nonetheless observed and are discussed below. As a 
group, LTNP exhibited more variability in the phenotypic profiles of their CD4 and CD8 T cells, 
which might be due to lower CD4 T-cell counts in two of them (L594 and S219). Single CD38 and 
PD-1 expression on the CD8 T-cell compartment was higher in L594 and S219 respectively, 
perhaps reflecting the low HIV-1-specific cytokine responses in these two individuals. LTNP have 
recently been shown to resemble ART-naϊve progressors in activation, senescence and apoptosis, 
whilst elite and HIV controllers appear to share these parameters more with HIV-1-uninfected 
subjects (Gaardbo et al., 2013). This may be due to higher plasma HIV-1 RNA load in LTNP, which 
drives an immunosenescent T-cell phenotype, compared to EC and HIC who persistently control 
plasma HIV-1 RNA in the absence of ART.  
 
Despite the observed variability in CD4 T-cell counts in the three groups, the majority of LTNP and 
HIC maintained lower frequencies of highly activated CD4 and CD8 T cells, consistent with current 
evidence suggesting that immune activation is a major predictor of disease progression (Hunt et 
al., 2003b; Deeks et al., 2004; Hunt et al., 2008). HIC exhibited variable lengths of HIV-1 infection, 
but all had high CD4 T-cell counts (>500 cells/µl blood) as well as other clinical parameters known 
to be important in HIV-1 control. Specifically, protective HLA-alleles were common and the majority 
of patients had low frequencies of CD8 T-cell count and consequently high CD4/CD8 ratios, which 
have been described to be favourable in ART-naïve and treated individuals (Serrano-Villar et al., 
2013; Buggert et al., 2014a; Serrano-Villar et al., 2014). Interestingly, LTNP L594 often had an 
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even lower CD8 T-cell count compared to the CD4 T-cell count, despite exhibiting variable plasma 
HIV-1 RNA load and high single CD38 expression on CD8 T cells. Longitudinal analysis on the 
CD8 T-cell functional responses of this individual will be important to comprehend the significance 
of these results.  
 
The viral fitness assay initially involved stimulating CD8+-depleted PBMC with PHA in the presence 
of IL-2. However, although successful on one ART-naϊve LTNP it proved difficult to detect HIV-1 
p24 in patients with lower plasma HIV-1 RNA loads. Co-culturing of patient PBMC with PHA-
activated PBMC from uninfected individuals in multiple rounds improved the assay and resulted in 
the detection of replication-competent virus from one treated individual and two HIC. The inability 
to isolate virus from more than one treated individual does however indicate that the assay lacked 
sufficient sensitivity. Several reasons could be behind this; PBMC rather than isolated CD4 T cells 
were used which probably resulted in low levels of resting CD4 T cells (the cells likely to contain 
the highest amount of virus in treated individuals and HIV controllers) (Finzi et al., 1999). 
Therefore, further improvements of the assay would involve isolating patient CD4 T cells to exclude 
other cell types that are not likely to harbour any virus or might inhibit HIV-1 replication (such as 
CD8 T cells).  
 
Activating isolated CD4 T cells from patients with irradiated PBMC from an HIV-negative donor in 
the presence of IL-2 and PHA might also have increased viral replication from resting CD4 T cells 
(Salgado et al., 2014). The use of latency reversing agents, such as the HDAC inhibitor SAHA, to 
activate latently infected CD4 T cells could further enhance the stimulation of replication-competent 
HIV-1 RNA from viral reservoirs (Margolis, 2011; Archin et al., 2012). This would be an added step 
prior to co-culturing with PHA-stimulated HIV-1-uninfected donor PBMC performed here. One 
caveat is that isolation of CD4 T cells would have required larger amounts of blood sample from 
each HIV controller, which was limited in the current study. Despite these limitations, HIV-1 p24 
was detected after one round of stimulation for HIC G993 whereas it took three stimulations (21 
days) for HIC W757. The reasons for this are unclear but may be due to different replication 
kinetics in the outgrown virus variants warranting further studies. Full-genome deep sequence 
analysis on circulating plasma HIV-1 as well as any isolated replication-competent clone (in this 
case from G993 and W757) would be the next step forward to identify potential escape mutations 
(Henn et al., 2012).  
 
There is increasing evidence that subtle reductions in the function of individual HIV-1 proteins may 
contribute to HIV-1 control (Lassen et al., 2009; Mwimanzi et al., 2013; Kuang et al., 2014). A 
recent study found considerable overlap between epitopes that were linked with HIV-1 control and 
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those that were predicted in silico to confer reduced protein stability (Pereyra et al., 2014). These 
epitopes were identified in several HIV-1 proteins and it was the targeting of these particular 
epitopes rather than the HLA-restriction that correlated with HIV-1 control. Thus, identifying 
epitopes that are important for protein stability and function may be particularly important for future 
immunotherapeutic and prophylactic vaccine developments. The ability of HIV-1 Nef to 
downmodulate CD4 and MHC class I and class II molecules has recently been described to be 
lower in a subset of elite controllers (Mwimanzi et al., 2013). Results from Chapter 3 and here 
demonstrated that HIV-1 Nef induces significant IL-10 production, and IL-10 has also been shown 
to downmodulate MHC class II expression through a different mechanism (Thibodeau et al., 2008).  
 
Future work should consider investigating the two different mechanisms of MHC class II 
downmodulation by Nef and IL-10, to better understand any role that this may have on HIV-1-
specific responses in chronically infected patients and controllers. The drawback of assessing viral 
fitness in controllers during the chronic phase of infection is that if attenuated viral fitness is 
detected, this does not always convey whether this was transmitted or whether early CD8 T-cell 
pressure led to the emergence of attenuated viral variants. Ultimately, the early events following 
HIV-1 infection will be key to investigate as early viral/host interactions are likely to contribute to 
controller status, which may be established as early as 6 months in some individuals (Goujard et 
al., 2009). Reduced ability to downregulate CD4 and HLA-class I has been detected in plasma 
RNA-derived Nef clones isolated from recently infected patients who went on to become HIV 
controllers, indicating that impaired Nef sequences may be transmitted and contribute to the 
resulting status (Kuang et al., 2014).  
 
Ultimately, transmission pairs may be more informative, as they would enable assessment of viral 
replication in the context of two different genetic host backgrounds (Goepfert et al., 2008). A recent 
study looked at two different populations with disparate frequencies of protective HLA-types and 
found that virus variants with reduced replicative capacity were more frequent in the population 
with a high frequency of protective alleles, compared to the population with a low frequency of 
protective alleles (Juarez-Molina et al., 2014). Further studies are required to support this finding 
but it does indicate that the immunological pressure exerted on HIV-1 results in attenuated strains 
that may be transmitted and in some individuals lead to a slower disease progression. However, 
the host immune response of the newly infected individual will play an important role as without a 
strong initial CD8 T-cell response, compensatory mutations may occur. Detailed longitudinal 
analysis of the primary CD8 T-cell response during acute HIV-1 infection suggests a strong initial 
CD8 T-cell pressure on the founder virus, which rapidly wanes and is replaced by CD8 T cells that 
target more conserved regions (Goonetilleke et al., 2009). A recent study on two heterosexual 
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transmission pairs compared contrasting clinical outcomes in two females infected with HIV-1 
clade A founder virus. Control of HIV-1 replication was associated with a transmitted attenuated 
viral fitness and a broad CD8 T-cell response in one subject, whilst HIV-1-specific CD8 T cells in 
the second individual, who did not control HIV-1, mainly targeted two epitopes, one of which 
eventually escaped (Yue et al., 2015). These studies demonstrate the complex interplay between 
several host and viral factors, which together may be underlying HIV-1 control in these individuals 
(Gaardbo et al., 2012; Wang, 2013).  
 
Polyfunctional responses were detected in a handful of controllers, mostly in individuals with known 
protective HLA-alleles, consistent with previous data (Migueles et al., 2002). Interestingly, one 
individual (pLTNP N542) produced low but detectable, IFN-γ, IL-10 and granzyme B in response to 
the HLA-B*27:05-restricted KK10 peptide, despite being HLA-B*27:05-. As strong responses to the 
immunogenic KK10 peptide have been associated with HIV-1 control, identifying the HLA-allele in 
N542, which modulated these CD8 T-cell responses to this peptide is warranted in future work. 
Individuals carrying the identified allele could then be examined for if they are able to present the 
KK10 peptide and whether this is associated with HIV-1 control in these individuals. Epitope fine 
mapping and HLA-binding assays may be carried out for this purpose (Frahm et al., 2005; Bihl et 
al., 2006).  
 
The absence of polyfunctional T-cell responses in the majority of controllers suggests the presence 
of other mechanisms of viral control in these individuals (Emu et al., 2008). Alternatively, the length 
of stimulation in the ELISpot assay might not have been long enough to detect polyfunctional 
responses. A previous study demonstrated that long-term stimulation of CD8 T cells from HIV 
controllers with no previously measurable HIV-1-specific IFN-γ ELISpot responses, led to the 
expansion of HIV-1-specific CD8 T cells that were predominantly polyfunctional, of a central 
memory phenotype and exhibited strong inhibitory function (Ndhlovu et al., 2012). This suggests 
that some individuals may be able to acquire these functions, an occurrence that will be imperative 
to examine in the controllers with absent polyfunctional responses assessed here. Understanding 
the underlying mechanisms of these distinct responses between controllers may also help 
understand why treated individuals do not acquire these functions (Migueles et al., 2009).  
 
Analysis of the phenotypic profiles of CD4 and CD8 T cells revealed some key differences between 
the two controller groups (LTNP and HIC) and pLTNP individuals (who had declining CD4 T-cell 
counts and increased HIV-1 RNA load). The difference was most apparent when looking at 
activation levels, but also noticeable in the differentiation profile. Higher frequencies of CD8 TEM 
cells and lower levels of TEMRA cells in pLTNP is consistent with the previously described HIV-1-
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associated maturation block from TEM to TEMRA subset (Champagne et al., 2001). This also 
supports results presented in Chapter 4, where higher CD8 TEM levels were detected in ART-naϊve 
patients compared to healthy controls (Chapter 4, Figure 4.2 D). Lower frequencies of CD8 TEM 
cells in controllers may reflect diminished levels of circulating HIV-1 antigen in these individuals but 
also appears to be linked to higher CD4 T-cell levels and a high CD4/CD8 ratio. Although results 
from Chapter 4 suggested similar frequencies of CD8 TEMRA cells between HIV-1-infected 
(untreated and treated) and uninfected subjects, it is demonstrated here that this subset is 
significantly increased in LTNP and may constitute more than 50% of total CD8 T cells in these 
individuals, concurring with previous studies (Addo et al., 2007). This suggests an improved ability 
to generate and maintain CD8 TEMRA cells compared to non-controllers, however activation levels 
on this subset did vary between LTNP.  
 
As observed in Chapter 4, ART does not lead to higher frequencies of CD8 TEMRA cells suggesting 
a persistent defect in the transcriptional programme of these cells in non-controllers. The role of 
the two transcription factors T-bet and Eomes in HIV-1 infection have been gaining considerable 
attention due to their important role in the differentiation and function of effector and memory CD8 
T cells (Intlekofer et al., 2005; Kaech and Cui, 2012; McLane et al., 2013). A balanced ratio of 
Eomes and T-bet appears to be particularly important as differential expression of these 
transcription factors during chronic infection results in deficient effector functions and inability to 
form long-term memory (Kaech and Cui, 2012; Paley et al., 2012). A recent study reported that T-
betdim and Eomeshigh HIV-1-specific CD8 T cells were associated with upregulation of inhibitory 
markers, a transitional memory phenotype (CD27+CD45RO+CCR7-) and impaired functional 
responses in ART-naïve and treated HIV-1-infected individuals (Buggert et al., 2014b). T-bet 
expression is higher in HIV-1-specific CD8 T cells from EC compared to chronically infected 
individuals and this is associated with increased perforin and granzyme B expression (Hersperger 
et al., 2011). Collectively, these studies demonstrate that high T-bet expression is beneficial in 
HIV-1 infection as it drives an increased differentiated effector phenotype and improves the 
functional capacity of HIV-1-specific CD8 T cells.  
 
The effector CD8 T-cell compartment (CD27-CD45RO-) harbours the highest levels of T-bet in 
HIV-1-uninfected healthy individuals (Hersperger et al., 2011; Knox et al., 2014), however, few 
studies have looked at T-bet expression on CD8 TEMRA cells defined by markers CCR7 and 
CD45RA. Since these cells most likely overlap with the CD27-CD45RO- phenotype (Sallusto et al., 
2004), T-bet levels on TEMRA cells are also expected to be high but need to be confirmed in HIV-1-
infected individuals. The presence of high CD8 TEMRA levels in the LTNP assessed here may reflect 
CHAPTER 5 
SPONTANEOUS HIV-1 CONTROL 
235 
an enhanced ability to upregulate T-bet as described in EC (Hersperger et al., 2011). Although the 
trend for higher frequencies of CD8 TEMRA cells in HIC was not significant, there is a possibility that 
HIC upregulate T-bet to a greater extent upon stimulation (Hersperger et al., 2011). The activation 
levels in CD8 TEM and TEMRA subsets were significantly lower in HIC, which may suggest improved 
function. T-bet expression has been linked to differentiation status, however, it is not clear whether 
more subtle variations in T-bet (and Eomes) expression occur within a given differentiation subset 
and whether this is linked to the generation of both dysfunctional and highly effective TEM and 
TEMRA cells. T-bet has been shown to repress PD-1 expression during chronic infection (Kao et al., 
2011), warranting further examination of the relationship between these two in HIV-1-specific CD8 
TEM and TEMRA subpopulations. LTNP R363, who exhibited polyfunctional T-cell responses, had 
high frequencies of total CD8 TEMRA cells, yet the majority of HLA-B*27:05-restricted KK10-specific 
CD8 T cells were of the TEM subset. In a previous study, KK10-specific CD8 T cells from HIV 
controllers had variable maturation phenotypes (Addo et al., 2007), indicating that the TEM 
phenotype is important for an effective response, but overexpansion of unresponsive CD8 TEM 
cells may be unfavourable as demonstrated in Chapter 4. Whether KK10-specific CD8 TEM cells 
from R363 upregulate T-bet and differentiate into a TEMRA phenotype upon stimulation will be 
important to examine. The cytokine IL-12 is an important modulator of T-bet and Eomes, primarily 
acting to drive CD8 T-cell differentiation by inducing T-bet and repress Eomes expression 
(Takemoto et al., 2006). This cytokine may therefore be important for continued differentiation of 
effector and memory T cells, although other cytokines including IL-21 also induce T-bet expression 
(Sutherland et al., 2013). Future work that examines T-bet expression levels will therefore have to 
take into consideration the role that these cytokines play in vivo, which may not be recapitulated in 
in vitro studies.  
 
The HLA-DR+CD38- phenotype on CD8 T cells, which has been linked to higher avidity and HIV-1 
control (Hua et al., 2014), was not significantly different between the three groups. However, it is 
noteworthy that a significant proportion of HLA-B*27:05-restricted KK10-specific CD8 T cells (with 
high cytotoxic activity) from R363 were of this phenotype compared to KK10-specific CD8 T cells 
from T883 with no polyfunctional qualities. The high frequency (9%) suggests that this phenotype 
is likely to play an important role in the overall response to HIV-1 in R363. A key question to 
address in future studies is whether the avidity is different between the KK10-specific CD8 T-cell 
populations in T883 and R363, as this might explain the distinct functional responses (Hua et al., 
2014). Furthermore, comparing functional activity between the HLA-DR-CD38- and HLA-DR+CD38- 
KK10-specific CD8 T-cell populations in R363 will determine whether the latter phenotype is 
indeed qualitatively superior. In this context, examination with the intracellular cytokine assay 
would have allowed for a more in depth characterisation of these cells, limiting the study. The 
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considerable lower frequencies of KK10-specific CD8 T cells (0.2%) in T883 compared to R363 
may also be behind the differences observed. The presence of TIM-3+PD-1- KK10-specific CD8 T 
cells in R363 as well as T883 and P993 was surprising considering the described role of TIM-3 as 
a negative regulator and mediator of T-cell exhaustion in HIV-1 infection (Jones et al., 2008; 
Sakhdari et al., 2012). Recent reports suggest that the inhibitory function of TIM-3 depends on the 
presence of CEACAM1 (Huang et al., 2015), indicating that other surface markers need to be 
assessed in conjunction with TIM-3. A previous study reported that reduced upregulation of TIM-3 
in stimulated HIV-1-specific CD8 T cells restricted by HLA-B*27 and B*57 rendered them less 
susceptible to Treg suppression compared to CD8 T cells restricted by other HLA alleles (Elahi et 
al., 2011). However, it is not clear whether KK10-specific CD8 T cells were specifically examined, 
requiring further studies to determine if reduced upregulation of TIM-3 is also observed in the HIV 
controllers of the current study. Increasing understanding of the various inhibitory markers that 
individually or together contribute to the exhaustive T-cell phenotype in HIV-1 infection will be 
imperative in order to reverse the persistent impairment of HIV-1-specific responses.  
 
The role of IL-10 in HIV-1 infection is complex as shown by previous studies linking both high- and 
low-producing IL-10 promoter variants to attenuated CD4 T-cell loss (Erikstrup et al., 2007; 
Oleksyk et al., 2009; Naicker et al., 2012). Results from the ELISpot analysis revealed variable IL-
10 responses in the three groups that were examined. CMV WL and HIV-1 Nef 20mer peptide pool 
stimulated the highest ELISpot responses, concurring with results presented in Chapter 3 (Figures 
3.6 and 3.9). This was particularly noticeable in the ART-naϊve pLTNP group, with strong IL-10 
responses to CMV WL, HIV-1 Nef 20mer peptide pool and HSV observed in all four individuals. 
LTNP and HIC were more variable in their IL-10 response, with perhaps a trend for overall lower 
IL-10 levels observed in response to CMV WL and HIV-1 Nef peptide pool. However, increasing 
the number of controllers will be required to determine whether these observations are significant 
in a large cohort.  
 
Three pLTNP produced low but positive IL-10 responses to HIV-1 Gag 20mer peptide pool and the 
fourth exhibited high IL-10 levels to HIV-1 Gag 9mer peptide pool. In contrast, very few of the 
controllers exhibited detectable levels under the same conditions. Considering the protective role 
of Gag-specific responses, it might be that the induction of IL-10 to this protein is particularly 
detrimental during HIV-1 infection. A protective Gag-specific response in controllers is associated 
with increased proliferative capacity (Migueles et al., 2002), which would imply a low induction of 
IL-10 (Brockman et al., 2009). However, it is intriguing that two of the individuals who exhibited 
polyfunctional responses to CMV WL, HIV-1 Gag and Nef peptide pools also produced IL-10 to 
these antigens. This might reflect a balanced immune response where the generation of strong 
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polyfunctional HIV-1-specific responses followed by strong immunomodulatory reactions allows an 
efficient immune response but is constrained to prevent excessive immune activation in these 
individuals. Indeed, the inhibitory role of IL-10 on pro-inflammatory cytokine responses 
underscores its importance for counteracting the immune activation and inflammation often 
observed during HIV-1 infection. This raises the question of whether IL-10 production in the 
absence of polyfunctional responses (as is the case in ART-naϊve progressors), results in a more 
suppressive response to antigen. Further knowledge is required of IL-10/IL-10R signalling, the 
downstream targets and how this is modulated in the context of chronic HIV-1 infection as well as 
in HIV controllers.  
 
The strong CMV-specific IL-10 responses detected with ELISpot both here and in Chapter 3, were 
harder to detect using ELISA. Individuals with the highest IL-10 ELISpot responses were also the 
ones who had detectable IL-10 ELISA responses demonstrating a consistency between the two 
assays. However, it also indicates that the ELISA assay may not have been sensitive enough to 
detect low-level IL-10 responses. Previous studies have used bead-based immunoassays (Kwon 
et al., 2012; Porichis et al., 2014b), which might be more sensitive in detecting IL-10 (Elshal and 
McCoy, 2006). In addition, the IL-10 capture antibodies in the two different assays were of two 
different clones, which might have contributed to the differences observed and needs to be 
addressed in future studies. Nevertheless, a strong induction of IL-10 in response to CMV WL was 
detected in the supernatants of three LTNP and one HIC, whilst plasma IL-10 levels were negative 
in these individuals. In contrast, of the eleven ART-naϊve patients (including five that were 
designated pLTNP), only two had detectable CMV WL-induced IL-10 production in the 
supernatants. This was surprising considering that all exhibited positive IL-10 responses to CMV in 
the ELISpot assay. Variability in IL-10 kinetics could be a factor behind the differences in ELISA 
and ELISpot detection. Although 48 hours was chosen as length of stimulation, ART-naϊve patients 
may utilize the secreted IL-10 more rapidly. Blocking IL-10 uptake with an anti-IL-10R antibody and 
increasing the number of early time points will be needed to determine whether this is the case. 
Including more healthy controls will also be essential in future work to examine CMV-specific IL-10 
production and uptake in the absence of HIV-1 infection.  
 
Expression of IL-10R will be essential to analyse if it varies between controllers and non-
controllers. A recent study reported that mucosal IFN-γ and TNF-α production was high in SIV-
infected rhesus macaques despite increased levels of mucosal IL-10 production. A failure to down-
modulate these inflammatory responses was attributed to increased internalisation of IL-10R on 
mucosal lymphocytes, rendering these un-responsive to IL-10 (Pan et al., 2014). The results need 
to be investigated in the context of HIV-1 infection but do suggest that IL-10R internalisation may 
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explain why HIV-1-uninfected individuals and some controllers exhibit strong IL-10 responses upon 
antigen stimulation yet have absent to low plasma IL-10 levels as observed here and in previous 
studies (Brockman et al., 2009; Kwon et al., 2012). Higher IL-10 responses as a consequence of 
ongoing viral replication and immune activation may eventually result in increased internalization of 
IL-10R rendering cells unresponsive and leading to high plasma IL-10 levels. Thus, future work 
should consider characterising the expression of IL-10R, whether this varies in healthy controls 
and different cohorts of HIV-1-infected individuals including controllers and non-controllers. 
Moreover, IL-10R expression may vary on different antigen-specific T cells, resulting in disparate 
responses to IL-10-mediated suppression. Considering the important role of IL-10 in mucosal 
homeostasis (Jarry et al., 2008), understanding the mechanisms of its dysregulation may be 
relevant to the development of an HIV-1 vaccine. IL-10 has been implicated in diminished 
response to vaccination with LCMV, influenza and Mycobacterium bovis bacillus Calmette-Guérin 
(BCG) (Brooks et al., 2008; Pitt et al., 2012; Mohanty et al., 2015). Furthermore, a recent follow-up 
study of previously immunised HIV-1-infected individuals with a therapeutic HIV-1 Gag vaccine 
reported that patients not responding to booster immunisations exhibited increased IL-10 and TGF-
β-mediated downregulation of vaccine-specific CD8 T-cell proliferation (Lind et al., 2013). 
Assessing the immunoregulatory responses that are generated in parallel to anti-viral responses 
may therefore be relevant when developing an HIV-1 vaccine and assessing its efficacy.  
 
The results presented in this study highlight the heterogeneity of clinical characteristics in HIV-1-
infected individuals with an atypical disease progression. An attempt to understand the replicative 
fitness in these individuals was constrained by the sensitivity of the assay and possible 
amendments have been highlighted to improve this method in future work. A comprehensive, 
phenotypic and functional assessment of the CD4 and CD8 T cells from the identified controllers 
revealed low activation levels in LTNP and HIC across all differentiation subsets and the HLA-
DR+CD38- phenotype was linked to high cytotoxicity in one HIC. Moreover, it was demonstrated 
that controllers maintain lower levels of CD8 TEM cells compared to progressing ART-naϊve HIV-1-
infected individuals and LTNP exhibit enhanced ability to generate and maintain CD8 TEMRA cells, 
which may contribute to HIV-1 control. Finally, IL-10 responses to CMV WL and HIV-1 Nef peptide 
pool were detected in controllers but were more variable compared to the strong responses 
observed in chronic progressors in Chapter 3. This may depend on differences in IL-10R 
expression, which will be important to examine in future work.  
 
The work presented here builds upon the data presented and discussed in Chapters 3 and 4, and 
highlight some phenotypic characteristics that may underline controller status. A low number of 
individuals were examined, and therefore the nature of the conclusions drawn here may be 
CHAPTER 5 
SPONTANEOUS HIV-1 CONTROL 
239 
regarded as preliminary. However, notwithstanding the low number of HIV-1 controllers identified, 
these results provide a framework for further investigations in larger cohort studies. Collectively, 
these studies may provide useful insight into the phenotypic and functional properties of CD4 and 
CD8 T cells in the context of both treatment-induced and spontaneous control of HIV-1. 
Understanding the protective responses observed in controllers but not in treated individuals will be 
important to fully assess how long-term control of HIV-1 is achieved and how this can be 
harnessed in the development of prophylactic and immunotherapeutic HIV-1 vaccines and 
approaches.  
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Chapter 6 Final Discussion and Future Work  
The ability of a tiny minority of HIV-1-infected individuals to spontaneously control HIV-1 replication 
for many years suggests that a functional HIV-1 cure is possible (Theze et al., 2011). Effective 
antiretroviral therapies represent a great step towards this goal and have increased life expectancy 
for the millions of individuals currently living with HIV-1. However, ART does not eradicate HIV-1 or 
fully restore immune function and viral rebound occurs upon treatment interruption. Further 
advances will therefore depend on better understanding the limitations of ART-mediated immune 
reconstitution to better tailor immunotherapeutic developments that can be administered 
concomitantly with ART. Moreover, identification of phenotypic and functional T-cell characteristics 
that are uniquely found in individuals who are able to control HIV-1 in the absence of ART, are 
highly relevant for both immunotherapeutic and prophylactic vaccine development. Growing 
evidence suggests that latent asymptomatic infection with the herpesvirus CMV contributes to 
immune senescence in elderly HIV-1-uninfected individuals (Hadrup et al., 2006; van de Berg et 
al., 2008). CMV is highly prevalent among HIV-1-infected individuals and although CMV-specific 
immunity is restored with ART initiation, its role in immune activation has become the focus of 
several studies in recent years (Hunt et al., 2011b; Wittkop et al., 2013). However, the underlying 
mechanisms that drive immune senescence and activation remain unclear.  
 
The primary aim of this thesis was to comprehensively investigate the phenotypic and functional 
characteristics of CD4 and CD8 T cells and the effect that plasma HIV-1 RNA levels and ART have 
on these responses in the context of divergent HIV-1 progression rates. CMV- and HIV-1-specific 
immune responses were also examined to identify mechanisms that may be behind the observed 
differences in immune reconstitution to these two viruses. Individuals who exhibit spontaneous 
control of HIV-1 were identified and further investigated for viral and host factors that might 
underlie their non-progression. In the absence of a functional HIV-1 cure, developing 
immunotherapeutic interventions that boost HIV-1-specific immune responses enough to induce an 
HIV controller status, where the patient is able to control HIV-1 replication even after treatment 
interruption, remains an ultimate aim of current research.  
 
6.1 Viral fitness assay 
There is increasing evidence that viral factors play a role in defining HIV-1 disease outcome, 
highlighting the need to examine both viral and host factors that may contribute to HIV-1 disease 
outcome (Claiborne et al., 2015). Transmission of viral variants with reduced replication capacity 
and attenuated function in individual HIV-1 proteins have been associated with lower plasma HIV-1 
load and delayed CD4 T-cell loss in different cohorts (Goepfert et al., 2008; Miura et al., 2010). 
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Viral fitness was evaluated here using the viral outgrowth assay on a subset of identified HIV 
controllers and LTNP, in order to determine if reduced HIV-1 RNA replication capacity was behind 
the lower levels of plasma HIV-1 RNA load in these individuals. This involved stimulating HIV-1 
RNA replication and measuring virus production at various time points using a commercially 
available ELISA. Co-culturing patient PBMC with PHA-activated PBMC from HIV-1-uninfected 
individuals in multiple rounds proved more successful at stimulating viral replication compared to 
stimulating patient cells with PHA only. However, the sensitivity of the viral fitness assay remained 
a challenge and would require further improvements to be able to detect residual HIV-1 in patients 
with low to undetectable plasma viral loads. Specifically, purification of CD4 T cells and the use of 
latency-reversing agents such as HDAC inhibitors may further enhance the stimulation of 
replication-competent virus from the viral reservoir (Archin et al., 2012; Salgado et al., 2014).  
 
Replication-competent virus was detected in two of the four HIV controllers assessed, where one 
individual required longer time before HIV-1 p24 protein levels were detected. Although this could 
imply a reduced viral fitness in that individual, in hindsight, the levels of HIV-1 RNA that were 
isolated should have been normalised, as different concentrations in the initial co-culture could 
have affected the length of time that it took to isolate HIV-1 p24. Thus, following initial isolation of 
replication-competent virus, supernatants with normalised HIV-1 p24 levels would then be used to 
infect purified CD4 T cells and assessed with ELISA as previously described (Blankson et al., 
2007).  
 
Recent studies on viral fitness have also focused on examining individual HIV-1 protein function 
(Mwimanzi et al., 2013; Kuang et al., 2014). As HIV-1 Nef isolates with a decreased ability to 
downmodulate CD4 as well as MHC class I and II molecules have been detected in a cohort of 
elite controllers (Mwimanzi et al., 2013), it would be of interest to examine if this is also observed in 
the HIV controllers assessed here to determine if this is a general feature of viral isolates from 
controllers. Future work could also investigate the functions of other proteins. For instance, as HIV-
1 Tat downregulates the receptor for IL-7 (CD127) on CD8 T cells in chronically infected individuals 
(Faller et al., 2014), this function requires assessment in controllers. These studies could highlight 
how variations in the ability of individual HIV-1 proteins to downmodulate host immune responses 
may contribute to HIV-1 control. Ultimately, the goal of studies that explore the role of viral 
characteristics in the pathogenesis of HIV-1 would first be to understand the extent to which 
reduced viral fitness contributes to HIV-1 control. Second, these studies may identify epitopes that 
are important for protein stability and function, which would make them relevant for incorporation 
into prophylactic and therapeutic vaccines.  
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6.2 Phenotypic T-cell profiles in the context of ART and disease 
progression 
HIV-1 infection is associated with an enormous modulation of the CD4 and CD8 T-cell phenotype, 
including persistent increases in exhaustion and activation levels as well as an impaired 
differentiation of CD8 T cells. In line with this, we show high levels of exhausted and highly 
activated CD4 and CD8 T cells in ART-naϊve HV-1-infected individuals (Day et al., 2006; Hunt et 
al., 2008). Treated individuals exhibited significantly reduced levels of exhaustion and activation, 
however activation levels remained high in a number of treated subjects compared to healthy 
controls, concurring with previous studies (Hunt et al., 2003b; Hunt et al., 2008). Further 
assessment of T cells demonstrated significantly higher frequencies of highly activated CD8 TEM 
and TEMRA subsets in particular, suggesting continued dysregulation of these subsets despite 
suppression of HIV-1 replication in the treated patients. Moreover, lower levels of CD8 naïve cells 
and higher frequencies of CD8 TEM cells were significantly associated with markers of disease 
progression (lower CD4 T-cell count and CD4/CD8 ratio). These results are consistent with two 
recent studies (Ghiglione et al., 2014; Serrano-Villar et al., 2014) and suggest that 
immunotherapeutic strategies aimed at improving CD8 T-cell homeostasis are needed to reverse 
CD8 T-cell dysfunction and improve HIV-1-specific immunity in treated patients. Treated individuals 
also exhibited significantly higher proportions of CMV-specific CD8 TEM cells compared to ART-
naϊve subjects, which suggests they may contribute to the high levels of CD8 TEM in these 
individuals. However, few individuals were examined for HIV-1- and CMV-specific CD8 T-cell 
profiles, limiting the study. In hindsight, it would have been of interest to carry out a longitudinal 
assessment using intracellular cytokine staining to examine the frequencies and function (including 
IFN-γ, perforin and granzyme B responses) of antigen-specific CD8 TEM and TEMRA cells before and 
after ART initiation. This would better highlight the changes that occur with treatment.  
 
In contrast to ART-naϊve and treated individuals, a larger proportion of CD8 T cells from LTNP 
were TEMRA rather than TEM. A similar observation of higher frequencies of CD8 TEMRA cells has 
previously been reported, although the study included HIV controllers rather than LTNP (Addo et 
al., 2007). The ability to maintain significant numbers of CD8 TEMRA cells may reflect a balanced 
differentiation profile and enhanced cytotoxic activity in these individuals (Sallusto et al., 1999; 
Champagne et al., 2001). However, HIV controllers assessed in the current study did not have 
significantly higher levels of CD8 TEMRA cells compared to ART-naϊve patients (pLTNP), indicating 
that higher TEMRA frequencies per se may not be essential for HIV-1 control. It is worth noting that 
the majority of HIV controllers had significant levels of CD8 naïve cells, which are associated with 
an improved CD8 T-cell homeostasis and a more favourable HIV-1 disease outcome as described 
above and previously (Serrano-Villar et al., 2014). Chronically HIV-1-infected individuals and 
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uninfected controls exhibited variable frequencies of CD8 TEMRA and these were not associated 
with any clinical parameters such as CD4 T-cell count or age in the HIV-1-infected group. Future 
work should therefore focus on examining the functional qualities of the CD8 TEMRA subset in order 
to determine if these are different between controllers and chronically HIV-1-infected individuals. 
Previous studies have mainly reported on the accumulation of less functional, senescent CD8 
TEMRA cells in healthy individuals over 65 years of age (Wikby et al., 2002; Griffiths et al., 2013). 
This progressive dysfunction of CD8 TEMRA cells has been associated with CMV infection (Wikby et 
al., 2002; Griffiths et al., 2013). In younger cohorts, HIV-1-specific CD8 T cells may progressively 
lose the ability to produce multiple cytokines as they become more differentiated whereas this is 
not observed for CMV-specific CD8 T cells (Riou et al., 2012). In view of this, changes that occur in 
CD8 TEMRA homeostasis and function, both in the context of increasing age as well as different HIV-
1 progression rates, will be important considerations in order to modulate age- and HIV-1 
associated dysfunction. In vitro studies have demonstrated that expression of CD45RA (which 
together with CCR7 defines TEMRA cells) can be induced in an antigen-independent manner through 
addition of exogenous IL-7 and/or IL-15 (both cytokines important for T-cell homeostasis) (Geginat 
et al., 2003; Griffiths et al., 2013). This suggests that examination of HIV-1-associated cytokine 
dysregulation and its effects on the transcriptional programmes that govern CD8 T-cell 
homeostasis may be particular revealing.  
 
Lower expression of T-bet, a transcription factor that promotes differentiation towards effector and 
effector memory fates and induces upregulation of perforin and granzyme B on antigen-specific T 
cells, has recently been associated with a less differentiated CD8 T-cell phenotype and impaired 
functional responses in chronic progressors (Buggert et al., 2014b). CD8 TEMRA cells have the 
highest level of perforin and granzyme B expression (Sallusto et al., 1999), suggesting that 
cytokines such as IL-12 and/or IL-21, both of which induce T-bet expression (Takemoto et al., 
2006; Sutherland et al., 2013), could be important for the cytotoxic function of these cells. IL-12 
expression from APCs is inhibited by the immunosuppressive cytokine IL-10 (O'Garra and Murphy, 
2009). Therefore, higher levels of IL-10 during untreated HIV-1 infection may indirectly affect T-bet 
expression and CD8 T-cell differentiation. One way of examining this could be to stimulate PBMC 
from ART-naϊve patients with different antigens such as HIV-1 Nef or CMV WL, in the absence and 
presence of an anti-IL-10R antibody and measure subsequent changes in the expression of T-bet 
on antigen-specific CD8 T cells. On the other hand, higher levels of IL-15 have been detected in 
monocytes from LTNP compared to progressors and healthy controls (Tarkowski et al., 2012). 
Assessment of any association between monocyte IL-15 expression and higher frequencies of 
CD8 TEMRA cells in these individuals may highlight another mechanism for the increased levels of 
CD8 TEMRA cells in LTNP. A recently described method for combining flow cytometric analysis with 
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fluorescent in situ hybridization (FISH) may be useful for examining both gene expression and 
protein levels of different transcription factors such as T-bet and cytokines in single cells (Porichis 
et al., 2014a). Examination of cytotoxic activity (perforin, granzyme B expression) and markers for 
replicative senescence (CD57) will enable further characterisation of TEMRA cells from LTNP and 
how these might differ to those from chronically infected individuals. Markers for apoptosis are also 
important to include (CD95 and caspase-8), in order to investigate if CD8 TEMRA cells from 
controllers are more resistant to apoptosis as suggested recently (Gaiha et al., 2014). The use of 
single-cell spectrometric analysis (cytometry by time-of-flight or CyTOF) in conjunction with 
peptide-MHC multimer staining will facilitate larger antibody panels for a more comprehensive 
assessment of antigen-specific CD8 T cells (Newell et al., 2012; Bjornson et al., 2013).  
 
In relation to the expression patterns of CD38 and HLA-DR on total CD4 and CD8 T cells, these 
varied considerably between HIV-1-infected and uninfected healthy subjects. Treated individuals 
even exhibited some phenotypes that were not observed elsewhere. Among these was the HLA-
DR+CD38- phenotype, which was significantly higher on both total, HIV-1- and CMV-specific CD8 T 
cells of treated individuals compared to ART-naïve individuals and uninfected controls. Further 
analysis did not find a significant enrichment of this phenotype in controllers and as such does not 
appear to be important for HIV-1 control in these individuals, in contrast to previous data (Giorgi et 
al., 1994; Saez-Cirion et al., 2007; Hua et al., 2014). However, in one LTNP, a significant 
proportion of HIV-1 KK10-specific CD8 T cells (with cytotoxic activity) were HLA-DR+CD38-, 
concurring with previous data (Hua et al., 2014). On CD8 T cells, HLA-DR expression in the 
absence of CD38 has been associated with increased proliferation, cytotoxicity and higher avidity 
(Saez-Cirion et al., 2007; Hua et al., 2014). Important considerations for the future is whether these 
functional characteristics are also observed in the HLA-DR+CD38- CD8 T cells from treated 
individuals. In vitro stimulation of PBMC with low EBV antigen levels has been shown to induce the 
HLA-DR+CD38- phenotype on CD8 T cells (Hua et al., 2014). Therefore, it could be that the low 
plasma HIV-1 RNA levels in treated individuals could be inducing this phenotype rather than a 
more highly activated phenotype (HLA-DR+CD38+) as observed in ART-naïve individuals with high 
plasma HIV-1 RNA levels. Alternatively, initiation of ART may reduce CD38 expression on HLA-
DR+CD38+ CD8 T cells but fail to reduce HLA-DR, leading to an accumulation of HLA-DR+CD38- 
CD8 T cells in treated individuals. The two different scenarios could indicate different functional 
roles for the HLA-DR+CD38- phenotype in treated individuals and controllers, meriting assessment 
of the functional profiles of this phenotype. For this purpose, the intracellular cytokine staining 
assay can be utilized in future work to examine perforin and granzyme B release in HLA-DR+CD38- 
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antigen-specific CD8 T cells. The proliferation and avidity of HLA-DR+CD38- HIV-1-specific CD8 T 
cells could also be evaluated to determine whether this is improved in treated individuals or 
uniquely found in controllers (Hua et al., 2014). Future work aiming to clarify the role and function 
of HLA-DR on CD8 T cells will be important in order to understand its induction in treated patients 
and controllers. 
6.3 HIV and CMV co-infection 
Increasing evidence suggests that CMV infection is associated with both AIDS- and non-AIDS 
defining morbidities and may contribute to immune activation (Hunt et al., 2011b; Lichtner et al., 
2015). We show here that ART-naϊve individuals exhibited high frequencies of both HIV-1 and 
CMV-specific CD8 T cells that were highly activated, consistent with the bystander activation that 
has previously been described for herpesviruses during HIV-1 infection (Smith et al., 2013). 
Activation levels on CD8 T cells specific for both viruses were significantly lower in treated 
individuals, although a few did exhibit high levels of highly activated CMV-specific CD8 T cells. 
CMV viraemia, which has been associated with increased T-cell immune activation, was not 
evaluated here, limiting the study. However recent studies suggest that measurement of CMV 
viraemia may be more relevant in tissues and seminal fluids. By examining both peripheral blood 
and seminal fluids, a recent study found that in contrast to ART-naïve subjects, the association 
between CMV viraemia and CD4 T-cell activation was significant only in the seminal fluids when 
treated individuals where assessed (Gianella et al., 2014). IL-10, which was produced in large 
quantities following CMV-stimulation, plays an important role in maintaining gut homeostasis 
(Shouval et al., 2014). Therefore, measuring CMV viraemia and CMV-specific responses (including 
IL-10 production) in mucosal tissue samples will determine if these become dysfunctional in HIV-1-
infected individuals compared to healthy controls. CMV gastroenteritis although rare, may be 
observed during advanced HIV-1 infection (You and Johnson, 2012), pointing to a role for CMV 
infection in mucosal tissues.  
 
In addition to its role in immune activation, another aspect of CMV-infection is the establishment of 
strong CMV-specific T-cell responses in HIV-1-uninfected individuals, which may be even higher in 
HIV-1-infected subjects, particularly those on ART (Sylwester et al., 2005; Naeger et al., 2010). On 
the other hand, ART only partially improves HIV-1-specific immunity. As T-cell 
expansion/proliferation is important for efficient immune host responses, we aimed to carry out a 
prospective longitudinal study on the proliferative responses to HIV-1 and CMV in seven HIV-1- 
and CMV-co-infected individuals, one of whom had very low CD4 T-cell counts and symptomatic 
CMV disease. Previous studies examining CMV-specific proliferative responses parallel to HIV-1 
were either cross-sectional or with short follow-up, resulting in conflicting results (Autran et al., 
1997; Keane et al., 2004). Here, continuous time points in the longitudinal study demonstrated 
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discordant increases of CMV- and HIV-1-specific proliferative responses; persistent impairment in 
HIV-1-specific proliferation even after 96 weeks of effective treatment whilst a strong induction of 
proliferative responses to CMV was observed during this time. However, although the length of 
study was longer compared to previous longitudinal reports, an even longer follow-up would have 
been required to determine if CMV-specific proliferative responses do indeed wane as observed in 
some studies (Gerna et al., 2001; Keane et al., 2004). In retrospect, carrying out CFSE staining to 
examine both phenotype and proliferation of CMV- and HIV-1-specific T cells would have enabled 
us to determine the differentiation and activation status of the proliferating antigen-specific T cells; 
whether CMV-specific T cells of a TEM phenotype are preferentially expanded following ART 
initiation and contribute to high levels of TEM as suggested above. Interestingly, data from the 
cross-sectional proliferation and ELISpot assays suggested that CMV-specific T cells from HIV-1-
uninfected individuals do not readily proliferate or produce IL-2 but are instead linked to high levels 
of IL-10. These results indicate that following stimulation, CMV-specific T-cell responses may be 
strictly regulated to limit their expansion and this regulation may be linked to IL-10 production. This 
would be consistent with previous studies demonstrating that both human IL-10 and the CMV 
homologue (cmvIL-10) limit the expansion of CMV-specific T-cell responses (Cheung et al., 2009; 
Jones et al., 2010). Moreover, blockade of IL-10 signalling results in higher CMV-specific T-cell 
proliferative responses in a subset of ART-naϊve HIV-1-infected individuals (Brockman et al., 
2009). On the other hand, the observed increase of CMV-specific T-cell responses in the elderly 
and long-term treated HIV-1-infected individuals implies that expansion of these cells does occur in 
some form. This could be due to progressive failure of CMV-specific T cells to control CMV 
viraemia (requiring more CMV-specific T cells) or these cells may lose the regulatory control that 
limits their expansion. As CMV infection may be an important factor in both age- and HIV-1-related 
morbidity (Wikby et al., 2002; Lichtner et al., 2015), understanding the mechanisms that regulate 
CMV-specific proliferation and expansion in healthy subjects and how this is affected by HIV-1 
infection, antiretroviral therapy and increasing age will be essential in future work.  
 
Previous studies have reported that blockade of IL-10 signalling improves proliferative, IFN-γ and 
IL-2 responses in HIV-1-specific T cells (Brockman et al., 2009; Porichis et al., 2014b). However, 
little is known about the mechanisms that lead to its upregulation during HIV-1 infection. Here, it 
was demonstrated that HIV-1-infected and uninfected healthy subjects produced high levels of IL-
10 in response to CMV and the magnitude of this response was significantly higher compared to 
both HIV-1 Gag- and Nef-specific IL-10 responses in the HIV-1-infected group. Moreover, IL-10 
production was higher in ART-naϊve patients compared to their treated counterparts, consistent 
with the previously described association between plasma HIV-1 RNA levels and IL-10 production 
(Brockman et al., 2009). This finding is indicative of a possible role for CMV and Nef-specific IL-10 
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production in HIV-1-infected individuals, particularly in the context of untreated infection where 
these responses may contribute to the high plasma IL-10 levels observed. However, the detection 
of HSV- and to a lesser extent EBV-specific IL-10 production in a subset of ART-naϊve progressors 
and controllers in Chapter 5 demonstrates that other herpesviruses induce IL-10 and may all 
contribute to the high levels of plasma IL-10 during untreated HIV-1 infection. Still, healthy subjects 
produced the highest IL-10 responses to CMV, highlighting the complexity of the IL-10 pathway, 
which is necessary for limiting antigen-specific responses and inflammation (Couper et al., 2008a), 
but may become dysfunctional in the context of chronic HIV-1 infection. In hindsight, proliferative 
responses and IL-10 production to various antigens should have been measured at the same time 
for a more comprehensive understanding of how these two functions are linked. CFSE staining 
may be used for this purpose.  
 
As healthy control subjects produced higher levels of CMV-specific IL-10, it would be of interest to 
examine whether IL-10R-blockade results in a more substantial increase of CMV-specific T-cell 
proliferation in these individuals compared to that observed for treated HIV-1-infected patients. 
Elite controllers examined in Chapter 3 exhibited significantly higher CMV-specific proliferative 
responses compared to both chronically HIV-1-infected patients and uninfected healthy subjects. 
This is consistent with an enhanced proliferative activity that is often reported for these individuals 
(Migueles et al., 2002), and could indicate lower IL-10 responses in these individuals. However, 
despite the strong link between IL-10 and proliferative responses (Brockman et al., 2009; Jones et 
al., 2010), other factors that regulate proliferation/expansion such as IL-2 and PD-1 will need to be 
taken into consideration and examined in parallel (Day et al., 2006; Porichis et al., 2014b). In 
Chapter 5, LTNP and HIV controllers demonstrated variable IL-10 responses but the ones who 
exhibited polyfunctional (IL-2 and granzyme B) responses to HIV-1 and CMV also produced IL-10 
to the same antigen. Thus, it will be important to measure IL-2, granzyme B and IL-10 production 
together with proliferative responses, to determine the role of IL-10 production in the enhanced 
immune responses often observed in controllers. 
  
Due to the previously described benefit of blocking IL-10R signalling on HIV-1-specific CD4 and 
CD8 T-cell function, these cells were examined for intracellular IL-10 production to HIV-1 and 
CMV. However, too few individuals were assessed and therefore further studies are required that 
also test different CMV peptide pools and examine other cell-types such as monocytes, which may 
be more relevant (Kwon et al., 2012). IL-10 production by T cells may be negligible as observed 
here in the intracellular cytokine assay and previously (Kwon et al., 2012) or only observed in 
advanced HIV-1 disease (Elrefaei et al., 2006; Elrefaei et al., 2007). It should be noted that 
stimulation of PBMC with the HIV-1 KK10 10mer peptide, which predominantly stimulates CD8 T 
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cells, led to detectable IL-10 production in three controllers and one ART-naϊve patient in Chapter 
5. Future work should consider measuring IL-10 production following stimulation with the KK10 
peptide in both the ELISpot and intracellular cytokine assay, to determine if different sensitivities or 
incubation periods between the two assays may have been behind the lower IL-10 levels detected 
in the latter assay. A subset of controllers were examined for both plasma IL-10 levels and CMV-
specific IL-10 production in the ELISA assay. In line with previous observations, none of the 
controllers had detectable levels of IL-10 protein in their plasma (Brockman et al., 2009), but they 
did exhibit positive CMV-specific IL-10 responses in both the ELISpot and ELISA assays. In 
contrast, despite positive responses in the ELISpot analysis, IL-10 was only detected in the 
supernatants of two ART-naϊve individuals when analysed by ELISA. The sensitivity of the ELISA 
assay, which appeared to be lower compared to ELISpot, could be behind these differences and 
should be examined in future work using more sensitive assays. Earlier time points and stimulation 
of PBMC in the presence of an anti-IL-10R antibody may also be important to determine whether 
uptake of IL-10 was faster in the PBMC of ART-naϊve individuals compared to controllers. It will 
also be relevant to measure the expression of IL-10R on antigen-specific T cells in HIV-1-infected 
and uninfected individuals, to better understand the kinetics of IL-10 production and uptake. 
Increased internalisation of IL-10R (rendering mucosal lymphocytes un-responsive to IL-10 
signalling) has been linked to persistent levels of pro-inflammatory cytokines in SIV infection (Pan 
et al., 2014). In view of this recent study, future work that examines any association between IL-
10R internalisation and increased plasma IL-10 in untreated HIV-1 infection is warranted. Whether 
CMV- and HIV-1-specific T cells exhibit different levels of IL-10R expression will also be of interest, 
as it may highlight different responsiveness to IL-10 signalling between the two antigen-specific T 
cells. 
 
Important considerations for the future are to investigate whether the high IL-10 CMV-specific 
responses that were detected in HIV-1-uninfected healthy controls have any association with the 
low proliferative responses in these individuals. Also, examination of how this is affected in the 
context of HIV-1 infection may further highlight why CMV-specific T-cell responses continue to 
expand during HIV-1 infection, whether changes in IL-10 production may be important. Previous in 
vitro studies and mouse models suggest an association between IL-10 and CMV-specific 
responses (Cheung et al., 2009; Jones et al., 2010), however this will have to be examined in 
different cohorts as other factors that control proliferative responses may also be important. Future 
work should also consider examining further the observed differences in HIV-1- and CMV-specific 
IL-10 production, in order to determine how this relates to the disparate proliferative capacities to 
these two viruses as observed here. Of particular interest will be to investigate the enhanced 
proliferative activity to CMV that was observed in controllers and not in healthy control subjects, 
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whether this reflects a better control of CMV infection in controllers. Concomitant polyfunctional 
and IL-10-specific responses to HIV-1 and CMV suggests an improved balance of pro-
inflammatory and immunoregulatory responses in these controllers. Thus, it may be more 
informative to assess the parallel induction of functional responses and the downmodulatory 
mechanisms that follow to better define whether an immune response is geared to be more pro-
inflammatory or more suppressive as suggested in previous studies (Lind et al., 2013; Lind et al., 
2014). This could provide targets for future immunotherapies that aim to improve HIV-1-specific 
responses in the context of ART. 
 
In summary, this study has detailed a comprehensive characterisation of total as well as CMV- and 
HIV-1-specific functional T-cell responses and phenotypes in the context of different disease 
progressions. The dynamics of CMV replication and the immense host responses that this virus 
generates may contribute to the abnormal T-cell activation, differentiation and senescence that 
characterises HIV-1 immunopathogenesis even among patients on effective ART. This research 
has highlighted the complexity of IL-10 responses to HIV-1 and CMV and the potential link to 
proliferative activity in T cells from different cohorts. As enhanced proliferative capacity is one of 
the strongest factors in HIV-1 control (Migueles et al., 2002), future work that examines the 
mechanisms that regulate this function will be important for development of strategies aimed at 
improving HIV-1 immunity in the context of ART. Moreover, considering that a high proportion of 
total T cells may be CMV-specific in healthy CMV seropositive, HIV-1-uninfected volunteers 
(Sylwester et al., 2005) and long-term treated HIV-1-infected individuals (Naeger et al., 2010), any 
dynamic changes in the responses of these cells are likely to contribute to the environmental milieu 
of different tissues in HIV-1-infected individuals. Thus, examination of IL-10 and how it regulates 
expansion of these antigen-specific T cells should be of more focus in future work. If subclinical 
CMV reactivation and concomitant loss of regulation drives such a high proportion of cell-mediated 
responses, and contributes to the skewed CD8 T-cell differentiation and immune activation, then 
anti-CMV therapy could be investigated as a means to delay immunosenescence and minimise 
pathogenic expansion in HIV-1-infected patients. The recent results from a large cross-sectional 
study of 6 111 HIV-1-infected individuals demonstrating that CMV/HIV-1 co-infection is associated 
with increased risk of severe non-AIDS events supports an independent role of CMV in 
vascular/degenerative organ disorders in HIV-1-infected patients (Lichtner et al., 2015). This is 
important to consider in terms of managing the overall clinical well being of HIV-1-infected patients. 
The potential links between CMV, immune activation, skewed differentiation, immunosenescence, 
morbidity and mortality in the context of anti-CMV treatment, warrant further assessment in larger 
clinical trials.  
 
CHAPTER 6 
FINAL DISCUSSION 
251 
Overall, data presented in this thesis provide a better understanding of the complex interplay 
between CMV and HIV-1 co-infection at different stages of disease, for which anti-CMV treatment 
may be of long-term benefit by targeting immune activation and preventing dysregulation of CMV-
specific responses. Recognising mechanisms that distinguish ART-mediated immune 
reconstitution from spontaneous immune suppression will be important in identifying targets for 
such immunotherapeutic interventions. 
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